BACKGROUND O O 0.9979144930839539
: O O 0.9999995231628418
We O O 0.9999860525131226
report O O 0.9999974966049194
on O O 0.9999921321868896
the O O 0.9998487234115601
manifestation O O 0.9995700716972351
of O O 0.9999246597290039
a O O 0.9600017070770264
levetiracetam B-Chemical B-Chemical 0.9996902942657471
( O O 0.9870807528495789
LEV B-Chemical B-Chemical 0.9997027516365051
) O O 0.948070764541626
- O O 0.9995457530021667
induced O O 0.9994432330131531
encephalopathy B-Disease B-Disease 0.9999531507492065
. O O 0.999961256980896

Diffusion O O 0.3564400374889374
- O O 0.977790892124176
weighted O O 0.993311882019043
imaging O O 0.9901437759399414
may O O 0.9999985694885254
be O O 0.999997615814209
useful O O 0.9999847412109375
in O O 0.9999579191207886
predicting O O 0.999980092048645
the O O 0.9998549222946167
outcomes O O 0.999836802482605
of O O 0.9999895095825195
the O O 0.9997593760490417
lesions O O 0.9957935810089111
of O O 0.9993832111358643
tacrolimus B-Chemical B-Chemical 0.9999725818634033
- O O 0.9989832043647766
induced O O 0.9998157620429993
neurotoxicity B-Disease B-Disease 0.9999614953994751
. O O 0.9999771118164062

Increase O O 0.9547582268714905
of O O 0.9964414238929749
Parkinson B-Disease B-Disease 0.9199142456054688
disability I-Disease I-Disease 0.9993627667427063
after O O 0.9995032548904419
fluoxetine B-Chemical B-Chemical 0.9999624490737915
medication O O 0.9918070435523987
. O O 0.9999996423721313

Abstract O O 0.968096911907196
Serum O O 0.992133378982544
aminotransferase O O 0.7596169114112854
elevations O O 0.9766353368759155
are O O 0.9999997615814209
a O O 0.9999897480010986
commonly O O 0.9999189376831055
known O O 0.9999529123306274
adverse O O 0.9933826923370361
effect O O 0.9991393089294434
of O O 0.9998874664306641
3 O B-Chemical 0.7885652184486389
- O I-Chemical 0.9675542116165161
hydroxy O I-Chemical 0.9984980821609497
- O I-Chemical 0.8200312256813049
3 O I-Chemical 0.9593501687049866
- O I-Chemical 0.994635283946991
methylglutaryl O I-Chemical 0.9993066787719727
coenzyme O I-Chemical 0.9854458570480347
A O I-Chemical 0.9649830460548401
reductase O I-Chemical 0.7751885056495667
inhibitor O I-Chemical 0.9812355041503906
( O O 0.9686185717582703
statin B-Chemical B-Chemical 0.9755133390426636
) O O 0.867651104927063
therapy O O 0.999832272529602
. O O 0.9999998807907104

After O O 0.9999386072158813
verifying O O 0.9998866319656372
the O O 0.9996964931488037
epidural O O 0.8750416040420532
space O O 0.9977649450302124
, O O 0.9999722242355347
bupivacaine B-Chemical B-Chemical 0.9996665716171265
and O O 0.9966117739677429
triamcinolone B-Chemical B-Chemical 0.9998589754104614
diacetate I-Chemical O 0.5954506993293762
were O O 0.9999725818634033
injected O O 0.9993403553962708
. O O 0.9999996423721313

On O O 0.9997803568840027
the O O 0.9999557733535767
other O O 0.9999973773956299
hand O O 0.9999909400939941
, O O 0.9999973773956299
pretreatment O O 0.9989996552467346
with O O 0.9999048709869385
p B-Chemical B-Chemical 0.7253667116165161
- I-Chemical I-Chemical 0.9910895824432373
chlorophenylalamine I-Chemical I-Chemical 0.9903337359428406
( O O 0.999283492565155
3 O O 0.5638916492462158
X O O 0.7182894945144653
320 O O 0.9606980681419373
mg O O 0.999638557434082
/ O O 0.9999942779541016
kg O O 0.999948263168335
i O O 0.9999798536300659
. O O 0.9999829530715942
p O O 0.9998447895050049
. O O 0.9999815225601196
, O O 0.9999152421951294
24 O O 0.9989712238311768
hr O O 0.9941866397857666
) O O 0.9998807907104492
, O O 0.9999982118606567
a O O 0.9994245767593384
serotonin B-Chemical B-Chemical 0.9844282865524292
depletor O O 0.43900638818740845
, O O 0.9999582767486572
caused O O 0.9999954700469971
no O O 0.999991774559021
significant O O 0.9999697208404541
change O O 0.999213695526123
in O O 0.9999346733093262
the O O 0.9988297820091248
hyperactivity B-Disease B-Disease 0.9971562623977661
. O O 0.999921441078186

Prenatal O O 0.920109212398529
exposure O O 0.9891567230224609
to O O 0.9999886751174927
selective O O 0.9830743670463562
COX O O 0.7765421271324158
- O O 0.9976310729980469
2 O O 0.9949901700019836
inhibitors O O 0.9986248016357422
does O O 0.9999958276748657
not O O 0.9999287128448486
increase O O 0.999890923500061
the O O 0.9998617172241211
risk O O 0.9999743700027466
of O O 0.9999831914901733
ventricular B-Disease B-Disease 0.8674241304397583
septal I-Disease I-Disease 0.9345257878303528
and I-Disease I-Disease 0.8914479613304138
midline I-Disease I-Disease 0.9705586433410645
defects I-Disease I-Disease 0.9998753070831299
in O O 0.976780891418457
rat O O 0.9954245686531067
when O O 0.9999868869781494
compared O O 0.9999126195907593
to O O 0.9999700784683228
non O O 0.987011194229126
- O O 0.9991208910942078
selective O O 0.9481143951416016
drugs O O 0.9715947508811951
and O O 0.9999098777770996
historic O O 0.9827455878257751
control O O 0.9895301461219788
. O O 0.9999997615814209

This O O 0.9992056488990784
method O O 0.9993295669555664
allowed O O 0.9999173879623413
frequent O O 0.9984294772148132
self O O 0.9982439279556274
- O O 0.9995301961898804
dosing O O 0.9977132081985474
of O O 0.9985243678092957
pethidine B-Chemical B-Chemical 0.9999624490737915
at O O 0.9999915361404419
short O O 0.9995332956314087
time O O 0.9998119473457336
intervals O O 0.9997151494026184
and O O 0.9999972581863403
rapid O O 0.9955317974090576
accumulation O O 0.9691804647445679
of O O 0.9963621497154236
pethidine B-Chemical B-Chemical 0.9999397993087769
and O O 0.9959718585014343
norpethidine B-Chemical B-Chemical 0.9999244213104248
. O O 0.9999918937683105

Other O O 0.999840497970581
antibacterial O O 0.9950106143951416
agents O O 0.9754848480224609
that O O 0.9999854564666748
showed O O 0.9999624490737915
associations O O 0.9900044798851013
included O O 0.9999610185623169
erythromycins B-Chemical B-Disease 0.7634310722351074
( O O 0.9963920712471008
2 O O 0.9776575565338135
defects O O 0.7015119194984436
) O O 0.9453451633453369
, O O 0.999946117401123
penicillins B-Chemical B-Disease 0.4825724959373474
( O O 0.9832825660705566
1 O O 0.943181574344635
defect O O 0.8609206676483154
) O O 0.827998697757721
, O O 0.9996656179428101
cephalosporins B-Chemical B-Chemical 0.7103568315505981
( O O 0.997564435005188
1 O O 0.942283570766449
defect O O 0.6794306635856628
) O O 0.8600661754608154
, O O 0.9995673298835754
and O O 0.9991023540496826
quinolones B-Chemical B-Disease 0.5585594177246094
( O O 0.9930598735809326
1 O O 0.980246365070343
defect O O 0.8365892767906189
) O O 0.9976678490638733
. O O 0.9999994039535522

Effect O O 0.999672532081604
of O O 0.9996845722198486
adriamycin B-Chemical B-Chemical 0.9998928308486938
combined O O 0.9995844960212708
with O O 0.999976634979248
whole O O 0.9985243678092957
body O O 0.9952249526977539
hyperthermia B-Disease B-Disease 0.991960346698761
on O O 0.994885265827179
tumor B-Disease B-Disease 0.998822033405304
and O O 0.9982267022132874
normal O O 0.9917499423027039
tissues O O 0.9712445139884949
. O O 0.9999997615814209

However O O 0.9999091625213623
, O O 0.9999980926513672
the O O 0.9999780654907227
occurrence O O 0.999974250793457
of O O 0.9999967813491821
central O O 0.9995571970939636
adverse O O 0.9910939335823059
effects O O 0.9966897964477539
should O O 0.9999986886978149
be O O 0.9999902248382568
taken O O 0.9999884366989136
into O O 0.9999910593032837
account O O 0.9999613761901855
, O O 0.9999992847442627
especially O O 0.9999840259552002
when O O 0.9999545812606812
using O O 0.9998144507408142
higher O O 0.9970532655715942
doses O O 0.9993360638618469
. O O 0.9999997615814209

Infarct B-Disease O 0.47789305448532104
- O O 0.9374070167541504
avid O O 0.9729593992233276
radiopharmaceuticals O O 0.994212806224823
are O O 0.9999985694885254
necessary O O 0.9999988079071045
for O O 0.9999980926513672
rapid O O 0.998891294002533
and O O 0.9998635053634644
timely O O 0.9999074935913086
diagnosis O O 0.9998384714126587
of O O 0.9999935626983643
acute O B-Disease 0.7105690240859985
myocardial B-Disease I-Disease 0.5761213898658752
infarction I-Disease I-Disease 0.9999523162841797
. O O 0.9998985528945923

Of O O 0.9999772310256958
those O O 0.9999982118606567
positive O O 0.999997615814209
for O O 0.9999852180480957
p24 O O 0.9220703840255737
antigen O O 0.4639034867286682
at O O 0.9999958276748657
the O O 0.999990701675415
commencement O O 0.9999736547470093
of O O 0.9999942779541016
the O O 0.9999841451644897
study O O 0.9999896287918091
67 O O 0.9999865293502808
% O O 0.9999982118606567
showed O O 0.9999964237213135
a O O 0.999742329120636
positive O O 0.9991689920425415
response O O 0.9998427629470825
, O O 0.9999983310699463
and O O 0.999968409538269
this O O 0.9998587369918823
was O O 0.9999977350234985
most O O 0.999990701675415
likely O O 0.9999940395355225
in O O 0.9999986886978149
those O O 0.9999940395355225
with O O 0.9999676942825317
CD4 O O 0.4270819127559662
+ O O 0.9988821148872375
lymphocyte O O 0.6921606659889221
subset O O 0.996906578540802
counts O O 0.9997664093971252
above O O 0.9999150037765503
100 O O 0.9997114539146423
mm3 O O 0.9995372295379639
. O O 0.9999992847442627

CONCLUSIONS O O 0.9996728897094727
: O O 0.9999994039535522
We O O 0.9999935626983643
conclude O O 0.9999991655349731
that O O 0.9999810457229614
in O O 0.9999548196792603
transplants O O 0.9993025064468384
, O O 0.9999996423721313
there O O 0.9999991655349731
is O O 0.9999996423721313
a O O 0.9999841451644897
strong O O 0.9997329115867615
association O O 0.9996237754821777
between O O 0.9999840259552002
well O O 0.9898305535316467
- O O 0.9990703463554382
developed O O 0.9996558427810669
PTCR O O 0.48638617992401123
and O O 0.990506112575531
TG B-Disease B-Disease 0.9288458228111267
, O O 0.9989618062973022
while O O 0.9999984502792358
the O O 0.9999839067459106
significance O O 0.9999228715896606
of O O 0.9999381303787231
mild O O 0.9992668032646179
PTCR O O 0.7908104658126831
and O O 0.981590747833252
its O O 0.9997974038124084
predictive O O 0.9996436834335327
value O O 0.997721254825592
in O O 0.9999994039535522
the O O 0.9999843835830688
absence O O 0.9990876913070679
of O O 0.9997261166572571
TG B-Disease B-Disease 0.9693670868873596
is O O 0.9996485710144043
unclear O O 0.9998883008956909
. O O 0.9999997615814209

TRI B-Chemical B-Chemical 0.8668331503868103
given O O 0.9993013143539429
repeatedly O O 0.998885452747345
to O O 0.9999014139175415
rats O O 0.9899882674217224
increases O O 0.9995909333229065
the O O 0.999355137348175
locomotor O B-Disease 0.7179296016693115
hyperactivity B-Disease I-Disease 0.8519421815872192
induced O O 0.9879549741744995
by O O 0.9979698061943054
d B-Chemical B-Chemical 0.8759268522262573
- I-Chemical I-Chemical 0.9977768063545227
amphetamine I-Chemical I-Chemical 0.9980517625808716
, O O 0.9829756617546082
quinpirole B-Chemical B-Chemical 0.9999032020568848
and O O 0.9993200302124023
( O B-Chemical 0.5116351842880249
+ O I-Chemical 0.9110414981842041
) O I-Chemical 0.9757552742958069
- O I-Chemical 0.9645642638206482
7 O I-Chemical 0.35231125354766846
- O I-Chemical 0.8964278697967529
hydroxy O I-Chemical 0.999085545539856
- O I-Chemical 0.8568295240402222
dipropyloaminotetralin O I-Chemical 0.9585574865341187
( O O 0.9975922107696533
dopamine B-Chemical B-Chemical 0.9999735355377197
D2 O O 0.6326775550842285
and O O 0.9994314312934875
D3 O O 0.8868792057037354
effects O O 0.9999279975891113
) O O 0.9999256134033203
. O O 0.9999995231628418

Haloperidol B-Chemical B-Chemical 0.998474657535553
administration O O 0.9987572431564331
( O O 0.999997615814209
one O O 0.9999126195907593
dose O O 0.9999662637710571
of O O 0.9999579191207886
12 O O 0.9995313882827759
mg O O 0.9998212456703186
/ O O 0.9999836683273315
kg O O 0.9998676776885986
once O O 0.9999991655349731
a O O 0.9999728202819824
week O O 0.9998911619186401
s O O 0.9998162388801575
. O O 0.999982476234436
c O O 0.9994204044342041
. O O 0.9999854564666748
) O O 0.9998561143875122
for O O 0.999964714050293
4 O O 0.9994691014289856
weeks O O 0.9998843669891357
caused O O 0.9999946355819702
an O O 0.9999223947525024
increase O O 0.9764724373817444
in O O 0.9941971302032471
vacuous O O 0.9915866851806641
chewing O O 0.8642303943634033
, O O 0.9992696642875671
tongue O O 0.9595363140106201
protrusion O O 0.9678437113761902
and O O 0.999975323677063
duration O O 0.9952204823493958
of O O 0.9998311996459961
facial O B-Disease 0.9298635721206665
twitching O I-Disease 0.8696489930152893
observed O O 0.9884405136108398
in O O 0.9999902248382568
four O O 0.9998899698257446
weekly O O 0.9974806904792786
evaluations O O 0.9994947910308838
. O O 1.0

The O O 0.9964390397071838
timolol B-Chemical B-Chemical 0.999951958656311
- O O 0.9952076077461243
treated O O 0.9998223185539246
patients O O 0.999983549118042
showed O O 0.9999997615814209
a O O 0.9998989105224609
small O O 0.9993163347244263
but O O 0.9999760389328003
significant O O 0.999786913394928
increase O O 0.8346297144889832
in O O 0.9242848753929138
heart O O 0.5947091579437256
size O O 0.8937986493110657
from O O 0.9498408436775208
baseline O O 0.7655946016311646
in O O 0.9998596906661987
contrast O O 0.9999884366989136
to O O 0.9999985694885254
a O O 0.998354971408844
decrease O O 0.9801915884017944
in O O 0.999755322933197
the O O 0.9995052814483643
placebo O O 0.9980485439300537
group O O 0.99912029504776
. O O 0.9999996423721313

To O O 0.9999585151672363
determine O O 0.9999973773956299
if O O 0.9999871253967285
the O O 0.9998985528945923
addition O O 0.9999425411224365
of O O 0.999948263168335
a O O 0.9953761100769043
buffering O O 0.693286657333374
solution O O 0.9996089339256287
to O O 0.9999904632568359
adjust O O 0.9993014335632324
the O O 0.9966371059417725
pH O O 0.9689844846725464
of O O 0.9970007538795471
lidocaine B-Chemical B-Chemical 0.9999943971633911
into O O 0.9998915195465088
the O O 0.9997836947441101
physiologic O O 0.9661144018173218
range O O 0.9996863603591919
would O O 0.9999986886978149
reduce O O 0.9983835220336914
pain B-Disease B-Disease 0.9998724460601807
during O O 0.9999507665634155
injection O O 0.9965605139732361
, O O 0.9999959468841553
we O O 0.9999436140060425
performed O O 0.9999983310699463
a O O 0.9998407363891602
blinded O O 0.9956967830657959
randomized O O 0.994025707244873
study O O 0.9997597336769104
in O O 0.9999988079071045
patients O O 0.9999986886978149
undergoing O O 0.9999853372573853
cardiac O O 0.8723496198654175
catheterization O O 0.88723224401474
. O O 0.9999353885650635

For O O 0.9999657869338989
both O O 0.9996682405471802
experiments O O 0.9992812275886536
the O O 0.9999613761901855
drug O O 0.9674777984619141
intake O O 0.9994480013847351
led O O 0.9999814033508301
to O O 0.9999982118606567
significant O O 0.999754011631012
increases O O 0.9212830066680908
in O O 0.8837434649467468
PRL O O 0.5093753337860107
secretion O O 0.7329182028770447
, O O 0.9999845027923584
acting O O 0.9996339082717896
preferentially O O 0.9997163414955139
on O O 0.9999321699142456
tonic O O 0.9961024522781372
secretion O O 0.9938749670982361
as O O 0.9999946355819702
pulse O O 0.6542792916297913
amplitude O O 0.5004334449768066
and O O 0.998175859451294
frequency O O 0.999407172203064
did O O 0.9999991655349731
not O O 0.9999896287918091
differ O O 0.9999995231628418
significantly O O 0.999994158744812
from O O 0.999966025352478
corresponding O O 0.9975714087486267
control O O 0.9886326193809509
values O O 0.9967663288116455
. O O 0.9999998807907104

Hydrocortisone B-Chemical B-Chemical 0.9982695579528809
acetate I-Chemical I-Chemical 0.9956562519073486
( O O 0.9996609687805176
50 O O 0.9992308616638184
mg O O 0.9982060194015503
) O O 0.9998013377189636
was O O 0.999968409538269
given O O 0.9999853372573853
orally O O 0.9998101592063904
every O O 0.9999980926513672
6 O O 0.9997815489768982
hours O O 0.999947190284729
for O O 0.9999974966049194
24 O O 0.9998028874397278
hours O O 0.9999631643295288
after O O 0.999998927116394
a O O 0.9998315572738647
5 O O 0.9962336421012878
- O O 0.9996402263641357
day O O 0.9998761415481567
fixed O O 0.9992309808731079
- O O 0.9972068667411804
salt O O 0.8656852841377258
diet O O 0.9897037148475647
( O O 0.9999984502792358
150 O O 0.9999586343765259
mmol O O 0.9991733431816101
/ O O 0.9999936819076538
d O O 0.9998661279678345
) O O 0.9998194575309753
. O O 0.9999995231628418

The O O 0.9996253252029419
normalized O O 0.9671952128410339
reflex O O 0.7132932543754578
amplitude O O 0.6186637878417969
increased O O 0.9997047781944275
with O O 0.9999823570251465
an O O 0.9998470544815063
increase O O 0.9782589673995972
in O O 0.9738309383392334
velocity O O 0.43387365341186523
at O O 0.9999696016311646
a O O 0.9999018907546997
given O O 0.999629020690918
displacement O O 0.973909318447113
, O O 0.9999959468841553
but O O 0.9999842643737793
remained O O 0.9998637437820435
constant O O 0.9994838237762451
with O O 0.9999942779541016
different O O 0.9993294477462769
displacements O O 0.7750335931777954
at O O 0.9999910593032837
a O O 0.9998419284820557
given O O 0.9997441172599792
velocity O O 0.98860102891922
. O O 0.9999998807907104

All O O 0.9989014863967896
four O O 0.999783456325531
agents O O 0.9928262233734131
were O O 0.9999840259552002
associated O O 0.9999977350234985
with O O 0.999909520149231
aortic O O 0.9964985847473145
arch O O 0.9749676585197449
branching O O 0.992565393447876
variants O O 0.9996080994606018
, O O 0.9999939203262329
although O O 0.9999954700469971
significantly O O 0.999980092048645
increased O O 0.9991342425346375
only O O 0.9998698234558105
for O O 0.999461829662323
Ro B-Chemical B-Chemical 0.9943975210189819
40 I-Chemical I-Chemical 0.8575693368911743
- I-Chemical I-Chemical 0.9905883073806763
5967 I-Chemical I-Chemical 0.9999483823776245
and O O 0.9929744005203247
verapamil B-Chemical B-Chemical 0.9993237257003784
. O O 0.9999768733978271

Pretreatment O O 0.9934926629066467
of O O 0.9990018010139465
TCR B-Chemical B-Chemical 0.9206525087356567
, O O 0.999553382396698
at O O 0.9999985694885254
a O O 0.9998109936714172
dose O O 0.999990701675415
of O O 0.9999778270721436
0 O O 0.9972522854804993
. O O 0.9999973773956299
5 O O 0.9999126195907593
mL O O 0.9997510313987732
/ O O 0.9999923706054688
100 O O 0.9999363422393799
g O O 0.9995515942573547
bodyweight O O 0.9760417938232422
per O O 0.9998924732208252
day O O 0.9999537467956543
, O O 0.9999940395355225
orally O O 0.9992614388465881
for O O 0.9999884366989136
30 O O 0.9997900128364563
days O O 0.9999910593032837
, O O 0.9999997615814209
prevented O O 0.999968409538269
the O O 0.9996190071105957
increase O O 0.931330144405365
in O O 0.9658017158508301
lipid O O 0.8940707445144653
peroxidation O O 0.7148200869560242
and O O 0.9998458623886108
activity O O 0.9968222379684448
of O O 0.9995094537734985
marker O O 0.9596982002258301
enzymes O O 0.9870786666870117
observed O O 0.9999831914901733
in O O 0.9997759461402893
isoproterenol B-Chemical B-Chemical 0.9999557733535767
- O O 0.9823383092880249
induced O O 0.9986240863800049
rats O O 0.9913977384567261
( O O 0.9999971389770508
85 O O 0.999835729598999
mg O O 0.9999305009841919
kg O O 0.9994940757751465
( O O 0.999958872795105
- O O 0.999626636505127
1 O O 0.9993322491645813
) O O 0.9997522234916687
s O O 0.9996579885482788
. O O 0.9999939203262329
c O O 0.9992741942405701
. O O 0.9999924898147583
for O O 0.9999908208847046
2 O O 0.999305009841919
days O O 0.9999823570251465
at O O 0.9999994039535522
an O O 0.9999692440032959
interval O O 0.9997391104698181
of O O 0.9999935626983643
24 O O 0.9998490810394287
h O O 0.9986918568611145
) O O 0.9999417066574097
. O O 0.9999992847442627

Gall O B-Disease 0.5023981332778931
bladder O I-Disease 0.9728168845176697
bile O I-Disease 0.9961620569229126
was O O 0.9930049777030945
obtained O O 0.9999403953552246
by O O 0.9999897480010986
ultrasound O O 0.9954084753990173
guided O O 0.9988941550254822
, O O 0.9999876022338867
fine O O 0.9975050091743469
needle O O 0.9914284348487854
puncture O O 0.8752080202102661
from O O 0.9999303817749023
six O O 0.9986005425453186
patients O O 0.9999836683273315
. O O 0.9999998807907104

Immunological O O 0.9557480216026306
activation O O 0.6808801889419556
has O O 0.9999533891677856
been O O 0.9999536275863647
proposed O O 0.9999785423278809
to O O 0.9999889135360718
play O O 0.9999608993530273
a O O 0.9999727010726929
role O O 0.9998465776443481
in O O 0.9998677968978882
methamphetamine B-Chemical B-Chemical 0.9999127388000488
- O O 0.9977793097496033
induced O O 0.9999524354934692
dopaminergic B-Disease O 0.6790950298309326
terminal I-Disease O 0.9851251840591431
damage I-Disease O 0.9446303844451904
. O O 0.9999566078186035

Interaction O O 0.996228814125061
of O O 0.9996439218521118
cyclosporin B-Chemical B-Chemical 0.9980536699295044
A I-Chemical I-Chemical 0.9976015686988831
with O O 0.9995193481445312
antineoplastic O O 0.935303270816803
agents O O 0.9646981358528137
. O O 0.9999995231628418

This O O 0.9999368190765381
study O O 0.9999866485595703
assessed O O 0.9999806880950928
the O O 0.9996316432952881
ability O O 0.9988548755645752
of O O 0.9998782873153687
IH636 B-Chemical B-Chemical 0.7603241205215454
grape I-Chemical I-Chemical 0.6595265865325928
seed I-Chemical I-Chemical 0.7039424777030945
proanthocyanidin I-Chemical I-Chemical 0.9761154055595398
extract I-Chemical I-Chemical 0.9964027404785156
( O O 0.9923991560935974
GSPE B-Chemical O 0.715753972530365
) O O 0.9984226226806641
to O O 0.999980092048645
prevent O O 0.9992483258247375
acetaminophen B-Chemical B-Chemical 0.9967568516731262
( O O 0.9978775978088379
AAP B-Chemical B-Chemical 0.9996389150619507
) O O 0.9755943417549133
- O O 0.9995591044425964
induced O O 0.9994118213653564
nephrotoxicity B-Disease B-Disease 0.9994912147521973
, O O 0.9995964169502258
amiodarone B-Chemical B-Chemical 0.9998376369476318
( O O 0.9993600249290466
AMI B-Chemical B-Chemical 0.9989175796508789
) O O 0.9904511570930481
- O O 0.9998883008956909
induced O O 0.9998393058776855
lung B-Disease B-Disease 0.5200576186180115
toxicity I-Disease I-Disease 0.9990326166152954
, O O 0.9985132813453674
and O O 0.9997640252113342
doxorubicin B-Chemical B-Chemical 0.9981368780136108
( O O 0.9966967105865479
DOX B-Chemical B-Chemical 0.9998501539230347
) O O 0.9847784638404846
- O O 0.9999033212661743
induced O O 0.9998370409011841
cardiotoxicity B-Disease B-Disease 0.9996353387832642
in O O 0.9995606541633606
mice O O 0.9995459914207458
. O O 0.9999997615814209

4 O O 0.804810643196106
. O O 0.9999712705612183

DISCUSSION O O 0.9994930028915405
: O O 0.9999964237213135
Cholestatic B-Disease B-Disease 0.5525563955307007
hepatitis I-Disease I-Disease 0.9666315913200378
is O O 0.9997783303260803
a O O 0.9998321533203125
rare O O 0.9996123909950256
complication O O 0.9889361262321472
of O O 0.9999089241027832
the O O 0.9993475079536438
antiplatelet O O 0.8846015334129333
agent O O 0.9453108310699463
ticlopidine B-Chemical B-Chemical 0.9999730587005615
; O O 0.9999935626983643
several O O 0.9999932050704956
cases O O 0.9998210072517395
have O O 0.9999990463256836
been O O 0.9999359846115112
reported O O 0.9999926090240479
but O O 0.9999983310699463
few O O 0.9999841451644897
in O O 0.9999942779541016
the O O 0.999729573726654
English O O 0.9873818755149841
literature O O 0.9986525177955627
. O O 0.9999998807907104

The O O 0.9999399185180664
results O O 0.9999579191207886
show O O 0.9999984502792358
that O O 0.9999606609344482
pretreatment O O 0.9983676075935364
with O O 0.9999121427536011
TCR B-Chemical B-Chemical 0.9700725078582764
may O O 0.9999637603759766
be O O 0.9999935626983643
useful O O 0.9999750852584839
in O O 0.9999583959579468
preventing O O 0.9999701976776123
the O O 0.9996547698974609
damage O O 0.5383383631706238
induced O O 0.9982337951660156
by O O 0.9996511936187744
isoproterenol B-Chemical B-Chemical 0.9999810457229614
in O O 0.9997938275337219
rat O O 0.9978354573249817
heart O O 0.9987873435020447
. O O 0.9999994039535522

The O O 0.999916672706604
other O O 0.9997766613960266
proteins O O 0.978840708732605
showed O O 0.9999992847442627
few O O 0.9999862909317017
changes O O 0.9971120357513428
, O O 0.9999884366989136
which O O 0.9999645948410034
were O O 0.9999806880950928
limited O O 0.999749481678009
to O O 0.9999845027923584
diseased O O 0.9331215620040894
areas O O 0.9982731342315674
. O O 0.9999996423721313

Therefore O O 0.9999551773071289
, O O 0.999996542930603
we O O 0.999943733215332
studied O O 0.9999700784683228
the O O 0.9995989203453064
hyperemic O B-Disease 0.9970856308937073
response O O 0.9808419942855835
to O O 0.9999687671661377
dipyridamole B-Chemical B-Chemical 0.9995467066764832
in O O 0.9999551773071289
seven O O 0.9998840093612671
open O O 0.9992479681968689
- O O 0.9998583793640137
chest O O 0.9973056316375732
anesthetized O O 0.8077206611633301
dogs O O 0.8164821863174438
after O O 0.999992847442627
pretreatment O O 0.9989495873451233
with O O 0.9999637603759766
either O O 0.9799514412879944
pentoxifylline B-Chemical B-Chemical 0.9999750852584839
( O O 0.9975503087043762
0 O O 0.9536835551261902
, O O 0.9932234287261963
7 O O 0.9854527115821838
. O O 0.9997490048408508
5 O O 0.9983727931976318
, O O 0.9999405145645142
or O O 0.999994158744812
15 O O 0.999901294708252
mg O O 0.9999376535415649
/ O O 0.9999934434890747
kg O O 0.9999294281005859
i O O 0.9999622106552124
. O O 0.9999793767929077
v O O 0.9997517466545105
. O O 0.9996126294136047
) O O 0.998735249042511
or O O 0.9994122982025146
theophylline B-Chemical B-Chemical 0.9999775886535645
( O O 0.9998667240142822
3 O O 0.9994843006134033
mg O O 0.9999066591262817
/ O O 0.9999922513961792
kg O O 0.9999269247055054
i O O 0.9999856948852539
. O O 0.9999946355819702
v O O 0.9999829530715942
. O O 0.9999744892120361
) O O 0.9998898506164551
. O O 0.9999958276748657

Hyperkalemia B-Disease B-Disease 0.9781748056411743
has O O 0.999180018901825
recently O O 0.9999951124191284
been O O 0.9999798536300659
recognized O O 0.9999977350234985
as O O 0.9999991655349731
a O O 0.9998327493667603
complication O O 0.9774076342582703
of O O 0.9995540976524353
nonsteroidal O O 0.940734326839447
antiinflammatory O O 0.8677698373794556
agents O O 0.5509462952613831
( O O 0.9999569654464722
NSAID O O 0.5525439381599426
) O O 0.9970983266830444
such O O 0.9999794960021973
as O O 0.999731719493866
indomethacin B-Chemical B-Chemical 0.995083749294281
. O O 0.9999499320983887

Subsequent O O 0.9992691874504089
amantadine B-Chemical B-Chemical 0.9999779462814331
treatments O O 0.998197615146637
produced O O 0.9999945163726807
enhancement O O 0.9024760723114014
of O O 0.7416081428527832
motility O O 0.9489520192146301
from O O 0.9958135485649109
corresponding O O 0.9958743453025818
control O O 0.9916566610336304
in O O 0.9999918937683105
all O O 0.9995625615119934
mouse O O 0.9897567629814148
strains O O 0.988874077796936
with O O 0.9999984502792358
the O O 0.999535083770752
BALB O O 0.9378401637077332
/ O O 0.9998239874839783
C O O 0.9634228944778442
mice O O 0.9970683455467224
being O O 0.9998378753662109
the O O 0.9999724626541138
least O O 0.9999793767929077
sensitive O O 0.9991469383239746
. O O 0.9999996423721313

In O O 0.9999839067459106
addition O O 0.9999750852584839
, O O 0.9999988079071045
the O O 0.9999147653579712
effect O O 0.999997615814209
of O O 0.9999850988388062
the O O 0.9996585845947266
specific O O 0.9867218732833862
endothelin O B-Chemical 0.980074405670166
type O O 0.47797632217407227
A O O 0.4771246016025543
receptor O O 0.9930166006088257
antagonist O O 0.9834432005882263
FR B-Chemical B-Chemical 0.9414938688278198
139317 I-Chemical I-Chemical 0.9985055923461914
on O O 0.9946224689483643
FK B-Chemical B-Chemical 0.9995042085647583
506 I-Chemical I-Chemical 0.9987964630126953
- O O 0.9883434772491455
induced O O 0.9997907280921936
hypertension B-Disease B-Disease 0.9999035596847534
in O O 0.9991070628166199
rats O O 0.9995303153991699
was O O 0.9999871253967285
studied O O 0.9998693466186523
. O O 0.9999997615814209

This O O 0.9994344115257263
effect O O 0.9999548196792603
was O O 0.9999982118606567
more O O 0.9999345541000366
relevant O O 0.9993067979812622
in O O 0.9999967813491821
patients O O 0.9999771118164062
treated O O 0.9999929666519165
with O O 0.9999934434890747
higher O O 0.9962092638015747
doses O O 0.9974814057350159
. O O 0.9999995231628418

Nevertheless O O 0.9999648332595825
, O O 0.9999852180480957
there O O 0.9999845027923584
occurs O O 0.9999948740005493
some O O 0.9999979734420776
real O O 0.9998984336853027
tolerance O O 0.9987049102783203
to O O 0.9999977350234985
this O O 0.9997920393943787
effect O O 0.9999854564666748
. O O 0.9999992847442627

The O O 0.999782145023346
stimulant O O 0.9731444120407104
action O O 0.997775137424469
of O O 0.9992319345474243
nicotine B-Chemical B-Chemical 0.9999885559082031
was O O 0.999705970287323
blocked O O 0.9994677901268005
by O O 0.9999969005584717
the O O 0.9996170997619629
central O O 0.9975863695144653
nicotinic O O 0.7254168391227722
antagonist O O 0.9821687340736389
mecamylamine B-Chemical B-Chemical 0.9999222755432129
but O O 0.9997956156730652
not O O 0.9999895095825195
by O O 0.9999971389770508
the O O 0.9998003840446472
peripheral O O 0.9846025705337524
nicotinic O O 0.8613221049308777
blocker O O 0.9745054244995117
hexamethonium B-Chemical B-Chemical 0.9920247793197632
, O O 0.9998769760131836
indicating O O 0.9999916553497314
that O O 0.9999575614929199
the O O 0.9995071887969971
response O O 0.9997853636741638
is O O 0.9999878406524658
probably O O 0.9999630451202393
mediated O O 0.999858021736145
by O O 0.9999924898147583
central O O 0.999114453792572
nicotinic O O 0.6164156198501587
receptors O O 0.9981074333190918
. O O 0.9999995231628418

Diabetic B-Disease B-Disease 0.9685364961624146
rats O O 0.5928919911384583
progressively O O 0.9993451237678528
developed O O 0.9996570348739624
albuminuria B-Disease B-Disease 0.9997466206550598
reaching O O 0.9979015588760376
40 O O 0.9970009922981262
. O O 0.9999744892120361
3 O O 0.9982306361198425
( O O 0.9999943971633911
32 O O 0.9998044371604919
. O O 0.9999788999557495
2 O O 0.9994444251060486
- O O 0.9993164539337158
62 O O 0.9980916380882263
. O O 0.9999819993972778
0 O O 0.9993048906326294
) O O 0.9997726082801819
mg O O 0.999440610408783
/ O O 0.9999759197235107
24 O O 0.9998041987419128
h O O 0.9966572523117065
after O O 0.9999911785125732
8 O O 0.9996646642684937
months O O 0.9999327659606934
in O O 0.9999954700469971
contrast O O 0.9999271631240845
to O O 0.9999765157699585
the O O 0.9994109869003296
control O O 0.9911934733390808
animals O O 0.9647036790847778
( O O 0.9999805688858032
0 O O 0.9996993541717529
. O O 0.9999637603759766
8 O O 0.9978645443916321
( O O 0.9999903440475464
0 O O 0.9998708963394165
. O O 0.999985933303833
2 O O 0.9997606873512268
- O O 0.9997777342796326
0 O O 0.9995719790458679
. O O 0.9999650716781616
9 O O 0.9993477463722229
) O O 0.9998784065246582
mg O O 0.9997038245201111
/ O O 0.9999881982803345
24 O O 0.9999412298202515
h O O 0.9987560510635376
, O O 0.9999614953994751
p O O 0.9994277358055115
< O O 0.9999746084213257
0 O O 0.9996743202209473
. O O 0.999987006187439
002 O O 0.9932990074157715
) O O 0.9999125003814697
. O O 0.9999988079071045

RESULTS O O 0.9989472031593323
: O O 0.9999971389770508
Nine O O 0.999966025352478
of O O 0.9999946355819702
30 O O 0.9999721050262451
patients O O 0.9999538660049438
receiving O O 0.9999808073043823
lidocaine B-Chemical B-Chemical 0.999993085861206
experienced O O 0.9998819828033447
TNSs B-Disease B-Disease 0.9851956367492676
, O O 0.9992432594299316
1 O O 0.9995222091674805
of O O 0.9999901056289673
30 O O 0.9999136924743652
patients O O 0.9999128580093384
receiving O O 0.9999716281890869
prilocaine B-Chemical B-Chemical 0.999862790107727
( O O 0.9997411370277405
P O O 0.8321396112442017
= O O 0.9997714161872864
0 O O 0.9988466501235962
. O O 0.9999854564666748
03 O O 0.9977320432662964
) O O 0.9998631477355957
had O O 0.999990701675415
them O O 0.998812198638916
, O O 0.9999979734420776
and O O 0.9999971389770508
none O O 0.9999970197677612
of O O 0.9999963045120239
30 O O 0.9999254941940308
patients O O 0.9999628067016602
receiving O O 0.9999657869338989
bupivacaine B-Chemical B-Chemical 0.999924898147583
had O O 0.9999134540557861
TNSs B-Disease B-Disease 0.9041154980659485
. O O 0.9991663694381714

Jaundice B-Disease B-Disease 0.9654178023338318
disappeared O O 0.9277614951133728
within O O 0.9998362064361572
3 O O 0.9991944432258606
months O O 0.9998977184295654
but O O 0.9999924898147583
was O O 0.9999257326126099
followed O O 0.9999970197677612
by O O 0.9999983310699463
prolonged O O 0.9988787770271301
anicteric O O 0.9311438798904419
cholestasis B-Disease B-Disease 0.6935111284255981
marked O O 0.9986714124679565
by O O 0.9998557567596436
pruritus B-Disease B-Chemical 0.8950383067131042
and O O 0.9998165965080261
high O O 0.9982665777206421
levels O O 0.9996103644371033
of O O 0.9996547698974609
alkaline O B-Chemical 0.9500957131385803
phosphatase O O 0.5563653707504272
and O O 0.9997633099555969
gammaglutamyltransferase O O 0.5196613669395447
activities O O 0.994721531867981
. O O 0.9999997615814209

Synthesis O O 0.8073869943618774
of O O 0.9991176724433899
N B-Chemical B-Chemical 0.9743084907531738
- I-Chemical I-Chemical 0.9891891479492188
pyrimidinyl I-Chemical I-Chemical 0.9987558126449585
- I-Chemical I-Chemical 0.9211915731430054
2 I-Chemical I-Chemical 0.9939019680023193
- I-Chemical I-Chemical 0.9805780649185181
phenoxyacetamides I-Chemical I-Chemical 0.9995284080505371
as O O 0.9981452226638794
adenosine B-Chemical B-Chemical 0.9843686819076538
A2A O O 0.7542332410812378
receptor O O 0.98285311460495
antagonists O O 0.9966189861297607
. O O 0.9999997615814209

In O O 0.9999946355819702
the O O 0.999990701675415
present O O 0.9999942779541016
study O O 0.9999971389770508
, O O 0.9999995231628418
we O O 0.999872088432312
have O O 0.9999964237213135
investigated O O 0.9999833106994629
the O O 0.9997774958610535
molecular O O 0.9765986204147339
mechanisms O O 0.9764513969421387
by O O 0.9999990463256836
which O O 0.9999949932098389
female O O 0.9971721768379211
hormones O O 0.9871912002563477
influence O O 0.9995792508125305
cholesterol B-Chemical B-Chemical 0.9997729659080505
metabolism O O 0.963495135307312
in O O 0.999977707862854
macrophages O O 0.9690555334091187
in O O 0.9999964237213135
response O O 0.9999818801879883
to O O 0.999997615814209
the O O 0.99930739402771
HIV O O 0.7903379201889038
protease O O 0.7532023191452026
inhibitor O O 0.9939879179000854
ritonavir B-Chemical B-Chemical 0.9994181394577026
. O O 0.9999804496765137

Flow O O 0.8785194754600525
and O O 0.9995505213737488
metabolism O O 0.9500723481178284
were O O 0.9999991655349731
measured O O 0.9999302625656128
5 O O 0.9989456534385681
- O O 0.9997591376304626
13 O O 0.9999136924743652
days O O 0.9999984502792358
after O O 0.9999991655349731
the O O 0.9998652935028076
subarachnoid B-Disease O 0.6320890784263611
haemorrhage I-Disease B-Disease 0.8044905662536621
by O O 0.9999924898147583
a O O 0.9997833371162415
modification O O 0.9997442364692688
of O O 0.999868631362915
the O O 0.9990680813789368
classical O O 0.9753261804580688
Kety O O 0.9361940622329712
- O O 0.9987254738807678
Schmidt O O 0.8382670283317566
technique O O 0.9997135996818542
using O O 0.9999278783798218
xenon B-Chemical O 0.8688543438911438
- O O 0.5370931029319763
133 O O 0.7939249873161316
i O O 0.9645508527755737
. O O 0.9999436140060425
v O O 0.9974990487098694
. O O 0.9998155236244202
Anaesthesia O O 0.8772170543670654
was O O 0.9974935054779053
maintained O O 0.9999161958694458
with O O 0.9999949932098389
an O O 0.9996688365936279
inspired O O 0.9873633980751038
isoflurane B-Chemical B-Chemical 0.997327446937561
concentration O O 0.9957484602928162
of O O 0.9999425411224365
0 O O 0.9947185516357422
. O O 0.9999932050704956
75 O O 0.9997639060020447
% O O 0.9999730587005615
( O O 0.9999713897705078
plus O O 0.9999350309371948
67 O O 0.9995214939117432
% O O 0.9998648166656494
nitrous B-Chemical B-Chemical 0.7539565563201904
oxide I-Chemical I-Chemical 0.980060338973999
in O O 0.9971189498901367
oxygen B-Chemical B-Chemical 0.9914679527282715
) O O 0.9971621036529541
, O O 0.9999959468841553
during O O 0.9999856948852539
which O O 0.9998923540115356
CBF O O 0.4756646752357483
and O O 0.9974126219749451
CMRO2 O O 0.9109352827072144
were O O 0.9999746084213257
34 O O 0.9987271428108215
. O O 0.9999982118606567
3 O O 0.9999521970748901
+ O O 0.999994158744812
/ O O 0.9999982118606567
- O O 0.9999402761459351
2 O O 0.9996036887168884
. O O 0.9999951124191284
1 O O 0.9998679161071777
ml O O 0.999566376209259
/ O O 0.9999910593032837
100 O O 0.9999227523803711
g O O 0.9996059536933899
min O O 0.9987573623657227
- O O 0.9991825222969055
1 O O 0.9981642365455627
and O O 0.999970555305481
2 O O 0.9992932081222534
. O O 0.9999967813491821
32 O O 0.9999433755874634
+ O O 0.9999957084655762
/ O O 0.9999980926513672
- O O 0.9999591112136841
0 O O 0.9997773766517639
. O O 0.999994158744812
16 O O 0.999862790107727
ml O O 0.9994655251502991
/ O O 0.9999929666519165
100 O O 0.9999380111694336
g O O 0.9996711015701294
min O O 0.9992449283599854
- O O 0.9991612434387207
1 O O 0.9974051117897034
at O O 0.999993085861206
PaCO2 O O 0.5568483471870422
4 O O 0.9749446511268616
. O O 0.9999979734420776
1 O O 0.9999737739562988
+ O O 0.9999955892562866
/ O O 0.999997615814209
- O O 0.9999349117279053
0 O O 0.9995262622833252
. O O 0.9999951124191284
1 O O 0.9997649788856506
kPa O O 0.6804116368293762
( O O 0.9999991655349731
mean O O 0.9999852180480957
+ O O 0.9999922513961792
/ O O 0.9999940395355225
- O O 0.9999054670333862
SEM O O 0.9549427628517151
) O O 0.999950647354126
. O O 0.9999986886978149

The O O 0.9986611604690552
rabbit B-Disease B-Disease 0.9828922748565674
syndrome I-Disease I-Disease 0.9992673993110657
is O O 0.9998801946640015
an O O 0.9999595880508423
extrapyramidal O O 0.5737593770027161
side O O 0.6753309965133667
effect O O 0.9755609631538391
associated O O 0.9999958276748657
with O O 0.9999912977218628
chronic O O 0.9839598536491394
neuroleptic O O 0.7553949952125549
therapy O O 0.9859742522239685
. O O 0.9999998807907104

METHODS O O 0.994655966758728
: O O 0.9999960660934448
Thirty O O 0.9998863935470581
- O O 0.9999492168426514
nine O O 0.9999628067016602
postmenopausal O O 0.8139755129814148
women O O 0.9996165037155151
with O O 0.9999842643737793
osteopenia B-Disease B-Disease 0.99913090467453
or O O 0.9594182372093201
osteoporosis B-Disease B-Disease 0.9763709306716919
were O O 0.9999456405639648
included O O 0.9999974966049194
in O O 0.9999973773956299
this O O 0.9998533725738525
prospective O O 0.9997255206108093
, O O 0.9999790191650391
controlled O O 0.999106228351593
clinical O O 0.9997937083244324
study O O 0.9999102354049683
. O O 0.9999996423721313

A O O 0.9962875843048096
61 O O 0.9991069436073303
- O O 0.9999679327011108
year O O 0.9999929666519165
- O O 0.9999750852584839
old O O 0.999956488609314
Japanese O O 0.9925386309623718
man O O 0.9996418952941895
with O O 0.999993085861206
nephrotic B-Disease B-Disease 0.9998799562454224
syndrome I-Disease I-Disease 0.9999765157699585
due O O 0.999893307685852
to O O 0.9999966621398926
focal B-Disease O 0.990186333656311
segmental I-Disease O 0.939054548740387
glomerulosclerosis I-Disease B-Disease 0.7526760697364807
was O O 0.9986955523490906
initially O O 0.9992349147796631
responding O O 0.9999964237213135
well O O 0.9999862909317017
to O O 0.9999804496765137
steroid B-Chemical B-Chemical 0.9980599284172058
therapy O O 0.9990586638450623
. O O 0.9999997615814209

Seven O O 0.9997151494026184
different O O 0.9998899698257446
life O O 0.9982402324676514
- O O 0.9990087747573853
threatening O O 0.9901655316352844
toxicities B-Disease B-Disease 0.9981729984283447
were O O 0.9997416138648987
observed O O 0.9999324083328247
in O O 0.999995231628418
patients O O 0.9999973773956299
while O O 0.9999977350234985
receiving O O 0.9999786615371704
treatment O O 0.9999701976776123
. O O 0.9999998807907104

The O O 0.9999492168426514
average O O 0.9998037219047546
FEV1 O O 0.8993807435035706
increases O O 0.968332827091217
during O O 0.9999713897705078
the O O 0.999768078327179
6 O O 0.9990308284759521
- O O 0.9995110034942627
hour O O 0.9979509711265564
observation O O 0.9990528225898743
period O O 0.9999996423721313
were O O 0.9999988079071045
18 O O 0.9999551773071289
% O O 0.9999955892562866
for O O 0.9998360872268677
ipratropium B-Chemical B-Chemical 0.9997779726982117
and O O 0.9996055960655212
8 O O 0.9991983771324158
% O O 0.9999665021896362
for O O 0.9997542500495911
theophylline B-Chemical B-Chemical 0.9999066591262817
. O O 0.9999932050704956

Subjects O O 0.9996697902679443
with O O 0.9999735355377197
SNHL B-Disease B-Chemical 0.7669262886047363
were O O 0.9999650716781616
submitted O O 0.999995231628418
to O O 0.9999923706054688
DFO B-Chemical B-Chemical 0.9594379663467407
reduction O O 0.9088958501815796
or O O 0.9997966885566711
temporary O O 0.9991100430488586
withdrawal O O 0.9961161613464355
. O O 0.9999970197677612

Ketamine B-Chemical B-Chemical 0.9998278617858887
reduced O O 0.9942947030067444
both O O 0.9997034668922424
the O O 0.9995394945144653
area O O 0.9949511289596558
of O O 0.9991858601570129
brush O O 0.9186777472496033
- O O 0.9980424642562866
evoked O O 0.9994376301765442
and O O 0.999599277973175
punctate O O 0.7003229260444641
- O O 0.9998123049736023
evoked O O 0.9988088607788086
hyperalgesia B-Disease B-Disease 0.9981991648674011
significantly O O 0.9852643013000488
and O O 0.9998419284820557
it O O 0.9999589920043945
tended O O 0.9999933242797852
to O O 0.9999819993972778
reduce O O 0.9980869293212891
brush O O 0.6775416731834412
- O O 0.9551517963409424
evoked O O 0.9987120628356934
pain B-Disease B-Disease 0.9993579983711243
. O O 0.9999909400939941

Thyroxine B-Chemical B-Chemical 0.9890719652175903
abuse O O 0.5510364770889282
: O O 0.9999896287918091
an O O 0.9999957084655762
unusual O O 0.9991254210472107
case O O 0.9999597072601318
of O O 0.999950647354126
thyrotoxicosis B-Disease B-Disease 0.9809736609458923
in O O 0.9995627999305725
pregnancy O O 0.9933818578720093
. O O 0.9999994039535522

Although O O 0.9999599456787109
these O O 0.9999833106994629
adverse O O 0.9976588487625122
effects O O 0.998062789440155
occur O O 0.9999873638153076
in O O 0.9999972581863403
some O O 0.9999297857284546
patients O O 0.9999974966049194
, O O 0.9999998807907104
their O O 0.999955415725708
occurrence O O 0.999538779258728
could O O 0.9999998807907104
be O O 0.9999990463256836
minimised O O 0.9998700618743896
by O O 0.9999986886978149
knowledge O O 0.9999716281890869
of O O 0.9999868869781494
the O O 0.9999293088912964
molecular O O 0.9811553955078125
effects O O 0.9989363551139832
of O O 0.9998292922973633
sirolimus B-Chemical B-Chemical 0.999958872795105
on O O 0.9989233613014221
the O O 0.9995397329330444
kidney O O 0.9958380460739136
, O O 0.9999986886978149
the O O 0.9999758005142212
use O O 0.9999126195907593
of O O 0.9997199177742004
sirolimus B-Chemical B-Chemical 0.9962235689163208
in O O 0.9999325275421143
appropriate O O 0.9996775388717651
patient O O 0.9976170659065247
populations O O 0.9991161227226257
, O O 0.9999997615814209
close O O 0.9996525049209595
monitoring O O 0.9986265897750854
of O O 0.9995427131652832
proteinuria B-Disease B-Disease 0.985162079334259
and O O 0.9773277044296265
renal O O 0.9808036684989929
function O O 0.6022986173629761
, O O 0.9999797344207764
use O O 0.9999202489852905
of O O 0.9995747208595276
angiotensin B-Chemical B-Chemical 0.9997960925102234
- O O 0.9668086171150208
converting O O 0.999588668346405
enzyme O O 0.9959510564804077
inhibitors O O 0.9826855659484863
or O O 0.9999492168426514
angiotensin B-Chemical B-Chemical 0.9564657211303711
II I-Chemical I-Chemical 0.9983580708503723
receptor O O 0.9620616436004639
blockers O O 0.9934631586074829
if O O 0.99996018409729
proteinuria B-Disease B-Disease 0.9920449256896973
occurs O O 0.9830073118209839
and O O 0.9998927116394043
withdrawal O O 0.9909342527389526
if O O 0.9999020099639893
needed O O 0.9999068975448608
. O O 0.9999997615814209

As O O 0.9998403787612915
a O O 0.9999862909317017
consequence O O 0.9999929666519165
of O O 0.999987006187439
blocking O O 0.9986610412597656
I O O 0.9226696491241455
( O O 0.9994924068450928
f O O 0.990413248538971
) O O 0.9990115165710449
, O O 0.9999077320098877
clonidine B-Chemical B-Chemical 0.9999388456344604
reduced O O 0.9919947385787964
the O O 0.9970453381538391
slope O O 0.9782341122627258
of O O 0.999883770942688
the O O 0.9996254444122314
diastolic O O 0.7353469133377075
depolarization O O 0.4769456088542938
and O O 0.9998335838317871
the O O 0.9999417066574097
frequency O O 0.9994320273399353
of O O 0.9997559189796448
pacemaker O O 0.871423065662384
potentials O O 0.9906107783317566
in O O 0.9999788999557495
sinoatrial O O 0.9506608843803406
node O O 0.962936282157898
cells O O 0.9998199343681335
from O O 0.9999841451644897
wild O O 0.9960368275642395
- O O 0.9985291957855225
type O O 0.9963816404342651
and O O 0.9996180534362793
alpha2ABC O O 0.6737399697303772
- O O 0.9992757439613342
knockout O O 0.8697332143783569
mice O O 0.9983147382736206
. O O 0.9999996423721313

These O O 0.9998247027397156
data O O 0.9992892742156982
might O O 0.9999998807907104
indicate O O 0.9999992847442627
that O O 0.999977707862854
the O O 0.9998347759246826
generation O O 0.9995561242103577
of O O 0.9997784495353699
reactive O O 0.9963122010231018
oxygen B-Chemical B-Chemical 0.9913651943206787
species O O 0.9610974192619324
and O O 0.9999227523803711
activation O O 0.9978335499763489
of O O 0.9991656541824341
NF O O 0.7910889387130737
- O O 0.9424661993980408
kappaB O O 0.45445236563682556
plays O O 0.9999397993087769
a O O 0.9999852180480957
more O O 0.9999479055404663
central O O 0.9996585845947266
role O O 0.9999160766601562
in O O 0.9999516010284424
seizure B-Disease B-Disease 0.9997549653053284
- O O 0.9917677640914917
associated O O 0.9999436140060425
neuronal B-Disease B-Disease 0.83058100938797
damage I-Disease I-Disease 0.9957351684570312
in O O 0.9855131506919861
the O O 0.9905970692634583
temporal O O 0.9745974540710449
cortex O O 0.9669582843780518
as O O 0.9999843835830688
compared O O 0.9999173879623413
to O O 0.9999843835830688
the O O 0.9997301697731018
hippocampal O O 0.7313079237937927
hilus O O 0.6932253837585449
. O O 0.9999924898147583

BACKGROUND O O 0.9921477437019348
: O O 0.999991774559021
Vasopressor O O 0.5832613706588745
agents O O 0.6709224581718445
are O O 0.9999866485595703
used O O 0.99998939037323
to O O 0.9999971389770508
correct O O 0.9996905326843262
anesthesia O O 0.7847735285758972
- O O 0.9976158142089844
induced O O 0.9995434880256653
hypotension B-Disease B-Disease 0.9995762705802917
. O O 0.9999752044677734

Alpha B-Chemical B-Chemical 0.9099957942962646
- I-Chemical I-Chemical 0.9192480444908142
lipoic I-Chemical I-Chemical 0.9996637105941772
acid I-Chemical I-Chemical 0.9999935626983643
protects O O 0.9999581575393677
sensory O O 0.9959702491760254
neurons O O 0.9874715209007263
through O O 0.9999994039535522
its O O 0.9999572038650513
anti O O 0.9971750974655151
- O O 0.9990608096122742
oxidant O O 0.9794172644615173
and O O 0.9999277591705322
mitochondrial O O 0.9964390397071838
regulatory O O 0.9969480633735657
functions O O 0.9952747821807861
, O O 0.9999988079071045
possibly O O 0.999971866607666
inducing O O 0.9999740123748779
the O O 0.9997709393501282
expression O O 0.9932257533073425
of O O 0.9997647404670715
frataxin O B-Chemical 0.9971227049827576
. O O 0.9999854564666748

The O O 0.9999724626541138
aim O O 0.9999960660934448
of O O 0.9999959468841553
this O O 0.9999669790267944
study O O 0.9999871253967285
was O O 0.9999996423721313
to O O 0.9999973773956299
describe O O 0.9999935626983643
this O O 0.9999617338180542
hearing B-Disease B-Disease 0.921198308467865
loss I-Disease I-Disease 0.9999502897262573
and O O 0.9994094371795654
to O O 0.9999982118606567
investigate O O 0.9999891519546509
other O O 0.9999758005142212
factors O O 0.9999876022338867
influencing O O 0.9999920129776001
the O O 0.9999575614929199
degree O O 0.9998281002044678
of O O 0.9999911785125732
hearing B-Disease B-Disease 0.9707688689231873
loss I-Disease I-Disease 0.9999905824661255
. O O 0.9993176460266113

The O O 0.9997847676277161
patient O O 0.9999072551727295
was O O 0.999966025352478
treated O O 0.9999842643737793
with O O 0.9999232292175293
methylprednisolone B-Chemical B-Chemical 0.999896764755249
and O O 0.9998811483383179
gradually O O 0.9991326928138733
improved O O 0.9997590184211731
. O O 0.9999972581863403

A O O 0.9984606504440308
case O O 0.9999297857284546
is O O 0.9999923706054688
reported O O 0.9999992847442627
of O O 0.9999957084655762
the O O 0.9996757507324219
hemolytic B-Disease B-Disease 0.903217077255249
uremic I-Disease I-Disease 0.998999297618866
syndrome I-Disease I-Disease 0.9998883008956909
( O O 0.9725717306137085
HUS B-Disease B-Disease 0.9994862079620361
) O O 0.9258265495300293
in O O 0.9999333620071411
a O O 0.9997740387916565
woman O O 0.9997770190238953
taking O O 0.9999924898147583
oral B-Chemical B-Chemical 0.6751314997673035
contraceptives I-Chemical I-Chemical 0.9997515082359314
. O O 0.9999548196792603

These O O 0.9999010562896729
results O O 0.9999151229858398
indicate O O 0.9999995231628418
that O O 0.9999758005142212
early O O 0.9999452829360962
changes O O 0.9994425177574158
in O O 0.9987238049507141
glutamate B-Chemical B-Chemical 0.9997459053993225
transport O O 0.973261833190918
may O O 0.9999996423721313
be O O 0.9999978542327881
related O O 0.9999847412109375
to O O 0.999984860420227
the O O 0.999829888343811
development O O 0.9989936947822571
of O O 0.9999376535415649
vacuous O O 0.9808617234230042
chewing O O 0.7296908497810364
movements O O 0.8894598484039307
in O O 0.9976796507835388
rats O O 0.999767005443573
. O O 0.9999997615814209

Different O O 0.9982813596725464
mechanisms O O 0.9992125034332275
have O O 0.9999994039535522
been O O 0.9999775886535645
suggested O O 0.9999963045120239
for O O 0.9999687671661377
cocaine B-Chemical B-Chemical 0.9943751096725464
toxicity B-Disease B-Disease 0.9961060881614685
including O O 0.9999617338180542
an O O 0.9998807907104492
increase O O 0.9567300081253052
in O O 0.974224865436554
oxidative O O 0.8421947956085205
stress O O 0.8557221293449402
but O O 0.999638557434082
the O O 0.9999738931655884
association O O 0.9994016885757446
between O O 0.9999552965164185
oxidative O O 0.9300891757011414
status O O 0.9698636531829834
in O O 0.999927282333374
the O O 0.9988927245140076
brain O O 0.9653331637382507
and O O 0.9999182224273682
cocaine B-Chemical B-Chemical 0.9998558759689331
induced O O 0.9983994364738464
- O O 0.99850994348526
behaviour O O 0.9638628363609314
is O O 0.9999979734420776
poorly O O 0.999901294708252
understood O O 0.9998118281364441
. O O 0.9999996423721313

To O O 0.9999889135360718
date O O 0.9999969005584717
there O O 0.9999985694885254
has O O 0.9999997615814209
been O O 0.9999992847442627
little O O 0.9999933242797852
documentation O O 0.9998408555984497
of O O 0.9999487400054932
clinically O O 0.9998718500137329
significant O O 0.9993213415145874
proteinuria B-Disease B-Disease 0.9998925924301147
linked O O 0.998741090297699
with O O 0.999990701675415
the O O 0.9995957016944885
use O O 0.9996722936630249
of O O 0.9989230036735535
sirolimus B-Chemical B-Chemical 0.9997207522392273
. O O 0.9999784231185913

Median O O 0.9743083715438843
survival O O 0.9999452829360962
was O O 0.9999996423721313
16 O O 0.9999356269836426
months O O 0.999894380569458
. O O 0.9999996423721313

PATIENTS O O 0.9997119307518005
: O O 0.9999992847442627
Seventy O O 0.9999769926071167
men O O 0.9998859167098999
, O O 0.999997615814209
aged O O 0.9999979734420776
50 O O 0.9999237060546875
- O O 0.9999725818634033
80 O O 0.9999253749847412
years O O 0.9999886751174927
, O O 0.9999997615814209
with O O 0.9999977350234985
advanced O O 0.9978150129318237
androgen O O 0.9205183982849121
- O O 0.998603880405426
independent O O 0.9971104860305786
prostate B-Disease B-Disease 0.983070433139801
cancer I-Disease I-Disease 0.999984622001648
. O O 0.9998893737792969

Findings O O 0.9995724558830261
of O O 0.999980092048645
initial O O 0.9998646974563599
and O O 0.9998766183853149
follow O O 0.9999390840530396
- O O 0.9998619556427002
up O O 0.9999439716339111
MRIs O O 0.9446955919265747
were O O 0.9999990463256836
retrospectively O O 0.9998111128807068
evaluated O O 0.9999822378158569
by O O 0.9999918937683105
2 O O 0.9976996779441833
neuroradiologists O O 0.9984784722328186
by O O 0.9999986886978149
consensus O O 0.9998471736907959
, O O 0.9999945163726807
to O O 0.99998939037323
analyze O O 0.9996323585510254
the O O 0.9999469518661499
presence O O 0.9996472597122192
of O O 0.9999332427978516
abnormal O O 0.7826855778694153
signal O O 0.5585480332374573
intensities O O 0.7708887457847595
, O O 0.9997761845588684
their O O 0.9999167919158936
locations O O 0.9993084669113159
, O O 0.9999966621398926
and O O 0.9999352693557739
signal O O 0.9986703395843506
changes O O 0.9921693205833435
on O O 0.9999662637710571
follow O O 0.9997662901878357
- O O 0.9998914003372192
up O O 0.9998507499694824
images O O 0.9998313188552856
. O O 0.9999998807907104

The O O 0.9998372793197632
residual O O 0.9960229396820068
serum O O 0.9965885877609253
concentrations O O 0.9997259974479675
of O O 0.9989941716194153
oxazepam B-Chemical B-Chemical 0.999835729598999
, O O 0.994234025478363
temazepam B-Chemical B-Chemical 0.9998698234558105
and O O 0.994330883026123
zopiclone B-Chemical B-Chemical 0.9999598264694214
were O O 0.999919056892395
analysed O O 0.9999574422836304
. O O 0.9999996423721313

When O O 0.9999829530715942
the O O 0.999970555305481
effects O O 0.9999806880950928
of O O 0.9999349117279053
IV O O 0.6818567514419556
drugs O O 0.9931556582450867
are O O 0.9999794960021973
inadequate O O 0.9948050379753113
in O O 0.9999979734420776
patients O O 0.999996542930603
receiving O O 0.9999871253967285
CVVHDF O O 0.683811604976654
, O O 0.9998573064804077
interference O O 0.7837755084037781
with O O 0.9971200227737427
adjacent O O 0.9201035499572754
catheters O O 0.40571048855781555
resulting O O 0.9997666478157043
in O O 0.9999573230743408
elimination O O 0.9857158064842224
of O O 0.9995113611221313
the O O 0.9983596205711365
drug O O 0.9987607002258301
by O O 0.9999841451644897
CVVHDF O B-Chemical 0.9676855802536011
should O O 0.9999179840087891
be O O 0.9999904632568359
suspected O O 0.99998939037323
. O O 0.9999995231628418

In O O 0.9999910593032837
the O O 0.9999836683273315
nine O O 0.9996780157089233
responders O O 0.9999305009841919
, O O 0.9999996423721313
median O O 0.9995710253715515
duration O O 0.9996709823608398
of O O 0.9995282888412476
chemotherapy O O 0.7282195687294006
response O O 0.9885522127151489
from O O 0.9999971389770508
the O O 0.9999830722808838
time O O 0.9999986886978149
of O O 0.9999674558639526
operation O O 0.9991266131401062
was O O 0.9999978542327881
25 O O 0.9997993111610413
weeks O O 0.9999603033065796
( O O 0.9999970197677612
range O O 0.9999887943267822
12 O O 0.9999616146087646
to O O 0.999997615814209
more O O 0.999996542930603
than O O 0.9999959468841553
91 O O 0.9999676942825317
weeks O O 0.9999608993530273
) O O 0.9999709129333496
. O O 0.9999995231628418

MAIN O O 0.9936493039131165
OUTCOME O O 0.9998096823692322
MEASURE O O 0.9999701976776123
: O O 0.9999961853027344
Odds O O 0.9833194613456726
ratios O O 0.9986794590950012
( O O 0.9999688863754272
ORs O O 0.9836259484291077
) O O 0.9999686479568481
measuring O O 0.9998981952667236
the O O 0.9998608827590942
association O O 0.998671293258667
between O O 0.9999819993972778
antibacterial O O 0.6833845376968384
use O O 0.9291085600852966
and O O 0.9999563694000244
selected O O 0.9985212683677673
birth B-Disease B-Disease 0.7963804602622986
defects I-Disease I-Disease 0.9994238615036011
adjusted O O 0.987655758857727
for O O 0.9999548196792603
potential O O 0.999601423740387
confounders O O 0.9962933659553528
. O O 0.9999997615814209

Subjects O O 0.9995693564414978
were O O 0.9999792575836182
receiving O O 0.9999089241027832
desferrioxamine B-Chemical B-Chemical 0.9999185800552368
( O O 0.9946635961532593
DFO B-Chemical B-Chemical 0.9997921586036682
) O O 0.9693993330001831
chelation O O 0.7184290885925293
treatment O O 0.9999880790710449
with O O 0.9999974966049194
a O O 0.9993807077407837
mean O O 0.9991604089736938
daily O O 0.9967054724693298
dose O O 0.9999595880508423
of O O 0.9999674558639526
50 O O 0.9931970834732056
- O O 0.9995243549346924
60 O O 0.9997351765632629
mg O O 0.9999732971191406
/ O O 0.9999717473983765
kg O O 0.9999210834503174
, O O 0.9999594688415527
5 O O 0.9989751577377319
- O O 0.9996032118797302
6 O O 0.9996412992477417
days O O 0.9999986886978149
a O O 0.9999977350234985
week O O 0.9999959468841553
during O O 0.9999991655349731
the O O 0.9999803304672241
first O O 0.9999943971633911
six O O 0.9998884201049805
years O O 0.9999977350234985
of O O 0.9999951124191284
the O O 0.999915599822998
study O O 0.9999284744262695
, O O 0.9999953508377075
which O O 0.999923825263977
was O O 0.9999021291732788
then O O 0.9997782111167908
reduced O O 0.9998940229415894
to O O 0.9999810457229614
40 O O 0.9990763664245605
- O O 0.9997976422309875
50 O O 0.9997734427452087
mg O O 0.9999599456787109
/ O O 0.9999891519546509
kg O O 0.9999537467956543
for O O 0.9999961853027344
the O O 0.9999926090240479
following O O 0.9999979734420776
eight O O 0.9999270439147949
years O O 0.9999845027923584
. O O 0.9999998807907104

Iatrogenically O O 0.9865973591804504
induced O O 0.9998797178268433
intractable O O 0.9922274351119995
atrioventricular B-Disease O 0.5399547815322876
reentrant I-Disease O 0.6017827391624451
tachycardia I-Disease B-Disease 0.6058217883110046
after O O 0.9992164373397827
verapamil B-Chemical B-Chemical 0.9993547797203064
and O O 0.9973803162574768
catheter O O 0.9121189117431641
ablation O O 0.8496223092079163
in O O 0.9999979734420776
a O O 0.9999277591705322
patient O O 0.99998939037323
with O O 0.999985933303833
Wolff B-Disease B-Disease 0.5818061828613281
- I-Disease I-Disease 0.8583855628967285
Parkinson I-Disease I-Disease 0.9938821792602539
- I-Disease I-Disease 0.9891128540039062
White I-Disease I-Disease 0.9987393021583557
syndrome I-Disease I-Disease 0.9999887943267822
and O O 0.9971868395805359
idiopathic B-Disease B-Disease 0.8686997890472412
dilated I-Disease I-Disease 0.8672929406166077
cardiomyopathy I-Disease I-Disease 0.9884709119796753
. O O 0.9999557733535767

We O O 0.9998140931129456
conclude O O 0.9999973773956299
that O O 0.9998792409896851
pentoxyifylline B-Chemical B-Chemical 0.9999061822891235
does O O 0.999911904335022
not O O 0.9994480013847351
inhibit O O 0.9866793751716614
dipyridamole B-Chemical B-Chemical 0.9999905824661255
- O O 0.9997250437736511
induced O O 0.9999587535858154
coronary O O 0.5885475873947144
hyperemia B-Disease B-Disease 0.5325426459312439
even O O 0.9941434264183044
at O O 0.9999978542327881
high O O 0.9985867738723755
doses O O 0.9995988011360168
. O O 0.9999998807907104

Epileptic B-Disease B-Disease 0.8950703144073486
seizures I-Disease I-Disease 0.9839308857917786
following O O 0.9999488592147827
cortical O O 0.995707094669342
application O O 0.9989281296730042
of O O 0.9991264939308167
fibrin O B-Chemical 0.9337769746780396
sealants O I-Chemical 0.9565173983573914
containing O O 0.9927379488945007
tranexamic B-Chemical B-Chemical 0.7424067258834839
acid I-Chemical I-Chemical 0.9999635219573975
in O O 0.9998651742935181
rats O O 0.9996411800384521
. O O 0.9999997615814209

In O O 0.9999920129776001
these O O 0.9998364448547363
patients O O 0.9999957084655762
, O O 0.9999998807907104
the O O 0.9999866485595703
magnitude O O 0.9993552565574646
of O O 0.9997679591178894
proteinuria B-Disease B-Disease 0.9989701509475708
was O O 0.9993257522583008
assessed O O 0.9999861717224121
on O O 0.9999834299087524
morning O O 0.9996966123580933
urine O O 0.9246266484260559
samples O O 0.9998049139976501
by O O 0.9999979734420776
turbidometric O O 0.9815080761909485
measurement O O 0.9988800883293152
or O O 0.9999902248382568
random O O 0.9982977509498596
urine O O 0.9187422394752502
protein O O 0.9971376657485962
: O O 0.9999905824661255
creatinine B-Chemical B-Chemical 0.9794917106628418
ratios O O 0.993073046207428
, O O 0.9999980926513672
an O O 0.9999878406524658
estimate O O 0.999945878982544
of O O 0.9997922778129578
grams O O 0.9981841444969177
of O O 0.9995878338813782
proteinuria B-Disease B-Disease 0.9422686696052551
/ O O 0.9697747826576233
day O O 0.9956860542297363
. O O 0.9999991655349731

Cancer B-Disease B-Disease 0.9942201375961304
patients O O 0.9929385781288147
who O O 0.9999971389770508
are O O 0.9999942779541016
chronic O O 0.8871713876724243
carriers O O 0.9779165387153625
of O O 0.9998846054077148
HBV O O 0.5683440566062927
have O O 0.9996346235275269
a O O 0.9999152421951294
higher O O 0.9987919926643372
hepatic B-Disease O 0.8916641473770142
complication I-Disease O 0.877366840839386
rate O O 0.9998099207878113
while O O 0.9999953508377075
receiving O O 0.9999748468399048
cytotoxic O O 0.8855785131454468
chemotherapy O O 0.905065655708313
( O O 0.9999890327453613
CT O O 0.6875070929527283
) O O 0.9991036057472229
and O O 0.9999600648880005
this O O 0.9998032450675964
has O O 0.9999959468841553
mainly O O 0.9999945163726807
been O O 0.9999550580978394
attributed O O 0.9999939203262329
to O O 0.9999797344207764
HBV O O 0.7457472681999207
reactivation O O 0.57559734582901
. O O 0.9999886751174927

Prazosin B-Chemical B-Chemical 0.9990002512931824
exerts O O 0.9995898604393005
its O O 0.9998832941055298
antihypertensive O O 0.8495816588401794
effects O O 0.9762557148933411
through O O 0.9999768733978271
vasodilatation O O 0.6101047396659851
caused O O 0.9998632669448853
by O O 0.9999778270721436
selective O O 0.9913057684898376
blockade O O 0.9957444071769714
of O O 0.9998620748519897
postsynaptic O O 0.9869330525398254
alpha O O 0.9391202330589294
- O O 0.9898624420166016
1 O O 0.993069589138031
adrenergic O O 0.9596452116966248
receptors O O 0.9979857206344604
. O O 0.9999997615814209

A O O 0.9998154044151306
comparable O O 0.9998213648796082
overexpression O O 0.8599759340286255
of O O 0.8511711955070496
Pgp O O 0.5404521226882935
in O O 0.9991456270217896
the O O 0.9996354579925537
BBB O O 0.9712619781494141
was O O 0.9999886751174927
obtained O O 0.999976634979248
after O O 0.99996018409729
pilocarpine B-Chemical B-Chemical 0.9999988079071045
- O O 0.9979971051216125
induced O O 0.9997654557228088
seizures B-Disease B-Disease 0.9998738765716553
in O O 0.9994794726371765
wild O O 0.9976281523704529
- O O 0.9991820454597473
type O O 0.9982866644859314
Wistar O O 0.8930561542510986
rats O O 0.9988514184951782
. O O 0.9999997615814209

NX O B-Chemical 0.860853910446167
caused O O 0.9999039173126221
an O O 0.999946117401123
additive O O 0.9651862978935242
deterioration O O 0.8805525898933411
in O O 0.9968698620796204
GFR O O 0.6560097336769104
which O O 0.9995697140693665
, O O 0.999954104423523
however O O 0.9999934434890747
, O O 0.9999635219573975
was O O 0.9999579191207886
ameliorated O O 0.9994248151779175
by O O 0.9999704360961914
HP O B-Chemical 0.9850050210952759
. O O 0.9999423027038574

In O O 0.9999325275421143
the O O 0.9993295669555664
antinociceptive O O 0.6607980132102966
and O O 0.9915024042129517
antiamnesic O O 0.5124252438545227
dose O O 0.8617894053459167
range O O 0.9977564215660095
, O O 0.9999959468841553
( O O 0.9999517202377319
+ O O 0.9999901056289673
/ O O 0.999976634979248
- O O 0.999339759349823
) O O 0.9954040050506592
- O O 0.9985021352767944
PG B-Chemical B-Chemical 0.9447888135910034
- I-Chemical I-Chemical 0.8844826817512512
9 I-Chemical I-Chemical 0.9979344606399536
did O O 0.9998606443405151
not O O 0.9999942779541016
impair O O 0.994507372379303
mouse O O 0.9563148021697998
performance O O 0.9857233166694641
evaluated O O 0.999966025352478
by O O 0.9999899864196777
the O O 0.9990547299385071
rota O O 0.9440345764160156
- O O 0.9998574256896973
rod O O 0.9968624114990234
test O O 0.9998874664306641
and O O 0.9998175501823425
Animex O O 0.6993547081947327
apparatus O O 0.9997425675392151
. O O 0.9999996423721313

Over O O 0.99996018409729
a O O 0.9997434020042419
range O O 0.9999047517776489
of O O 0.9999731779098511
1 O O 0.9972060322761536
- O O 0.9998179078102112
150 O O 0.9998420476913452
days O O 0.9999958276748657
of O O 0.9998984336853027
DES B-Chemical B-Chemical 0.9983546137809753
treatment O O 0.9996988773345947
, O O 0.9999983310699463
pairs O O 0.9899449944496155
of O O 0.9970601201057434
control O O 0.9813159704208374
and O O 0.9975918531417847
DES B-Chemical B-Chemical 0.9977826476097107
- O O 0.994831383228302
treated O O 0.9997863173484802
rats O O 0.9995840191841125
were O O 0.9999972581863403
sacrificed O O 0.9999408721923828
, O O 0.9999970197677612
and O O 0.9999860525131226
their O O 0.9995840191841125
pituitaries O O 0.8129661083221436
dissociated O O 0.9985615611076355
enzymatically O O 0.9742836952209473
into O O 0.9999508857727051
single O O 0.9979547262191772
- O O 0.9997016787528992
cell O O 0.9996720552444458
preparations O O 0.9988446235656738
. O O 0.9999998807907104

Five O O 0.9997121691703796
hours O O 0.9999808073043823
after O O 0.9999896287918091
exposure O O 0.9988157749176025
, O O 0.9999949932098389
he O O 0.9990367889404297
developed O O 0.9999673366546631
disulfiram B-Chemical B-Disease 0.9757376909255981
- O I-Disease 0.8858899474143982
like O I-Disease 0.6367448568344116
syndrome O I-Disease 0.9947726130485535
with O O 0.9993913173675537
flushing B-Disease B-Disease 0.9558799266815186
, O I-Disease 0.8628242015838623
tachycardia B-Disease I-Disease 0.8153225779533386
, O O 0.9899561405181885
and O O 0.9988476037979126
arterial B-Disease B-Disease 0.5768612027168274
hypotension I-Disease I-Disease 0.9242111444473267
after O O 0.9998977184295654
consuming O O 0.9999384880065918
three O O 0.9979304075241089
glasses O O 0.9947845339775085
of O O 0.9994451403617859
wine O O 0.9102948307991028
. O O 0.9999986886978149

The O O 0.9998829364776611
remaining O O 0.9999475479125977
1 O O 0.9987369179725647
patient O O 0.9998904466629028
( O O 0.9999951124191284
20 O O 0.9998852014541626
. O O 0.9999949932098389
0 O O 0.9999542236328125
% O O 0.9999803304672241
) O O 0.9998190999031067
showed O O 0.9999972581863403
lower O O 0.9989377856254578
than O O 0.9997414946556091
normal O O 0.9994233846664429
ADC O O 0.6680638790130615
value O O 0.9992352724075317
and O O 0.9999963045120239
showed O O 0.9999964237213135
incomplete O O 0.9261922240257263
resolution O O 0.9385818243026733
with O O 0.9999929666519165
cortical B-Disease B-Disease 0.953086256980896
laminar I-Disease I-Disease 0.47291362285614014
necrosis I-Disease I-Disease 0.9091581702232361
. O O 0.9999604225158691

OBJECTIVE O O 0.9930014610290527
: O O 0.9999935626983643
This O O 0.9998985528945923
is O O 0.9999922513961792
to O O 0.999995231628418
present O O 0.999998927116394
reversible O O 0.999671459197998
inferior B-Disease O 0.8039461374282837
colliculus I-Disease O 0.776020884513855
lesions I-Disease O 0.6875289678573608
in O O 0.9962261915206909
metronidazole B-Chemical B-Chemical 0.9999021291732788
- O O 0.9961698651313782
induced O O 0.9993247985839844
encephalopathy B-Disease B-Disease 0.9999715089797974
, O O 0.9999346733093262
to O O 0.9999874830245972
focus O O 0.9999395608901978
on O O 0.9998546838760376
the O O 0.9994508624076843
diffusion O O 0.9573982954025269
- O O 0.9994502663612366
weighted O O 0.9951620697975159
imaging O O 0.9988692402839661
( O O 0.999992847442627
DWI O O 0.9254071712493896
) O O 0.999887228012085
and O O 0.9999537467956543
fluid O O 0.9863411784172058
attenuated O O 0.988421618938446
inversion O O 0.9823957085609436
recovery O O 0.9990981817245483
( O O 0.9999948740005493
FLAIR O O 0.9425557851791382
) O O 0.999710738658905
imaging O O 0.9989467263221741
. O O 0.9999997615814209

The O O 0.9995859265327454
symptoms O O 0.8117797374725342
occurred O O 0.9999732971191406
around O O 0.9999732971191406
2 O O 0.9999414682388306
weeks O O 0.9999793767929077
after O O 0.999996542930603
starting O O 0.9985514283180237
clozapine B-Chemical B-Chemical 0.9999936819076538
in O O 0.9999786615371704
an O O 0.999985933303833
inpatient O O 0.9963518381118774
setting O O 0.9995958209037781
. O O 1.0

Here O O 0.9987730383872986
its O O 0.9998589754104614
ability O O 0.9999364614486694
to O O 0.9999948740005493
antagonize O O 0.998532772064209
the O O 0.999921441078186
prolonged O O 0.9973342418670654
depletion O O 0.9273346662521362
of O O 0.99434894323349
dopamine B-Chemical B-Chemical 0.9999932050704956
in O O 0.9999032020568848
the O O 0.9992554783821106
striatum O O 0.9593012928962708
by O O 0.999996542930603
amphetamine B-Chemical B-Chemical 0.9999823570251465
in O O 0.9973568916320801
iprindole B-Chemical B-Chemical 0.9992563128471375
- O O 0.9895421266555786
treated O O 0.9998260140419006
rats O O 0.997717022895813
is O O 0.9999916553497314
reported O O 0.9999985694885254
. O O 0.9999994039535522

Furthermore O O 0.9999376535415649
, O O 0.9999936819076538
the O O 0.9999560117721558
effects O O 0.9999188184738159
are O O 0.9999891519546509
mediated O O 0.9996277093887329
through O O 0.9999467134475708
dopamine B-Chemical B-Chemical 0.9999970197677612
rather O O 0.9997907280921936
than O O 0.9994580149650574
norepinephrine B-Chemical B-Chemical 0.9998760223388672
and O O 0.9998791217803955
do O O 0.9999879598617554
not O O 0.9999693632125854
require O O 0.9999986886978149
the O O 0.9999208450317383
carotid O O 0.9714075326919556
sinus O O 0.9903106093406677
baroreceptors O O 0.9258824586868286
. O O 0.9999997615814209

These O O 0.9998445510864258
data O O 0.999591052532196
were O O 0.9999984502792358
correlated O O 0.9999856948852539
with O O 0.9999823570251465
histologically O O 0.9905101656913757
scored O O 0.9995680451393127
cervical O O 0.9782382249832153
cord B-Disease O 0.8680076003074646
damage I-Disease O 0.9521029591560364
in O O 0.9999375343322754
a O O 0.9999535083770752
separate O O 0.9994662404060364
group O O 0.9997337460517883
of O O 0.9999850988388062
similarly O O 0.99933260679245
dosed O O 0.9975361824035645
rats O O 0.9986382126808167
sampled O O 0.9999974966049194
14 O O 0.9988158941268921
- O O 0.9998148083686829
21 O O 0.9997590184211731
days O O 0.9999955892562866
post O O 0.9999536275863647
- O O 0.9984514713287354
exposure O O 0.9981405735015869
. O O 0.9999994039535522

These O O 0.9991772770881653
episodes O O 0.9932938814163208
are O O 0.999990701675415
asymptomatic O O 0.9467900395393372
and O O 0.9999163150787354
reversible O O 0.9998965263366699
when O O 0.9999438524246216
therapy O O 0.998650848865509
is O O 0.9999909400939941
discontinued O O 0.9998021721839905
. O O 0.9999997615814209

Our O O 0.9997774958610535
study O O 0.9999850988388062
was O O 0.9999973773956299
designed O O 0.9999966621398926
to O O 0.9999985694885254
determine O O 0.999992847442627
the O O 0.9999579191207886
effects O O 0.9999798536300659
of O O 0.9999748468399048
combined O O 0.9949541687965393
nitroglycerin B-Chemical B-Chemical 0.9988441467285156
and O O 0.9960983991622925
phenylephrine B-Chemical B-Chemical 0.9999743700027466
therapy O O 0.9997841715812683
. O O 0.9999997615814209

Patients O O 0.9993378520011902
were O O 0.9999979734420776
divided O O 0.9995444416999817
into O O 0.9999563694000244
three O O 0.9978495836257935
groups O O 0.9998855590820312
: O O 0.9999898672103882
Controls O O 0.9834420084953308
, O O 0.9999836683273315
no O O 0.9667012095451355
CRF B-Disease O 0.5065863728523254
or O O 0.9994730353355408
ESRD B-Disease O 0.33148372173309326
, O O 0.9997134804725647
n O O 0.9837887287139893
= O O 0.9996547698974609
748 O O 0.9731630682945251
; O O 0.9999904632568359
CRF B-Disease O 0.5702502727508545
, O O 0.999872088432312
sustained O O 0.9989890456199646
serum O O 0.9949439167976379
creatinine B-Chemical B-Chemical 0.9993029832839966
> O O 0.9987252354621887
2 O O 0.9951726794242859
. O O 0.999996542930603
5 O O 0.9999427795410156
mg O O 0.9999432563781738
/ O O 0.9999929666519165
dl O O 0.9998316764831543
, O O 0.9999574422836304
n O O 0.9996907711029053
= O O 0.9999563694000244
41 O O 0.9981940388679504
; O O 0.9999641180038452
and O O 0.9998121857643127
ESRD B-Disease O 0.39552757143974304
, O O 0.999459445476532
n O O 0.9986279010772705
= O O 0.999972939491272
45 O O 0.9906129837036133
. O O 0.9999991655349731

However O O 0.9999446868896484
, O O 0.9999964237213135
use O O 0.9998127818107605
of O O 0.9991151690483093
BZDs B-Chemical B-Chemical 0.9978995323181152
/ O O 0.9884832501411438
RDs O O 0.5719667673110962
was O O 0.9999382495880127
associated O O 0.9999959468841553
with O O 0.9999877214431763
dizziness B-Disease B-Disease 0.9989370703697205
, O O 0.9989437460899353
inability B-Disease O 0.9314395785331726
to I-Disease O 0.9996352195739746
sleep I-Disease O 0.993184506893158
after O O 0.9999874830245972
awaking O O 0.7925985455513
at O O 0.9993795156478882
night O O 0.9992724061012268
and O O 0.9999964237213135
tiredness B-Disease B-Disease 0.9971089959144592
in O O 0.9997219443321228
the O O 0.9999939203262329
mornings O O 0.9999940395355225
during O O 0.9999996423721313
the O O 0.9999850988388062
week O O 0.9999973773956299
prior O O 0.999998927116394
to O O 0.9999980926513672
admission O O 0.9998307228088379
and O O 0.9999992847442627
with O O 0.9999983310699463
stronger O O 0.9978539347648621
depressive B-Disease B-Disease 0.9910362958908081
symptoms I-Disease I-Disease 0.9745948910713196
measured O O 0.8880934119224548
at O O 0.9999926090240479
the O O 0.999992847442627
beginning O O 0.9999949932098389
of O O 0.9999943971633911
the O O 0.9999449253082275
hospital O O 0.9936615228652954
stay O O 0.9999101161956787
. O O 0.9999997615814209

Based O O 0.9998859167098999
on O O 0.9999926090240479
these O O 0.9999524354934692
observations O O 0.9996994733810425
, O O 0.9999998807907104
it O O 0.9999934434890747
is O O 0.9999951124191284
concluded O O 0.9999988079071045
that O O 0.9999544620513916
5 O B-Chemical 0.783259391784668
- O I-Chemical 0.6151212453842163
HT2 O I-Chemical 0.9351842999458313
blockade O O 0.7500825524330139
obtained O O 0.9998883008956909
with O O 0.9997147917747498
risperidone B-Chemical B-Chemical 0.9999665021896362
at O O 0.999929666519165
D2 O O 0.9875577688217163
occupancy O O 0.9975481629371643
rates O O 0.9999703168869019
of O O 0.9999748468399048
60 O O 0.9996674060821533
% O O 0.9999885559082031
and O O 0.9999606609344482
above O O 0.9975601434707642
does O O 0.9999977350234985
not O O 0.9999326467514038
appear O O 0.9999959468841553
to O O 0.99997878074646
protect O O 0.9994887113571167
against O O 0.9999091625213623
the O O 0.9999134540557861
risk O O 0.9999631643295288
for O O 0.9999972581863403
extrapyramidal O O 0.4957813620567322
side O O 0.7746661305427551
effects O O 0.7547659277915955
. O O 0.9999878406524658

RESULTS O O 0.9984859824180603
: O O 0.9999973773956299
Sixty O O 0.9994683861732483
- O O 0.9998762607574463
seven O O 0.9999253749847412
of O O 0.9999779462814331
926 O O 0.9938483834266663
patients O O 0.9999542236328125
( O O 0.999994158744812
7 O O 0.9998314380645752
. O O 0.9999912977218628
2 O O 0.9999617338180542
% O O 0.9999773502349854
) O O 0.9996055960655212
required O O 0.999982476234436
discontinuation O O 0.9894429445266724
of O O 0.9972167015075684
spironolactone B-Chemical B-Chemical 0.9952217936515808
due O O 0.9999957084655762
to O O 0.9999165534973145
hyperkalemia B-Disease B-Disease 0.9997312426567078
( O O 0.9993923902511597
n O O 0.9826499223709106
= O O 0.9997528195381165
33 O O 0.9882416129112244
) O O 0.9981532692909241
or O O 0.9999768733978271
renal B-Disease B-Disease 0.9075248837471008
failure I-Disease I-Disease 0.9999991655349731
( O O 0.9991932511329651
n O O 0.9987875819206238
= O O 0.9999715089797974
34 O O 0.9987075328826904
) O O 0.9997099041938782
. O O 0.9999995231628418

Triazolam B-Chemical B-Chemical 0.9991539716720581
- O O 0.9996795654296875
induced O O 0.9999809265136719
brief O O 0.9954522252082825
episodes O O 0.9686144590377808
of O O 0.9998258948326111
secondary O B-Disease 0.9656442999839783
mania B-Disease I-Disease 0.8868085741996765
in O O 0.9994446635246277
a O O 0.9996744394302368
depressed B-Disease B-Disease 0.9991932511329651
patient O O 0.9627248644828796
. O O 0.9999997615814209

Laryngeal O O 0.7922446727752686
electromyography O O 0.9203896522521973
( O O 0.9969456791877747
thyroarytenoid O O 0.7857377529144287
muscle O O 0.6737205386161804
) O O 0.9977890253067017
showed O O 0.999998927116394
ample O O 0.998961329460144
denervation O O 0.4585513472557068
potentials O O 0.9972066283226013
. O O 0.9999997615814209

CONCLUSION O O 0.9999312162399292
: O O 0.9999985694885254
This O O 0.9999843835830688
work O O 0.999849796295166
shows O O 0.9999949932098389
that O O 0.9999568462371826
confusion B-Disease B-Disease 0.9856778979301453
with O O 0.9985439777374268
valproic B-Chemical B-Chemical 0.6587899327278137
acid I-Chemical I-Chemical 0.9997699856758118
is O O 0.9999604225158691
a O O 0.9999830722808838
serious O O 0.9998152852058411
, O O 0.9999877214431763
rather O O 0.9999364614486694
frequent O O 0.9985566735267639
but O O 0.9999803304672241
reversible O O 0.9999097585678101
adverse O O 0.976364016532898
drug O O 0.619743824005127
reaction O O 0.9744680523872375
. O O 0.9996047616004944

Granulocyte O O 0.49994635581970215
nadir O O 0.44294044375419617
was O O 0.9996862411499023
on O O 0.9999890327453613
day O O 0.9986671209335327
14 O O 0.9985172152519226
( O O 0.9999570846557617
range O O 0.9999133348464966
, O O 0.9999854564666748
4 O O 0.9991914629936218
- O O 0.9985583424568176
22 O O 0.9927709698677063
) O O 0.9992530941963196
. O O 0.9999988079071045

A O O 0.9995063543319702
second O O 0.9999270439147949
group O O 0.9998371601104736
of O O 0.9998677968978882
rats O O 0.9868144989013672
was O O 0.9998587369918823
treated O O 0.9999806880950928
identically O O 0.9999656677246094
and O O 0.9999908208847046
, O O 0.9999686479568481
in O O 0.9999973773956299
addition O O 0.9999767541885376
, O O 0.9999970197677612
received O O 0.9999808073043823
an O O 0.9999023675918579
infusion O O 0.9913555979728699
of O O 0.9970098733901978
saralasin B-Chemical B-Chemical 0.9998793601989746
( O O 0.9998890161514282
a O O 0.9984486103057861
competitive O O 0.9907302260398865
inhibitor O O 0.9947000741958618
of O O 0.9995916485786438
angiotensin B-Chemical B-Chemical 0.9862703680992126
II I-Chemical I-Chemical 0.9978923201560974
) O O 0.9961147308349609
throughout O O 0.9999927282333374
the O O 0.9999099969863892
experimental O O 0.9959730505943298
period O O 0.999984622001648
. O O 0.9999998807907104

We O O 0.9999254941940308
report O O 0.9999997615814209
a O O 0.999994158744812
case O O 0.9999940395355225
of O O 0.9999861717224121
a O O 0.9996148347854614
51 O O 0.998588502407074
- O O 0.9999487400054932
year O O 0.9999841451644897
- O O 0.9999731779098511
old O O 0.9999562501907349
man O O 0.999582827091217
who O O 0.9999947547912598
developed O O 0.9999598264694214
severe O O 0.9935839772224426
, O O 0.9991368651390076
disabling O O 0.9049766063690186
negative O O 0.8741934299468994
myoclonus B-Disease B-Disease 0.5042645335197449
of O I-Disease 0.8728909492492676
the O I-Disease 0.630020260810852
upper O I-Disease 0.9586068987846375
and O I-Disease 0.825626015663147
lower O I-Disease 0.9546332955360413
extremities O I-Disease 0.9982302784919739
after O O 0.9999401569366455
the O O 0.9999401569366455
infusion O O 0.9972960352897644
of O O 0.9986166954040527
ifosfamide B-Chemical B-Chemical 0.9998989105224609
for O O 0.9993366599082947
plasmacytoma B-Disease B-Disease 0.9962005019187927
. O O 0.9998239874839783

The O O 0.999927282333374
corresponding O O 0.9992538094520569
urine O O 0.606316864490509
concentrations O O 0.9942697286605835
amounted O O 0.9999874830245972
to O O 0.9999740123748779
374 O O 0.9986951947212219
and O O 0.9999681711196899
554 O O 0.9999352693557739
mg O O 0.999921441078186
/ O O 0.9999927282333374
l O O 0.9993938207626343
. O O 0.9999966621398926

The O O 0.9999110698699951
initial O O 0.9998082518577576
dose O O 0.9998838901519775
of O O 0.999413251876831
amantadine B-Chemical B-Chemical 0.999963641166687
depressed B-Disease O 0.9330676794052124
locomotor O O 0.791010320186615
activity O O 0.526044487953186
in O O 0.9999436140060425
all O O 0.9998063445091248
mouse O O 0.9940308928489685
strains O O 0.9561814069747925
studied O O 0.9999558925628662
with O O 0.9999904632568359
the O O 0.999144434928894
BALB O O 0.8940044045448303
/ O O 0.9997792840003967
C O O 0.9309319257736206
mice O O 0.9973631501197815
being O O 0.9998341798782349
the O O 0.9999897480010986
most O O 0.9999624490737915
sensitive O O 0.9994677901268005
. O O 0.9999992847442627

METHODS O O 0.9943575263023376
: O O 0.9999903440475464
For O O 0.9999945163726807
a O O 0.9999371767044067
period O O 0.999998927116394
of O O 0.9999860525131226
2 O O 0.9995566010475159
weeks O O 0.9999032020568848
, O O 0.9999816417694092
CsA B-Chemical B-Chemical 0.9911913275718689
15 O O 0.8134704232215881
mg O O 0.9985896944999695
/ O O 0.9999865293502808
kg O O 0.9997135996818542
/ O O 0.9999850988388062
day O O 0.9997586607933044
( O O 0.9999916553497314
given O O 0.9999159574508667
orally O O 0.9928721785545349
) O O 0.9996424913406372
, O O 0.9998828172683716
FK506 B-Chemical B-Chemical 0.9964002370834351
3 O O 0.7118567228317261
. O O 0.9999793767929077
0 O O 0.9998881816864014
mg O O 0.9999428987503052
/ O O 0.9999916553497314
kg O O 0.9997933506965637
/ O O 0.9999922513961792
day O O 0.999854564666748
( O O 0.999993085861206
given O O 0.9999066591262817
orally O O 0.9964457154273987
) O O 0.9994088411331177
or O O 0.9999306201934814
SRL B-Chemical B-Chemical 0.9667775630950928
0 O O 0.5770251750946045
. O O 0.999980092048645
4 O O 0.9999351501464844
mg O O 0.9999597072601318
/ O O 0.9999901056289673
kg O O 0.9997926354408264
/ O O 0.9999921321868896
day O O 0.9998444318771362
( O O 0.9999945163726807
given O O 0.9998881816864014
intraperitoneally O O 0.9197160601615906
) O O 0.9989694356918335
was O O 0.999958872795105
administered O O 0.9999603033065796
once O O 0.9999985694885254
a O O 0.9999762773513794
day O O 0.9999920129776001
as O O 0.9999991655349731
these O O 0.9998855590820312
doses O O 0.9998682737350464
have O O 0.9999994039535522
earlier O O 0.9999967813491821
been O O 0.9999643564224243
found O O 0.9999972581863403
to O O 0.9999939203262329
achieve O O 0.9999053478240967
a O O 0.999859094619751
significant O O 0.9995362758636475
immunosuppressive O O 0.8934340476989746
effect O O 0.9757813811302185
in O O 0.9999926090240479
Sprague O O 0.9700911641120911
- O O 0.9992282390594482
Dawley O O 0.9773115515708923
rats O O 0.9990910291671753
. O O 0.9999998807907104

All O O 0.9998061060905457
but O O 0.999993085861206
one O O 0.999943733215332
of O O 0.9999972581863403
the O O 0.9999866485595703
patients O O 0.9999858140945435
were O O 0.9999986886978149
over O O 0.999983549118042
60 O O 0.9999756813049316
years O O 0.9999963045120239
old O O 0.9999338388442993
, O O 0.9999992847442627
and O O 0.9999958276748657
the O O 0.9999889135360718
6 O O 0.999249279499054
who O O 0.999983549118042
died O O 0.9999310970306396
were O O 0.9999983310699463
all O O 0.9999200105667114
older O O 0.9996057152748108
than O O 0.9999125003814697
65 O O 0.9844357967376709
. O O 0.9999996423721313

Prospective O O 0.9995531439781189
study O O 0.9999725818634033
of O O 0.999990701675415
the O O 0.9999668598175049
long O O 0.9983905553817749
- O O 0.9993517994880676
term O O 0.9999203681945801
effects O O 0.9999499320983887
of O O 0.999812662601471
somatostatin O B-Chemical 0.9996606111526489
analog O O 0.6396256685256958
( O O 0.9967945218086243
octreotide B-Chemical B-Chemical 0.9956658482551575
) O O 0.9933980703353882
on O O 0.9998961687088013
gallbladder O O 0.9818912148475647
function O O 0.9928237199783325
and O O 0.9999843835830688
gallstone B-Disease O 0.5549235939979553
formation O O 0.606145977973938
in O O 0.9999463558197021
Chinese O O 0.983773946762085
acromegalic B-Disease B-Disease 0.9921876192092896
patients O O 0.9445921182632446
. O O 0.9999997615814209

The O O 0.9997809529304504
effects O O 0.9999234676361084
may O O 0.9999979734420776
be O O 0.999985933303833
further O O 0.9997788071632385
exploited O O 0.9998334646224976
for O O 0.9999967813491821
potential O O 0.9998142123222351
therapeutic O O 0.9982150793075562
uses O O 0.9995362758636475
. O O 0.9999998807907104

Bupropion B-Chemical B-Chemical 0.9901518225669861
is O O 0.999951958656311
a O O 0.9998582601547241
monocyclic O O 0.9365288615226746
antidepressant B-Chemical B-Chemical 0.9934248924255371
structurally O O 0.9969488978385925
related O O 0.9999620914459229
to O O 0.9998947381973267
amphetamine B-Chemical B-Chemical 0.9999575614929199
. O O 0.9999706745147705

The O O 0.9998993873596191
results O O 0.9998457431793213
with O O 0.999997615814209
respect O O 0.9999890327453613
to O O 0.9999969005584717
the O O 0.9995377063751221
use O O 0.9998990297317505
of O O 0.9999423027038574
third O O 0.9990690350532532
- O O 0.999439537525177
generation O O 0.9997103810310364
oral B-Chemical B-Chemical 0.9238120913505554
contraceptives I-Chemical I-Chemical 0.9996591806411743
were O O 0.9999709129333496
inconclusive O O 0.9995601773262024
but O O 0.9999983310699463
suggested O O 0.9999986886978149
that O O 0.9999877214431763
the O O 0.999913215637207
risk O O 0.999852180480957
was O O 0.9999955892562866
lower O O 0.9980664849281311
than O O 0.9999483823776245
the O O 0.9998898506164551
risk O O 0.9997488856315613
associated O O 0.9999979734420776
with O O 0.9999558925628662
second O O 0.9995903372764587
- O O 0.9991704225540161
generation O O 0.9996036887168884
oral B-Chemical B-Chemical 0.977626383304596
contraceptives I-Chemical I-Chemical 0.9997708201408386
. O O 0.9999871253967285

Patients O O 0.9997187256813049
were O O 0.9999980926513672
randomized O O 0.9998582601547241
in O O 0.9999939203262329
a O O 0.9997933506965637
1 O O 0.9994708895683289
: O O 0.999954104423523
1 O O 0.9986955523490906
ratio O O 0.9999784231185913
to O O 0.999997615814209
receive O O 0.9999343156814575
the O O 0.9987496137619019
4 O O 0.933887779712677
- O O 0.955760657787323
mg O O 0.9916759729385376
nicotine B-Chemical B-Chemical 0.9999401569366455
lozenge O O 0.4033708870410919
or O O 0.9993011951446533
4 O O 0.6555621027946472
- O O 0.679070234298706
mg O O 0.9511387348175049
nicotine B-Chemical B-Chemical 0.9986729621887207
gum O O 0.9587582349777222
. O O 0.9999984502792358

After O O 0.9994428753852844
re O B-Disease 0.6037430167198181
- O I-Disease 0.8384749889373779
infarction B-Disease I-Disease 0.714988112449646
, O O 0.9998723268508911
heart O O 0.8450755476951599
size O O 0.8515708446502686
increased O O 0.9991987347602844
in O O 0.9999717473983765
the O O 0.9996265172958374
placebo O O 0.997717022895813
group O O 0.9993528723716736
and O O 0.9999722242355347
remained O O 0.9986556768417358
unchanged O O 0.9984279870986938
in O O 0.9999957084655762
the O O 0.9994606375694275
timolol B-Chemical B-Chemical 0.9976168870925903
group O O 0.995867133140564
. O O 0.9999996423721313

Ketoconazole B-Chemical B-Chemical 0.999679446220398
- O O 0.9974784255027771
induced O O 0.999866247177124
neurologic B-Disease B-Disease 0.9617069363594055
sequelae I-Disease I-Disease 0.9996460676193237
. O O 0.9998123049736023

Associations O O 0.9996143579483032
between O O 0.9999858140945435
use O O 0.9997137188911438
of O O 0.9996044039726257
benzodiazepines B-Chemical B-Chemical 0.9988849759101868
or O O 0.9997451901435852
related O O 0.9733162522315979
drugs O O 0.9321284294128418
and O O 0.9995354413986206
health O O 0.9959760308265686
, O O 0.9999816417694092
physical O O 0.9986959099769592
abilities O O 0.9891304969787598
and O O 0.9999862909317017
cognitive O O 0.9856158494949341
function O O 0.5925851464271545
: O O 0.9999984502792358
a O O 0.9997575879096985
non O O 0.9954487681388855
- O O 0.999553382396698
randomised O O 0.9975360631942749
clinical O O 0.9997594952583313
study O O 0.9998399019241333
in O O 0.9999991655349731
the O O 0.9998182654380798
elderly O O 0.9874712824821472
. O O 0.9999998807907104

We O O 0.9998576641082764
report O O 0.9999995231628418
the O O 0.9999982118606567
case O O 0.9999963045120239
of O O 0.9999872446060181
a O O 0.9998077750205994
70 O O 0.9990968704223633
- O O 0.9999475479125977
year O O 0.9999861717224121
- O O 0.9999599456787109
old O O 0.9999020099639893
hypertensive B-Disease B-Disease 0.9604886174201965
man O O 0.9098429083824158
with O O 0.9999986886978149
a O O 0.9885799288749695
solitary O B-Disease 0.5227451324462891
kidney O I-Disease 0.8500582575798035
and O O 0.9900646805763245
chronic B-Disease B-Disease 0.8802916407585144
renal I-Disease I-Disease 0.6944185495376587
insufficiency I-Disease I-Disease 0.9999901056289673
who O O 0.9957947731018066
developed O O 0.9999808073043823
two O O 0.9994540810585022
episodes O O 0.9510688781738281
of O O 0.9997400641441345
transient O O 0.7725382447242737
anuria B-Disease B-Disease 0.7478243112564087
after O O 0.9996227025985718
losartan B-Chemical B-Chemical 0.9940681457519531
administration O O 0.9930996894836426
. O O 0.9999996423721313

Transient O O 0.9356646537780762
platypnea B-Disease B-Disease 0.8094289302825928
- I-Disease I-Disease 0.5763154029846191
orthodeoxia I-Disease I-Disease 0.827023446559906
- I-Disease I-Disease 0.7563241124153137
like I-Disease I-Disease 0.9124191999435425
syndrome I-Disease I-Disease 0.9997953772544861
induced O O 0.970223069190979
by O O 0.9993971586227417
propafenone B-Chemical B-Chemical 0.9958772659301758
overdose B-Disease B-Disease 0.9889816045761108
in O O 0.9996495246887207
a O O 0.9999207258224487
young O O 0.9984692931175232
woman O O 0.9996917247772217
with O O 0.9999876022338867
Ebstein B-Disease B-Disease 0.9828133583068848
' I-Disease I-Disease 0.9884151220321655
s I-Disease I-Disease 0.9991366267204285
anomaly I-Disease I-Disease 0.9999591112136841
. O O 0.9999425411224365

Mean O O 0.9948948621749878
arterial O O 0.9975922703742981
pressure O O 0.9954957962036133
( O O 0.9999992847442627
as O O 0.999993085861206
a O O 0.9999421834945679
percentage O O 0.9999673366546631
of O O 0.9998989105224609
control O O 0.9994655251502991
+ O O 0.9999784231185913
/ O O 0.9999853372573853
- O O 0.9995228052139282
SEM O O 0.8009123206138611
) O O 0.99997878074646
during O O 0.9999946355819702
randomized O O 0.9854564070701599
infusions O O 0.9831453561782837
of O O 0.9998712539672852
0 O O 0.9979779124259949
. O O 0.999983549118042
03 O O 0.9991033673286438
, O O 0.9998841285705566
0 O O 0.9996932744979858
. O O 0.9999951124191284
1 O O 0.9996521472930908
, O O 0.999886155128479
0 O O 0.9995686411857605
. O O 0.9999887943267822
3 O O 0.9990426898002625
, O O 0.9999163150787354
or O O 0.9999842643737793
1 O O 0.9995754361152649
. O O 0.9999980926513672
0 O O 0.9998987913131714
microgram O O 0.9991617202758789
/ O O 0.9999783039093018
kg O O 0.999607503414154
/ O O 0.9999858140945435
min O O 0.9996538162231445
was O O 0.9999655485153198
99 O O 0.9998278617858887
+ O O 0.9999915361404419
/ O O 0.9999973773956299
- O O 0.9999629259109497
1 O O 0.9997339844703674
, O O 0.9999785423278809
95 O O 0.9998437166213989
+ O O 0.9999905824661255
/ O O 0.9999974966049194
- O O 0.9999449253082275
1 O O 0.9995625615119934
( O O 0.9999909400939941
p O O 0.9996944665908813
less O O 0.9997714161872864
than O O 0.9998664855957031
0 O O 0.9998428821563721
. O O 0.9999728202819824
05 O O 0.999248206615448
) O O 0.9998383522033691
, O O 0.9999839067459106
93 O O 0.9996553659439087
+ O O 0.9999833106994629
/ O O 0.9999969005584717
- O O 0.9998946189880371
1 O O 0.9990900754928589
( O O 0.999980092048645
p O O 0.9992881417274475
less O O 0.9995513558387756
than O O 0.9997785687446594
0 O O 0.9997580647468567
. O O 0.9999524354934692
01 O O 0.9987131357192993
) O O 0.9998112320899963
, O O 0.9999768733978271
or O O 0.9999728202819824
79 O O 0.9997187256813049
+ O O 0.9999798536300659
/ O O 0.9999954700469971
- O O 0.9999567270278931
6 O O 0.9998619556427002
% O O 0.999975323677063
( O O 0.9999732971191406
p O O 0.9990794658660889
less O O 0.9995477795600891
than O O 0.9997242093086243
0 O O 0.9996237754821777
. O O 0.9999440908432007
001 O O 0.9941476583480835
) O O 0.9998564720153809
, O O 0.9999936819076538
respectively O O 0.9999818801879883
, O O 0.9999877214431763
but O O 0.9999849796295166
no O O 0.9994205236434937
tachycardia B-Disease B-Disease 0.999219536781311
and O O 0.99936443567276
no O O 0.9993695616722107
augmentation O O 0.9812635183334351
of O O 0.9987623691558838
the O O 0.9988476037979126
norepinephrine B-Chemical B-Chemical 0.9990140199661255
release O O 0.9945830702781677
rate O O 0.999923825263977
( O O 0.9999971389770508
up O O 0.9999561309814453
to O O 0.9999736547470093
0 O O 0.9997296929359436
. O O 0.9999939203262329
3 O O 0.9999186992645264
microgram O O 0.9990993738174438
/ O O 0.9999732971191406
kg O O 0.9998431205749512
/ O O 0.9999880790710449
min O O 0.9997852444648743
) O O 0.9997320771217346
were O O 0.9999843835830688
observed O O 0.9998223185539246
, O O 0.9999874830245972
which O O 0.9998823404312134
is O O 0.9999666213989258
in O O 0.9999887943267822
contrast O O 0.9999725818634033
to O O 0.9999979734420776
comparable O O 0.9986875653266907
hypotension B-Disease B-Disease 0.9996042847633362
induced O O 0.9848909974098206
by O O 0.999197781085968
hydralazine B-Chemical B-Chemical 0.9999302625656128
or O O 0.99775630235672
nitroglycerin B-Chemical B-Chemical 0.9999303817749023
. O O 0.999983549118042

Topical O O 0.9757105708122253
papaverine B-Chemical B-Chemical 0.9997695088386536
was O O 0.9998186230659485
used O O 0.9999899864196777
as O O 0.9999954700469971
a O O 0.999894380569458
direct O O 0.9990900754928589
therapeutic O O 0.9978639483451843
action O O 0.9992440938949585
to O O 0.9999966621398926
manage O O 0.9931695461273193
vasospasm B-Disease B-Disease 0.9991355538368225
in O O 0.9998863935470581
a O O 0.9999794960021973
total O O 0.9999892711639404
of O O 0.9999300241470337
11 O O 0.9984673857688904
patients O O 0.9999678134918213
. O O 0.9999998807907104

The O O 0.9999788999557495
purpose O O 0.9999938011169434
of O O 0.9999979734420776
the O O 0.9999842643737793
present O O 0.9999567270278931
study O O 0.9999825954437256
was O O 0.9999992847442627
to O O 0.9999949932098389
examine O O 0.9999446868896484
the O O 0.9998877048492432
safety O O 0.9992634654045105
and O O 0.9998542070388794
efficacy O O 0.9991223216056824
of O O 0.9993064403533936
ketamine B-Chemical B-Chemical 0.9999960660934448
for O O 0.9998904466629028
sedation O O 0.9940903782844543
in O O 0.999997615814209
the O O 0.9998902082443237
treatment O O 0.9999722242355347
of O O 0.9999885559082031
children O O 0.9929607510566711
' O O 0.9986814856529236
s O O 0.9721686244010925
fractures B-Disease B-Disease 0.9889496564865112
in O O 0.9999240636825562
the O O 0.9998001456260681
emergency O O 0.997428834438324
department O O 0.9998125433921814
. O O 0.9999997615814209

This O O 0.9999150037765503
work O O 0.999830961227417
evaluates O O 0.9999511241912842
the O O 0.9995937943458557
antinociceptive O O 0.6772757172584534
and O O 0.9891930222511292
constipating B-Disease O 0.9132437705993652
effects O O 0.9996899366378784
of O O 0.9999732971191406
the O O 0.9993677735328674
combination O O 0.9996222257614136
of O O 0.9999551773071289
3 O O 0.9756066203117371
. O O 0.999988317489624
2 O O 0.9999144077301025
mg O O 0.9999097585678101
/ O O 0.9999840259552002
kg O O 0.9997151494026184
s O O 0.9976262450218201
. O O 0.9999752044677734
c O O 0.9841859936714172
. O O 0.9999086856842041
morphine B-Chemical B-Chemical 0.9990271329879761
with O O 0.9997699856758118
177 O O 0.9641419053077698
. O O 0.9999990463256836
8 O O 0.9999256134033203
mg O O 0.9999532699584961
/ O O 0.999992847442627
kg O O 0.9998489618301392
s O O 0.9980210065841675
. O O 0.999962568283081
c O O 0.9701846241950989
. O O 0.9997641444206238
metamizol B-Chemical B-Chemical 0.9997401833534241
in O O 0.9998383522033691
acutely O O 0.9981340765953064
and O O 0.999690055847168
chronically O O 0.9706025123596191
treated O O 0.987919807434082
( O O 0.9999866485595703
once O O 0.9999966621398926
a O O 0.9999719858169556
day O O 0.9999711513519287
for O O 0.9999985694885254
12 O O 0.9998754262924194
days O O 0.9999736547470093
) O O 0.9999184608459473
rats O O 0.999821126461029
. O O 0.9999997615814209

One O O 0.9988980293273926
patient O O 0.999995231628418
showed O O 0.9999997615814209
no O O 0.9999721050262451
recovery O O 0.9973192811012268
of O O 0.9998524188995361
later O O 0.9981846213340759
waves O O 0.8334195613861084
and O O 0.9999961853027344
a O O 0.9995617270469666
delayed O O 0.9987969398498535
profound O O 0.9994138479232788
sensorineural B-Disease O 0.9458377957344055
hearing I-Disease B-Disease 0.47795721888542175
loss I-Disease I-Disease 0.9999790191650391
. O O 0.9998064637184143

Protection O O 0.9770070314407349
against O O 0.9998537302017212
amphetamine B-Chemical B-Chemical 0.9999536275863647
- O O 0.9976032376289368
induced O O 0.9997312426567078
neurotoxicity B-Disease B-Disease 0.9998660087585449
toward O O 0.9994288086891174
striatal O O 0.9951512813568115
dopamine B-Chemical B-Chemical 0.9921999573707581
neurons O O 0.9901948571205139
in O O 0.9999840259552002
rodents O O 0.9969140291213989
by O O 0.9999639987945557
LY274614 B-Chemical B-Chemical 0.9996984004974365
, O O 0.9999748468399048
an O O 0.999955415725708
excitatory O O 0.8151059746742249
amino B-Chemical B-Chemical 0.9655072689056396
acid I-Chemical I-Chemical 0.9998773336410522
antagonist O O 0.860527753829956
. O O 0.9999966621398926

Eight O O 0.999038577079773
glaucomatous B-Disease B-Disease 0.9819678664207458
patients O O 0.929368257522583
chronically O O 0.6309521794319153
treated O O 0.9906251430511475
with O O 0.9999147653579712
timolol B-Chemical B-Chemical 0.9996649026870728
0 O O 0.5361467599868774
. O O 0.999893307685852
5 O O 0.9998051524162292
% O O 0.9999836683273315
/ O O 0.9999680519104004
12h O O 0.9940954446792603
, O O 0.9999885559082031
suffering O O 0.9999767541885376
from O O 0.9999433755874634
depression B-Disease B-Disease 0.9996520280838013
diagnosed O O 0.9892706871032715
through O O 0.9999939203262329
DMS O O 0.9205499291419983
- O O 0.9979598522186279
III O O 0.9891574382781982
- O O 0.999893307685852
R O O 0.9878606200218201
criteria O O 0.9999700784683228
, O O 0.9999998807907104
were O O 0.9999974966049194
included O O 0.9999983310699463
in O O 0.9999969005584717
the O O 0.999950647354126
study O O 0.9999852180480957
. O O 0.9999996423721313

In O O 0.9999860525131226
addition O O 0.9999818801879883
, O O 0.9999927282333374
reflex O O 0.770389199256897
bradycardia B-Disease B-Disease 0.764201819896698
caused O O 0.9997020363807678
by O O 0.9999635219573975
injected O O 0.9789765477180481
norepinephrine B-Chemical B-Chemical 0.9992110729217529
was O O 0.9999557733535767
significantly O O 0.9999886751174927
enhanced O O 0.9997625946998596
by O O 0.9998186230659485
L B-Chemical B-Chemical 0.951839804649353
- I-Chemical I-Chemical 0.9973433613777161
dopa I-Chemical I-Chemical 0.99996018409729
, O O 0.9952490329742432
DL B-Chemical B-Chemical 0.926852285861969
- I-Chemical I-Chemical 0.5786483287811279
Threo I-Chemical I-Chemical 0.9582836627960205
- I-Chemical O 0.5516921877861023
dihydroxyphenylserine I-Chemical B-Chemical 0.867577075958252
had O O 0.9999814033508301
no O O 0.9999375343322754
effect O O 0.9998948574066162
on O O 0.99992835521698
blood O O 0.9930927753448486
pressure O O 0.8802516460418701
, O O 0.9999949932098389
heart O O 0.9878841042518616
rate O O 0.9620287418365479
or O O 0.99981290102005
reflex O O 0.8846742510795593
responses O O 0.9833155870437622
to O O 0.9999797344207764
norepinephrine B-Chemical B-Chemical 0.9995431900024414
. O O 0.9999912977218628

SETTING O O 0.9992127418518066
: O O 0.9999982118606567
National O O 0.9997714161872864
Institutes O O 0.9995585083961487
of O O 0.9996389150619507
Health O O 0.9985265731811523
clinical O O 0.9997977614402771
research O O 0.9988431930541992
center O O 0.9998204112052917
. O O 0.9999998807907104

The O O 0.9999451637268066
pharmacological O O 0.9956915974617004
challenge O O 0.999758780002594
data O O 0.9999401569366455
suggest O O 0.999998927116394
that O O 0.9997838139533997
tolerance O O 0.8395684957504272
may O O 0.999996542930603
occur O O 0.9997779726982117
to O O 0.999990701675415
seizure B-Disease B-Disease 0.9990878105163574
activity O O 0.7885309457778931
induced O O 0.9996312856674194
by O O 0.9998158812522888
PTZ B-Chemical B-Chemical 0.9903068542480469
and O O 0.9978391528129578
PTX B-Chemical B-Chemical 0.9950474500656128
24 O O 0.6245248913764954
h O O 0.8602138757705688
after O O 0.9999290704727173
gamma B-Chemical B-Chemical 0.7571321129798889
- I-Chemical I-Chemical 0.9673098921775818
HCH I-Chemical I-Chemical 0.9996547698974609
, O O 0.9999160766601562
since O O 0.9999985694885254
the O O 0.9999499320983887
response O O 0.9999904632568359
to O O 0.9999991655349731
only O O 0.9999732971191406
these O O 0.9998725652694702
two O O 0.9963700771331787
seizure B-Disease B-Disease 0.999452531337738
- O O 0.9884935021400452
inducing O O 0.9992642998695374
agents O O 0.9236992597579956
is O O 0.9999884366989136
decreased O O 0.999077320098877
. O O 0.9999986886978149

These O O 0.9995025396347046
defects O O 0.9835789203643799
explain O O 0.999994158744812
the O O 0.9998894929885864
abnormal O O 0.9107452034950256
erythrocyte O O 0.8175744414329529
shape O O 0.9891332983970642
and O O 0.999993085861206
decreased O O 0.9972136616706848
mechanical O O 0.988077700138092
stability O O 0.7772809267044067
promoted O O 0.9937728047370911
by O O 0.9998586177825928
TAM B-Chemical B-Chemical 0.9992425441741943
, O O 0.9996607303619385
resulting O O 0.9999876022338867
in O O 0.9999443292617798
hemolytic B-Disease B-Disease 0.7926803231239319
anemia I-Disease I-Disease 0.9992400407791138
. O O 0.99993896484375

The O O 0.9996030926704407
convulsant O O 0.585279643535614
activity O O 0.9683950543403625
of O O 0.9991875290870667
bupivacaine B-Chemical B-Chemical 0.9998055100440979
was O O 0.9998807907104492
not O O 0.9999771118164062
significantly O O 0.9999850988388062
modified O O 0.9997095465660095
but O O 0.9999624490737915
calcium B-Chemical B-Chemical 0.9998192191123962
channel O O 0.9734969735145569
blockers O O 0.9902732968330383
decreased O O 0.9997671246528625
the O O 0.999889612197876
time O O 0.9999723434448242
of O O 0.9998481273651123
latency O O 0.9910846948623657
to O O 0.9999839067459106
obtain O O 0.991706371307373
bupivacaine B-Chemical B-Chemical 0.9999202489852905
- O O 0.9993681311607361
induced O O 0.9996417760848999
convulsions B-Disease B-Disease 0.9985530972480774
; O O 0.9997360110282898
this O O 0.9997536540031433
effect O O 0.9999537467956543
was O O 0.9999984502792358
less O O 0.9999668598175049
pronounced O O 0.9994762539863586
with O O 0.9999011754989624
bepridil B-Chemical B-Chemical 0.9964981079101562
. O O 0.9999808073043823

Furthermore O O 0.9999433755874634
, O O 0.9999655485153198
it O O 0.999981164932251
appears O O 0.9999984502792358
that O O 0.9999765157699585
striatal O O 0.9395313858985901
- O O 0.9962957501411438
resident O O 0.9995554089546204
microglia O O 0.815039873123169
respond O O 0.9999505281448364
to O O 0.9999799728393555
METH B-Chemical B-Chemical 0.9759964942932129
with O O 0.9997552037239075
an O O 0.9998500347137451
activation O O 0.9449068307876587
cascade O O 0.9519866108894348
and O O 0.9999984502792358
then O O 0.9999755620956421
return O O 0.9996626377105713
to O O 0.999907374382019
a O O 0.9994839429855347
surveying O O 0.9852590560913086
state O O 0.99895179271698
without O O 0.9999994039535522
undergoing O O 0.999771773815155
apoptosis O B-Disease 0.9356783628463745
or O O 0.9939735531806946
migration O O 0.7491392493247986
. O O 0.9999357461929321

METHODS O O 0.9930563569068909
: O O 0.9999967813491821
Behavioral O O 0.9977999329566956
experiments O O 0.9875679016113281
and O O 0.9999536275863647
electrophysiological O O 0.9984138011932373
recordings O O 0.9921592473983765
were O O 0.999998927116394
performed O O 0.9999960660934448
in O O 0.9999990463256836
the O O 0.9999562501907349
present O O 0.9999583959579468
study O O 0.9999830722808838
. O O 0.9999998807907104

BACKGROUND O O 0.9950212240219116
: O O 0.999998927116394
An O O 0.9999970197677612
association O O 0.9999405145645142
between O O 0.9999815225601196
the O O 0.999393105506897
use O O 0.9999432563781738
of O O 0.999925971031189
oral B-Chemical B-Chemical 0.7034828662872314
contraceptives I-Chemical I-Chemical 0.9997864365577698
and O O 0.9996883869171143
the O O 0.9999719858169556
risk O O 0.999942421913147
of O O 0.9999881982803345
myocardial B-Disease B-Disease 0.9549601674079895
infarction I-Disease I-Disease 0.9999436140060425
has O O 0.9982245564460754
been O O 0.9999818801879883
found O O 0.9999977350234985
in O O 0.9999966621398926
some O O 0.9999758005142212
, O O 0.999981164932251
but O O 0.9999964237213135
not O O 0.9999992847442627
all O O 0.9999699592590332
, O O 0.9999964237213135
studies O O 0.9999443292617798
. O O 0.9999996423721313

In O O 0.999985933303833
four O O 0.9999591112136841
patients O O 0.9999711513519287
HBV O O 0.9570369720458984
DNA O O 0.8356264233589172
levels O O 0.999945878982544
were O O 0.9999724626541138
higher O O 0.9996020197868347
than O O 0.999943733215332
normal O O 0.996025562286377
at O O 0.9999881982803345
baseline O O 0.9990278482437134
. O O 0.9999998807907104

Infusions O O 0.9116522073745728
of O O 0.9974887371063232
epinephrine B-Chemical B-Chemical 0.9999492168426514
( O O 0.9993452429771423
4 O O 0.9931647181510925
mug O O 0.9956637024879456
per O O 0.9999258518218994
kilogram O O 0.9963060617446899
per O O 0.9999929666519165
minute O O 0.9999146461486816
for O O 0.9999951124191284
6 O O 0.9995039701461792
hours O O 0.9997205138206482
) O O 0.9999344348907471
increased O O 0.9993405938148499
radiocalcium B-Chemical B-Chemical 0.9994128942489624
uptakes O O 0.9450475573539734
into O O 0.9999862909317017
intact O O 0.9990471005439758
myocardium O O 0.8155090808868408
and O O 0.999567449092865
each O O 0.999849796295166
of O O 0.9999552965164185
its O O 0.9998873472213745
subcellular O O 0.965794026851654
components O O 0.9942252039909363
with O O 0.9999980926513672
the O O 0.9998925924301147
mitochondrial O O 0.9659996628761292
fraction O O 0.5972336530685425
showing O O 0.9999916553497314
the O O 0.9999805688858032
most O O 0.9999463558197021
consistent O O 0.9969053864479065
changes O O 0.9941704869270325
when O O 0.9999915361404419
compared O O 0.999882698059082
to O O 0.9999157190322876
saline O O 0.49138107895851135
- O O 0.9995471835136414
infused O O 0.9979222416877747
control O O 0.9963962435722351
animals O O 0.9956458210945129
( O O 0.9999809265136719
4 O O 0.9968993663787842
, O O 0.9996596574783325
957 O O 0.9943901896476746
vs O O 0.9999151229858398
. O O 0.9999969005584717
827 O O 0.9991312623023987
counts O O 0.9999277591705322
per O O 0.9999979734420776
minute O O 0.9999892711639404
per O O 0.9999903440475464
gram O O 0.9998914003372192
of O O 0.999896764755249
dried O O 0.7771763801574707
tissue O O 0.9213861227035522
or O O 0.9998822212219238
fraction O O 0.9887621998786926
) O O 0.9999327659606934
. O O 0.9999995231628418

A O O 0.9995927214622498
total O O 0.9999955892562866
of O O 0.9999669790267944
sixty O O 0.9996758699417114
patients O O 0.9999843835830688
were O O 0.9999970197677612
trated O O 0.9997220635414124
with O O 0.9998880624771118
bromperidol B-Chemical B-Chemical 0.9995439648628235
first O O 0.9945290684700012
in O O 0.999982476234436
open O O 0.9970738887786865
conditions O O 0.9857777953147888
( O O 0.9999994039535522
20 O O 0.9998652935028076
patients O O 0.999975323677063
) O O 0.9999760389328003
, O O 0.9999957084655762
then O O 0.9999582767486572
on O O 0.999975323677063
a O O 0.9996567964553833
double O O 0.999241828918457
blind O O 0.9923549890518188
basis O O 0.9987586736679077
( O O 0.9999990463256836
40 O O 0.9998645782470703
patients O O 0.999974250793457
) O O 0.999971866607666
with O O 0.9999700784683228
haloperidol B-Chemical B-Chemical 0.9998779296875
as O O 0.9997853636741638
the O O 0.9999288320541382
reference O O 0.9938136339187622
substance O O 0.9984846711158752
. O O 0.9999998807907104

Cocaine B-Chemical B-Chemical 0.9999595880508423
- O O 0.9985007047653198
induced O O 0.999840497970581
anxiety B-Disease B-Disease 0.9997242093086243
was O O 0.9993485808372498
also O O 0.9998728036880493
attenuated O O 0.9991602897644043
in O O 0.9999921321868896
Dbh O O 0.9338280558586121
+ O O 0.9999371767044067
/ O O 0.9999613761901855
- O O 0.9998811483383179
mice O O 0.9994186162948608
following O O 0.9999985694885254
administration O O 0.9975401163101196
of O O 0.9990845918655396
disulfiram B-Chemical B-Chemical 0.9937973618507385
, O O 0.9994825124740601
a O O 0.9970152378082275
dopamine B-Chemical B-Chemical 0.9999250173568726
beta O I-Chemical 0.9207143187522888
- O I-Chemical 0.8382425904273987
hydroxylase O I-Chemical 0.989896297454834
( O O 0.9982157945632935
DBH O O 0.8273218274116516
) O O 0.9758457541465759
inhibitor O O 0.8414428234100342
. O O 0.999996542930603

No O O 0.998781144618988
hepatic O O 0.7061378955841064
preneoplastic O O 0.7184059023857117
nodules O O 0.6995258927345276
or O O 0.999922513961792
hepatocellular B-Disease B-Disease 0.7223148345947266
carcinomas I-Disease I-Disease 0.9988535642623901
developed O O 0.9965577721595764
in O O 0.9998230338096619
rats O O 0.9991298317909241
fed O O 0.9994708895683289
the O O 0.999517560005188
plain O O 0.9710640907287598
choline B-Chemical B-Chemical 0.9986287355422974
- O O 0.9981368780136108
supplemented O O 0.9997870326042175
diet O O 0.9822404980659485
, O O 0.9999910593032837
while O O 0.999993085861206
one O O 0.9994906187057495
preneoplastic O O 0.7135862112045288
nodule O O 0.9810494184494019
and O O 0.999996542930603
one O O 0.9999032020568848
hepatocellular B-Disease B-Disease 0.5974410772323608
carcinoma I-Disease I-Disease 0.9989427924156189
developed O O 0.9931314587593079
in O O 0.9999728202819824
two O O 0.9997038245201111
rats O O 0.9995385408401489
fed O O 0.9998754262924194
the O O 0.9998776912689209
same O O 0.9972854852676392
diet O O 0.9934630393981934
containing O O 0.9999266862869263
phenobarbital B-Chemical B-Chemical 0.9933506846427917
. O O 0.9998855590820312

High O O 0.9984626770019531
doses O O 0.9999479055404663
of O O 0.9995385408401489
vitamin B-Chemical B-Chemical 0.9999494552612305
D I-Chemical I-Chemical 0.9995296001434326
are O O 0.998695433139801
known O O 0.9999940395355225
to O O 0.9999822378158569
cause O O 0.9998127818107605
calcification B-Disease B-Disease 0.9973793029785156
of I-Disease I-Disease 0.6672781705856323
the I-Disease I-Disease 0.9327537417411804
artery I-Disease I-Disease 0.9999005794525146
media O O 0.6657783389091492
in O O 0.9997616410255432
as O O 0.999995231628418
little O O 0.9999867677688599
as O O 0.9999958276748657
3 O O 0.9998480081558228
to O O 0.9999703168869019
4 O O 0.9995594620704651
days O O 0.9999727010726929
. O O 0.9999998807907104

In O O 0.999985933303833
behavioral O O 0.9974315762519836
tests O O 0.9978634715080261
, O O 0.999998927116394
animals O O 0.9695876836776733
treated O O 0.9999092817306519
with O O 0.9998985528945923
terbutaline B-Chemical B-Chemical 0.9998948574066162
on O O 0.9997029900550842
PN O O 0.9028101563453674
2 O O 0.9973723888397217
to O O 0.9999618530273438
5 O O 0.9885451197624207
showed O O 0.9999971389770508
consistent O O 0.9963427186012268
patterns O O 0.9971016049385071
of O O 0.9999276399612427
hyper O O 0.7455230355262756
- O O 0.8584807515144348
reactivity O O 0.5882697105407715
to O O 0.9988120794296265
novelty O B-Disease 0.9516093730926514
and O O 0.9964861869812012
aversive O O 0.9684879779815674
stimuli O O 0.46555447578430176
when O O 0.999970555305481
assessed O O 0.9995761513710022
in O O 0.9999914169311523
a O O 0.999896764755249
novel O O 0.9962664246559143
open O O 0.9967473745346069
field O O 0.9997169375419617
, O O 0.9999985694885254
as O O 0.9999897480010986
well O O 0.9999769926071167
as O O 0.9999878406524658
in O O 0.9999710321426392
the O O 0.9998718500137329
acoustic O O 0.9739185571670532
startle O O 0.4737164080142975
response O O 0.9975044131278992
test O O 0.999980092048645
. O O 0.9999998807907104

Repeated O O 0.9985238909721375
transient O O 0.8713298439979553
anuria B-Disease B-Disease 0.7101602554321289
following O O 0.9998785257339478
losartan B-Chemical B-Chemical 0.9992347955703735
administration O O 0.9671294093132019
in O O 0.9999970197677612
a O O 0.9997907280921936
patient O O 0.9999529123306274
with O O 0.9999980926513672
a O O 0.9919919371604919
solitary O O 0.7112884521484375
kidney O O 0.9295922517776489
. O O 0.998478353023529

The O O 0.9995793700218201
convulsant O O 0.6810303926467896
activity O O 0.7667684555053711
, O O 0.9999909400939941
the O O 0.9999892711639404
time O O 0.9999977350234985
of O O 0.9999264478683472
latency O O 0.9901761412620544
to O O 0.9998874664306641
convulse O O 0.8071281313896179
and O O 0.9983362555503845
the O O 0.9998290538787842
mortality O O 0.924149215221405
rate O O 0.9999396800994873
were O O 0.999990701675415
assessed O O 0.9999579191207886
in O O 0.9999953508377075
each O O 0.9997928738594055
group O O 0.9997879862785339
. O O 0.9999995231628418

Clotiazepam B-Chemical B-Chemical 0.9992401599884033
- O O 0.9996781349182129
induced O O 0.9999892711639404
acute O B-Disease 0.5167945027351379
hepatitis B-Disease I-Disease 0.902430534362793
. O O 0.9996353387832642

A O O 0.9993777275085449
frequency O O 0.9998393058776855
of O O 0.9998376369476318
bradycardia B-Disease B-Disease 0.9986531734466553
of O O 0.9795395135879517
50 O O 0.9968200922012329
% O O 0.9999189376831055
was O O 0.9999935626983643
noted O O 0.9999943971633911
in O O 0.9999985694885254
the O O 0.9998781681060791
control O O 0.9871019721031189
group O O 0.9996968507766724
, O O 0.9999966621398926
but O O 0.9999818801879883
this O O 0.9998946189880371
was O O 0.9999914169311523
not O O 0.9999914169311523
significantly O O 0.9999943971633911
different O O 0.9999822378158569
from O O 0.9999812841415405
the O O 0.9998525381088257
frequency O O 0.9997883439064026
with O O 0.9999995231628418
the O O 0.999922513961792
active O O 0.9818323850631714
drugs O O 0.9969786405563354
. O O 0.9999992847442627

Many O O 0.9999263286590576
new O O 0.9999464750289917
serotonergic B-Chemical O 0.43848860263824463
antidepressants I-Chemical B-Chemical 0.9220248460769653
have O O 0.9999641180038452
been O O 0.9998388290405273
introduced O O 0.9999579191207886
over O O 0.9999979734420776
the O O 0.9999635219573975
past O O 0.9999977350234985
decade O O 0.9999523162841797
. O O 0.9999996423721313

The O O 0.9996023774147034
adenylate O O 0.8713388442993164
energy O O 0.7033095359802246
charge O O 0.998981773853302
was O O 0.9999871253967285
found O O 0.9999922513961792
to O O 0.9999903440475464
be O O 0.9999719858169556
significantly O O 0.9999222755432129
decreased O O 0.9991494417190552
, O O 0.9999722242355347
while O O 0.9999778270721436
the O O 0.9997134804725647
phophorylcreatine B-Chemical B-Chemical 0.9990000128746033
mole O O 0.9386051297187805
fraction O O 0.9990897178649902
was O O 0.9999890327453613
unchanged O O 0.9999161958694458
. O O 0.9999996423721313

The O O 0.9989616870880127
deformations B-Disease O 0.9272114634513855
caused O O 0.9958859086036682
by O O 0.9999620914459229
both O O 0.9684522151947021
coniine B-Chemical B-Chemical 0.9994196891784668
and O O 0.9972840547561646
nicotine B-Chemical B-Chemical 0.999977707862854
sulfate O O 0.6550195217132568
were O O 0.9999985694885254
excessive B-Disease O 0.8365914821624756
flexion I-Disease O 0.5800302624702454
or I-Disease O 0.9997209906578064
extension I-Disease O 0.995071530342102
of I-Disease O 0.9989365935325623
one I-Disease O 0.9952136278152466
or I-Disease O 0.9999921321868896
more I-Disease O 0.9998995065689087
toes I-Disease O 0.9990569949150085
. O O 0.9999998807907104

In O O 0.999937891960144
contrast O O 0.9999288320541382
, O O 0.9999948740005493
dosages O O 0.9976806640625
of O O 0.9977765679359436
Mipafox B-Chemical B-Chemical 0.9994893074035645
( O O 0.9997325539588928
less O O 0.9995896220207214
than O O 0.9997833371162415
or O O 0.9998213648796082
equal O O 0.999940037727356
to O O 0.9999779462814331
5 O O 0.9998552799224854
mg O O 0.9999208450317383
/ O O 0.9999548196792603
kg O O 0.9997954964637756
) O O 0.9999271631240845
which O O 0.9999511241912842
inhibited O O 0.9957711100578308
mean O O 0.9991531372070312
NTE O O 0.5878288149833679
activity O O 0.9966135621070862
in O O 0.9999444484710693
spinal O O 0.9978575110435486
cord O O 0.9909308552742004
less O O 0.9996428489685059
than O O 0.9999630451202393
or O O 0.9998345375061035
equal O O 0.9999263286590576
to O O 0.9999833106994629
61 O O 0.9997900128364563
% O O 0.9999275207519531
and O O 0.9998716115951538
brain O O 0.9829575419425964
less O O 0.9996222257614136
than O O 0.9999537467956543
or O O 0.9999181032180786
equal O O 0.9999873638153076
to O O 0.9999892711639404
60 O O 0.9998970031738281
% O O 0.99998939037323
produced O O 0.9999806880950928
this O O 0.9999507665634155
degree O O 0.9995137453079224
of O O 0.999969482421875
cord B-Disease O 0.9888715147972107
damage I-Disease O 0.7115089297294617
in O O 0.9999747276306152
only O O 0.999990701675415
9 O O 0.999907374382019
% O O 0.9999935626983643
of O O 0.9999839067459106
the O O 0.9997965693473816
animals O O 0.9976145029067993
. O O 0.9999998807907104

The O O 0.9998791217803955
possibility O O 0.9999994039535522
of O O 0.9999953508377075
a O O 0.999834418296814
clinically O O 0.9998078942298889
relevant O O 0.999536395072937
dopamine B-Chemical B-Chemical 0.99993896484375
- O O 0.9979302883148193
antagonistic O O 0.9584823846817017
capacity O O 0.9990172386169434
of O O 0.9996767044067383
fluoxetine B-Chemical B-Chemical 0.9971215128898621
in O O 0.9999184608459473
Parkinson B-Disease B-Disease 0.5236556529998779
' I-Disease I-Disease 0.9993258714675903
s I-Disease I-Disease 0.9999934434890747
disease I-Disease I-Disease 0.9999949932098389
patients O O 0.9929898977279663
must O O 0.9999997615814209
be O O 0.9999964237213135
considered O O 0.9999943971633911
. O O 0.9999988079071045

BACKGROUND O O 0.9961419701576233
: O O 0.9999945163726807
In O O 0.9999969005584717
man O O 0.9997203946113586
, O O 0.999998927116394
differences O O 0.9959679841995239
in O O 0.9993188381195068
angiotensin B-Chemical B-Chemical 0.9990947246551514
- O I-Chemical 0.8756610751152039
converting O I-Chemical 0.968302309513092
enzyme O I-Chemical 0.6816464066505432
( O I-Chemical 0.9272639155387878
ACE O I-Chemical 0.7253221869468689
) O O 0.8349445462226868
levels O O 0.9989705085754395
, O O 0.9999966621398926
related O O 0.9999299049377441
to O O 0.9998145699501038
ACE O B-Chemical 0.9132180213928223
( O O 0.9991846680641174
I O O 0.8837489485740662
/ O O 0.9988837838172913
D O O 0.8807852864265442
) O O 0.9989691972732544
genotype O O 0.4966053068637848
, O O 0.9999936819076538
are O O 0.9999620914459229
associated O O 0.9999991655349731
with O O 0.999994158744812
renal O B-Disease 0.9174874424934387
prognosis O I-Disease 0.9856773614883423
. O O 0.9997512698173523

Eating B-Disease B-Disease 0.8516643643379211
disorders I-Disease I-Disease 0.9963401556015015
and O O 0.9998466968536377
the O O 0.999962568283081
associated O O 0.9998040795326233
behavioural O B-Disease 0.6399996280670166
problems O I-Disease 0.9978051781654358
and O O 0.9935283064842224
drug B-Disease B-Disease 0.7904320359230042
abuse I-Disease I-Disease 0.9986909031867981
are O O 0.9984028935432434
uncommon O O 0.9920205473899841
in O O 0.999969482421875
pregnancy O O 0.998379111289978
. O O 0.9999996423721313

Passive O O 0.9946649074554443
avoidance O O 0.9909991025924683
paradigm O O 0.9654996991157532
and O O 0.9999712705612183
elevated O O 0.9879850745201111
plus O O 0.9950308799743652
maze O O 0.981230616569519
test O O 0.9999666213989258
were O O 0.9999884366989136
used O O 0.9999837875366211
to O O 0.9999938011169434
assess O O 0.9996403455734253
cognitive O O 0.9439239501953125
function O O 0.7161206007003784
. O O 0.9999724626541138

This O O 0.9995841383934021
complication O O 0.9573289155960083
reappeared O O 0.9999692440032959
on O O 0.9999663829803467
day O O 0.9985795021057129
25 O O 0.9978367686271667
during O O 0.9999964237213135
the O O 0.9999275207519531
second O O 0.9999470710754395
dose O O 0.9999837875366211
of O O 0.9998528957366943
5 B-Chemical B-Chemical 0.8802459239959717
- I-Chemical I-Chemical 0.9976983666419983
fluorouracil I-Chemical I-Chemical 0.9997143149375916
and O O 0.9915545582771301
folinic B-Chemical B-Chemical 0.9649595022201538
acid I-Chemical I-Chemical 0.9999891519546509
, O O 0.9998056292533875
which O O 0.9999401569366455
were O O 0.9999786615371704
then O O 0.9999600648880005
the O O 0.999985933303833
only O O 0.9999728202819824
drugs O O 0.9982765913009644
given O O 0.9999902248382568
. O O 0.9999985694885254

However O O 0.9999678134918213
, O O 0.9999977350234985
for O O 0.9999929666519165
recipients O O 0.9999716281890869
of O O 0.9999747276306152
organ O O 0.9978353381156921
transplantation O O 0.9996885061264038
, O O 0.9999994039535522
removing O O 0.9999549388885498
the O O 0.9998279809951782
inciting O O 0.8118876218795776
agent O O 0.9164702296257019
is O O 0.9999924898147583
not O O 0.9999896287918091
without O O 0.9999977350234985
the O O 0.999969482421875
attendant O O 0.998960018157959
risk O O 0.9999896287918091
of O O 0.9999984502792358
precipitating O O 0.9998427629470825
acute O O 0.9196828007698059
rejection O O 0.8980595469474792
and O O 0.9984027743339539
graft O B-Disease 0.9557396173477173
loss O I-Disease 0.9999457597732544
. O O 0.9995991587638855

This O O 0.999962329864502
report O O 0.999993085861206
describes O O 0.9999979734420776
the O O 0.9999825954437256
first O O 0.9999804496765137
published O O 0.9999762773513794
case O O 0.9999918937683105
of O O 0.9999876022338867
cardiorespiratory B-Disease B-Disease 0.8867371678352356
arrest I-Disease I-Disease 0.9981279969215393
and O O 0.994364857673645
death B-Disease B-Disease 0.9997854828834534
associated O O 0.997569739818573
with O O 0.9999521970748901
intramuscular O O 0.9796522259712219
administration O O 0.9725350737571716
of O O 0.996601939201355
midazolam B-Chemical B-Chemical 0.9954261183738708
. O O 0.9999648332595825

The O O 0.9986246824264526
nitric B-Chemical B-Chemical 0.7566375732421875
oxide I-Chemical I-Chemical 0.9999121427536011
( O O 0.9985610842704773
NO B-Chemical B-Chemical 0.9899411797523499
) O O 0.9925163388252258
inhibitor O O 0.9861603379249573
nitro B-Chemical B-Chemical 0.8433642983436584
- I-Chemical I-Chemical 0.8313368558883667
L I-Chemical I-Chemical 0.8713392019271851
- I-Chemical I-Chemical 0.9942822456359863
arginine I-Chemical I-Chemical 0.9999338388442993
methyl I-Chemical I-Chemical 0.9434491991996765
ester I-Chemical I-Chemical 0.999643087387085
( O O 0.9995481371879578
L B-Chemical B-Chemical 0.9519789218902588
- I-Chemical I-Chemical 0.9975161552429199
NAME I-Chemical I-Chemical 0.9998468160629272
) O O 0.9954648613929749
may O O 0.9999974966049194
act O O 0.9999818801879883
as O O 0.9999924898147583
an O O 0.9996048808097839
otoprotectant O O 0.49696600437164307
against O O 0.99994957447052
high B-Disease O 0.9988991022109985
- I-Disease O 0.9985550045967102
frequency I-Disease O 0.9997497200965881
hearing I-Disease B-Disease 0.9919309020042419
loss I-Disease I-Disease 0.9999934434890747
caused O O 0.9837469458580017
by O O 0.9999107122421265
gentamicin B-Chemical B-Chemical 0.9999208450317383
, O O 0.9999003410339355
but O O 0.9999955892562866
further O O 0.9999911785125732
studies O O 0.9999256134033203
are O O 0.9999994039535522
needed O O 0.9999990463256836
to O O 0.9999992847442627
confirm O O 0.9999945163726807
this O O 0.9995576739311218
. O O 0.9999982118606567
Aminoglycoside B-Chemical B-Chemical 0.9994837045669556
antibiotics O O 0.8520925045013428
are O O 0.9999912977218628
still O O 0.9999585151672363
widely O O 0.9993793964385986
used O O 0.999974250793457
by O O 0.9999924898147583
virtue O O 0.9992771744728088
of O O 0.9999676942825317
their O O 0.9998655319213867
efficacy O O 0.9978352189064026
and O O 0.9999943971633911
low O O 0.9985764026641846
cost O O 0.9986487030982971
. O O 0.9999995231628418

In O O 0.9997212290763855
controls O O 0.9995384216308594
, O O 0.9999997615814209
no O O 0.9999839067459106
predictive O O 0.9989960789680481
values O O 0.9901028871536255
for O O 0.9999738931655884
renal O O 0.9126251935958862
parameters O O 0.9355368614196777
were O O 0.9992063641548157
observed O O 0.9998880624771118
. O O 0.9999994039535522

Finally O O 0.9993423819541931
, O O 0.9999971389770508
the O O 0.9998894929885864
dose O O 0.99843829870224
response O O 0.9999217987060547
for O O 0.9999990463256836
cardiovascular O B-Disease 0.860828697681427
events O I-Disease 0.9834293127059937
of O O 0.7498491406440735
nicotine B-Chemical B-Chemical 0.9999703168869019
appears O O 0.999945878982544
to O O 0.9999890327453613
be O O 0.9999815225601196
flat O O 0.9995229244232178
, O O 0.9999971389770508
suggesting O O 0.9999967813491821
that O O 0.9999619722366333
if O O 0.9998724460601807
nicotine B-Chemical B-Chemical 0.9999724626541138
is O O 0.9998584985733032
involved O O 0.9999958276748657
, O O 0.9999997615814209
adverse O O 0.9975907802581787
effects O O 0.9987241625785828
might O O 0.9999994039535522
be O O 0.9999971389770508
seen O O 0.999984860420227
with O O 0.9999959468841553
relatively O O 0.9999477863311768
low O O 0.9993410706520081
- O O 0.9992576241493225
level O O 0.9980499744415283
cigarette O O 0.7013137936592102
exposures O O 0.9802683591842651
. O O 0.9999994039535522

These O O 0.9997163414955139
patients O O 0.9999533891677856
showed O O 0.9999997615814209
persistently O O 0.9997819066047668
good O O 0.999288022518158
graft O O 0.9451432824134827
function O O 0.9618671536445618
. O O 0.9999996423721313

Veno B-Disease B-Disease 0.5613185167312622
- I-Disease I-Disease 0.755173921585083
occlusive I-Disease I-Disease 0.9088792204856873
liver I-Disease I-Disease 0.5665859580039978
disease I-Disease I-Disease 0.9999494552612305
after O O 0.9993809461593628
dacarbazine B-Chemical B-Chemical 0.9999788999557495
therapy O O 0.9990359544754028
( O O 0.9999990463256836
DTIC B-Chemical O 0.5493019223213196
) O O 0.9997864365577698
for O O 0.9999874830245972
melanoma B-Disease B-Disease 0.9996838569641113
. O O 0.9998880624771118

Whether O O 0.9997637867927551
or O O 0.9999995231628418
not O O 0.9999991655349731
the O O 0.9999831914901733
neuronal O O 0.9462899565696716
transmission O O 0.6994277834892273
may O O 0.999974250793457
be O O 0.9999465942382812
affected O O 0.9999281167984009
by O O 0.9999806880950928
cystitis B-Disease B-Disease 0.9986030459403992
was O O 0.999173104763031
presently O O 0.9999819993972778
investigated O O 0.9999809265136719
. O O 0.9999996423721313

Details O O 0.9986392855644226
of O O 0.9999135732650757
spinal O O 0.9915537238121033
puncture O O 0.46693360805511475
, O O 0.9998592138290405
extension O O 0.9972099661827087
and O O 0.9998582601547241
regression O O 0.9613967537879944
of O O 0.9979681372642517
spinal O O 0.9750990867614746
block O O 0.9290589690208435
, O O 0.9882699251174927
and O O 0.999908447265625
the O O 0.9999723434448242
times O O 0.9999703168869019
to O O 0.9999959468841553
reach O O 0.9999110698699951
discharge O O 0.8983699083328247
criteria O O 0.9980137348175049
were O O 0.9999996423721313
noted O O 0.9999977350234985
. O O 0.9999994039535522

Simultaneous O O 0.9998396635055542
administration O O 0.9993376135826111
of O O 0.99860018491745
morphine B-Chemical B-Chemical 0.9998700618743896
with O O 0.9983373880386353
metamizol B-Chemical B-Chemical 0.9999772310256958
resulted O O 0.9999332427978516
in O O 0.9999696016311646
a O O 0.9993566870689392
markedly O O 0.9994456171989441
antinociceptive O O 0.6201794743537903
potentiation O O 0.7035567164421082
and O O 0.9999916553497314
an O O 0.9999598264694214
increasing O O 0.9970118999481201
of O O 0.9992815852165222
the O O 0.9997218251228333
duration O O 0.9947583079338074
of O O 0.9996732473373413
action O O 0.9782289862632751
after O O 0.9999990463256836
a O O 0.9996953010559082
single O O 0.9976346492767334
( O O 0.9999719858169556
298 O O 0.9999099969863892
+ O O 0.999988317489624
/ O O 0.9999969005584717
- O O 0.9999556541442871
7 O O 0.9997214674949646
vs O O 0.9999009370803833
. O O 0.9999943971633911
139 O O 0.9998366832733154
+ O O 0.9999922513961792
/ O O 0.9999963045120239
- O O 0.9999120235443115
36 O O 0.9989246726036072
units O O 0.9997696280479431
area O O 0.9982484579086304
( O O 0.9999898672103882
ua O O 0.9861980080604553
) O O 0.999836802482605
; O O 0.9999852180480957
P O O 0.9898207187652588
< O O 0.9999614953994751
0 O O 0.9991814494132996
. O O 0.9999827146530151
001 O O 0.9852997064590454
) O O 0.9999271631240845
and O O 0.9999890327453613
repeated O O 0.979121744632721
administration O O 0.9980576634407043
( O O 0.9999902248382568
280 O O 0.9999405145645142
+ O O 0.9999961853027344
/ O O 0.9999986886978149
- O O 0.9999681711196899
17 O O 0.9997813105583191
vs O O 0.9999237060546875
. O O 0.9999921321868896
131 O O 0.9998823404312134
+ O O 0.999994158744812
/ O O 0.9999979734420776
- O O 0.999969482421875
22 O O 0.9998598098754883
ua O O 0.9974105954170227
; O O 0.9999963045120239
P O O 0.9969743490219116
< O O 0.999983549118042
0 O O 0.9995296001434326
. O O 0.9999889135360718
001 O O 0.9914994835853577
) O O 0.9999443292617798
. O O 0.9999994039535522

He O O 0.9993237257003784
complained O O 0.9999961853027344
of O O 0.9999544620513916
pain B-Disease B-Disease 0.9999557733535767
and I-Disease O 0.9998438358306885
visual I-Disease B-Disease 0.779308021068573
disturbance I-Disease I-Disease 0.9991878867149353
in I-Disease O 0.9937785267829895
the I-Disease O 0.9989956021308899
ipsilateral I-Disease O 0.8630472421646118
eye I-Disease O 0.5492814183235168
30 O O 0.9712715148925781
h O O 0.9832947850227356
after O O 0.9999980926513672
the O O 0.9998644590377808
injection O O 0.9991816878318787
. O O 0.9999996423721313

Mean O O 0.9828669428825378
serum O O 0.9981464147567749
creatinine B-Chemical B-Chemical 0.9998401403427124
level O O 0.9998478889465332
before O O 0.9999736547470093
conversion O O 0.9984992742538452
was O O 0.9999923706054688
2 O O 0.9993578791618347
. O O 0.9999945163726807
21 O O 0.9999502897262573
mg O O 0.9998995065689087
/ O O 0.9999916553497314
dL O O 0.9993768334388733
and O O 0.9999587535858154
thereafter O O 0.9999960660934448
, O O 0.9999905824661255
4 O O 0.9992700219154358
. O O 0.9999886751174927
93 O O 0.9999022483825684
mg O O 0.9998156428337097
/ O O 0.9999915361404419
dL O O 0.9991798996925354
( O O 0.9999948740005493
P O O 0.9991466999053955
= O O 0.9999855756759644
. O O 0.9999681711196899
02 O O 0.9974005222320557
) O O 0.9996227025985718
. O O 0.9999985694885254

The O O 0.9974098801612854
timolol B-Chemical B-Chemical 0.9999336004257202
- O O 0.9864722490310669
related O O 0.9990070462226868
increase O B-Disease 0.6459251046180725
in O I-Disease 0.7650887966156006
heart O I-Disease 0.7172788977622986
size O I-Disease 0.986415684223175
was O O 0.9782561659812927
observed O O 0.9991053938865662
only O O 0.9999779462814331
in O O 0.9999955892562866
patients O O 0.9999984502792358
with O O 0.9999943971633911
normal O O 0.9699586629867554
and O O 0.9922420978546143
borderline O O 0.9749852418899536
heart O O 0.8517943620681763
size O O 0.6623685956001282
. O O 0.9999845027923584

The O O 0.9999208450317383
temporal O O 0.9968326687812805
relationship O O 0.9995658993721008
between O O 0.9999855756759644
lipid O O 0.7588363885879517
peroxidation O O 0.46036529541015625
in O O 0.9999796152114868
the O O 0.9996122717857361
kidney O O 0.96622633934021
and O O 0.9998874664306641
proteinuria B-Disease B-Disease 0.9840040802955627
was O O 0.9994469285011292
examined O O 0.999992847442627
in O O 0.9999996423721313
this O O 0.9999595880508423
study O O 0.999984622001648
. O O 0.9999997615814209

When O O 0.9994651675224304
drugs O O 0.9915894865989685
disappear O O 0.9896444082260132
from O O 0.9999641180038452
the O O 0.998846173286438
patient O O 0.9999330043792725
: O O 0.9999991655349731
elimination O O 0.9799602627754211
of O O 0.9997580647468567
intravenous O O 0.790500283241272
medication O O 0.5157548189163208
by O O 0.9998831748962402
hemodiafiltration O B-Chemical 0.8783371448516846
. O O 0.9999852180480957

NRA0160 B-Chemical B-Chemical 0.9957169890403748
has O O 0.9999829530715942
negligible O O 0.9979189038276672
affinity O O 0.9733155965805054
for O O 0.9999485015869141
the O O 0.9995334148406982
human O O 0.9901763796806335
cloned O O 0.9941124320030212
dopamine B-Chemical B-Chemical 0.9999269247055054
D3 O O 0.8753730654716492
receptor O O 0.9989798665046692
( O O 0.9999669790267944
Ki O O 0.9659350514411926
= O O 0.9999169111251831
39 O O 0.9973926544189453
nM O O 0.9902104139328003
) O O 0.9999006986618042
, O O 0.999982476234436
rat O O 0.9905778169631958
serotonin B-Chemical B-Chemical 0.9801985621452332
( O O 0.9991262555122375
5 B-Chemical B-Chemical 0.6916294097900391
- I-Chemical I-Chemical 0.6284404397010803
HT I-Chemical I-Chemical 0.9964445233345032
) O O 0.7906543612480164
2A O O 0.8852408528327942
receptors O O 0.9995284080505371
( O O 0.9999951124191284
Ki O O 0.9696597456932068
= O O 0.9999680519104004
180 O O 0.9993048906326294
nM O O 0.99762362241745
) O O 0.9999332427978516
and O O 0.9999605417251587
rat O O 0.9940077066421509
alpha1 O O 0.9846280813217163
adrenoceptor O O 0.9729046821594238
( O O 0.9997406601905823
Ki O O 0.6559655070304871
= O O 0.9990166425704956
237 O O 0.9954428672790527
nM O O 0.9937233328819275
) O O 0.9999681711196899
. O O 0.9999997615814209

Habitual O O 0.9615014791488647
use O O 0.9970212578773499
of O O 0.9995617270469666
acetaminophen B-Chemical B-Chemical 0.999984622001648
as O O 0.9999384880065918
a O O 0.9998955726623535
risk O O 0.9980055689811707
factor O O 0.9999673366546631
for O O 0.9999994039535522
chronic B-Disease B-Disease 0.612863302230835
renal I-Disease I-Disease 0.9085481762886047
failure I-Disease I-Disease 0.999997615814209
: O O 0.9998680353164673
a O O 0.9998992681503296
comparison O O 0.9999212026596069
with O O 0.9999719858169556
phenacetin B-Chemical B-Chemical 0.9974978566169739
. O O 0.9999732971191406

Previously O O 0.9996830224990845
recognized O O 0.9999837875366211
side O O 0.9997333884239197
effects O O 0.9999594688415527
, O O 0.9999990463256836
particularly O O 0.9996693134307861
tremor B-Disease B-Disease 0.9997569918632507
and O O 0.9977300763130188
gastrointestinal B-Disease B-Disease 0.7931294441223145
problems I-Disease I-Disease 0.999836802482605
, O O 0.999396562576294
were O O 0.9999743700027466
more O O 0.999896764755249
frequent O O 0.9994981288909912
in O O 0.9999964237213135
the O O 0.9996224641799927
mexiletine B-Chemical B-Chemical 0.9933898448944092
group O O 0.9935316443443298
than O O 0.9999879598617554
in O O 0.9999912977218628
the O O 0.9998998641967773
placebo O O 0.9981167316436768
group O O 0.9995662569999695
. O O 0.9999996423721313

CONCLUSIONS O O 0.9978436231613159
: O O 0.9999958276748657
Sub O O 0.9767513275146484
- O O 0.9998670816421509
chronic O O 0.9959153532981873
low O O 0.990929901599884
dose O O 0.9994291663169861
GVG B-Chemical B-Chemical 0.9890297055244446
potentiates O O 0.9968217611312866
and O O 0.9999643564224243
extends O O 0.9999442100524902
the O O 0.9995545744895935
inhibition O O 0.8741375803947449
of O O 0.9986416697502136
cocaine B-Chemical B-Chemical 0.9999982118606567
- O O 0.9997405409812927
induced O O 0.9999191761016846
increases O O 0.793412446975708
in O O 0.802941620349884
dopamine B-Chemical B-Chemical 0.9999861717224121
, O O 0.9999758005142212
effectively O O 0.9999701976776123
reducing O O 0.999417781829834
cumulative O O 0.9776650667190552
exposures O O 0.9723233580589294
and O O 0.9999878406524658
the O O 0.9999637603759766
risk O O 0.9999412298202515
for O O 0.9999706745147705
VFDS O B-Disease 0.9821484088897705
. O O 0.9993482232093811

The O O 0.9998223185539246
patient O O 0.9998821020126343
' O O 0.9995743632316589
s O O 0.9912000298500061
symptoms O O 0.9494733810424805
improved O O 0.9999581575393677
slightly O O 0.9999862909317017
over O O 0.9999997615814209
the O O 0.999996542930603
next O O 0.999995231628418
few O O 0.9999679327011108
hours O O 0.9999650716781616
. O O 0.9999998807907104

Thirty O O 0.9999059438705444
minutes O O 0.9999970197677612
from O O 0.9999980926513672
the O O 0.9999773502349854
start O O 0.9999946355819702
of O O 0.9999964237213135
the O O 0.9999144077301025
procedure O O 0.9999347925186157
, O O 0.9999997615814209
the O O 0.9999182224273682
donor O O 0.9944111704826355
noted O O 0.999964714050293
tingling O O 0.8250118494033813
around O O 0.9513444304466248
the O O 0.8795679807662964
mouth O O 0.7756579518318176
, O O 0.9983067512512207
hands O O 0.9975938200950623
, O O 0.9999898672103882
and O O 0.9999786615371704
feet O O 0.9993890523910522
. O O 0.9999997615814209

A O O 0.9998158812522888
total O O 0.9999953508377075
of O O 0.9999642372131348
167 O O 0.9997112154960632
courses O O 0.9987590312957764
at O O 0.9999955892562866
doses O O 0.9999178647994995
of O O 0.9998842477798462
15 O O 0.9987204074859619
to O O 0.9999560117721558
70 O O 0.9997220635414124
mg O O 0.9998487234115601
/ O O 0.999974250793457
m2 O O 0.9998754262924194
were O O 0.9999544620513916
evaluable O O 0.9998574256896973
. O O 0.9999996423721313

There O O 0.9999686479568481
were O O 0.9999995231628418
no O O 0.9999961853027344
severe O O 0.9999053478240967
events O O 0.9961394667625427
and O O 0.9999990463256836
there O O 0.999998927116394
was O O 0.9999998807907104
no O O 0.9999972581863403
need O O 0.9999985694885254
to O O 0.9999986886978149
interrupt O O 0.9998581409454346
the O O 0.9998358488082886
examinations O O 0.9998569488525391
. O O 0.9999996423721313

No O O 0.999975323677063
significant O O 0.9999910593032837
differences O O 0.9974786639213562
between O O 0.9997218251228333
groups O O 0.9994751811027527
were O O 0.9999955892562866
found O O 0.9999921321868896
at O O 0.9999903440475464
enrollment O O 0.9984523057937622
. O O 0.9999997615814209

Amount O O 0.9996440410614014
of O O 0.9996638298034668
bleeding B-Disease B-Disease 0.9870411157608032
and O O 0.9236623048782349
hematoma B-Disease B-Disease 0.9118123650550842
size O O 0.8947339653968811
in O O 0.999859094619751
the O O 0.9988019466400146
collagenase O O 0.8582537174224854
- O O 0.9993576407432556
induced O O 0.9996417760848999
intracerebral B-Disease B-Disease 0.6276978254318237
hemorrhage I-Disease I-Disease 0.9955417513847351
rat O O 0.8176169991493225
model O O 0.9993078708648682
. O O 0.9999991655349731

The O O 0.9999715089797974
purpose O O 0.9999921321868896
of O O 0.9999977350234985
the O O 0.9999798536300659
present O O 0.9999572038650513
study O O 0.999981164932251
was O O 0.9999994039535522
to O O 0.9999957084655762
determine O O 0.9999955892562866
if O O 0.9999595880508423
prenatal O O 0.894672691822052
dexamethasone B-Chemical B-Chemical 0.9990777969360352
programmed O O 0.9999867677688599
a O O 0.9998316764831543
progressive O O 0.982501208782196
increase B-Disease B-Disease 0.8084110021591187
in I-Disease I-Disease 0.7027498483657837
blood I-Disease I-Disease 0.9336925148963928
pressure I-Disease I-Disease 0.9998300075531006
and O O 0.9903275370597839
renal B-Disease B-Disease 0.574191153049469
injury I-Disease I-Disease 0.9996882677078247
in O O 0.9935477375984192
rats O O 0.9992784857749939
. O O 0.9999996423721313

In O O 0.9999860525131226
the O O 0.9999516010284424
five O O 0.9991893172264099
rats O O 0.9982703924179077
that O O 0.9999880790710449
developed O O 0.9998217225074768
somatic B-Disease B-Disease 0.8986648917198181
rigidity I-Disease I-Disease 0.9378082752227783
, O O 0.9993104934692383
ICP O O 0.4688348174095154
and O O 0.9738742709159851
CVP O O 0.6350886821746826
increased O O 0.9991328120231628
significantly O O 0.9999598264694214
above O O 0.9994227886199951
baseline O O 0.9856329560279846
( O O 0.9999678134918213
delta O O 0.6263871788978577
ICP O O 0.764370322227478
7 O O 0.9954128861427307
. O O 0.9999980926513672
5 O O 0.9999620914459229
+ O O 0.9999961853027344
/ O O 0.9999986886978149
- O O 0.9999690055847168
1 O O 0.999808132648468
. O O 0.9999936819076538
0 O O 0.999800980091095
mmHg O O 0.9935134053230286
, O O 0.9999207258224487
delta O O 0.6593578457832336
CVP O O 0.6743548512458801
5 O O 0.9874695539474487
. O O 0.9999973773956299
9 O O 0.9999581575393677
+ O O 0.9999961853027344
/ O O 0.9999988079071045
- O O 0.9999821186065674
1 O O 0.9999076128005981
. O O 0.9999953508377075
3 O O 0.9999082088470459
mmHg O O 0.9951817393302917
) O O 0.9999358654022217
. O O 0.9999988079071045

Although O O 0.9999226331710815
the O O 0.9998196959495544
sP120T O O 0.8447761535644531
substitution O O 0.9885539412498474
also O O 0.9999711513519287
impaired O O 0.9927581548690796
HBsAg B-Chemical B-Chemical 0.9595586061477661
secretion O O 0.8108994364738464
, O O 0.9999934434890747
it O O 0.9999467134475708
did O O 0.9999963045120239
not O O 0.9999858140945435
enhance O O 0.9998981952667236
the O O 0.9995279312133789
replication O O 0.9923256635665894
of O O 0.9976727366447449
LAM B-Chemical B-Chemical 0.9987655878067017
- O O 0.9909267425537109
resistant O O 0.9995085000991821
clones O O 0.9897414445877075
. O O 0.9999995231628418

This O O 0.9999557733535767
study O O 0.9999933242797852
suggests O O 0.9999970197677612
that O O 0.9999477863311768
for O O 0.9999665021896362
healthy O O 0.9846546649932861
older O O 0.9983945488929749
adults O O 0.9995525479316711
who O O 0.9999964237213135
are O O 0.9999877214431763
not O O 0.9998989105224609
suffering O O 0.9999703168869019
from O O 0.9999809265136719
chronic B-Disease O 0.8374768495559692
pain I-Disease B-Disease 0.5453932881355286
, O O 0.9997062087059021
neurocognitive O O 0.508455216884613
and O O 0.7604551315307617
pharmacodynamic O O 0.6697895526885986
changes O O 0.655668318271637
in O O 0.9901688098907471
response O O 0.9987955093383789
to O O 0.999995231628418
a O O 0.9996905326843262
10 O O 0.9991024732589722
- O O 0.9994404911994934
mg O O 0.9983735084533691
dose O O 0.9999222755432129
of O O 0.9999746084213257
immediate O O 0.9989450573921204
- O O 0.999327540397644
release O O 0.9992050528526306
oxycodone B-Chemical B-Chemical 0.9998483657836914
are O O 0.9999898672103882
similar O O 0.9999892711639404
to O O 0.9999860525131226
those O O 0.9999716281890869
observed O O 0.9999679327011108
for O O 0.9999932050704956
middle O O 0.9992324113845825
- O O 0.9998219609260559
aged O O 0.999963641166687
adults O O 0.999626874923706
. O O 0.9999998807907104

Other O O 0.9998853206634521
side O O 0.9998766183853149
effects O O 0.9999520778656006
were O O 0.9999940395355225
rare O O 0.9915122389793396
, O O 0.9999938011169434
and O O 0.9999884366989136
peripheral B-Disease B-Disease 0.5412620306015015
neurotoxicity I-Disease I-Disease 0.838478147983551
has O O 0.9997386336326599
been O O 0.9999901056289673
minor O O 0.9793010950088501
( O O 0.9999842643737793
26 O O 0.9999533891677856
% O O 0.9999932050704956
grade O O 0.9998026490211487
1 O O 0.9985835552215576
) O O 0.9989537000656128
. O O 0.999998927116394

The O O 0.9999339580535889
results O O 0.9999469518661499
suggest O O 0.9999995231628418
the O O 0.9999698400497437
existence O O 0.9999585151672363
of O O 0.9999717473983765
residual O O 0.9989262223243713
beneficial O O 0.9979077577590942
clinical O O 0.9993670582771301
aftereffects O O 0.9971812963485718
of O O 0.9999624490737915
consecutive O O 0.9998716115951538
daily O O 0.9963755011558533
applications O O 0.9994737505912781
of O O 0.9999088048934937
low O O 0.9959503412246704
- O O 0.9986510872840881
frequency O O 0.9995686411857605
rTMS O O 0.5077738165855408
on O O 0.9995632767677307
dyskinesias B-Disease B-Disease 0.8993262052536011
in O O 0.9981738328933716
PD B-Disease B-Disease 0.9553781747817993
. O O 0.9999527931213379

In O O 0.9999516010284424
acute B-Disease O 0.9013828039169312
pain I-Disease B-Disease 0.543201208114624
models O O 0.985714316368103
, O O 0.9996374845504761
N B-Chemical B-Chemical 0.969546914100647
- I-Chemical I-Chemical 0.9939548373222351
methyl I-Chemical I-Chemical 0.9993662238121033
- I-Chemical I-Chemical 0.9946887493133545
D I-Chemical I-Chemical 0.9997710585594177
- I-Chemical I-Chemical 0.9855747222900391
aspartate I-Chemical I-Chemical 0.9977204203605652
( O O 0.9979301691055298
NMDA B-Chemical B-Chemical 0.9998699426651001
) O O 0.9847416281700134
antagonists O O 0.9840518236160278
enhance O O 0.9997292160987854
the O O 0.9992252588272095
antinociceptive O O 0.8151108622550964
effects O O 0.9994564652442932
of O O 0.9998338222503662
morphine B-Chemical B-Chemical 0.9999548196792603
to O O 0.9999707937240601
a O O 0.9999598264694214
greater O O 0.999846339225769
extent O O 0.9994435906410217
in O O 0.9999959468841553
males O O 0.9992460012435913
than O O 0.9999924898147583
females O O 0.996487021446228
. O O 0.9999997615814209

Both O O 0.9998137354850769
the O O 0.9998144507408142
trigeminal O O 0.5189316868782043
and O O 0.9978300929069519
the O O 0.9998155236244202
cranial O O 0.993184506893158
parasympathetic O O 0.8481395244598389
systems O O 0.9756125211715698
may O O 0.999998927116394
be O O 0.9999892711639404
involved O O 0.9999924898147583
in O O 0.9999872446060181
mediating O O 0.9999626874923706
these O O 0.9996931552886963
dysfunctions O O 0.8741407990455627
. O O 0.9999992847442627

In O O 0.9999798536300659
experimental O O 0.9992958307266235
animals O O 0.980563759803772
excess O O 0.9471161961555481
deposition O O 0.9752551317214966
of O O 0.9990147352218628
collagen O O 0.768688440322876
and O O 0.998806357383728
glycoaminoglycans O B-Chemical 0.9442865252494812
was O O 0.9997513890266418
observed O O 0.9999532699584961
in O O 0.9999653100967407
the O O 0.9995176792144775
subendothelial O O 0.9568939805030823
and O O 0.9995408058166504
medial O O 0.9987865090370178
layer O O 0.9986974596977234
of O O 0.9998366832733154
the O O 0.999396562576294
aortic O O 0.9759956002235413
wall O O 0.9947679042816162
, O O 0.9999946355819702
together O O 0.999995231628418
with O O 0.9999756813049316
prominent O O 0.9996956586837769
basal O O 0.9932436347007751
membrane O O 0.9951766729354858
substance O O 0.9994082450866699
around O O 0.9999773502349854
aortic O O 0.9934701919555664
smooth O O 0.9688376188278198
muscle O O 0.6541138291358948
cells O O 0.9937540888786316
. O O 0.9999996423721313

Maternal O O 0.9811501502990723
lithium B-Chemical B-Chemical 0.9999724626541138
and O O 0.9998151659965515
neonatal O O 0.9872244596481323
Ebstein B-Disease B-Disease 0.5530725717544556
' I-Disease I-Disease 0.7359525561332703
s I-Disease I-Disease 0.9758688807487488
anomaly I-Disease I-Disease 0.9999053478240967
: O O 0.9994805455207825
evaluation O O 0.9997327923774719
with O O 0.9999849796295166
cross O O 0.982047438621521
- O O 0.9846963882446289
sectional O O 0.9744515419006348
echocardiography O O 0.561674177646637
. O O 0.9999988079071045

Based O O 0.9998828172683716
on O O 0.999988317489624
these O O 0.9999035596847534
data O O 0.9994619488716125
, O O 0.9999996423721313
it O O 0.9999908208847046
can O O 0.9999788999557495
be O O 0.9999951124191284
postulated O O 0.999976396560669
that O O 0.9999725818634033
( O O 0.9998736381530762
+ O O 0.9999849796295166
/ O O 0.9999791383743286
- O O 0.9993769526481628
) O O 0.997448742389679
- O O 0.9972394704818726
PG B-Chemical B-Chemical 0.9515931010246277
- I-Chemical I-Chemical 0.9595353007316589
9 I-Chemical I-Chemical 0.9992641806602478
exerted O O 0.998744010925293
an O O 0.9995556473731995
antinociceptive O O 0.6591783761978149
effect O O 0.9650648236274719
mediated O O 0.9998170733451843
by O O 0.9999972581863403
a O O 0.999716579914093
central O O 0.9980044960975647
potentiation O O 0.9989583492279053
of O O 0.9998335838317871
cholinergic O O 0.5656745433807373
transmission O O 0.9818858504295349
. O O 0.9999998807907104

Galanthamine B-Chemical B-Chemical 0.997318685054779
hydrobromide I-Chemical I-Chemical 0.9674602746963501
, O O 0.9999666213989258
a O O 0.9997001886367798
longer O O 0.9995425939559937
acting O O 0.9654977917671204
anticholinesterase O O 0.7265164852142334
drug O O 0.8684589862823486
, O O 0.999754011631012
in O O 0.9999854564666748
the O O 0.9992560744285583
treatment O O 0.9999680519104004
of O O 0.9999887943267822
the O O 0.9995740056037903
central O O 0.9877099990844727
effects O O 0.9988483190536499
of O O 0.9993033409118652
scopolamine B-Chemical B-Chemical 0.9999780654907227
( O O 0.9951437711715698
Hyoscine B-Chemical B-Chemical 0.9998588562011719
) O O 0.9927492141723633
. O O 0.9999988079071045

In O O 0.9999958276748657
the O O 0.9999815225601196
absence O O 0.9998703002929688
of O O 0.9994741082191467
caffeine B-Chemical B-Chemical 0.9999886751174927
, O O 0.9990443587303162
acetaminophen B-Chemical B-Chemical 0.9999961853027344
( O O 0.9997314810752869
up O O 0.9993416666984558
to O O 0.9999737739562988
300 O O 0.999902606010437
mg O O 0.9998654127120972
/ O O 0.9999641180038452
kg O O 0.9997474551200867
) O O 0.9999070167541504
did O O 0.9999977350234985
not O O 0.9999569654464722
modify O O 0.999884843826294
the O O 0.9980131387710571
seizures B-Disease B-Disease 0.9993699193000793
induced O O 0.9976193308830261
by O O 0.9999758005142212
maximal O O 0.9863839745521545
electroshock O O 0.5616796016693115
and O O 0.9999576807022095
did O O 0.999992847442627
not O O 0.9999674558639526
alter O O 0.9999785423278809
the O O 0.9996077418327332
convulsant O O 0.6287647485733032
dose O O 0.9976564645767212
of O O 0.9993690848350525
pentylenetetrezol B-Chemical B-Chemical 0.9998960494995117
in O O 0.9995179176330566
mice O O 0.9983891248703003
( O O 0.9999960660934448
tests O O 0.9998766183853149
performed O O 0.9999974966049194
by O O 0.9999973773956299
the O O 0.9990900754928589
Anticonvulsant O O 0.8049363493919373
Screening O O 0.9735864996910095
Project O O 0.9999058246612549
of O O 0.9998043179512024
NINCDS O O 0.35906606912612915
) O O 0.9988871216773987
. O O 0.9999994039535522

MDMA B-Chemical O 0.4747399687767029
polydrug O O 0.4289146363735199
users O O 0.9991534948348999
show O O 0.9999914169311523
process O O 0.9998524188995361
- O O 0.9998262524604797
specific O O 0.9997356534004211
central O B-Disease 0.996944010257721
executive O I-Disease 0.9647688269615173
impairments O I-Disease 0.9844346642494202
coupled O O 0.9993101358413696
with O O 0.9999953508377075
impaired B-Disease O 0.9777041673660278
social I-Disease O 0.9393102526664734
and I-Disease O 0.7412870526313782
emotional I-Disease O 0.509974479675293
judgement I-Disease O 0.9292159080505371
processes I-Disease O 0.5419144630432129
. O O 0.9999867677688599

kg O O 0.8937793374061584
- O O 0.9505577087402344
1 O O 0.7075271010398865
. O O 0.9998302459716797

With O O 0.999866247177124
either O O 0.9997859597206116
discontinuation O O 0.7153220176696777
or O O 0.9998838901519775
decreased O O 0.9990491271018982
dosage O O 0.9978368878364563
of O O 0.9999397993087769
the O O 0.9984215497970581
drug O O 0.9983437061309814
the O O 0.999935507774353
symptoms O O 0.9368676543235779
disappeared O O 0.9988232254981995
and O O 0.9999877214431763
did O O 0.9999951124191284
not O O 0.9999457597732544
recur O O 0.998537540435791
. O O 0.9999996423721313

Development O O 0.9988893866539001
of O O 0.9987945556640625
levodopa B-Chemical B-Chemical 0.9999887943267822
- O O 0.9934238195419312
induced O O 0.9997875094413757
dyskinesias B-Disease B-Disease 0.9990633130073547
in O O 0.9997532963752747
parkinsonian B-Disease O 0.6717221140861511
monkeys O O 0.5334897041320801
may O O 0.9999935626983643
depend O O 0.9999972581863403
upon O O 0.9999709129333496
rate O O 0.9999775886535645
of O O 0.999927282333374
symptom O O 0.7800424695014954
onset O O 0.953850507736206
and O O 0.9999686479568481
/ O O 0.9999333620071411
or O O 0.9999791383743286
duration O O 0.9990122318267822
of O O 0.9999663829803467
symptoms O O 0.9691988825798035
. O O 0.9999992847442627

Seven O O 0.999849796295166
patients O O 0.9999825954437256
had O O 0.9999995231628418
previously O O 0.9999701976776123
received O O 0.9999418258666992
radiotherapy O O 0.9760168194770813
and O O 0.9999939203262329
seven O O 0.999882698059082
had O O 0.9999861717224121
received O O 0.9999504089355469
hormone O O 0.5748615264892578
therapy O O 0.9988877177238464
. O O 0.9999997615814209

Chronic O O 0.4901646375656128
hyperprolactinemia B-Disease B-Disease 0.8067307472229004
induced O O 0.9985186457633972
by O O 0.999975323677063
the O O 0.9952152967453003
dopamine B-Chemical B-Chemical 0.9999624490737915
antagonist O O 0.9644612073898315
sulpiride B-Chemical B-Chemical 0.9445987939834595
caused O O 0.999981164932251
a O O 0.9997593760490417
40 O O 0.9997268319129944
% O O 0.9995965361595154
reduction O O 0.9284889698028564
LH O O 0.8930262327194214
pulse O O 0.5651532411575317
frequency O O 0.9535543918609619
in O O 0.9999604225158691
ovariectomized O O 0.8670585751533508
rats O O 0.9762091040611267
, O O 0.9999936819076538
but O O 0.9999908208847046
only O O 0.9999803304672241
in O O 0.9999806880950928
the O O 0.9999178647994995
presence O O 0.999847412109375
of O O 0.999988317489624
chronic O O 0.9577282071113586
low O O 0.947280764579773
levels O O 0.9851174354553223
of O O 0.99901282787323
estradiol B-Chemical B-Chemical 0.9973700046539307
. O O 0.9999251365661621

Laryngoscopy O B-Disease 0.5013000965118408
revealed O O 0.999873161315918
asymmetric O O 0.9653326869010925
vocal O B-Disease 0.9274019002914429
fold O I-Disease 0.8675216436386108
movements O I-Disease 0.9913018941879272
during O O 0.9886032342910767
phonation O O 0.5036978125572205
. O O 0.999997615814209

His O O 0.9994408488273621
renal O O 0.9934537410736084
function O O 0.877187192440033
remained O O 0.999920129776001
impaired O O 0.9005287289619446
but O O 0.9996141195297241
stable O O 0.9966082572937012
during O O 0.9999986886978149
2 O O 0.9995941519737244
years O O 0.9999834299087524
' O O 0.9999912977218628
treatment O O 0.9999816417694092
with O O 0.999975323677063
captopril B-Chemical B-Chemical 0.9999115467071533
but O O 0.9998941421508789
returned O O 0.9999074935913086
to O O 0.9999949932098389
pre O O 0.999061644077301
- O O 0.9980617165565491
treatment O O 0.9994398951530457
levels O O 0.9999887943267822
soon O O 0.9999843835830688
after O O 0.9999868869781494
cessation O O 0.9993984699249268
of O O 0.999974250793457
the O O 0.9968947172164917
drug O O 0.9965822100639343
. O O 0.9999978542327881

METHODS O O 0.9968478083610535
: O O 0.9999985694885254
We O O 0.9999915361404419
present O O 0.9999992847442627
the O O 0.9999911785125732
first O O 0.9999493360519409
case O O 0.9999755620956421
report O O 0.9999865293502808
of O O 0.9999938011169434
a O O 0.9996157884597778
woman O O 0.9986421465873718
with O O 0.9999650716781616
hyperthyroidism B-Disease B-Disease 0.9992710947990417
treated O O 0.9693751335144043
with O O 0.9998446702957153
propylthiouracil B-Chemical B-Chemical 0.9994879961013794
in O O 0.9992508292198181
whom O O 0.999983549118042
a O O 0.9974333643913269
syndrome O O 0.9354430437088013
of O O 0.9998916387557983
pericarditis B-Disease B-Disease 0.9995331764221191
, O O 0.9093360900878906
fever B-Disease B-Disease 0.8161807060241699
, O O 0.9964244961738586
and O O 0.9992017149925232
glomerulonephritis B-Disease B-Disease 0.9984846711158752
developed O O 0.9828373193740845
. O O 0.999997615814209

Differences O O 0.9335041046142578
in O O 0.990882396697998
the O O 0.9962487816810608
parameters O O 0.9986230134963989
of O O 0.9998693466186523
training O O 0.9990843534469604
under O O 0.9999934434890747
the O O 0.9999023675918579
influence O O 0.9984012246131897
of O O 0.9996354579925537
pentobarbital B-Chemical B-Chemical 0.9727158546447754
between O O 0.9966307282447815
Groups O O 0.9983433485031128
1 O O 0.9973694086074829
and O O 0.9999526739120483
2 O O 0.9981916546821594
were O O 0.9999954700469971
revealed O O 0.999996542930603
. O O 0.9999990463256836

Possible O O 0.9999817609786987
risk O O 0.999790370464325
factors O O 0.999984860420227
for O O 0.9999990463256836
the O O 0.9998639822006226
development O O 0.9983844757080078
of O O 0.9999245405197144
hepatotoxicity B-Disease B-Disease 0.9999120235443115
in O O 0.999393105506897
patients O O 0.9999947547912598
treated O O 0.9999887943267822
with O O 0.9999920129776001
therapeutic O O 0.9863442182540894
doses O O 0.9998458623886108
of O O 0.9998689889907837
paracetamol B-Chemical B-Chemical 0.9999582767486572
are O O 0.9999359846115112
discussed O O 0.9999959468841553
. O O 0.9999998807907104

Admission O O 0.9995965361595154
laboratory O O 0.999900221824646
tests O O 0.999974250793457
were O O 0.9999994039535522
as O O 0.9999182224273682
follows O O 0.9998722076416016
: O O 0.9999855756759644
alanine B-Chemical B-Chemical 0.995755672454834
aminotransferase O O 0.648904025554657
, O O 0.9998517036437988
67 O O 0.9895755052566528
U O O 0.990812361240387
/ O O 0.9999722242355347
L O O 0.9939151406288147
( O O 0.999943733215332
reference O O 0.9994884729385376
range O O 0.9998123049736023
, O O 0.9999667406082153
10 O O 0.9993977546691895
- O O 0.9996134638786316
37 O O 0.9993950128555298
U O O 0.9993041753768921
/ O O 0.9999901056289673
L O O 0.9991523027420044
) O O 0.9996054768562317
; O O 0.9999873638153076
aspartate B-Chemical B-Chemical 0.9972100853919983
aminotransferase O O 0.4075620174407959
, O O 0.9996960163116455
98 O O 0.9906477332115173
U O O 0.9838398098945618
/ O O 0.999972939491272
L O O 0.9900538921356201
( O O 0.9999253749847412
10 O O 0.9997100234031677
- O O 0.9997747540473938
40 O O 0.9996795654296875
U O O 0.999346911907196
/ O O 0.9999909400939941
L O O 0.9990552067756653
) O O 0.9994301199913025
; O O 0.9999842643737793
alkaline O B-Chemical 0.9957275390625
phosphatase O O 0.8191670179367065
, O O 0.9974996447563171
513 O O 0.9733507037162781
U O O 0.9823750853538513
/ O O 0.9999796152114868
L O O 0.9907703399658203
( O O 0.9998598098754883
0 O O 0.9991047978401184
- O O 0.9998032450675964
270 O O 0.9997645020484924
U O O 0.99949049949646
/ O O 0.9999938011169434
L O O 0.9993100166320801
) O O 0.9996449947357178
; O O 0.9999911785125732
gamma O B-Chemical 0.6308525800704956
- O I-Chemical 0.5864711403846741
glutamyltransferase O I-Chemical 0.9730623364448547
, O O 0.9937902092933655
32 O O 0.983138918876648
U O O 0.9882602691650391
/ O O 0.9999781847000122
L O O 0.9934852719306946
( O O 0.9998874664306641
7 O O 0.9988422989845276
- O O 0.9995570778846741
49 O O 0.9995574355125427
U O O 0.9993969202041626
/ O O 0.999992847442627
L O O 0.9988176226615906
) O O 0.9993139505386353
; O O 0.9999778270721436
amylase O B-Chemical 0.9741148948669434
, O O 0.9763380885124207
46 O O 0.9790513515472412
U O O 0.9763578772544861
/ O O 0.9999736547470093
L O O 0.993858277797699
( O O 0.9999314546585083
0 O O 0.9995059967041016
- O O 0.999854564666748
220 O O 0.9998513460159302
U O O 0.9996102452278137
/ O O 0.9999958276748657
L O O 0.9994910955429077
) O O 0.9997878670692444
; O O 0.9999972581863403
total O O 0.9957780838012695
bilirubin B-Chemical B-Chemical 0.9996577501296997
, O O 0.9970269799232483
20 O O 0.9960120916366577
. O O 0.9999939203262329
1 O O 0.9998974800109863
mg O O 0.9998471736907959
/ O O 0.9999817609786987
dL O O 0.9988565444946289
( O O 0.9999688863754272
0 O O 0.9997352957725525
. O O 0.9999805688858032
2 O O 0.9996669292449951
- O O 0.9998015761375427
1 O O 0.999693751335144
. O O 0.9999939203262329
0 O O 0.9999262094497681
mg O O 0.999910831451416
/ O O 0.9999909400939941
dL O O 0.9991845488548279
) O O 0.9998637437820435
; O O 0.9999974966049194
direct O O 0.9960512518882751
bilirubin B-Chemical B-Chemical 0.999535322189331
, O O 0.9971422553062439
14 O O 0.9917484521865845
. O O 0.9999929666519165
8 O O 0.9998487234115601
mg O O 0.9998887777328491
/ O O 0.9999868869781494
dL O O 0.9991002082824707
( O O 0.9999713897705078
0 O O 0.9997681975364685
- O O 0.9998459815979004
0 O O 0.9997665286064148
. O O 0.9999939203262329
3 O O 0.9999504089355469
mg O O 0.9999420642852783
/ O O 0.9999915361404419
dL O O 0.9994121789932251
) O O 0.9998195767402649
; O O 0.9999915361404419
and O O 0.9998030066490173
albumin O O 0.5969641804695129
, O O 0.9975525736808777
4 O O 0.9960928559303284
. O O 0.9999935626983643
7 O O 0.9999198913574219
mg O O 0.9998723268508911
/ O O 0.9999887943267822
dL O O 0.9991844296455383
( O O 0.9999780654907227
3 O O 0.9997205138206482
. O O 0.9999822378158569
5 O O 0.9997861981391907
- O O 0.9998840093612671
5 O O 0.9998095631599426
. O O 0.9999914169311523
4 O O 0.9999518394470215
mg O O 0.9999191761016846
/ O O 0.999994158744812
dL O O 0.9995176792144775
) O O 0.9999086856842041
. O O 0.9999991655349731

OBJECTIVE O O 0.9953104853630066
: O O 0.9999963045120239
To O O 0.9999961853027344
examine O O 0.9999899864196777
the O O 0.999942421913147
effect O O 0.9999856948852539
of O O 0.9996738433837891
raloxifene B-Chemical B-Chemical 0.9999970197677612
on O O 0.9999852180480957
major O O 0.997658371925354
adverse O O 0.9385466575622559
events O O 0.5618561506271362
that O O 0.9986950755119324
occur O O 0.9999309778213501
with O O 0.9999959468841553
postmenopausal O O 0.9899745583534241
estrogen B-Chemical B-Chemical 0.9969303011894226
therapy O O 0.9991734623908997
or O O 0.9999499320983887
tamoxifen B-Chemical B-Chemical 0.9994587302207947
. O O 0.9999836683273315

OBJECTIVE O O 0.9868975877761841
: O O 0.9999948740005493
to O O 0.9999843835830688
analyze O O 0.999909520149231
aspects O O 0.9999829530715942
of O O 0.9998747110366821
TEE O O 0.7901757955551147
safety O O 0.9832063913345337
associated O O 0.9999327659606934
to O O 0.9999836683273315
the O O 0.9981903433799744
use O O 0.9995805621147156
of O O 0.9989043474197388
Midazolan B-Chemical B-Chemical 0.99937903881073
( O O 0.970147430896759
MZ B-Chemical B-Chemical 0.9973516464233398
) O O 0.9762568473815918
and O O 0.9983516931533813
Flumazenil B-Chemical B-Chemical 0.9979566335678101
( O O 0.9943314790725708
FL B-Chemical B-Chemical 0.9843074679374695
) O O 0.9942141175270081
and O O 0.9999741315841675
the O O 0.9999290704727173
influence O O 0.9955436587333679
of O O 0.9999793767929077
the O O 0.9999361038208008
clinical O O 0.9987772107124329
variables O O 0.9991663694381714
on O O 0.999987006187439
the O O 0.9998086094856262
event O O 0.9987357258796692
rate O O 0.9999915361404419
. O O 0.9999998807907104

There O O 0.9999701976776123
is O O 0.9999997615814209
evidence O O 0.9999979734420776
that O O 0.9999724626541138
growth O O 0.7821270823478699
hormone O O 0.9343743324279785
may O O 0.9997935891151428
be O O 0.9999980926513672
related O O 0.9999881982803345
to O O 0.9999861717224121
the O O 0.999846339225769
progression O O 0.9996165037155151
of O O 0.9999368190765381
weakness B-Disease O 0.5489642024040222
in O O 0.9875602126121521
Duchenne B-Disease B-Disease 0.6961140036582947
dystrophy I-Disease I-Disease 0.9993556141853333
. O O 0.9999781847000122

Since O O 0.9999771118164062
it O O 0.999966025352478
takes O O 0.9999958276748657
three O O 0.9998447895050049
to O O 0.9999926090240479
12 O O 0.9998663663864136
months O O 0.9999815225601196
to O O 0.9999983310699463
achieve O O 0.9999613761901855
maximal O O 0.997267484664917
effects O O 0.9992707371711731
, O O 0.9999992847442627
those O O 0.9999758005142212
patients O O 0.9999821186065674
who O O 0.9999985694885254
are O O 0.9999960660934448
unable O O 0.9999487400054932
to O O 0.999994158744812
continue O O 0.9999634027481079
the O O 0.9998574256896973
drug O O 0.9966456294059753
receive O O 0.9999902248382568
little O O 0.9999964237213135
benefit O O 0.9998829364776611
from O O 0.9999886751174927
it O O 0.9958674907684326
. O O 0.9999990463256836

L B-Chemical B-Chemical 0.9911535382270813
- I-Chemical I-Chemical 0.9967929720878601
NAME I-Chemical I-Chemical 0.999711811542511
reduced O O 0.9897687435150146
gentamicin B-Chemical B-Chemical 0.9995602965354919
- O O 0.9985255599021912
induced O O 0.9996225833892822
hearing B-Disease B-Disease 0.9638075828552246
loss I-Disease I-Disease 0.9999929666519165
in O O 0.996771514415741
the O O 0.9998028874397278
high O O 0.9988309741020203
- O O 0.9988502264022827
frequency O O 0.9977104663848877
range O O 0.9997612833976746
, O O 0.9999865293502808
but O O 0.9999715089797974
gave O O 0.9999099969863892
no O O 0.9998012185096741
protection O O 0.997620165348053
in O O 0.9999908208847046
the O O 0.9997395873069763
middle O O 0.9989191293716431
or O O 0.9999567270278931
low O O 0.997850775718689
frequencies O O 0.9988839030265808
. O O 0.9999998807907104

Massive O O 0.9801768064498901
proteinuria B-Disease B-Disease 0.995216965675354
and O O 0.9996689558029175
acute B-Disease B-Disease 0.6273034811019897
renal I-Disease I-Disease 0.9494614601135254
failure I-Disease I-Disease 1.0
after O O 0.9999392032623291
oral O O 0.9512719511985779
bisphosphonate B-Chemical B-Chemical 0.9897053837776184
( O O 0.9772006273269653
alendronate B-Chemical B-Chemical 0.9885508418083191
) O O 0.845512866973877
administration O O 0.9914661645889282
in O O 0.9999935626983643
a O O 0.9997593760490417
patient O O 0.9999954700469971
with O O 0.9999977350234985
focal B-Disease B-Disease 0.8151502013206482
segmental I-Disease I-Disease 0.5085105895996094
glomerulosclerosis I-Disease I-Disease 0.8273215889930725
. O O 0.9997939467430115

Any O O 0.9994020462036133
pain B-Disease B-Disease 0.9999494552612305
during O O 0.9999915361404419
the O O 0.9999608993530273
reduction O O 0.9800080060958862
was O O 0.9999814033508301
rated O O 0.9999980926513672
by O O 0.9999963045120239
the O O 0.999907374382019
orthopaedic O O 0.9881821274757385
surgeon O O 0.9996309280395508
treating O O 0.9999538660049438
the O O 0.9995794892311096
patient O O 0.9999951124191284
according O O 0.9999996423721313
to O O 0.9999797344207764
the O O 0.999893069267273
Children O O 0.9999163150787354
' O O 0.9998800754547119
s O O 0.9990078806877136
Hospital O O 0.9941872358322144
of O O 0.9999046325683594
Eastern O O 0.9875597357749939
Ontario O O 0.6308832764625549
Pain B-Disease B-Disease 0.5530284643173218
Scale O O 0.981603741645813
( O O 0.9999922513961792
CHEOPS O O 0.892955482006073
) O O 0.9996077418327332
. O O 0.9999990463256836

MRP2 O B-Chemical 0.8872823715209961
is O O 0.9997075200080872
absent O O 0.9998825788497925
in O O 0.9999940395355225
the O O 0.9997132420539856
transport O O 0.9964553117752075
- O O 0.999625563621521
deficient O O 0.9937345385551453
( O O 0.9999366998672485
TR O O 0.7986254692077637
( O O 0.9986805319786072
- O O 0.9953497052192688
) O O 0.9936240911483765
) O O 0.9993855953216553
Wistar O O 0.7339579463005066
rat O O 0.9807527661323547
mutant O O 0.9920931458473206
, O O 0.9999922513961792
so O O 0.9999641180038452
that O O 0.9999569654464722
this O O 0.9992918968200684
rat O O 0.9981979727745056
strain O O 0.990536630153656
was O O 0.999994158744812
very O O 0.9996707439422607
helpful O O 0.9995554089546204
in O O 0.9999796152114868
defining O O 0.9997188448905945
substrates O O 0.9793336987495422
of O O 0.9995149374008179
MRP2 O O 0.8005821108818054
by O O 0.9999902248382568
comparing O O 0.999752938747406
tissue O O 0.985504686832428
concentrations O O 0.9984038472175598
or O O 0.9999892711639404
functional O O 0.9984095692634583
activities O O 0.998857855796814
of O O 0.9997778534889221
compounds O O 0.9945065379142761
in O O 0.9999721050262451
MRP2 O O 0.6257767081260681
- O O 0.9993817806243896
deficient O O 0.9934763312339783
rats O O 0.9988865256309509
with O O 0.9999969005584717
those O O 0.9999105930328369
in O O 0.9999526739120483
transport O O 0.9970671534538269
- O O 0.999975323677063
competent O O 0.9985509514808655
Wistar O O 0.9177679419517517
rats O O 0.9989879727363586
. O O 0.9999998807907104

The O O 0.9998561143875122
optimal O O 0.997159481048584
rat O O 0.9938685297966003
size O O 0.9996376037597656
to O O 0.999990701675415
begin O O 0.9995962977409363
phenobarbitone B-Chemical B-Chemical 0.9846028089523315
was O O 0.9998774528503418
determined O O 0.999997615814209
as O O 0.999984860420227
100 O O 0.9993359446525574
g O O 0.9978035092353821
, O O 0.999745786190033
and O O 0.999963641166687
this O O 0.9997217059135437
size O O 0.999907374382019
as O O 0.9999948740005493
a O O 0.9995416402816772
group O O 0.9996405839920044
had O O 0.9999984502792358
a O O 0.9997233748435974
mean O O 0.9997660517692566
maximum O O 0.9983412027359009
relative O O 0.9989688396453857
liver O O 0.9776131510734558
weight O O 0.931444525718689
increase O O 0.9928489923477173
47 O O 0.9995741248130798
% O O 0.9999817609786987
greater O O 0.9999228715896606
than O O 0.9999850988388062
normal O O 0.99852055311203
rats O O 0.9995892643928528
of O O 0.9999816417694092
the O O 0.9999042749404907
same O O 0.9984662532806396
body O O 0.9968476891517639
weight O O 0.9988889098167419
. O O 0.9999997615814209

Trimipramine B-Chemical B-Chemical 0.9989542961120605
( O O 0.9990629553794861
TRI B-Chemical B-Chemical 0.9995155334472656
) O O 0.9955183267593384
, O O 0.999954342842102
which O O 0.9999266862869263
shows O O 0.9999822378158569
a O O 0.9998133778572083
clinical O O 0.9974679946899414
antidepressant B-Chemical O 0.7874047160148621
activity O O 0.9910436868667603
, O O 0.9999501705169678
is O O 0.999911904335022
chemically O O 0.9910655617713928
related O O 0.9998406171798706
to O O 0.9999333620071411
imipramine B-Chemical B-Chemical 0.9999181032180786
but O O 0.9998471736907959
does O O 0.9999933242797852
not O O 0.9997774958610535
inhibit O O 0.9995036125183105
the O O 0.9992294311523438
reuptake O O 0.8635779619216919
of O O 0.9963145852088928
noradrenaline B-Chemical B-Chemical 0.999954342842102
and O O 0.9936115145683289
5 B-Chemical B-Chemical 0.9957869648933411
- I-Chemical I-Chemical 0.9984069466590881
hydroxytryptamine I-Chemical I-Chemical 0.9968696236610413
, O O 0.9997959733009338
nor O O 0.9998645782470703
does O O 0.9999021291732788
it O O 0.9998679161071777
induce O O 0.9997099041938782
beta O O 0.8339802026748657
- O O 0.9386283755302429
adrenergic O O 0.8585353493690491
down O O 0.9995025396347046
- O O 0.9994668364524841
regulation O O 0.9990711212158203
. O O 0.9999998807907104

The O O 0.9999504089355469
present O O 0.9999649524688721
study O O 0.999987006187439
was O O 0.9999978542327881
undertaken O O 0.9999810457229614
to O O 0.9999979734420776
investigate O O 0.999972939491272
the O O 0.9998703002929688
effects O O 0.9999668598175049
of O O 0.9998522996902466
TET B-Chemical B-Chemical 0.9987757802009583
and O O 0.9961258769035339
FAN B-Chemical B-Chemical 0.9998316764831543
on O O 0.9996645450592041
the O O 0.9997822642326355
experimental O O 0.9519152045249939
thrombosis B-Disease B-Disease 0.9451901316642761
induced O O 0.9929072856903076
by O O 0.9997063279151917
collagen O O 0.5407260060310364
plus O O 0.9917763471603394
epinephrine B-Chemical B-Chemical 0.9990541338920593
( O O 0.9988216757774353
EP B-Chemical B-Chemical 0.9894018769264221
) O O 0.9844329357147217
in O O 0.9999678134918213
mice O O 0.9992672801017761
, O O 0.9999815225601196
and O O 0.9998577833175659
platelet B-Disease O 0.9022459387779236
aggregation I-Disease O 0.9264520406723022
and O O 0.9725834131240845
blood B-Disease O 0.9294663071632385
coagulation I-Disease O 0.9698489904403687
in O O 0.9977203011512756
vitro O O 0.9959040284156799
. O O 0.9999954700469971

However O O 0.9999264478683472
, O O 0.9999973773956299
the O O 0.9999644756317139
increase O O 0.994111955165863
in O O 0.9992971420288086
release O O 0.9959508180618286
of O O 0.998202919960022
ACh B-Chemical B-Chemical 0.9866151213645935
produced O O 0.9993780851364136
by O O 0.999976396560669
the O O 0.9996232986450195
first O O 0.9997877478599548
application O O 0.9995121955871582
of O O 0.9990530610084534
KCl B-Chemical B-Chemical 0.9949900507926941
was O O 0.9995705485343933
2 O O 0.9918853044509888
- O O 0.9978554844856262
fold O O 0.9987654685974121
higher O O 0.999962568283081
in O O 0.9999362230300903
WSP O O 0.7491574883460999
versus O O 0.9990783929824829
WSR O O 0.5131335258483887
mice O O 0.9949896931648254
. O O 0.9999994039535522

An O O 0.9998138546943665
allergic B-Disease B-Disease 0.9694021344184875
reaction I-Disease I-Disease 0.9995906949043274
consisting O O 0.9983199238777161
of O O 0.9999189376831055
angioneurotic B-Disease B-Disease 0.5935366749763489
edema I-Disease I-Disease 0.936660647392273
secondary O O 0.9248064160346985
to O O 0.9997990727424622
continuous O O 0.9895702600479126
infusion O O 0.9753751754760742
5 B-Chemical B-Chemical 0.6200264096260071
- I-Chemical I-Chemical 0.9319003224372864
fluorouracil I-Chemical I-Chemical 0.9996001124382019
occurred O O 0.9998829364776611
in O O 0.9999912977218628
a O O 0.9997784495353699
patient O O 0.9999958276748657
with O O 0.999998927116394
recurrent O B-Disease 0.8913928866386414
carcinoma B-Disease I-Disease 0.7445039749145508
of I-Disease I-Disease 0.9344791173934937
the I-Disease I-Disease 0.975753903388977
oral I-Disease I-Disease 0.8831202983856201
cavity I-Disease I-Disease 0.9885712265968323
, O O 0.9952933192253113
cirrhosis B-Disease B-Disease 0.9964554309844971
, O O 0.9985289573669434
and O O 0.9979748129844666
cisplatin B-Chemical B-Chemical 0.9998888969421387
- O O 0.9993953704833984
induced O O 0.9998183846473694
impaired B-Disease B-Disease 0.843869686126709
renal I-Disease I-Disease 0.5252841711044312
function I-Disease I-Disease 0.9972466230392456
. O O 0.999796450138092

Reversibility O O 0.9828293919563293
of O O 0.9987622499465942
captopril B-Chemical B-Chemical 0.9999638795852661
- O O 0.9990270137786865
induced O O 0.9999619722366333
renal B-Disease B-Disease 0.7416815161705017
insufficiency I-Disease I-Disease 0.9999918937683105
after O O 0.9999048709869385
prolonged O O 0.9964555501937866
use O O 0.998688280582428
in O O 0.9999992847442627
an O O 0.9999953508377075
unusual O O 0.9993950128555298
case O O 0.9999631643295288
of O O 0.9999806880950928
renovascular B-Disease B-Disease 0.7010695338249207
hypertension I-Disease I-Disease 0.8946062326431274
. O O 0.9999195337295532

The O O 0.9998855590820312
patient O O 0.9999173879623413
was O O 0.9999896287918091
extubated O O 0.9609668254852295
1 O O 0.9997645020484924
week O O 0.9999961853027344
later O O 0.9999990463256836
. O O 0.9999994039535522

As O O 0.999936580657959
a O O 0.9999983310699463
result O O 0.9999977350234985
of O O 0.9999988079071045
these O O 0.999983549118042
and O O 0.9999779462814331
other O O 0.9999799728393555
studies O O 0.9999496936798096
, O O 0.9999861717224121
phenacetin B-Chemical B-Chemical 0.9988834261894226
has O O 0.9999024868011475
now O O 0.9999916553497314
been O O 0.9999697208404541
withdrawn O O 0.9999042749404907
from O O 0.999987006187439
the O O 0.9987679123878479
market O O 0.9997616410255432
in O O 0.9999990463256836
most O O 0.9999464750289917
countries O O 0.9999063014984131
. O O 0.9999995231628418

Suxamethonium B-Chemical B-Chemical 0.9978304505348206
infusion O O 0.9847434759140015
rate O O 0.9999254941940308
and O O 0.99997878074646
observed O O 0.9976868629455566
fasciculations B-Disease O 0.5981208086013794
. O O 0.9999914169311523

Preliminary O O 0.999733030796051
studies O O 0.9999529123306274
suggest O O 0.9999978542327881
that O O 0.9998186230659485
statins B-Chemical B-Chemical 0.9872960448265076
could O O 0.9999780654907227
interfere O O 0.9999812841415405
with O O 0.9999932050704956
the O O 0.9998794794082642
risk O O 0.9999815225601196
of O O 0.9999738931655884
recurrence O O 0.8063113689422607
after O O 0.9998636245727539
electrical O O 0.9812100529670715
cardioversion O O 0.9568843245506287
. O O 0.9997091889381409

Neuropsychological O O 0.996203601360321
testing O O 0.9998956918716431
showed O O 0.9999979734420776
impaired B-Disease O 0.917730987071991
word I-Disease O 0.8127224445343018
fluency I-Disease O 0.8892741203308105
, I-Disease O 0.9961269497871399
psychomotor I-Disease O 0.9773298501968384
speed I-Disease O 0.9199472665786743
and I-Disease O 0.9998351335525513
working I-Disease O 0.9996581077575684
memory I-Disease O 0.9243041276931763
. O O 0.999993085861206

BACKGROUND O O 0.9865099787712097
: O O 0.9999490976333618
Methamphetamine B-Chemical B-Chemical 0.9999285936355591
is O O 0.9999600648880005
a O O 0.9999657869338989
very O O 0.9985408782958984
addictive O O 0.9152328372001648
, O O 0.9988596439361572
powerful O O 0.9853288531303406
stimulant O O 0.7751226425170898
that O O 0.9999834299087524
increases O O 0.992786705493927
wakefulness O O 0.5754399299621582
and O O 0.9956140518188477
physical O O 0.9965413212776184
activity O O 0.9631462693214417
and O O 0.9999806880950928
can O O 0.9999402761459351
produce O O 0.9999936819076538
other O O 0.999626636505127
effects O O 0.9999322891235352
such O O 0.9999986886978149
as O O 0.9999632835388184
cardiac B-Disease B-Disease 0.9113500118255615
dysrhythmias I-Disease I-Disease 0.9990339279174805
, O O 0.997837245464325
hypertension B-Disease B-Disease 0.9999468326568604
, O O 0.9990643858909607
hallucinations B-Disease B-Disease 0.9998044371604919
, O O 0.9995090961456299
and O O 0.9997013211250305
violent B-Disease B-Disease 0.9425113201141357
behavior I-Disease I-Disease 0.9993140697479248
. O O 0.9997296929359436

Hypothalamic O O 0.9086945056915283
prolactin O O 0.8117806911468506
receptor O O 0.9995617270469666
messenger O O 0.9979105591773987
ribonucleic B-Chemical B-Chemical 0.5176500678062439
acid I-Chemical I-Chemical 0.9997696280479431
levels O O 0.9996020197868347
, O O 0.9999923706054688
prolactin O O 0.9600491523742676
signaling O O 0.8010008335113525
, O O 0.9999798536300659
and O O 0.9999086856842041
hyperprolactinemic B-Disease O 0.5932730436325073
inhibition O O 0.9251400828361511
of O O 0.9995954632759094
pulsatile O O 0.6328029036521912
luteinizing O O 0.9783148765563965
hormone O O 0.9891636371612549
secretion O O 0.9964064955711365
are O O 0.9999963045120239
dependent O O 0.9999732971191406
on O O 0.9997879862785339
estradiol B-Chemical B-Chemical 0.994322657585144
. O O 0.9998642206192017

A O O 0.9973776340484619
single O O 0.9994193315505981
18 O O 0.997808039188385
. O O 0.9999945163726807
4 O O 0.9999204874038696
mg O O 0.9998693466186523
/ O O 0.9999827146530151
kg O O 0.9993652701377869
( O O 0.9999970197677612
i O O 0.9999686479568481
. O O 0.9999618530273438
p O O 0.9998210072517395
. O O 0.9999818801879883
) O O 0.9999034404754639
dose O O 0.9999306201934814
of O O 0.9999562501907349
( O O 0.999053418636322
+ O O 0.9999605417251587
/ O O 0.9999299049377441
- O O 0.9976933598518372
) O O 0.9743194580078125
- O O 0.9858607053756714
amphetamine B-Chemical B-Chemical 0.9960713386535645
hemisulfate O O 0.7609766721725464
, O O 0.9999198913574219
given O O 0.9999735355377197
to O O 0.9999402761459351
rats O O 0.996181845664978
pretreated O O 0.999987006187439
with O O 0.9999082088470459
iprindole B-Chemical B-Chemical 0.9997907280921936
, O O 0.9998849630355835
resulted O O 0.9999244213104248
in O O 0.9999727010726929
persistent O O 0.9988137483596802
depletion O O 0.6511080861091614
of O O 0.9678705930709839
dopamine B-Chemical B-Chemical 0.9999938011169434
in O O 0.9999648332595825
the O O 0.999703586101532
striatum O O 0.8924030065536499
1 O O 0.9998738765716553
week O O 0.9999879598617554
later O O 0.999998927116394
. O O 0.9999996423721313

The O O 0.9998733997344971
biochemical O O 0.9984409213066101
results O O 0.9999045133590698
of O O 0.9999431371688843
brain O O 0.9972923398017883
biogenic O O 0.9975110292434692
amines B-Chemical O 0.5827739834785461
of O O 0.9980341792106628
BALB O O 0.5364277958869934
/ O O 0.9995689988136292
C O O 0.9573079347610474
mouse O O 0.9965786337852478
strain O O 0.9988420605659485
suggest O O 0.9999997615814209
a O O 0.9997531771659851
probable O O 0.9998393058776855
decrease O O 0.9740461111068726
of O O 0.9908656477928162
catecholamine B-Chemical B-Chemical 0.9995336532592773
turnover O O 0.9508650898933411
rate O O 0.9991039633750916
and O O 0.9999738931655884
/ O O 0.9991477727890015
or O O 0.9995582699775696
metabolism O O 0.5480561852455139
by O O 0.9999779462814331
monoamine O B-Chemical 0.9968320727348328
oxidase O O 0.8124270439147949
and O O 0.9999536275863647
a O O 0.9998252987861633
resulting O O 0.9998664855957031
increase O O 0.980237603187561
in O O 0.9972699284553528
O O O 0.8521089553833008
- O O 0.7680057883262634
methylation O O 0.6799109578132629
of O O 0.9790322780609131
norepinephrine B-Chemical B-Chemical 0.9998621940612793
which O O 0.9995614886283875
may O O 0.9999947547912598
account O O 0.9999990463256836
for O O 0.9999991655349731
a O O 0.9995274543762207
behavioral B-Disease B-Disease 0.7016422748565674
depression I-Disease I-Disease 0.8737780451774597
caused O O 0.9966637492179871
by O O 0.9998212456703186
amantadine B-Chemical B-Chemical 0.9999915361404419
in O O 0.9999380111694336
the O O 0.9997773766517639
BALB O O 0.9836493730545044
/ O O 0.999948263168335
C O O 0.9826693534851074
mice O O 0.9994619488716125
. O O 0.9999997615814209

Verapamil B-Chemical B-Chemical 0.9995123147964478
- O O 0.9880738854408264
induced O O 0.9998377561569214
carbamazepine B-Chemical B-Chemical 0.9746769666671753
neurotoxicity B-Disease B-Disease 0.9969491362571716
. O O 0.9999724626541138

The O O 0.9996769428253174
contents O O 0.999669075012207
of O O 0.9998351335525513
albumin O O 0.93088698387146
in O O 0.9984933137893677
the O O 0.999515175819397
lungs O O 0.9924060702323914
were O O 0.9999992847442627
not O O 0.9999879598617554
changed O O 0.9999713897705078
, O O 0.9999978542327881
indicating O O 0.9999903440475464
that O O 0.9995600581169128
Captopril B-Chemical B-Chemical 0.9989557266235352
did O O 0.9999809265136719
not O O 0.9999778270721436
influence O O 0.9998993873596191
the O O 0.9996507167816162
extravasation O O 0.9591176509857178
of O O 0.9958133101463318
protein O O 0.9337073564529419
. O O 0.9999985694885254

Combined O O 0.9987769722938538
effects O O 0.9999778270721436
of O O 0.9999592304229736
prolonged O O 0.9898282289505005
prostaglandin B-Chemical B-Chemical 0.9968587160110474
E1 I-Chemical I-Chemical 0.9604344964027405
( O O 0.9978165626525879
PGE1 B-Chemical B-Chemical 0.9993046522140503
) O O 0.952563464641571
- O O 0.9996770620346069
induced O O 0.9996284246444702
hypotension B-Disease B-Disease 0.9996607303619385
and O O 0.9973006844520569
haemodilution B-Disease B-Disease 0.9975615739822388
on O O 0.9986355900764465
hepatic O O 0.9837837815284729
function O O 0.9183433055877686
were O O 0.999998927116394
studied O O 0.9999529123306274
in O O 0.9999995231628418
30 O O 0.9998084902763367
patients O O 0.9999984502792358
undergoing O O 0.9999815225601196
hip O O 0.8940847516059875
surgery O O 0.6939101815223694
. O O 0.9999679327011108

Adult O O 0.9862943291664124
rats O O 0.997219443321228
given O O 0.9999744892120361
dexamethasone B-Chemical B-Chemical 0.9999771118164062
on O O 0.999885082244873
days O O 0.9999827146530151
15 O O 0.9997469782829285
and O O 0.9999780654907227
16 O O 0.9993002414703369
of O O 0.9999490976333618
gestation O O 0.9944943785667419
had O O 0.999992847442627
more O O 0.999841570854187
glomeruli O O 0.528489351272583
with O O 0.996422290802002
glomerulosclerosis B-Disease B-Disease 0.9995562434196472
than O O 0.9976966977119446
control O O 0.9259259104728699
rats O O 0.9981092214584351
. O O 0.9999998807907104

Urinary B-Disease O 0.9769384264945984
bladder I-Disease B-Disease 0.5096806883811951
cancer I-Disease I-Disease 0.9970294237136841
in O O 0.9999096393585205
Wegener B-Disease B-Disease 0.6609616279602051
' I-Disease I-Disease 0.9693060517311096
s I-Disease I-Disease 0.9991569519042969
granulomatosis I-Disease I-Disease 0.9996052384376526
: O O 0.9989252686500549
risks O O 0.985524594783783
and O O 0.9998888969421387
relation O O 0.9997153878211975
to O O 0.9999170303344727
cyclophosphamide B-Chemical B-Chemical 0.9992642998695374
. O O 0.9999916553497314

Forty O O 0.9980961680412292
- O O 0.9999052286148071
three O O 0.9999632835388184
ovarian B-Disease B-Disease 0.6218789219856262
cancer I-Disease I-Disease 0.9588878750801086
patients O O 0.9893471002578735
were O O 0.9999991655349731
available O O 0.9999955892562866
for O O 0.9999979734420776
analysis O O 0.9974538683891296
following O O 0.9999997615814209
six O O 0.9995705485343933
cycles O O 0.9997010827064514
of O O 0.9999897480010986
the O O 0.9997898936271667
same O O 0.9974290728569031
PAC B-Chemical B-Chemical 0.9865593910217285
- O O 0.9965537786483765
containing O O 0.9997773766517639
regimen O O 0.7745819091796875
: O O 0.9998718500137329
23 O O 0.9727258682250977
had O O 0.999991774559021
been O O 0.9996310472488403
supplemented O O 0.9999160766601562
by O O 0.999944806098938
glutamate B-Chemical B-Chemical 0.999946117401123
all O O 0.9901927709579468
along O O 0.9998564720153809
the O O 0.9984492063522339
treatment O O 0.9998995065689087
period O O 0.9999973773956299
, O O 0.9999978542327881
at O O 0.9999984502792358
a O O 0.9997043013572693
daily O O 0.9972742199897766
dose O O 0.9999477863311768
of O O 0.9999799728393555
three O O 0.9994255304336548
times O O 0.9999954700469971
500 O O 0.9998657703399658
mg O O 0.9990140199661255
( O O 0.9999810457229614
group O O 0.9988306164741516
G O O 0.9674800038337708
) O O 0.9997859597206116
, O O 0.9999560117721558
and O O 0.9999635219573975
20 O O 0.9986498951911926
had O O 0.9999953508377075
received O O 0.9999891519546509
a O O 0.9996689558029175
placebo O O 0.9980472326278687
( O O 0.9998997449874878
group O O 0.9975711703300476
P O O 0.9745340943336487
) O O 0.9998620748519897
. O O 0.9999990463256836

1 O O 0.8951836824417114
. O O 0.9999786615371704

Causes O O 0.9999278783798218
of O O 0.999969482421875
death B-Disease B-Disease 0.9996942281723022
, O O 0.9998557567596436
with O O 0.9999958276748657
special O O 0.9953954815864563
reference O O 0.9990184307098389
to O O 0.9999982118606567
cerebral B-Disease B-Disease 0.9606310725212097
haemorrhage I-Disease I-Disease 0.9992176294326782
, O O 0.9999122619628906
among O O 0.9999959468841553
240 O O 0.9999170303344727
patients O O 0.9999819993972778
with O O 0.9999988079071045
pathologically O O 0.9704289436340332
verified O O 0.9790942072868347
Parkinson B-Disease B-Disease 0.9790072441101074
' I-Disease I-Disease 0.9999847412109375
s I-Disease I-Disease 0.999995231628418
disease I-Disease I-Disease 0.9999971389770508
were O O 0.9999287128448486
investigated O O 0.9999748468399048
using O O 0.9999877214431763
the O O 0.9996101260185242
Annuals O O 0.9739536046981812
of O O 0.9999725818634033
the O O 0.9996988773345947
Pathological O O 0.9226258397102356
Autopsy O O 0.9714925289154053
Cases O O 0.9982227683067322
in O O 0.9999963045120239
Japan O O 0.9970833659172058
from O O 0.9999997615814209
1981 O O 0.9999971389770508
to O O 0.9999990463256836
1985 O O 0.9999428987503052
. O O 0.9999997615814209

Vascular O O 0.9832673668861389
eNOS O O 0.9941275119781494
mRNA O O 0.9680124521255493
was O O 0.9999617338180542
assessed O O 0.999995231628418
by O O 0.999984622001648
semi O O 0.995388388633728
- O O 0.9998494386672974
quantitative O O 0.9993672966957092
reverse O O 0.9972596168518066
transcription O O 0.9935279488563538
- O O 0.9994540810585022
polymerase O O 0.6695635318756104
chain O O 0.9947324991226196
reaction O O 0.9513465762138367
. O O 0.9999996423721313

Future O O 0.9999521970748901
research O O 0.9999545812606812
with O O 0.9999984502792358
larger O O 0.9997751116752625
number O O 0.999482274055481
of O O 0.9999570846557617
patients O O 0.9999148845672607
is O O 0.999998927116394
needed O O 0.999998927116394
to O O 0.9999988079071045
find O O 0.9999514818191528
out O O 0.9999927282333374
modifiable O O 0.9994221925735474
factors O O 0.9999301433563232
that O O 0.9999959468841553
will O O 0.9999912977218628
improve O O 0.9999277591705322
the O O 0.9997321963310242
safety O O 0.9985206723213196
of O O 0.9997778534889221
ribavirin B-Chemical B-Chemical 0.9999796152114868
therapy O O 0.9997161030769348
. O O 0.9999996423721313

Orthostatic B-Disease B-Disease 0.7861160039901733
hypotension I-Disease I-Disease 0.9794178605079651
was O O 0.9994645714759827
ameliorated O O 0.9995858073234558
4 O O 0.999862790107727
days O O 0.9999949932098389
after O O 0.9999977350234985
withdrawal O O 0.9974297881126404
of O O 0.9972339272499084
selegiline B-Chemical B-Chemical 0.9999970197677612
and O O 0.9996848106384277
totally O O 0.9997658133506775
abolished O O 0.9983501434326172
7 O O 0.9991335272789001
days O O 0.9999836683273315
after O O 0.9999979734420776
discontinuation O O 0.9979161620140076
of O O 0.9999443292617798
the O O 0.9968116879463196
drug O O 0.998113751411438
. O O 0.999998927116394

She O O 0.9988148212432861
underwent O O 0.9999723434448242
liver O O 0.9863694906234741
transplantation O O 0.6803799867630005
with O O 0.9999892711639404
an O O 0.9999531507492065
uneventful O O 0.9948065876960754
postoperative O O 0.9158855080604553
course O O 0.9971696734428406
. O O 0.9999996423721313

Risperidone B-Chemical B-Chemical 0.9995922446250916
is O O 0.9999822378158569
an O O 0.999883770942688
antipsychotic O O 0.7516839504241943
drug O O 0.9776518940925598
with O O 0.9999860525131226
high O O 0.9965111613273621
affinity O O 0.9180791974067688
at O O 0.9999961853027344
dopamine B-Chemical B-Chemical 0.9999313354492188
D2 O O 0.4923429489135742
and O O 0.9998131394386292
serotonin B-Chemical B-Chemical 0.9928695559501648
5 I-Chemical O 0.5146710872650146
- I-Chemical O 0.7385044097900391
HT2 I-Chemical O 0.5692495107650757
receptors O O 0.9991114735603333
. O O 0.9999996423721313

Amnesia B-Disease B-Disease 0.8867413997650146
produced O O 0.9968076944351196
by O O 0.9988515377044678
scopolamine B-Chemical B-Chemical 0.999983549118042
and O O 0.9974019527435303
cycloheximide B-Chemical B-Chemical 0.9998301267623901
were O O 0.9999504089355469
reversed O O 0.9999434947967529
by O O 0.9999769926071167
morphine B-Chemical B-Chemical 0.9999934434890747
given O O 0.9999754428863525
30 O O 0.9995303153991699
min O O 0.996216356754303
before O O 0.9999911785125732
the O O 0.9999097585678101
test O O 0.9998719692230225
trial O O 0.9992539286613464
( O O 0.9999974966049194
pre O O 0.9995331764221191
- O O 0.9984059929847717
test O O 0.9989916682243347
) O O 0.9995827078819275
, O O 0.9999514818191528
and O O 0.9999412298202515
pre O O 0.9982314705848694
- O O 0.99959796667099
test O O 0.9998534917831421
morphine B-Chemical B-Chemical 0.9999896287918091
also O O 0.9999086856842041
facilitated O O 0.9999853372573853
the O O 0.9998816251754761
memory O O 0.7953635454177856
retrieval O O 0.7220180630683899
in O O 0.9999417066574097
the O O 0.9999107122421265
animals O O 0.9973391890525818
administered O O 0.999942421913147
naloxone B-Chemical B-Chemical 0.9998086094856262
during O O 0.9999758005142212
the O O 0.9997404217720032
training O O 0.9987736344337463
trial O O 0.9999856948852539
. O O 0.9999997615814209

Pituitary B-Disease B-Disease 0.661518394947052
tumors I-Disease I-Disease 0.9589775204658508
were O O 0.9997957348823547
induced O O 0.9998144507408142
in O O 0.9999855756759644
F344 O O 0.9944329857826233
female O O 0.9854674935340881
rats O O 0.9989038705825806
by O O 0.9999990463256836
chronic O O 0.9637433290481567
treatment O O 0.9984272718429565
with O O 0.9998667240142822
diethylstilbestrol B-Chemical B-Chemical 0.9998637437820435
( O O 0.9925917387008667
DES B-Chemical B-Chemical 0.9996950626373291
, O O 0.9439014792442322
8 O O 0.9120781421661377
- O O 0.8378115892410278
10 O O 0.7447686195373535
mg O O 0.7004115581512451
) O O 0.9454838633537292
implanted O O 0.997591495513916
subcutaneously O O 0.9958006739616394
in O O 0.999985933303833
silastic O O 0.9734912514686584
capsules O O 0.993099570274353
. O O 0.9999998807907104

These O O 0.9999454021453857
findings O O 0.9999716281890869
suggest O O 0.9999994039535522
that O O 0.9999099969863892
overgrowth O O 0.6319519281387329
of O O 0.7828339338302612
the O O 0.9377203583717346
exencephalic B-Disease O 0.8938270807266235
neural O O 0.905796468257904
tissue O O 0.9989086389541626
causes O O 0.9999921321868896
the O O 0.999815046787262
altered O O 0.9871556758880615
distribution O O 0.94266277551651
patterns O O 0.9969077706336975
of O O 0.9996938705444336
vessels O O 0.9946209192276001
, O O 0.9999994039535522
subsequent O O 0.9999780654907227
peripheral O B-Disease 0.9113195538520813
circulatory B-Disease I-Disease 0.6052018404006958
failure I-Disease I-Disease 0.9998037219047546
and O O 0.9979879856109619
/ O O 0.994452178478241
or O O 0.999688982963562
hemorrhaging B-Disease B-Disease 0.9617342948913574
in O O 0.9964704513549805
various O O 0.9997743964195251
parts O O 0.9985182881355286
of O O 0.9997598528862
the O O 0.998285710811615
exencephalic B-Disease O 0.9008446931838989
head O O 0.7040855884552002
, O O 0.9999260902404785
leading O O 0.9999709129333496
to O O 0.9999772310256958
the O O 0.9998831748962402
multiple O O 0.9971318244934082
modes O O 0.9997145533561707
of O O 0.9998973608016968
tissue O O 0.5050012469291687
reduction O O 0.9506208300590515
during O O 0.9895086288452148
transformation O O 0.9867303371429443
from O O 0.9998766183853149
exencephaly B-Disease B-Disease 0.9095510244369507
to O O 0.9759529232978821
anencephaly B-Disease B-Disease 0.880530595779419
. O O 0.9997449517250061

Patients O O 0.9999328851699829
who O O 0.9999974966049194
experienced O O 0.9999953508377075
a O O 0.9978522062301636
manic B-Disease O 0.8780999183654785
or O O 0.6363517045974731
hypomanic B-Disease B-Disease 0.9562123417854309
switch O O 0.527130663394928
were O O 0.9999929666519165
compared O O 0.99998939037323
with O O 0.9999740123748779
those O O 0.9999864101409912
who O O 0.9999864101409912
did O O 0.9999829530715942
not O O 0.9999942779541016
on O O 0.9999873638153076
several O O 0.9997376799583435
variables O O 0.9934120774269104
including O O 0.9999964237213135
age O O 0.9989182949066162
, O O 0.9999853372573853
sex O O 0.976266622543335
, O O 0.9999786615371704
diagnosis O O 0.868114173412323
( O O 0.9999899864196777
DSM B-Disease O 0.6961628794670105
- I-Disease O 0.9743825197219849
IV I-Disease O 0.9463267922401428
bipolar I-Disease B-Disease 0.8226562738418579
I I-Disease I-Disease 0.9818156361579895
vs O O 0.7459023594856262
. O O 0.9997865557670593
bipolar B-Disease O 0.9246455430984497
II I-Disease O 0.7050283551216125
) O O 0.9979265928268433
, O O 0.9999983310699463
number O O 0.9998594522476196
of O O 0.9999874830245972
previous O O 0.9999643564224243
manic B-Disease O 0.7982776165008545
episodes O O 0.7969257831573486
, O O 0.9996633529663086
type O O 0.9997060894966125
of O O 0.9996139407157898
antidepressant B-Chemical B-Chemical 0.9951744675636292
therapy O O 0.9939338564872742
used O O 0.9999643564224243
( O O 0.9999722242355347
electroconvulsive O O 0.6179405450820923
therapy O O 0.9939855933189392
vs O O 0.999599039554596
. O O 0.9999381303787231
antidepressant B-Chemical O 0.6702772378921509
drugs O O 0.992397129535675
and O O 0.9999881982803345
, O O 0.9999825954437256
more O O 0.9999476671218872
particularly O O 0.9996023774147034
, O O 0.9999445676803589
selective O O 0.9752904772758484
serotonin B-Chemical O 0.8780669569969177
reuptake I-Chemical O 0.7323156595230103
inhibitors I-Chemical O 0.5218849778175354
[ O O 0.9872140884399414
SSRIs B-Chemical O 0.5723250508308411
] O O 0.9486870765686035
) O O 0.9981997013092041
, O O 0.9999901056289673
use O O 0.9995414018630981
and O O 0.9999696016311646
type O O 0.9996097683906555
of O O 0.9997186064720154
mood O O 0.9297264218330383
stabilizers O O 0.900282084941864
( O O 0.9999901056289673
lithium B-Chemical B-Chemical 0.9997175335884094
vs O O 0.9433063268661499
. O O 0.9996106028556824
anticonvulsants O O 0.728819727897644
) O O 0.9998619556427002
, O O 0.9999961853027344
and O O 0.9999581575393677
temperament O O 0.9401638507843018
of O O 0.9984086155891418
the O O 0.9984266757965088
patient O O 0.9999715089797974
, O O 0.999998927116394
assessed O O 0.9999730587005615
during O O 0.999993085861206
a O O 0.9981635212898254
normothymic O O 0.7666622400283813
period O O 0.9974496960639954
using O O 0.9999946355819702
the O O 0.9995724558830261
hyperthymia O B-Disease 0.9519280791282654
component O O 0.9943761825561523
of O O 0.9999650716781616
the O O 0.999144434928894
Semi O O 0.9391441941261292
- O O 0.999937891960144
structured O O 0.999755322933197
Affective O O 0.8357873558998108
Temperament O O 0.5914633274078369
Interview O O 0.9890803694725037
. O O 0.9999994039535522

During O O 0.9999821186065674
the O O 0.9999632835388184
first O O 0.9999876022338867
day O O 0.9999951124191284
of O O 0.9999878406524658
hospitalization O O 0.8728770017623901
( O O 0.99992835521698
while O O 0.9998894929885864
intubated O O 0.6306318044662476
) O O 0.9965459704399109
, O O 0.9999957084655762
intravenous O O 0.9895755052566528
metoprolol B-Chemical B-Chemical 0.9999936819076538
was O O 0.9995766282081604
given O O 0.9999804496765137
, O O 0.9999910593032837
resulting O O 0.9999727010726929
in O O 0.9999750852584839
severe O O 0.995357096195221
angioedema B-Disease B-Disease 0.9974149465560913
. O O 0.9994786381721497

Results O O 0.9985968470573425
thus O O 0.9999841451644897
far O O 0.9999717473983765
suggest O O 0.9999994039535522
no O O 0.9998359680175781
dose O O 0.9999650716781616
- O O 0.9993577599525452
response O O 0.998582124710083
effect O O 0.9999927282333374
for O O 0.9999470710754395
paclitaxel B-Chemical B-Chemical 0.9999849796295166
doses O O 0.9987087249755859
above O O 0.9996211528778076
200 O O 0.9998617172241211
mg O O 0.9999179840087891
/ O O 0.9999666213989258
m2 O O 0.9996104836463928
. O O 0.9999990463256836

dP O O 0.8151136040687561
/ O O 0.9892667531967163
dtejc O O 0.6691392064094543
outcome O O 0.9961832165718079
was O O 0.9999984502792358
combined O O 0.999996542930603
with O O 0.9999948740005493
the O O 0.9997344613075256
ECG O O 0.8398070931434631
results O O 0.9984558820724487
, O O 0.9999995231628418
giving O O 0.9999712705612183
an O O 0.9997125267982483
ECG O O 0.6277135610580444
- O O 0.9948604702949524
enhanced O O 0.998343825340271
value O O 0.9988002777099609
, O O 0.999991774559021
and O O 0.9999445676803589
compared O O 0.9998326301574707
to O O 0.9997573494911194
ECG O O 0.5100380182266235
alone O O 0.9910481572151184
. O O 0.9999995231628418

METHODS O O 0.9867588877677917
: O O 0.9999837875366211
Using O O 0.9998346567153931
immune O O 0.9919232726097107
stainings O O 0.9216296076774597
, O O 0.9999984502792358
semiquantitative O O 0.9867934584617615
measurement O O 0.9744645357131958
was O O 0.9999799728393555
performed O O 0.9999940395355225
under O O 0.9999901056289673
the O O 0.9998480081558228
electron O O 0.9878929257392883
microscope O O 0.9868203997612
. O O 0.9999998807907104

Alpha B-Chemical B-Chemical 0.8649343252182007
- I-Chemical I-Chemical 0.8815522789955139
lipoic I-Chemical I-Chemical 0.999276340007782
acid I-Chemical I-Chemical 0.9999865293502808
exerts O O 0.9999465942382812
neuroprotective O O 0.8960350155830383
effects O O 0.9917364716529846
against O O 0.9999085664749146
chemotherapy O O 0.9361956715583801
induced O O 0.9999129772186279
neurotoxicity B-Disease B-Disease 0.9998282194137573
in O O 0.9994269609451294
sensory O O 0.9959152340888977
neurons O O 0.9647517204284668
: O O 0.9999967813491821
it O O 0.999881386756897
rescues O O 0.9996066689491272
the O O 0.9998388290405273
mitochondrial B-Disease B-Disease 0.8639693260192871
toxicity I-Disease I-Disease 0.8738781213760376
and O O 0.9975468516349792
induces O O 0.9999321699142456
the O O 0.9997479319572449
expression O O 0.9904595613479614
of O O 0.999535083770752
frataxin O O 0.9171891212463379
, O O 0.9999082088470459
an O O 0.9999781847000122
essential O O 0.9995242357254028
mitochondrial O O 0.9852299094200134
protein O O 0.9898657202720642
with O O 0.9999946355819702
anti O O 0.9981734752655029
- O O 0.9974232912063599
oxidant O O 0.923375129699707
and O O 0.9997507929801941
chaperone O B-Chemical 0.9939447045326233
properties O O 0.9931043982505798
. O O 0.9999998807907104

Pregnant O O 0.9860463738441467
rats O O 0.9995469450950623
were O O 0.9999977350234985
given O O 0.9999960660934448
either O O 0.9993981122970581
vehicle O O 0.9763302206993103
or O O 0.999881386756897
2 O O 0.9980595707893372
daily O O 0.9993392825126648
intraperitoneal O O 0.9084551930427551
injections O O 0.9949352145195007
of O O 0.9996838569641113
dexamethasone B-Chemical B-Chemical 0.9999686479568481
( O O 0.9986812472343445
0 O O 0.9979547262191772
. O O 0.9999911785125732
2 O O 0.9998576641082764
mg O O 0.9999396800994873
/ O O 0.9999840259552002
kg O O 0.9998262524604797
body O O 0.9990384578704834
weight O O 0.9989749193191528
) O O 0.9999794960021973
on O O 0.9999929666519165
gestational O O 0.9948911666870117
days O O 0.999255359172821
11 O O 0.9998998641967773
and O O 0.9999874830245972
12 O O 0.9998375177383423
, O O 0.999985933303833
13 O O 0.9998314380645752
and O O 0.9999903440475464
14 O O 0.9998050332069397
, O O 0.9999914169311523
15 O O 0.9998584985733032
and O O 0.9999921321868896
16 O O 0.9997991919517517
, O O 0.999991774559021
17 O O 0.9998749494552612
and O O 0.999993085861206
18 O O 0.9996485710144043
, O O 0.9999771118164062
or O O 0.9999908208847046
19 O O 0.9997825026512146
and O O 0.9999915361404419
20 O O 0.9977611303329468
. O O 0.9999977350234985

Injection O O 0.9925816059112549
of O O 0.9969462752342224
Captopril B-Chemical B-Chemical 0.999936580657959
( O O 0.9976102113723755
1 O O 0.9980347752571106
mg O O 0.9996298551559448
/ O O 0.9998722076416016
kg O O 0.9983556866645813
) O O 0.9996974468231201
, O O 0.9999974966049194
an O O 0.9998646974563599
inhibitor O O 0.9908125996589661
of O O 0.9993877410888672
angiotensin B-Chemical B-Chemical 0.9968125224113464
converting O I-Chemical 0.6572303771972656
enzyme O I-Chemical 0.9716318845748901
( O O 0.9491639733314514
ACE O O 0.6766369342803955
) O O 0.9921892881393433
, O O 0.9999929666519165
reduced O O 0.9992402791976929
both O O 0.9978546500205994
pulmonary B-Disease B-Disease 0.593078076839447
and I-Disease I-Disease 0.6761837005615234
renal I-Disease I-Disease 0.8408094048500061
insufficiency I-Disease I-Disease 0.9999548196792603
in O O 0.9956588745117188
this O O 0.9986061453819275
rat O O 0.9895057082176208
model O O 0.9998276233673096
. O O 0.9999996423721313

In O O 0.9999856948852539
addition O O 0.9999675750732422
, O O 0.9999988079071045
mitochondrial O O 0.9824073314666748
respiratory B-Disease B-Disease 0.6257214546203613
dysfunction I-Disease I-Disease 0.99986732006073
characterized O O 0.9993871450424194
by O O 0.999969482421875
decreased O O 0.997441291809082
respiratory O O 0.9913352131843567
control O O 0.9577988386154175
ratio O O 0.9994416832923889
and O O 0.9999383687973022
ADP B-Chemical O 0.7572730183601379
/ O O 0.9940778017044067
O O O 0.8418364524841309
was O O 0.9997478127479553
observed O O 0.9999526739120483
in O O 0.9999281167984009
isoproterenol B-Chemical B-Chemical 0.9998736381530762
- O O 0.9926895499229431
treated O O 0.999413251876831
rats O O 0.9993114471435547
. O O 0.9999998807907104

DESIGN O O 0.9964297413825989
, O O 0.9999172687530518
SETTING O O 0.9997696280479431
, O O 0.9999532699584961
AND O O 0.9998613595962524
PARTICIPANTS O O 0.9998169541358948
: O O 0.9999946355819702
Population O O 0.9979604482650757
- O O 0.9991421699523926
based O O 0.9998775720596313
, O O 0.9999328851699829
multisite O O 0.9365479946136475
, O O 0.9999674558639526
case O O 0.999772846698761
- O O 0.9998396635055542
control O O 0.9995280504226685
study O O 0.9999626874923706
of O O 0.9999939203262329
women O O 0.9999563694000244
who O O 0.9999946355819702
had O O 0.9999862909317017
pregnancies O O 0.6746349930763245
affected O O 0.9991914629936218
by O O 0.9999951124191284
1 O O 0.9988577365875244
of O O 0.9999603033065796
more O O 0.9999473094940186
than O O 0.9999434947967529
30 O O 0.999782383441925
eligible O O 0.9998534917831421
major O O 0.9938847422599792
birth B-Disease B-Disease 0.9672266840934753
defects I-Disease I-Disease 0.9999513626098633
identified O O 0.9991369843482971
via O O 0.9997300505638123
birth B-Disease O 0.7021148204803467
defect I-Disease O 0.9620668292045593
surveillance O O 0.674812912940979
programs O O 0.9866772890090942
in O O 0.9999908208847046
10 O O 0.9992751479148865
states O O 0.9996324777603149
( O O 0.9999986886978149
n O O 0.9998719692230225
= O O 0.999988317489624
13 O O 0.9995002746582031
155 O O 0.9899849891662598
) O O 0.9999411106109619
and O O 0.9999958276748657
control O O 0.998258650302887
women O O 0.999920129776001
randomly O O 0.9999701976776123
selected O O 0.9999978542327881
from O O 0.9999973773956299
the O O 0.9999537467956543
same O O 0.9995298385620117
geographical O O 0.9480926394462585
regions O O 0.9993970394134521
( O O 0.9999996423721313
n O O 0.9998971223831177
= O O 0.9999836683273315
4941 O O 0.998350977897644
) O O 0.9999573230743408
. O O 0.9999995231628418

Extrapyramidal B-Disease O 0.6263651847839355
symptoms I-Disease O 0.9693011045455933
reported O O 0.9980643391609192
as O O 0.9997419714927673
AEs O O 0.5539225339889526
occurred O O 0.9987950325012207
in O O 0.999992847442627
15 O O 0.9999369382858276
% O O 0.9999791383743286
and O O 0.9999849796295166
18 O O 0.999897837638855
% O O 0.9999878406524658
, O O 0.9999793767929077
34 O O 0.9999253749847412
% O O 0.9999872446060181
, O O 0.9999791383743286
and O O 0.999977707862854
10 O O 0.9999134540557861
% O O 0.9999818801879883
of O O 0.9999147653579712
the O O 0.9983187913894653
asenapine B-Chemical B-Chemical 0.9999760389328003
at O O 0.9999526739120483
5 O O 0.9926778078079224
and O O 0.9999394416809082
10 O O 0.9995494484901428
mg O O 0.9997846484184265
BID O O 0.522624671459198
, O O 0.999488353729248
haloperidol B-Chemical B-Chemical 0.9998382329940796
, O O 0.9987558126449585
and O O 0.9995538592338562
placebo O O 0.9884788393974304
groups O O 0.9993810653686523
, O O 0.9999966621398926
respectively O O 0.9999939203262329
. O O 0.9999995231628418

CONCLUSIONS O O 0.9994674324989319
: O O 0.9999996423721313
The O O 0.9999942779541016
results O O 0.9999425411224365
indicated O O 0.9999995231628418
a O O 0.999832034111023
favorable O O 0.9995415210723877
therapeutic O O 0.9929400682449341
profile O O 0.9994852542877197
for O O 0.999984860420227
haloperidol B-Chemical B-Chemical 0.9976181387901306
in O O 0.9996066689491272
doses O O 0.9999445676803589
of O O 0.9999600648880005
2 O O 0.9964994192123413
- O O 0.999024510383606
3 O O 0.9993658661842346
mg O O 0.9995761513710022
/ O O 0.9999891519546509
day O O 0.9999536275863647
, O O 0.9999954700469971
although O O 0.999998927116394
a O O 0.9998708963394165
subgroup O O 0.99940025806427
developed O O 0.9999974966049194
moderate O O 0.9949927926063538
to O O 0.9997995495796204
severe O O 0.9978775978088379
extrapyramidal B-Disease O 0.7307968735694885
signs I-Disease O 0.9669077396392822
. O O 0.9988355040550232

Clinicians O O 0.9995720982551575
should O O 0.9999979734420776
be O O 0.9999644756317139
aware O O 0.9999864101409912
of O O 0.999984622001648
potential O O 0.9973593354225159
hepatotoxicity B-Disease B-Disease 0.9969977140426636
with O O 0.9997304081916809
simvastatin B-Chemical B-Chemical 0.99285888671875
- I-Chemical I-Chemical 0.5393784642219543
ezetimibe I-Chemical I-Chemical 0.8833634257316589
especially O O 0.9997323155403137
in O O 0.9999866485595703
elderly O O 0.9969636797904968
patients O O 0.9999948740005493
and O O 0.9999955892562866
should O O 0.9999959468841553
carefully O O 0.9999216794967651
monitor O O 0.9995604157447815
serum O O 0.9982694387435913
aminotransferase O B-Chemical 0.9616149663925171
levels O O 0.9997109770774841
when O O 0.9999966621398926
starting O O 0.9965623021125793
therapy O O 0.9998893737792969
and O O 0.9999927282333374
titrating O O 0.9918813109397888
the O O 0.9948267340660095
dosage O O 0.9984922409057617
. O O 0.9999998807907104

Higher O O 0.9923490285873413
optical O O 0.9883301258087158
density O O 0.9861443042755127
of O O 0.9997863173484802
an O O 0.9990955591201782
antigen O O 0.7086937427520752
assay O O 0.9055617451667786
predicts O O 0.9999463558197021
thrombosis B-Disease B-Disease 0.9999531507492065
in O O 0.9996987581253052
patients O O 0.9999992847442627
with O O 0.9999631643295288
heparin B-Chemical B-Chemical 0.9998726844787598
- O O 0.9894905686378479
induced O O 0.9998173117637634
thrombocytopenia B-Disease B-Disease 0.9997040629386902
. O O 0.9999452829360962

Thalidomide B-Chemical B-Chemical 0.9990420937538147
has O O 0.9999561309814453
limited O O 0.999653697013855
single O O 0.9949533343315125
- O O 0.9957866072654724
agent O O 0.985837996006012
activity O O 0.9982642531394958
in O O 0.9999737739562988
relapsed O O 0.8528543710708618
or O O 0.9944612979888916
refractory O O 0.9842028617858887
indolent O O 0.9882679581642151
non B-Disease O 0.9799867272377014
- I-Disease O 0.9977717995643616
Hodgkin I-Disease B-Disease 0.9723659753799438
lymphomas I-Disease I-Disease 0.7198467254638672
: O O 0.9999797344207764
a O O 0.9995548129081726
phase O O 0.9994427561759949
II O O 0.9578890800476074
trial O O 0.9998260140419006
of O O 0.9999579191207886
the O O 0.9943484663963318
Cancer B-Disease B-Disease 0.9913702011108398
and O O 0.9680870771408081
Leukemia B-Disease B-Disease 0.9413439631462097
Group O O 0.7648510336875916
B O O 0.8024803400039673
. O O 0.9999359846115112

RESULTS O O 0.995272696018219
: O O 0.9999558925628662
Endophthalmitis B-Disease B-Disease 0.9768486618995667
resolved O O 0.9988089799880981
with O O 0.9999909400939941
improvement O O 0.9911141991615295
in O O 0.9987267851829529
visual O O 0.9845253825187683
acuity O O 0.895625650882721
to O O 0.9997802376747131
6 O O 0.9996964931488037
/ O O 0.9999731779098511
24 O O 0.9995273351669312
at O O 0.9999988079071045
three O O 0.9999784231185913
months O O 0.9999470710754395
. O O 0.9999998807907104

The O O 0.9998400211334229
effects O O 0.9999810457229614
of O O 0.9999710321426392
short O O 0.9972752928733826
- O O 0.9974617958068848
term O O 0.9981107711791992
raloxifene B-Chemical B-Chemical 0.9999743700027466
therapy O O 0.9998069405555725
on O O 0.9998846054077148
fibrinolysis O O 0.6469685435295105
markers O O 0.9985131621360779
: O O 0.9999793767929077
TAFI O O 0.7437052130699158
, O O 0.9995397329330444
tPA O O 0.8513265252113342
, O O 0.9997004270553589
and O O 0.9996404647827148
PAI O O 0.867121696472168
- O O 0.9983957409858704
1 O O 0.9899431467056274
. O O 0.9999982118606567

Tacrolimus B-Chemical B-Chemical 0.9957655668258667
, O O 0.9996563196182251
MMF B-Chemical B-Chemical 0.9208061695098877
, O O 0.999233603477478
and O O 0.9995310306549072
steroids B-Chemical B-Chemical 0.9982829093933105
were O O 0.9998464584350586
given O O 0.9999926090240479
as O O 0.9998738765716553
immunosuppressant O O 0.6777713298797607
. O O 0.999868631362915

The O O 0.9998577833175659
images O O 0.9992576241493225
were O O 0.999995231628418
subsequently O O 0.999975323677063
processed O O 0.9998868703842163
to O O 0.999998927116394
obtain O O 0.9999483823776245
volumetric O O 0.9912216663360596
data O O 0.9979457259178162
for O O 0.9999961853027344
the O O 0.9990109205245972
cerebellum O O 0.8251047134399414
. O O 0.9999994039535522

BACKGROUND O O 0.9935901165008545
: O O 0.9999839067459106
Fibrin O B-Chemical 0.8109766840934753
sealants O I-Chemical 0.9650352001190186
( O O 0.9980891346931458
FS O O 0.7648622989654541
) O O 0.9996845722198486
derived O O 0.9997840523719788
from O O 0.9999291896820068
human O O 0.9966918230056763
plasma O O 0.9836718440055847
are O O 0.9999634027481079
frequently O O 0.9998973608016968
used O O 0.9999834299087524
in O O 0.9999741315841675
neurosurgery O O 0.8409687876701355
. O O 0.9999977350234985

On O O 0.9999135732650757
hospital O O 0.999473512172699
admission O O 0.9999016523361206
, O O 0.9999988079071045
blood O O 0.9957119226455688
pressure O O 0.98475581407547
of O O 0.9999364614486694
the O O 0.9992468357086182
intubated O O 0.7134742140769958
, O O 0.9958211183547974
bradyarrhythmic O O 0.37947267293930054
patient O O 0.9963484406471252
was O O 0.9999983310699463
100 O O 0.9997411370277405
/ O O 0.9999804496765137
65 O O 0.9998579025268555
mmHg O O 0.98997962474823
. O O 0.9999996423721313

Patients O O 0.9997842907905579
with O O 0.9999983310699463
large O O 0.9913908243179321
pelvic B-Disease B-Disease 0.948364794254303
tumor I-Disease I-Disease 0.9209464192390442
loads O O 0.5861300826072693
are O O 0.9999892711639404
, O O 0.9999938011169434
according O O 0.9999966621398926
to O O 0.999984622001648
existing O O 0.9991461038589478
classifications O O 0.9994176626205444
, O O 0.9999992847442627
at O O 0.9999983310699463
high O O 0.9997506737709045
risk O O 0.9999774694442749
to O O 0.9999967813491821
die O O 0.9670163989067078
and O O 0.9999821186065674
to O O 0.9999897480010986
develop O O 0.9997950196266174
drug O O 0.9316865801811218
resistance O O 0.9457499384880066
. O O 0.9998881816864014

We O O 0.9999027252197266
report O O 0.9999994039535522
the O O 0.9999953508377075
case O O 0.999992847442627
of O O 0.9999872446060181
a O O 0.9997747540473938
30 O O 0.9991238713264465
- O O 0.9999511241912842
year O O 0.9999897480010986
- O O 0.9999581575393677
old O O 0.9999169111251831
Caucasian O O 0.9367954730987549
man O O 0.999873161315918
who O O 0.9999896287918091
came O O 0.9999344348907471
to O O 0.999984860420227
the O O 0.99958735704422
emergency O O 0.991452693939209
department O O 0.9998220801353455
in O O 0.9999910593032837
atrial B-Disease B-Disease 0.5824443697929382
fibrillation I-Disease I-Disease 0.999729573726654
with O O 0.9998412132263184
rapid O O 0.9826874136924744
ventricular O O 0.8967799544334412
response O O 0.7255526185035706
. O O 0.9999966621398926

We O O 0.9996927976608276
aimed O O 0.9999978542327881
to O O 0.9999951124191284
determine O O 0.9999876022338867
the O O 0.9999517202377319
causes O O 0.9993494153022766
of O O 0.9999184608459473
thrombotic B-Disease B-Disease 0.9035394787788391
microangiopathy I-Disease I-Disease 0.9736068248748779
in O O 0.9997590184211731
a O O 0.9999197721481323
population O O 0.9996405839920044
of O O 0.999970555305481
renal O O 0.9959138035774231
transplantation O O 0.9897596836090088
recipients O O 0.9997815489768982
and O O 0.9999995231628418
discuss O O 0.9999953508377075
the O O 0.9998487234115601
literature O O 0.9987180233001709
. O O 0.9999998807907104

A O O 0.9969022870063782
72 O O 0.9993372559547424
- O O 0.9999873638153076
year O O 0.9999963045120239
- O O 0.9999842643737793
old O O 0.9999191761016846
woman O O 0.9998575448989868
was O O 0.9999483823776245
admitted O O 0.9999200105667114
to O O 0.9999624490737915
the O O 0.999376118183136
hospital O O 0.9999805688858032
with O O 0.9999984502792358
" O O 0.9964057207107544
flash O B-Disease 0.9749865531921387
" O I-Disease 0.9500518441200256
pulmonary B-Disease I-Disease 0.9625217318534851
edema I-Disease I-Disease 0.9999840259552002
, O O 0.9995724558830261
preceded O O 0.9999974966049194
by O O 0.9999974966049194
chest B-Disease B-Disease 0.5305028557777405
pain I-Disease I-Disease 0.9937694668769836
, O O 0.9998171925544739
requiring O O 0.9999676942825317
intubation O O 0.5105829238891602
. O O 0.999996542930603

Further O O 0.9998775720596313
studies O O 0.9999521970748901
are O O 0.9999992847442627
necessary O O 0.9999995231628418
to O O 0.9999974966049194
determine O O 0.9999960660934448
the O O 0.9999890327453613
exact O O 0.9999561309814453
extent O O 0.9999985694885254
of O O 0.9999961853027344
this O O 0.9996274709701538
problem O O 0.9934397339820862
and O O 0.9999974966049194
to O O 0.9999943971633911
improve O O 0.9998522996902466
the O O 0.9994083642959595
efficacy O O 0.9984645843505859
of O O 0.9997168183326721
diagnostic O O 0.9584674835205078
methods O O 0.9984874725341797
. O O 0.9999996423721313

Because O O 0.9998842477798462
of O O 0.9999850988388062
the O O 0.9999604225158691
rapid O O 0.9988295435905457
systemic O O 0.9969727993011475
clearance O O 0.9994447827339172
of O O 0.9992883801460266
BCNU B-Chemical B-Chemical 0.9986721277236938
( O O 0.9888829588890076
1 B-Chemical B-Chemical 0.8576953411102295
, I-Chemical I-Chemical 0.922566831111908
3 I-Chemical I-Chemical 0.9891594052314758
- I-Chemical I-Chemical 0.9944660067558289
bis I-Chemical I-Chemical 0.9944191575050354
- I-Chemical I-Chemical 0.9899485111236572
( I-Chemical I-Chemical 0.8899402618408203
2 I-Chemical I-Chemical 0.9892591834068298
- I-Chemical I-Chemical 0.9992947578430176
chloroethyl I-Chemical I-Chemical 0.9999339580535889
) I-Chemical I-Chemical 0.9595947265625
- I-Chemical I-Chemical 0.9803479313850403
1 I-Chemical I-Chemical 0.9958206415176392
- I-Chemical I-Chemical 0.9986867308616638
nitrosourea I-Chemical I-Chemical 0.9999486207962036
) O O 0.9293748736381531
, O O 0.999915361404419
intra O O 0.834850013256073
- O O 0.9620267748832703
arterial O O 0.7288775444030762
administration O O 0.9982954859733582
should O O 0.9999978542327881
provide O O 0.9999992847442627
a O O 0.9999749660491943
substantial O O 0.9998835325241089
advantage O O 0.999854564666748
over O O 0.9999877214431763
intravenous O O 0.9715875387191772
administration O O 0.9983084201812744
for O O 0.999997615814209
the O O 0.9996769428253174
treatment O O 0.9999797344207764
of O O 0.9999912977218628
malignant B-Disease B-Disease 0.9090028405189514
gliomas I-Disease I-Disease 0.9832862615585327
. O O 0.9999613761901855

However O O 0.999976634979248
, O O 0.9999973773956299
we O O 0.999954342842102
suggest O O 0.9999990463256836
that O O 0.999993085861206
a O O 0.9997493624687195
low O O 0.9935467839241028
solution O O 0.9839720726013184
concentration O O 0.9997923970222473
should O O 0.9999979734420776
be O O 0.9999818801879883
preferred O O 0.9999774694442749
for O O 0.9999964237213135
unilateral O O 0.9952360987663269
spinal O O 0.9770764708518982
anaesthesia O O 0.7773154377937317
with O O 0.9999970197677612
a O O 0.9986494183540344
hyperbaric O O 0.7293077707290649
anaesthetic O O 0.4754113256931305
solution O O 0.8933643102645874
( O O 0.9999958276748657
if O O 0.9999691247940063
pencil O O 0.7552811503410339
- O O 0.9863507151603699
point O O 0.9918644428253174
needle O O 0.9930623173713684
and O O 0.9999799728393555
slow O O 0.9937239289283752
injection O O 0.9983299374580383
rate O O 0.9999892711639404
are O O 0.9999959468841553
employed O O 0.9999134540557861
) O O 0.9999587535858154
, O O 0.9999940395355225
in O O 0.9999868869781494
order O O 0.9999854564666748
to O O 0.999998927116394
minimize O O 0.9998487234115601
the O O 0.9998763799667358
risk O O 0.9999641180038452
of O O 0.9999949932098389
a O O 0.9993745684623718
localized O O 0.9923574328422546
high O O 0.9949356317520142
peak O O 0.9918879866600037
anaesthetic O O 0.5379586815834045
concentration O O 0.969478189945221
, O O 0.9999977350234985
which O O 0.9999305009841919
might O O 0.9999979734420776
lead O O 0.9999923706054688
to O O 0.9999984502792358
a O O 0.9998377561569214
transient O O 0.9863998889923096
neurological B-Disease B-Disease 0.5631626844406128
deficit I-Disease I-Disease 0.9997727274894714
. O O 0.9997729659080505

Prospective O O 0.999680757522583
studies O O 0.999934196472168
on O O 0.9999486207962036
ATT O O 0.8843036890029907
- O O 0.9748725891113281
ALF B-Disease B-Disease 0.9968359470367432
are O O 0.999968409538269
lacking O O 0.9999340772628784
. O O 0.9999982118606567

Renal O O 0.962883472442627
function O O 0.7653797268867493
remained O O 0.999876856803894
normal O O 0.9992187023162842
in O O 0.9999984502792358
all O O 0.9984764456748962
patients O O 0.9999922513961792
. O O 0.9999998807907104

Subjects O O 0.9995588660240173
were O O 0.9999994039535522
1210 O O 0.9996528625488281
inpatients O O 0.9996638298034668
with O O 0.9999934434890747
New O O 0.9874367713928223
York O O 0.9452359676361084
Heart O O 0.6822247505187988
Association O O 0.8978468179702759
( O O 0.9778156280517578
NYHA O O 0.9526274800300598
) O O 0.9998738765716553
functional O O 0.999112069606781
class O O 0.9995399713516235
II O O 0.9115375280380249
and O O 0.9999794960021973
III O O 0.7342037558555603
. O O 0.9999990463256836

This O O 0.9996187686920166
agent O O 0.9957787990570068
was O O 0.9999854564666748
well O O 0.9873600602149963
tolerated O O 0.9838098287582397
in O O 0.999995231628418
healthy O O 0.9928754568099976
volunteers O O 0.9979113936424255
at O O 0.9999983310699463
doses O O 0.9999055862426758
up O O 0.9998996257781982
to O O 0.9999887943267822
100 O O 0.999769389629364
micrograms O O 0.9980091452598572
/ O O 0.9999810457229614
kg O O 0.9997525811195374
/ O O 0.9999624490737915
min O O 0.9997701048851013
. O O 0.9999967813491821

Thirty O O 0.9998175501823425
days O O 0.9999810457229614
after O O 0.999980092048645
amiodarone B-Chemical B-Chemical 0.9993917942047119
discontinuation O O 0.935114860534668
, O O 0.9999966621398926
His O O 0.9968858361244202
bundle O O 0.9956011772155762
electrograms O O 0.9875180125236511
showed O O 0.999997615814209
atrial B-Disease B-Disease 0.9096298217773438
flutter I-Disease I-Disease 0.9780222177505493
without O O 0.9992249011993408
intra O O 0.9384992122650146
- O O 0.959266185760498
Hisian O O 0.4112256169319153
or O O 0.9998365640640259
infra O O 0.7965806722640991
- O O 0.7839823961257935
Hisian O O 0.42651039361953735
delay O O 0.9763789772987366
. O O 0.999998927116394

Patients O O 0.9993938207626343
treated O O 0.9999915361404419
with O O 0.9999881982803345
alkylating B-Chemical O 0.5474292635917664
agents I-Chemical O 0.9407076239585876
have O O 0.9999674558639526
an O O 0.9999876022338867
increased O O 0.9986358284950256
risk O O 0.999984622001648
of O O 0.9999967813491821
development O O 0.9983737468719482
of O O 0.9999880790710449
acute B-Disease B-Disease 0.5473598837852478
nonlymphocytic I-Disease I-Disease 0.8555676341056824
leukemia I-Disease I-Disease 0.9998908042907715
, O O 0.9993321299552917
and O O 0.9999622106552124
both O O 0.999808132648468
alkylating B-Chemical O 0.49432528018951416
agents I-Chemical O 0.8090620040893555
and O O 0.9967240691184998
azathioprine B-Chemical B-Chemical 0.9999786615371704
are O O 0.9998264908790588
associated O O 0.9999982118606567
with O O 0.9999982118606567
the O O 0.9998598098754883
development O O 0.9992204904556274
of O O 0.9999899864196777
non B-Disease B-Disease 0.7913418412208557
- I-Disease I-Disease 0.8118258714675903
Hodgkin I-Disease I-Disease 0.4259417653083801
' I-Disease I-Disease 0.9998867511749268
s I-Disease I-Disease 0.9999450445175171
lymphoma I-Disease I-Disease 0.9999960660934448
. O O 0.9999473094940186

Our O O 0.9997668862342834
aim O O 0.9999861717224121
was O O 0.9999995231628418
to O O 0.9999901056289673
characterize O O 0.9997064471244812
both O O 0.9943506717681885
lines O O 0.9986129999160767
' O O 0.99996018409729
sensitivities O O 0.9946415424346924
to O O 0.9999995231628418
various O O 0.9998359680175781
physiological O O 0.9392775297164917
effects O O 0.9990400671958923
of O O 0.9999743700027466
other O O 0.9994646906852722
ligands O O 0.9909776449203491
of O O 0.9999186992645264
the O O 0.9977864027023315
GABA B-Chemical B-Chemical 0.998975396156311
( O O 0.997334361076355
A O O 0.6197285652160645
) O O 0.997876763343811
receptor O O 0.9915761351585388
. O O 0.9999997615814209

PURPOSE O O 0.999079704284668
: O O 0.9999985694885254
This O O 0.9999860525131226
study O O 0.9999769926071167
was O O 0.9999938011169434
designed O O 0.9999961853027344
to O O 0.9999979734420776
establish O O 0.9999767541885376
a O O 0.9982509016990662
rat O O 0.975463330745697
model O O 0.9998078942298889
of O O 0.9999580383300781
thoracic B-Disease B-Disease 0.6326801776885986
aortic I-Disease I-Disease 0.9325922727584839
aneurysm I-Disease I-Disease 0.9999083280563354
( O O 0.9951648712158203
TAA B-Disease B-Disease 0.9980950951576233
) O O 0.9973465204238892
by O O 0.9999879598617554
calcium B-Chemical B-Chemical 0.9993072748184204
chloride I-Chemical I-Chemical 0.9989436268806458
( O O 0.999708354473114
CaCl B-Chemical B-Chemical 0.9992177486419678
( I-Chemical I-Chemical 0.6930642127990723
2 I-Chemical I-Chemical 0.9929042458534241
) I-Chemical I-Chemical 0.9949331879615784
) O O 0.8360186815261841
- O O 0.9804506301879883
induced O O 0.9998528957366943
arterial B-Disease B-Disease 0.8235825896263123
injury I-Disease I-Disease 0.9985060691833496
and O O 0.9988266825675964
to O O 0.999975323677063
explore O O 0.999830961227417
the O O 0.9998942613601685
potential O O 0.9999715089797974
role O O 0.9999513626098633
of O O 0.999972939491272
a O O 0.9822836518287659
disintegrin O B-Chemical 0.8990735411643982
and O O 0.9938471913337708
metalloproteinase O O 0.8717980980873108
( O O 0.9995833039283752
ADAM O B-Chemical 0.9909732341766357
) O O 0.9977869987487793
, O O 0.9999762773513794
matrix O O 0.9302021861076355
metalloproteinases O O 0.7650858163833618
( O O 0.9999922513961792
MMPs O O 0.538184404373169
) O O 0.9992154836654663
and O O 0.999995231628418
their O O 0.9995390176773071
endogenous O O 0.9742388725280762
inhibitors O O 0.973466157913208
( O O 0.9999130964279175
TIMPs O O 0.5138346552848816
) O O 0.9993674159049988
in O O 0.9999849796295166
TAA B-Disease B-Disease 0.6897844076156616
formation O O 0.8403303623199463
. O O 0.9999946355819702

A O O 0.9992528557777405
conjunction O O 0.9969152212142944
analysis O O 0.9997770190238953
of O O 0.9999626874923706
the O O 0.9995823502540588
encode O O 0.9816741943359375
and O O 0.9999661445617676
recall O O 0.9994632601737976
phases O O 0.9998769760131836
of O O 0.9999804496765137
the O O 0.9999336004257202
task O O 0.9982705116271973
revealed O O 0.9999866485595703
ecstasy B-Chemical B-Chemical 0.9962751865386963
- O O 0.9977387189865112
specific O O 0.9968816041946411
hyperactivity B-Disease B-Disease 0.9872905611991882
in O O 0.9978569149971008
bilateral O O 0.9986035227775574
frontal O O 0.9945631623268127
regions O O 0.9992138147354126
, O O 0.9999986886978149
left O O 0.9990543723106384
temporal O O 0.9986334443092346
, O O 0.9999750852584839
right O O 0.9995338916778564
parietal O O 0.9963517189025879
, O O 0.9998766183853149
bilateral O O 0.9989461302757263
temporal O O 0.9963764548301697
, O O 0.9999237060546875
and O O 0.9999542236328125
bilateral O O 0.999228835105896
occipital O O 0.9867426156997681
brain O O 0.8806703686714172
regions O O 0.9933244585990906
. O O 0.9999997615814209

It O O 0.99972003698349
is O O 0.9999943971633911
therefore O O 0.9999972581863403
suggested O O 0.9999995231628418
that O O 0.9999700784683228
caution O O 0.9943295121192932
should O O 0.9999996423721313
be O O 0.9999914169311523
exercised O O 0.9998594522476196
when O O 0.9999961853027344
prescribing O O 0.9996213912963867
vasodilator O O 0.5372612476348877
drugs O O 0.9964805245399475
in O O 0.9999960660934448
diabetic B-Disease B-Disease 0.9987749457359314
patients O O 0.9758437871932983
, O O 0.9999978542327881
particularly O O 0.9999983310699463
those O O 0.999995231628418
with O O 0.9999954700469971
autonomic B-Disease B-Disease 0.6098971366882324
neuropathy I-Disease I-Disease 0.9959186911582947
. O O 0.9999666213989258

This O O 0.9995261430740356
occurred O O 0.9999960660934448
in O O 0.9999966621398926
association O O 0.999987006187439
with O O 0.9999879598617554
an O O 0.9998356103897095
increase O O 0.9818083643913269
in O O 0.9876678586006165
urinary O O 0.9696723222732544
protein O O 0.5449973344802856
content O O 0.9495041370391846
from O O 0.9999810457229614
1 O O 0.9988980293273926
. O O 0.9999964237213135
8 O O 0.9999325275421143
+ O O 0.9999955892562866
/ O O 0.9999982118606567
- O O 0.999921441078186
1 O O 0.999612033367157
to O O 0.9999551773071289
99 O O 0.9973354935646057
. O O 0.9999995231628418
0 O O 0.9999555349349976
+ O O 0.9999970197677612
/ O O 0.9999979734420776
- O O 0.9999713897705078
61 O O 0.9997991919517517
mg O O 0.9998775720596313
/ O O 0.9999954700469971
day O O 0.9999687671661377
( O O 0.9999964237213135
p O O 0.9998701810836792
< O O 0.9999898672103882
0 O O 0.999923825263977
. O O 0.9999858140945435
001 O O 0.9974668025970459
) O O 0.9998949766159058
. O O 0.999998927116394

We O O 0.9996764659881592
believe O O 0.9999955892562866
the O O 0.9999891519546509
results O O 0.9999783039093018
of O O 0.9999977350234985
those O O 0.9999889135360718
studies O O 0.9999169111251831
may O O 0.9999991655349731
have O O 0.9999991655349731
been O O 0.9999862909317017
affected O O 0.9999655485153198
by O O 0.9999986886978149
residual O O 0.9980818033218384
confounding O O 0.9289626479148865
. O O 0.999993085861206

PTCR O B-Chemical 0.8169958591461182
also O O 0.9817466735839844
occurs O O 0.9999874830245972
in O O 0.9999967813491821
certain O O 0.9996180534362793
native O O 0.9982666969299316
kidney B-Disease B-Disease 0.8365150690078735
diseases I-Disease I-Disease 0.9999192953109741
, O O 0.9994696974754333
though O O 0.9999997615814209
the O O 0.9999637603759766
association O O 0.9997953772544861
is O O 0.9999961853027344
not O O 0.9999970197677612
as O O 0.9999953508377075
strong O O 0.9999315738677979
as O O 0.9999936819076538
that O O 0.999901533126831
for O O 0.9999402761459351
TG B-Disease B-Disease 0.8920727372169495
. O O 0.9998237490653992

The O O 0.9999185800552368
mechanism O O 0.9999591112136841
of O O 0.9999935626983643
chest B-Disease B-Disease 0.9154989719390869
pain I-Disease I-Disease 0.9736086130142212
related O O 0.99972003698349
to O O 0.9999487400054932
cocaine B-Chemical B-Chemical 0.9999011754989624
use O O 0.9755749702453613
is O O 0.9999985694885254
discussed O O 0.99998939037323
and O O 0.999996542930603
treatment O O 0.9996728897094727
dilemmas O O 0.892216145992279
are O O 0.9999935626983643
discussed O O 0.9999912977218628
. O O 0.9999997615814209

INTRODUCTION O O 0.9987248778343201
: O O 0.9997605681419373
Antibiotic O O 0.6673464775085449
- O O 0.9936642646789551
associated O O 0.999665379524231
hepatotoxicity B-Disease B-Disease 0.9998713731765747
is O O 0.9996246099472046
rare O O 0.9984678626060486
. O O 0.9999996423721313

The O O 0.9999731779098511
purpose O O 0.9999926090240479
of O O 0.9999973773956299
this O O 0.9999771118164062
study O O 0.9999812841415405
was O O 0.9999991655349731
to O O 0.9999911785125732
evaluate O O 0.9998819828033447
and O O 0.9999434947967529
compare O O 0.9999496936798096
the O O 0.9995606541633606
effects O O 0.9998444318771362
of O O 0.9988157749176025
coniine B-Chemical B-Chemical 0.9999784231185913
and O O 0.9940381050109863
nicotine B-Chemical B-Chemical 0.999984860420227
in O O 0.9999539852142334
the O O 0.9998955726623535
developing O O 0.9926475286483765
chick O O 0.9805684089660645
. O O 0.9999992847442627

We O O 0.9992713332176208
tested O O 0.9999929666519165
the O O 0.9990154504776001
hypothesis O O 0.9954761862754822
that O O 0.9999983310699463
the O O 0.9998573064804077
antagonistic O O 0.500468909740448
effect O O 0.9991562366485596
of O O 0.999907374382019
IL O O 0.9194375276565552
- O O 0.98827064037323
3 O O 0.9307371973991394
and O O 0.9992901086807251
EPO O O 0.5859439373016357
on O O 0.9999537467956543
erythroid O O 0.7835410833358765
cells O O 0.9948602318763733
may O O 0.9999973773956299
be O O 0.999975323677063
mediated O O 0.9998742341995239
by O O 0.999975323677063
endothelial O O 0.8417689204216003
cells O O 0.9921890497207642
. O O 0.999998927116394

Long O O 0.9967066645622253
- O O 0.9986893534660339
term O O 0.9987659454345703
glutamate B-Chemical B-Chemical 0.9998396635055542
supplementation O O 0.9975956082344055
failed O O 0.9999464750289917
to O O 0.9999915361404419
protect O O 0.9993427395820618
against O O 0.9999496936798096
peripheral B-Disease B-Disease 0.6052950024604797
neurotoxicity I-Disease I-Disease 0.8245310187339783
of O O 0.9120497107505798
paclitaxel B-Chemical B-Chemical 0.999406099319458
. O O 0.9999825954437256

However O O 0.9999419450759888
, O O 0.999993085861206
pretreatment O O 0.9983312487602234
with O O 0.9998806715011597
RAMH B-Chemical B-Chemical 0.9981912970542908
significantly O O 0.9999545812606812
reversed O O 0.9997829794883728
such O O 0.9999512434005737
an O O 0.9998332262039185
effect O O 0.9999585151672363
of O O 0.9996500015258789
THP B-Chemical B-Chemical 0.9995629191398621
( O O 0.9997619986534119
15 O O 0.9998549222946167
mg O O 0.9998934268951416
/ O O 0.9999912977218628
kg O O 0.9999574422836304
i O O 0.999984860420227
. O O 0.9999868869781494
p O O 0.999927282333374
. O O 0.9999884366989136
) O O 0.9998996257781982
. O O 0.9999957084655762

Hallucinations B-Disease B-Disease 0.9683590531349182
occurred O O 0.9975084066390991
in O O 0.9999862909317017
4 O O 0.9970025420188904
patients O O 0.9999748468399048
, O O 0.9999990463256836
and O O 0.9999980926513672
an O O 0.9999537467956543
unpleasant O B-Disease 0.5307183265686035
sensation O I-Disease 0.9882764220237732
( O O 0.9997193217277527
" O O 0.9935703277587891
empty O O 0.5695478916168213
head O O 0.6342400908470154
" O O 0.9901261329650879
) O O 0.9983087778091431
was O O 0.9999514818191528
also O O 0.9999227523803711
reported O O 0.9999891519546509
by O O 0.9999899864196777
2 O O 0.9973167777061462
patients O O 0.9999713897705078
. O O 0.9999998807907104

It O O 0.9997432827949524
is O O 0.9999951124191284
suggested O O 0.9999986886978149
that O O 0.9999843835830688
the O O 0.999658465385437
drug O O 0.9986472725868225
acted O O 0.9998838901519775
in O O 0.9999860525131226
a O O 0.9996860027313232
selective O O 0.9894617199897766
and O O 0.996841311454773
tissue O O 0.9970529079437256
- O O 0.9999206066131592
specific O O 0.9996410608291626
manner O O 0.9990272521972656
to O O 0.9999954700469971
enhance O O 0.9975025057792664
ribosomal O O 0.9455125331878662
RNA O O 0.8482137322425842
synthesis O O 0.8798071146011353
in O O 0.9998266100883484
the O O 0.9991705417633057
liver O O 0.9872989058494568
and O O 0.9999840259552002
depress O O 0.981717586517334
such O O 0.9994833469390869
synthesis O O 0.5473652482032776
in O O 0.9999105930328369
the O O 0.9997382760047913
muscle O O 0.9597358703613281
. O O 0.9999969005584717

By O O 0.9996053576469421
using O O 0.9996331930160522
transthoracic O O 0.9754483699798584
echocardiography O O 0.9759830832481384
, O O 0.9999923706054688
anterior O O 0.986671507358551
and O O 0.9975047707557678
posterior O O 0.9964738488197327
wall O O 0.9953624606132507
thickness O O 0.9880293011665344
, O O 0.9999984502792358
LV O O 0.9340376257896423
diameters O O 0.9545921087265015
and O O 0.9998847246170044
LV O O 0.938623309135437
fractional O O 0.9943971633911133
shortening O O 0.745591938495636
( O O 0.9967091083526611
FS O O 0.9368254542350769
) O O 0.99985671043396
were O O 0.9999927282333374
measured O O 0.9999634027481079
in O O 0.9999896287918091
all O O 0.9997066855430603
rats O O 0.9995858073234558
before O O 0.999990701675415
DOX B-Chemical B-Chemical 0.9995071887969971
or O O 0.9995380640029907
saline O O 0.9519553780555725
, O O 0.9999837875366211
and O O 0.9999912977218628
at O O 0.9999984502792358
weeks O O 0.9999891519546509
6 O O 0.9997432827949524
and O O 0.9999672174453735
9 O O 0.9930866360664368
after O O 0.999990701675415
treatment O O 0.9999735355377197
in O O 0.999998927116394
all O O 0.9998940229415894
surviving O O 0.9937289953231812
rats O O 0.9972373247146606
. O O 0.9999998807907104

Simultaneous O O 0.9997233748435974
measurements O O 0.9993249177932739
of O O 0.9994658827781677
ECG O O 0.6783625483512878
and O O 0.9991003274917603
brachial O O 0.9593438506126404
artery O O 0.959104061126709
dP O O 0.9644541144371033
/ O O 0.9998785257339478
dtejc O O 0.5424594283103943
were O O 0.9999887943267822
performed O O 0.9999923706054688
at O O 0.9999914169311523
each O O 0.9997028708457947
dobutamine B-Chemical B-Chemical 0.993298351764679
level O O 0.9998998641967773
. O O 0.9999998807907104

Male O O 0.9969543218612671
Wistar O O 0.9862959980964661
rats O O 0.9985101819038391
were O O 0.9999867677688599
implanted O O 0.9977033734321594
bilaterally O O 0.9996681213378906
with O O 0.9997922778129578
cannulae O B-Chemical 0.9709161520004272
into O O 0.9997196793556213
the O O 0.9994199275970459
accumbens O O 0.9958051443099976
shell O O 0.9977837204933167
or O O 0.9999535083770752
core O O 0.9967345595359802
, O O 0.9999878406524658
and O O 0.999987006187439
then O O 0.9999486207962036
were O O 0.9999926090240479
locally O O 0.9995307922363281
injected O O 0.9997881054878235
with O O 0.999951958656311
GR B-Chemical B-Chemical 0.9966000914573669
55562 I-Chemical I-Chemical 0.9997190833091736
( O O 0.999955415725708
an O O 0.9994939565658569
antagonist O O 0.9939800500869751
of O O 0.9999312162399292
5 O O 0.7693114280700684
- O O 0.6194061040878296
HT1B O O 0.9212841391563416
receptors O O 0.99222332239151
) O O 0.9997575879096985
or O O 0.9999644756317139
CP B-Chemical B-Chemical 0.9544543027877808
93129 I-Chemical I-Chemical 0.9997754693031311
( O O 0.9999336004257202
an O O 0.9997827410697937
agonist O O 0.9944297671318054
of O O 0.9998406171798706
5 O O 0.8357269167900085
- O O 0.8178828954696655
HT1B O O 0.7142200469970703
receptors O O 0.9988403916358948
) O O 0.9999443292617798
. O O 0.9999995231628418

In O O 0.9999909400939941
four O O 0.999914288520813
subacute O O 0.88372802734375
toxicity B-Disease B-Disease 0.8326040506362915
studies O O 0.9218266010284424
, O O 0.9999994039535522
the O O 0.9999301433563232
intravenous O O 0.9754322171211243
administration O O 0.9985881447792053
of O O 0.999535083770752
cefonicid B-Chemical B-Chemical 0.9985792636871338
or O O 0.9846407175064087
cefazedone B-Chemical B-Chemical 0.9999439716339111
to O O 0.9999651908874512
beagle O O 0.6853859424591064
dogs O O 0.9587374925613403
caused O O 0.9999978542327881
a O O 0.998965859413147
dose O O 0.9996728897094727
- O O 0.9998536109924316
dependent O O 0.9998879432678223
incidence O O 0.9993929862976074
of O O 0.9999042749404907
anemia B-Disease B-Disease 0.9996849298477173
, O O 0.9906085729598999
neutropenia B-Disease B-Disease 0.9998000264167786
, O O 0.9992842078208923
and O O 0.9995587468147278
thrombocytopenia B-Disease B-Disease 0.9999511241912842
after O O 0.9999704360961914
1 O O 0.9996024966239929
- O O 0.999674916267395
3 O O 0.9994200468063354
months O O 0.9999887943267822
of O O 0.9999898672103882
treatment O O 0.9999451637268066
. O O 0.9999998807907104

Methamphetamine B-Chemical B-Chemical 0.9998868703842163
- O O 0.9945284724235535
induced O O 0.9996042847633362
neurotoxicity B-Disease B-Disease 0.9999090433120728
and O O 0.9988906979560852
microglial O O 0.8901629447937012
activation O O 0.6266211271286011
are O O 0.9999872446060181
not O O 0.9999638795852661
mediated O O 0.9999563694000244
by O O 0.9999663829803467
fractalkine O B-Chemical 0.9983710646629333
receptor O O 0.9955968260765076
signaling O O 0.9924595952033997
. O O 0.9999997615814209

These O O 0.9998301267623901
6 O O 0.9987775683403015
patients O O 0.9999607801437378
had O O 0.9999972581863403
both O O 0.9960029721260071
renal B-Disease B-Disease 0.8249697089195251
and I-Disease I-Disease 0.8517715930938721
liver I-Disease I-Disease 0.9348485469818115
dysfunction I-Disease I-Disease 0.9999967813491821
( O O 0.99649578332901
P O O 0.867729902267456
less O O 0.9753885865211487
than O O 0.9954500794410706
0 O O 0.9979908466339111
. O O 0.999809205532074
05 O O 0.9963881969451904
) O O 0.9995185136795044
, O O 0.9999836683273315
as O O 0.9999368190765381
well O O 0.9999003410339355
as O O 0.999804675579071
cimetidine B-Chemical B-Chemical 0.9999117851257324
trough O O 0.9918944239616394
- O O 0.9989801049232483
concentrations O O 0.995792031288147
of O O 0.9999780654907227
more O O 0.9997798800468445
than O O 0.9998218417167664
1 O O 0.9988600015640259
. O O 0.9999953508377075
25 O O 0.9999186992645264
microgram O O 0.998927891254425
/ O O 0.9999549388885498
ml O O 0.9978148937225342
( O O 0.9999275207519531
P O O 0.9956977367401123
less O O 0.9986478686332703
than O O 0.9999262094497681
0 O O 0.9996505975723267
. O O 0.9999641180038452
05 O O 0.9980517625808716
) O O 0.999446451663971
. O O 0.9999990463256836

In O O 0.999983549118042
four O O 0.9999158382415771
patients O O 0.9999884366989136
, O O 0.9999974966049194
polymorphous O O 0.7363104224205017
ventricular B-Disease B-Disease 0.6042870879173279
tachycardia I-Disease I-Disease 0.9971876740455627
appeared O O 0.9990593791007996
after O O 0.9999983310699463
intravenous O O 0.9962759017944336
administration O O 0.9983564019203186
of O O 0.9999614953994751
200 O O 0.9993540644645691
to O O 0.9999704360961914
400 O O 0.9997660517692566
mg O O 0.997654914855957
of O O 0.9969730377197266
procainamide B-Chemical B-Chemical 0.9999828338623047
for O O 0.999921441078186
the O O 0.9996873140335083
treatment O O 0.9999710321426392
of O O 0.9999699592590332
sustained O O 0.9595814347267151
ventricular B-Disease B-Disease 0.9509585499763489
tachycardia I-Disease I-Disease 0.9997827410697937
. O O 0.9995872378349304

MATERIALS O O 0.9936143755912781
AND O O 0.9997075200080872
METHODS O O 0.9994614720344543
: O O 0.9999268054962158
Testosterone B-Chemical B-Chemical 0.9999524354934692
and O O 0.9997417330741882
prolactin O O 0.4967198669910431
were O O 0.9997959733009338
determined O O 0.9999958276748657
by O O 0.9999469518661499
radioimmunoassay O B-Chemical 0.9642590284347534
. O O 0.9999809265136719

The O O 0.9997219443321228
administration O O 0.9997662901878357
of O O 0.998009979724884
phenobarbitone B-Chemical B-Chemical 0.999962329864502
and O O 0.993829071521759
carbamazepine B-Chemical B-Chemical 0.9999967813491821
for O O 0.9998038411140442
21days O O 0.9447590112686157
caused O O 0.9999934434890747
a O O 0.9999395608901978
significant O O 0.9998589754104614
impairment B-Disease B-Disease 0.8658655881881714
of I-Disease I-Disease 0.705110490322113
learning I-Disease I-Disease 0.9979730248451233
and I-Disease I-Disease 0.9714402556419373
memory I-Disease I-Disease 0.9999735355377197
as O O 0.956460177898407
well O O 0.9927984476089478
as O O 0.9999924898147583
an O O 0.9999728202819824
increased O O 0.9954670667648315
oxidative O O 0.9473932981491089
stress O O 0.8837136626243591
. O O 0.9999947547912598

Among O O 0.9999220371246338
547 O O 0.9998471736907959
preterm O O 0.7268698811531067
infants O O 0.9377129077911377
of O O 0.9998384714126587
< O O 0.9999440908432007
or O O 0.999911904335022
= O O 0.9999892711639404
34 O O 0.9995090961456299
weeks O O 0.9998180270195007
gestation O O 0.9993977546691895
born O O 0.9999955892562866
between O O 0.999992847442627
1987 O O 0.9998152852058411
and O O 0.9999988079071045
1991 O O 0.9998775720596313
, O O 0.9999992847442627
8 O O 0.9994737505912781
children O O 0.9996260404586792
( O O 0.9999980926513672
1 O O 0.999906063079834
. O O 0.9999951124191284
46 O O 0.9999759197235107
% O O 0.9999942779541016
) O O 0.9999414682388306
developed O O 0.9999949932098389
severe O O 0.9986677169799805
progressive O O 0.8718153238296509
and O O 0.991521954536438
bilateral O O 0.9964728951454163
sensorineural B-Disease B-Disease 0.98659747838974
hearing I-Disease I-Disease 0.5500365495681763
loss I-Disease I-Disease 0.9999324083328247
. O O 0.999842643737793

Endothelial O O 0.983848512172699
cell O O 0.9941521286964417
culture O O 0.9937475919723511
supernatants O O 0.980499804019928
separated O O 0.9991315007209778
by O O 0.9999068975448608
ultrafiltration O O 0.806746780872345
and O O 0.9995936751365662
ultracentrifugation O O 0.7113276720046997
from O O 0.9997780919075012
cells O O 0.9994983673095703
treated O O 0.999987006187439
with O O 0.9999547004699707
EPO O O 0.5054414868354797
and O O 0.9989084005355835
IL O O 0.9283386468887329
- O O 0.9951274394989014
3 O O 0.9749017953872681
significantly O O 0.9999736547470093
reduced O O 0.9970266222953796
thymidine B-Chemical B-Chemical 0.9978556036949158
incorporation O O 0.9773443341255188
into O O 0.9999263286590576
erythroid O O 0.9828823804855347
cells O O 0.9998412132263184
as O O 0.9999904632568359
compared O O 0.9999371767044067
to O O 0.9999929666519165
identical O O 0.9990043044090271
fractions O O 0.8638850450515747
obtained O O 0.9997194409370422
from O O 0.9999890327453613
the O O 0.9992977380752563
media O O 0.99931800365448
of O O 0.999976634979248
cells O O 0.9998592138290405
cultured O O 0.9997286200523376
with O O 0.9999752044677734
EPO O B-Disease 0.8531785607337952
alone O O 0.9493535757064819
. O O 0.9999985694885254

Findings O O 0.9977936744689941
were O O 0.9999916553497314
confirmed O O 0.9999833106994629
ultrastructurally O O 0.9996071457862854
. O O 0.9999992847442627

Nitroglycerin B-Chemical B-Chemical 0.9995003938674927
has O O 0.999879002571106
been O O 0.999988317489624
shown O O 0.9999938011169434
to O O 0.9999818801879883
reduce O O 0.9977036118507385
ST O O 0.5959521532058716
- O O 0.846350908279419
segment O O 0.9010125398635864
elevation O O 0.6382884979248047
during O O 0.9999972581863403
acute B-Disease B-Disease 0.888668417930603
myocardial I-Disease I-Disease 0.41019096970558167
infarction I-Disease I-Disease 0.9993318915367126
, O O 0.9997746348381042
an O O 0.9998334646224976
effect O O 0.9997429251670837
potentiated O O 0.9998512268066406
in O O 0.9999935626983643
the O O 0.9997053742408752
dog O O 0.9829597473144531
by O O 0.9999959468841553
agents O O 0.9786619544029236
that O O 0.9999886751174927
reverse O O 0.9948691129684448
nitroglycerin B-Chemical B-Chemical 0.999823272228241
- O O 0.9921042919158936
induced O O 0.9993157386779785
hypotension B-Disease B-Disease 0.9997046589851379
. O O 0.9999724626541138

Cerebral B-Disease B-Disease 0.6780067086219788
vasculitis I-Disease I-Disease 0.9968420267105103
associated O O 0.9991894364356995
with O O 0.9999603033065796
amphetamine B-Disease B-Chemical 0.9975201487541199
abuse I-Disease O 0.5499042868614197
is O O 0.9999299049377441
well O O 0.9990426898002625
documented O O 0.9995884299278259
, O O 0.9999980926513672
and O O 0.9999929666519165
in O O 0.9999984502792358
rare O O 0.9999310970306396
cases O O 0.9999963045120239
ischaemic B-Disease B-Disease 0.8649262189865112
stroke I-Disease I-Disease 0.9937088489532471
has O O 0.9996829032897949
been O O 0.999984622001648
reported O O 0.9999797344207764
after O O 0.9999550580978394
methylphenidate B-Chemical B-Chemical 0.9999806880950928
intake O O 0.9944232106208801
in O O 0.9999921321868896
children O O 0.9996558427810669
. O O 0.9999997615814209

Because O O 0.9978740215301514
proteinuria B-Disease B-Disease 0.997990608215332
is O O 0.9998693466186523
a O O 0.999993085861206
major O O 0.9999651908874512
predictive O O 0.9997828602790833
factor O O 0.9999452829360962
of O O 0.9999929666519165
poor O O 0.9966625571250916
transplantation O O 0.9882799386978149
outcome O O 0.9996547698974609
, O O 0.9999998807907104
many O O 0.9999966621398926
studies O O 0.9999264478683472
focused O O 0.9999977350234985
on O O 0.9999880790710449
this O O 0.9998555183410645
adverse O O 0.9945057034492493
event O O 0.9976842403411865
during O O 0.9999992847442627
the O O 0.9999943971633911
past O O 0.999997615814209
years O O 0.9999594688415527
. O O 0.9999997615814209

Mean O O 0.9903282523155212
follow O O 0.9999350309371948
- O O 0.9996331930160522
up O O 0.997735857963562
on O O 0.9999606609344482
SRL B-Chemical B-Chemical 0.9981005787849426
therapy O O 0.9999148845672607
was O O 0.9999991655349731
20 O O 0.9999366998672485
+ O O 0.9999971389770508
/ O O 0.9999985694885254
- O O 0.9999806880950928
12 O O 0.9998148083686829
( O O 0.9999949932098389
6 O O 0.999954342842102
to O O 0.9999738931655884
43 O O 0.9993601441383362
) O O 0.9999039173126221
months O O 0.99996018409729
. O O 0.9999998807907104

The O O 0.9999572038650513
first O O 0.9999549388885498
case O O 0.999976634979248
involved O O 0.9999986886978149
a O O 0.9997764229774475
59 O O 0.999147891998291
- O O 0.9999687671661377
year O O 0.9999821186065674
- O O 0.9999476671218872
old O O 0.9999430179595947
man O O 0.9995355606079102
who O O 0.9999697208404541
used O O 0.9987481832504272
Dormex B-Chemical B-Chemical 0.9996781349182129
, O O 0.9972444772720337
which O O 0.9987788796424866
contains O O 0.9991142153739929
hydrogen B-Chemical B-Chemical 0.847295880317688
cyanamide I-Chemical I-Chemical 0.9570848941802979
, O O 0.9995571970939636
without O O 0.999990701675415
protection O O 0.9924831986427307
after O O 0.9999982118606567
consuming O O 0.999188244342804
a O O 0.9989340901374817
large O O 0.9987278580665588
amount O O 0.9999403953552246
of O O 0.9996141195297241
alcohol B-Chemical B-Chemical 0.9986352324485779
during O O 0.9999649524688721
a O O 0.9997751116752625
meal O O 0.9966452717781067
. O O 0.9999992847442627

Macrophage O O 0.5693375468254089
- O O 0.9706754088401794
migration O O 0.8854281902313232
inhibition O O 0.5491547584533691
( O O 0.9994105100631714
MIF O O 0.8754218220710754
) O O 0.9995980858802795
test O O 0.9999663829803467
with O O 0.9999810457229614
ampicillin B-Chemical B-Chemical 0.9996582269668579
was O O 0.9992247819900513
positive O O 0.9999773502349854
. O O 0.9999992847442627

All O O 0.9983450174331665
complaints O O 0.5828264355659485
faded O O 0.9908736944198608
away O O 0.9997109770774841
within O O 0.9999626874923706
24 O O 0.9995059967041016
h O O 0.9944427609443665
. O O 0.9999982118606567

All O O 0.9959426522254944
rats O O 0.9992194175720215
were O O 0.9999954700469971
terminated O O 0.9997561573982239
either O O 0.9999933242797852
24 O O 0.9999357461929321
h O O 0.9997530579566956
or O O 0.9999967813491821
3 O O 0.9998968839645386
weeks O O 0.9999788999557495
after O O 0.9999992847442627
the O O 0.9998732805252075
DFP B-Chemical B-Chemical 0.9995658993721008
injection O O 0.9977194666862488
. O O 0.9999992847442627

The O O 0.9995324611663818
pathophysiology O O 0.9911284446716309
of O O 0.9999918937683105
painful O O 0.8713254332542419
temporomandibular B-Disease B-Disease 0.8923912644386292
disorders I-Disease I-Disease 0.9999902248382568
is O O 0.9999449253082275
not O O 0.9999972581863403
fully O O 0.9999669790267944
understood O O 0.9999245405197144
, O O 0.9999992847442627
but O O 0.9999963045120239
evidence O O 0.9999736547470093
suggests O O 0.9999991655349731
that O O 0.9999430179595947
muscle B-Disease B-Disease 0.8956588506698608
pain I-Disease I-Disease 0.985535740852356
modulates O O 0.9992043375968933
motor O O 0.9973099231719971
function O O 0.9854195713996887
in O O 0.9999967813491821
characteristic O O 0.994382381439209
ways O O 0.9998512268066406
. O O 0.9999994039535522

Elevated O O 0.9849697351455688
atherosclerotic B-Disease O 0.6878265738487244
parameters O O 0.5880385041236877
, O O 0.999903678894043
such O O 0.9999724626541138
as O O 0.9998157620429993
serum O O 0.9933085441589355
calcium B-Chemical B-Chemical 0.9998894929885864
, O O 0.9998792409896851
total O O 0.9925704598426819
cholesterol B-Chemical B-Chemical 0.9995157718658447
and O O 0.9998494386672974
low O O 0.995765209197998
- O O 0.9924063086509705
density O O 0.9943683743476868
lipoprotein O B-Chemical 0.9993656277656555
concentration O O 0.9929978847503662
were O O 0.9999977350234985
obtained O O 0.9999436140060425
in O O 0.999990701675415
atherosclerotic B-Disease B-Disease 0.9566566944122314
rats O O 0.7487092018127441
. O O 0.9999986886978149

Most O O 0.9999306201934814
side O O 0.9998595714569092
effects O O 0.9999446868896484
were O O 0.9999948740005493
mild O O 0.997593343257904
and O O 0.9999638795852661
related O O 0.9999252557754517
to O O 0.9999396800994873
the O O 0.9978011250495911
GI O O 0.7331224083900452
tract O O 0.9896019101142883
. O O 0.9999994039535522

Patients O O 0.999294638633728
in O O 0.9999887943267822
Group O O 0.9966296553611755
C O O 0.9778304696083069
received O O 0.9999926090240479
2 O O 0.9988723397254944
ml O O 0.9974865913391113
normal O O 0.9881913065910339
saline O O 0.7978512644767761
, O O 0.998860239982605
Group O O 0.5493865013122559
L O O 0.6735004782676697
, O O 0.9717633128166199
2 O O 0.9919838309288025
ml O O 0.9868810176849365
, O O 0.9993471503257751
lidocaine B-Chemical B-Chemical 0.9999938011169434
2 O O 0.8587967157363892
% O O 0.994903564453125
( O O 0.9998887777328491
40 O O 0.9996387958526611
mg O O 0.9987321496009827
) O O 0.9998086094856262
and O O 0.9998921155929565
Group O O 0.9419106245040894
T O O 0.9223531484603882
, O O 0.9997987151145935
2 O O 0.9994039535522461
ml O O 0.9992074370384216
thiopentone B-Chemical B-Chemical 0.9987070560455322
2 O O 0.520306408405304
. O O 0.9996752738952637
5 O O 0.9998958110809326
% O O 0.9999685287475586
( O O 0.9999818801879883
50 O O 0.9999154806137085
mg O O 0.9994845390319824
) O O 0.9998302459716797
. O O 0.9999991655349731

Its O O 0.9989669322967529
activity O O 0.9982648491859436
is O O 0.9999974966049194
believed O O 0.9999990463256836
to O O 0.999993085861206
be O O 0.9999605417251587
due O O 0.9999951124191284
modulation O O 0.9986355900764465
of O O 0.9999189376831055
the O O 0.9990063309669495
tumour B-Disease B-Disease 0.9931156039237976
milieu O O 0.8629494905471802
, O O 0.9999954700469971
including O O 0.9999904632568359
downregulation O O 0.9683882594108582
of O O 0.9990295171737671
angiogenesis O O 0.5124601721763611
and O O 0.9996100068092346
inflammatory O O 0.9674248695373535
cytokines O O 0.5267673134803772
. O O 0.9999969005584717

2 O O 0.8630373477935791
. O O 0.9999755620956421

Renal O O 0.9814755916595459
function O O 0.9650148749351501
was O O 0.9999980926513672
investigated O O 0.999984622001648
by O O 0.9999786615371704
measuring O O 0.9996649026870728
plasma O O 0.9875166416168213
and O O 0.997816801071167
urinary O O 0.9923999309539795
electrolytes O O 0.9554093480110168
, O O 0.9999696016311646
glucosuria B-Disease B-Disease 0.9530979990959167
, O O 0.9969064593315125
proteinuria B-Disease B-Disease 0.9838473200798035
, O O 0.9978107810020447
aminoaciduria B-Disease B-Disease 0.827756941318512
, O O 0.9994427561759949
urinary O O 0.9827322959899902
pH O O 0.698767900466919
, O O 0.9997326731681824
osmolarity O O 0.5676998496055603
, O O 0.9999226331710815
creatinine B-Chemical B-Chemical 0.999727189540863
clearance O O 0.9985514283180237
, O O 0.9999810457229614
phosphate B-Chemical O 0.4983431398868561
tubular O O 0.9865104556083679
reabsorption O O 0.9877176284790039
, O O 0.9999860525131226
beta O O 0.9859581589698792
2 O O 0.9838288426399231
microglobulinuria O O 0.8956685066223145
, O O 0.9999066591262817
and O O 0.9993011951446533
lysozymuria O O 0.781419575214386
. O O 0.999945878982544

The O O 0.9998557567596436
intensity O O 0.9957591891288757
of O O 0.9997187256813049
headache B-Disease B-Disease 0.9971390962600708
and O O 0.9724503755569458
nausea B-Disease B-Disease 0.9938408136367798
was O O 0.9993197917938232
measured O O 0.9999769926071167
with O O 0.9999927282333374
a O O 0.9997854828834534
100 O O 0.9996402263641357
- O O 0.9997941851615906
mm O O 0.9993820190429688
visual O O 0.9950172305107117
analog O O 0.9961650371551514
scale O O 0.9967101812362671
. O O 0.9999996423721313

INTERPRETATION O O 0.994106650352478
: O O 0.9999861717224121
Tranexamic B-Chemical B-Chemical 0.5419031381607056
acid I-Chemical I-Chemical 0.9996381998062134
retains O O 0.9989272952079773
its O O 0.9997274279594421
convulsive B-Disease B-Disease 0.9748564958572388
action O O 0.9503414630889893
within O O 0.9813593626022339
FS O O 0.8576783537864685
. O O 0.9999966621398926

The O O 0.9998414516448975
three O O 0.9993084669113159
compounds O O 0.9929051995277405
vary O O 0.9999961853027344
in O O 0.9999496936798096
their O O 0.999748170375824
affinities O O 0.9949235320091248
for O O 0.999997615814209
sigma2 O O 0.9593569040298462
receptors O O 0.9962504506111145
and O O 0.9999959468841553
exhibit O O 0.9993821382522583
negligible O O 0.9967582821846008
affinities O O 0.9944769740104675
for O O 0.9999855756759644
dopamine B-Chemical B-Chemical 0.9999183416366577
, O O 0.9993060827255249
opioid O O 0.38431939482688904
, O O 0.9712309241294861
GABA B-Chemical B-Chemical 0.9968492388725281
( O O 0.9990818500518799
A O O 0.6871995329856873
) O O 0.9975925087928772
and O O 0.9994274377822876
NMDA B-Chemical B-Chemical 0.9981268048286438
receptors O O 0.9970491528511047
. O O 0.9999996423721313

However O O 0.9999330043792725
, O O 0.9999947547912598
in O O 0.9999979734420776
many O O 0.9999760389328003
cases O O 0.9999963045120239
, O O 0.9999991655349731
the O O 0.9998642206192017
exencephalic B-Disease O 0.8587202429771423
brain O O 0.7830891013145447
tissue O O 0.9770268797874451
was O O 0.9999899864196777
preserved O O 0.999970555305481
with O O 0.9999958276748657
more O O 0.9999125003814697
or O O 0.9999392032623291
less O O 0.9998983144760132
reduction O O 0.9900651574134827
during O O 0.9999960660934448
this O O 0.9999488592147827
period O O 0.9999980926513672
. O O 0.9999995231628418

RESULTS O O 0.9989972710609436
: O O 0.9999978542327881
The O O 0.9999728202819824
age O O 0.9998660087585449
- O O 0.9996148347854614
adjusted O O 0.9995924830436707
incidence O O 0.9184861779212952
rate O O 0.9998714923858643
ratio O O 0.9999699592590332
for O O 0.9999656677246094
CPA B-Chemical B-Chemical 0.9700414538383484
/ O O 0.9958475828170776
EE B-Chemical B-Chemical 0.9309614896774292
versus O O 0.9998974800109863
conventional O O 0.9984695315361023
COCs O O 0.6606850028038025
was O O 0.9999939203262329
2 O O 0.9994350075721741
. O O 0.9999876022338867
20 O O 0.9988101720809937
[ O O 0.9999858140945435
95 O O 0.9997245669364929
% O O 0.9999866485595703
confidence O O 0.9929995536804199
interval O O 0.9989719390869141
( O O 0.9999665021896362
CI O O 0.9959369897842407
) O O 0.9998123049736023
1 O O 0.9997648596763611
. O O 0.9999933242797852
35 O O 0.9997727274894714
- O O 0.9996527433395386
3 O O 0.9996576309204102
. O O 0.9999788999557495
58 O O 0.9960553646087646
] O O 0.9997867941856384
. O O 0.9999951124191284

The O O 0.9998949766159058
two O O 0.9999326467514038
hypotensive B-Disease B-Disease 0.9980278611183167
patients O O 0.9962193369865417
required O O 0.9999977350234985
treatment O O 0.9999943971633911
for O O 0.999998927116394
shock B-Disease B-Disease 0.9875849485397339
. O O 0.9993896484375

The O O 0.9999561309814453
goal O O 0.9998145699501038
of O O 0.9999973773956299
these O O 0.9999490976333618
studies O O 0.9999513626098633
was O O 0.9999985694885254
to O O 0.9999839067459106
use O O 0.9999637603759766
an O O 0.9995409250259399
animal O O 0.9936842322349548
model O O 0.9999217987060547
to O O 0.999998927116394
examine O O 0.9999638795852661
the O O 0.9996925592422485
effects O O 0.9999713897705078
of O O 0.9999818801879883
prenatal O O 0.9733206629753113
protein O O 0.8034401535987854
deprivation O O 0.5083678364753723
on O O 0.999749481678009
behaviors O O 0.9499163627624512
and O O 0.9994485974311829
receptor O O 0.9931319355964661
binding O O 0.98972487449646
with O O 0.9999902248382568
relevance O O 0.9956364035606384
to O O 0.9999951124191284
schizophrenia B-Disease B-Disease 0.9996016621589661
. O O 0.9999630451202393

The O O 0.9999566078186035
present O O 0.9999563694000244
study O O 0.9999755620956421
was O O 0.9999988079071045
done O O 0.9999943971633911
to O O 0.999998927116394
investigate O O 0.9999767541885376
the O O 0.9999027252197266
protective O O 0.9770343899726868
effect O O 0.9998237490653992
of O O 0.9998335838317871
TCR B-Chemical B-Chemical 0.9992401599884033
on O O 0.9993160963058472
experimentally O O 0.9991258978843689
induced O O 0.9993608593940735
myocardial B-Disease B-Disease 0.8590092658996582
infarction I-Disease I-Disease 0.9999895095825195
in O O 0.9990565180778503
rats O O 0.9998183846473694
. O O 0.9999998807907104

Such O O 0.9992547631263733
disparity O O 0.944006085395813
suggests O O 0.999998927116394
an O O 0.999962568283081
inhibition O O 0.9455897212028503
of O O 0.9984616041183472
creatine B-Chemical B-Chemical 0.9944709539413452
phosphokinase O O 0.5139524936676025
. O O 0.9999920129776001

The O O 0.9980030655860901
pathogenesis O O 0.8263974189758301
of O O 0.9990437626838684
5 B-Chemical B-Chemical 0.9026668071746826
- I-Chemical I-Chemical 0.993851900100708
fluorouracil I-Chemical I-Chemical 0.9989787340164185
neurotoxicity B-Disease B-Disease 0.9980077147483826
may O O 0.9999585151672363
be O O 0.9999957084655762
due O O 0.9999998807907104
to O O 0.999988317489624
a O O 0.9984896183013916
Krebs O O 0.7991068363189697
cycle O O 0.8425107002258301
blockade O O 0.8073961734771729
by O O 0.9998317956924438
fluoroacetate B-Chemical B-Chemical 0.9998805522918701
and O O 0.9967142343521118
fluorocitrate B-Chemical B-Chemical 0.9995514750480652
, O O 0.9985415935516357
thiamine B-Chemical B-Chemical 0.999504804611206
deficiency O O 0.7690132260322571
, O O 0.9999772310256958
or O O 0.9997288584709167
dihydrouracil B-Chemical B-Chemical 0.9684102535247803
dehydrogenase O O 0.5433624386787415
deficiency O O 0.7996411919593811
. O O 0.9999855756759644

Fifteen O O 0.9989684820175171
polydrug O O 0.8812706470489502
ecstasy B-Chemical B-Chemical 0.9916256070137024
users O O 0.9893013834953308
and O O 0.9999442100524902
15 O O 0.9924724102020264
polydrug O O 0.930253267288208
non O O 0.9960293769836426
- O O 0.9974768757820129
ecstasy B-Chemical B-Chemical 0.9846138954162598
user O O 0.9933740496635437
controls O O 0.9993903636932373
completed O O 0.9999967813491821
a O O 0.9995929598808289
general O O 0.997963547706604
drug O O 0.9916388392448425
use O O 0.999184787273407
questionnaire O O 0.9996094107627869
, O O 0.9999997615814209
the O O 0.9999473094940186
Brixton O O 0.9956157207489014
Spatial O O 0.9960343241691589
Anticipation O O 0.9996147155761719
task O O 0.9997857213020325
( O O 0.9999985694885254
set O O 0.9992577433586121
shifting O O 0.9960468411445618
) O O 0.9998857975006104
, O O 0.9999842643737793
Backward O O 0.9658137559890747
Digit O O 0.9148526787757874
Span O O 0.9984346032142639
procedure O O 0.9999039173126221
( O O 0.9999991655349731
memory O O 0.9951989054679871
updating O O 0.9971529245376587
) O O 0.9999809265136719
, O O 0.9999945163726807
Inhibition O O 0.8765036463737488
of O O 0.9900057911872864
Return O O 0.9592036604881287
( O O 0.9999909400939941
inhibition O O 0.9070680737495422
) O O 0.999913215637207
, O O 0.9999983310699463
an O O 0.9999399185180664
emotional O O 0.9924308657646179
intelligence O O 0.9951460957527161
scale O O 0.9994773268699646
, O O 0.9999996423721313
the O O 0.9999196529388428
Tromso O O 0.9709435701370239
Social O O 0.986664891242981
Intelligence O O 0.9982210993766785
Scale O O 0.9992011189460754
and O O 0.9999945163726807
the O O 0.9994537234306335
Dysexecutive O O 0.6964468955993652
Questionnaire O O 0.9782071709632874
( O O 0.9999902248382568
DEX O O 0.7427316308021545
) O O 0.9998308420181274
. O O 0.9999995231628418

OBJECTIVES O O 0.9929178357124329
: O O 0.9999978542327881
To O O 0.9999905824661255
assess O O 0.9999423027038574
the O O 0.9999285936355591
added O O 0.9993984699249268
diagnostic O O 0.9943529367446899
value O O 0.9998015761375427
of O O 0.9999841451644897
a O O 0.9993411898612976
new O O 0.9993498921394348
cardiac O O 0.97175532579422
performance O O 0.9947019219398499
index O O 0.9898543953895569
( O O 0.9999674558639526
dP O O 0.9849157333374023
/ O O 0.9998629093170166
dtejc O O 0.8435469269752502
) O O 0.9923420548439026
measurement O O 0.9990053772926331
, O O 0.9999988079071045
based O O 0.9999936819076538
on O O 0.9999810457229614
brachial O O 0.9846354722976685
artery O O 0.7582869529724121
flow O O 0.9362131357192993
changes O O 0.9939135909080505
, O O 0.9999949932098389
as O O 0.9999837875366211
compared O O 0.999934196472168
to O O 0.999990701675415
standard O O 0.9993913173675537
12 O O 0.8640902638435364
- O O 0.9592044949531555
lead O O 0.9625445008277893
ECG O O 0.6275204420089722
, O O 0.9999518394470215
for O O 0.9999908208847046
detecting O O 0.9986997842788696
dobutamine B-Chemical B-Chemical 0.9998421669006348
- O O 0.9997650980949402
induced O O 0.9998090863227844
myocardial B-Disease B-Disease 0.9354994893074036
ischemia I-Disease I-Disease 0.9998552799224854
, O O 0.9997773766517639
using O O 0.9998157620429993
Tc99m B-Chemical O 0.5826546549797058
- I-Chemical O 0.9815924763679504
Sestamibi I-Chemical O 0.4846639931201935
single O O 0.9980829954147339
- O O 0.999607503414154
photon O O 0.9788049459457397
emission O O 0.9976293444633484
computed O O 0.9993689656257629
tomography O O 0.9990481734275818
as O O 0.9999986886978149
the O O 0.9999802112579346
gold O O 0.9904925227165222
standard O O 0.9999794960021973
of O O 0.9999439716339111
comparison O O 0.9998155236244202
to O O 0.9999958276748657
assess O O 0.9998736381530762
the O O 0.9998855590820312
presence O O 0.9991058707237244
or O O 0.9999924898147583
absence O O 0.990672767162323
of O O 0.9995470643043518
ischemia B-Disease B-Disease 0.9925925135612488
. O O 0.9999253749847412

The O O 0.9999321699142456
present O O 0.9999779462814331
results O O 0.9998359680175781
are O O 0.9999991655349731
consistent O O 0.9999934434890747
with O O 0.9999947547912598
the O O 0.9997052550315857
carcinogenicity O O 0.7723764777183533
experiment O O 0.983985960483551
suggesting O O 0.9999927282333374
that O O 0.9999673366546631
different O O 0.9995336532592773
mechanisms O O 0.9992901086807251
are O O 0.9999954700469971
involved O O 0.9999843835830688
in O O 0.9998258948326111
FANFT B-Chemical O 0.5624070167541504
carcinogenesis B-Disease O 0.8056124448776245
in O O 0.988950788974762
the O O 0.9825181365013123
bladder O O 0.7040185928344727
and O O 0.9963460564613342
forestomach O O 0.4399143159389496
, O O 0.999832272529602
and O O 0.9999586343765259
that O O 0.9999740123748779
aspirin B-Chemical B-Chemical 0.99544358253479
' O O 0.984488844871521
s O O 0.9872350096702576
effect O O 0.9991994500160217
on O O 0.9998419284820557
FANFT B-Chemical B-Chemical 0.9723104238510132
in O O 0.9996436834335327
the O O 0.9994569420814514
forestomach O O 0.6216305494308472
is O O 0.9999760389328003
not O O 0.9999892711639404
due O O 0.9999998807907104
to O O 0.9999948740005493
an O O 0.9997605681419373
irritant O O 0.9095814824104309
effect O O 0.9516569972038269
associated O O 0.9999889135360718
with O O 0.9999943971633911
increased O O 0.9971177577972412
cell O O 0.9793603420257568
proliferation O O 0.8446380496025085
. O O 0.9999432563781738

Central B-Disease B-Disease 0.9793829321861267
nervous I-Disease I-Disease 0.7606231570243835
system I-Disease I-Disease 0.9936342239379883
complications I-Disease I-Disease 0.9990229606628418
during O O 0.9991751313209534
treatment O O 0.9999905824661255
of O O 0.9999971389770508
acute B-Disease B-Disease 0.739802896976471
lymphoblastic I-Disease I-Disease 0.9519104361534119
leukemia I-Disease I-Disease 0.9997045397758484
in O O 0.9998120665550232
a O O 0.9999679327011108
single O O 0.9999200105667114
pediatric O O 0.9891917109489441
institution O O 0.9994947910308838
. O O 0.9999998807907104

Laboratory O O 0.9994149208068848
results O O 0.9999266862869263
were O O 0.9999977350234985
compared O O 0.9999896287918091
between O O 0.9999814033508301
prior O O 0.9999178647994995
, O O 0.9999600648880005
during O O 0.9999507665634155
and O O 0.9999485015869141
following O O 0.9999845027923584
sirolimus B-Chemical B-Chemical 0.9997283816337585
use O O 0.9968225955963135
. O O 0.9999997615814209

Hypertensive B-Disease B-Disease 0.9552147388458252
patients O O 0.9754683375358582
with O O 0.9999804496765137
psychiatric B-Disease B-Disease 0.965744137763977
histories O I-Disease 0.9907404184341431
had O O 0.9998940229415894
a O O 0.9999860525131226
higher O O 0.9996854066848755
prevalence O O 0.9981886744499207
of O O 0.9999593496322632
depression B-Disease B-Disease 0.9992303848266602
than O O 0.9979172348976135
the O O 0.9998828172683716
comparison O O 0.9401388764381409
patients O O 0.9999595880508423
. O O 0.9999997615814209

These O O 0.9999443292617798
seven O O 0.9999524354934692
cases O O 0.999886155128479
demonstrate O O 0.9999932050704956
that O O 0.9996402263641357
procainamide B-Chemical B-Chemical 0.9999525547027588
can O O 0.9994775652885437
produce O O 0.9999059438705444
an O O 0.9992964267730713
acquired O O 0.9984502792358398
prolonged B-Disease O 0.9927985668182373
Q I-Disease B-Disease 0.393285870552063
- I-Disease I-Disease 0.872545063495636
T I-Disease I-Disease 0.9946635961532593
syndrome I-Disease I-Disease 0.9927102327346802
with O O 0.9987438321113586
polymorphous O O 0.7153773903846741
ventricular B-Disease B-Disease 0.7358004450798035
tachycardia I-Disease I-Disease 0.9990735054016113
. O O 0.9999065399169922

Optimization O O 0.9807249307632446
of O O 0.9985291957855225
levodopa B-Chemical B-Chemical 0.9998192191123962
therapy O O 0.9994613528251648
. O O 0.9999996423721313

Systolic O O 0.9659756422042847
blood O O 0.9944812059402466
pressure O O 0.965410053730011
( O O 0.9999935626983643
SBP O O 0.9688883423805237
) O O 0.9998538494110107
was O O 0.9999837875366211
measured O O 0.9999699592590332
on O O 0.999983549118042
alternate O O 0.99796462059021
days O O 0.9999524354934692
using O O 0.9999918937683105
the O O 0.9995212554931641
tail O O 0.9977526068687439
- O O 0.9998674392700195
cuff O O 0.9853518605232239
method O O 0.9994826316833496
. O O 0.9999998807907104

Simvastatin B-Chemical B-Chemical 0.9920676946640015
is O O 0.9990530610084534
metabolized O O 0.9990158081054688
by O O 0.9999380111694336
CYP3A4 O B-Chemical 0.9728260636329651
. O O 0.9999867677688599

The O O 0.9998413324356079
increase O O 0.9913623929023743
in O O 0.9988873600959778
dP O O 0.8051754832267761
/ O O 0.9983794689178467
dtejc O O 0.9164950847625732
during O O 0.9992245435714722
infusion O O 0.9895366430282593
of O O 0.998635470867157
dobutamine B-Chemical B-Chemical 0.9999520778656006
in O O 0.999903678894043
this O O 0.9993155002593994
group O O 0.9996408224105835
was O O 0.9999536275863647
severely O O 0.9995649456977844
impaired O O 0.9929413795471191
as O O 0.9999878406524658
compared O O 0.9999188184738159
to O O 0.9999754428863525
the O O 0.9998886585235596
non O O 0.9882800579071045
- O O 0.9975728392601013
ischemic O O 0.5448530912399292
group O O 0.8431941270828247
. O O 0.9999909400939941

Proteinuria O B-Disease 0.9937340617179871
increased O O 0.9919418096542358
significantly O O 0.9998970031738281
from O O 0.9999856948852539
a O O 0.9998599290847778
median O O 0.9998447895050049
of O O 0.9999194145202637
0 O O 0.999269425868988
. O O 0.9999942779541016
13 O O 0.9998212456703186
g O O 0.9997071623802185
/ O O 0.9999895095825195
day O O 0.9998747110366821
( O O 0.9999531507492065
range O O 0.9996988773345947
0 O O 0.9994446635246277
- O O 0.9995150566101074
5 O O 0.9990276098251343
. O O 0.999972939491272
7 O O 0.9990220069885254
) O O 0.9994459748268127
preswitch O O 0.6824990510940552
to O O 0.9989116191864014
0 O O 0.9992254972457886
. O O 0.9999971389770508
23 O O 0.9999111890792847
g O O 0.9998188614845276
/ O O 0.9999949932098389
day O O 0.9999591112136841
( O O 0.9999898672103882
0 O O 0.9998496770858765
- O O 0.9998973608016968
9 O O 0.9997841715812683
. O O 0.999972939491272
88 O O 0.9985887408256531
) O O 0.9998483657836914
at O O 0.999998927116394
24 O O 0.9999228715896606
months O O 0.9999483823776245
postswitch O O 0.9972558617591858
( O O 0.9999985694885254
p O O 0.9998983144760132
= O O 0.9999945163726807
0 O O 0.9997991919517517
. O O 0.9999785423278809
0024 O O 0.9915892481803894
) O O 0.9999122619628906
. O O 0.9999990463256836

Rhabdomyolysis B-Disease B-Disease 0.9848930835723877
is O O 0.9999697208404541
a O O 0.999983549118042
potentially O O 0.9993627667427063
lethal O B-Disease 0.9494174122810364
syndrome O I-Disease 0.9991996884346008
that O O 0.9965417981147766
psychiatric B-Disease B-Disease 0.9709973335266113
patients O O 0.7454958558082581
seem O O 0.9996891021728516
predisposed O O 0.9999681711196899
to O O 0.9999682903289795
develop O O 0.9996046423912048
. O O 0.9999983310699463

METHODS O O 0.988888680934906
: O O 0.9999947547912598
Using O O 0.9999533891677856
the O O 0.9996412992477417
General O O 0.9842793345451355
Practice O O 0.9998772144317627
Research O O 0.9997971653938293
Database O O 0.9998862743377686
we O O 0.9999990463256836
conducted O O 0.9999991655349731
a O O 0.9998716115951538
cohort O O 0.961863100528717
analysis O O 0.9987012147903442
and O O 0.9999973773956299
case O O 0.9998231530189514
- O O 0.9996540546417236
control O O 0.9992594122886658
study O O 0.9998977184295654
nested O O 0.9999934434890747
within O O 0.9999058246612549
a O O 0.9991089701652527
population O O 0.9986440539360046
of O O 0.9999880790710449
women O O 0.9999313354492188
aged O O 0.999998927116394
between O O 0.9999955892562866
15 O O 0.9997325539588928
and O O 0.9999977350234985
39 O O 0.9999676942825317
years O O 0.9999942779541016
with O O 0.9999951124191284
acne B-Disease B-Disease 0.9839768409729004
, O O 0.9946541786193848
hirsutism B-Disease B-Disease 0.9905741810798645
or O O 0.9996411800384521
PCOS B-Disease B-Disease 0.7092163562774658
to O O 0.999805748462677
estimate O O 0.9999837875366211
the O O 0.9999024868011475
risk O O 0.9999196529388428
of O O 0.999951958656311
VTE B-Disease B-Disease 0.9977443218231201
associated O O 0.9929129481315613
with O O 0.9997296929359436
CPA B-Chemical B-Chemical 0.984970211982727
/ O O 0.9960649609565735
EE B-Chemical B-Chemical 0.9767326712608337
. O O 0.999992847442627

Liver O O 0.934021532535553
function O O 0.7275084853172302
tests O O 0.9971074461936951
, O O 0.9999966621398926
hepatitis B-Disease B-Disease 0.9158902168273926
B I-Disease I-Disease 0.9930425882339478
virus O O 0.9521427154541016
( O O 0.5766515135765076
HBV O O 0.7534410953521729
) O O 0.5384569764137268
serologic O O 0.9232574105262756
markers O O 0.9533367156982422
, O O 0.9982346296310425
and O O 0.9998356103897095
HBV O O 0.9200754165649414
DNA O O 0.49920472502708435
levels O O 0.9991769194602966
of O O 0.9999780654907227
the O O 0.9994151592254639
patients O O 0.9999769926071167
during O O 0.9999939203262329
follow O O 0.9997939467430115
- O O 0.9997710585594177
up O O 0.999859094619751
were O O 0.9999994039535522
obtained O O 0.9999979734420776
from O O 0.9999982118606567
hospital O O 0.999550998210907
file O O 0.999842643737793
records O O 0.9995601773262024
. O O 0.9999998807907104

The O O 0.999758780002594
interpeduncular O O 0.8825586438179016
nucleus O O 0.47103628516197205
regulates O O 0.9998651742935181
nicotine B-Chemical B-Chemical 0.999966025352478
' O O 0.9955623149871826
s O O 0.9805322289466858
effects O O 0.9990590214729309
on O O 0.9998107552528381
free O O 0.9990577101707458
- O O 0.9985272884368896
field O O 0.9947919249534607
activity O O 0.9972809553146362
. O O 0.9999998807907104

His O O 0.9992393255233765
bundle O O 0.9967836141586304
recordings O O 0.9996296167373657
showed O O 0.9999984502792358
an O O 0.9998928308486938
atrial B-Disease B-Disease 0.8604034185409546
tachycardia I-Disease I-Disease 0.9075332283973694
with O O 0.9992547631263733
intermittent O O 0.9943589568138123
exit O O 0.9419218301773071
block O O 0.6217969059944153
and O O 0.9994545578956604
greatly O O 0.9998550415039062
prolonged O O 0.9915910959243774
BH O O 0.5973318815231323
and O O 0.9983023405075073
HV O O 0.46994343400001526
intervals O O 0.8743976354598999
( O O 0.9999692440032959
40 O O 0.9996139407157898
and O O 0.999966025352478
100 O O 0.9999030828475952
msec O O 0.9985802173614502
, O O 0.9999927282333374
respectively O O 0.9999904632568359
) O O 0.9998911619186401
. O O 0.9999992847442627

3 O O 0.8376827836036682
. O O 0.9999791383743286

Direct O O 0.9959096908569336
inhibition O O 0.9843495488166809
of O O 0.9997528195381165
cardiac O O 0.9611061811447144
hyperpolarization O O 0.4968273639678955
- O O 0.9949913620948792
activated O O 0.9996293783187866
cyclic B-Chemical O 0.9671164751052856
nucleotide I-Chemical O 0.7434481978416443
- O O 0.9989122152328491
gated O O 0.9994970560073853
pacemaker O O 0.878034234046936
channels O O 0.9982151985168457
by O O 0.9999911785125732
clonidine B-Chemical B-Chemical 0.9999266862869263
. O O 0.9999759197235107

Severe O O 0.997675359249115
ocular B-Disease B-Disease 0.7920994758605957
and I-Disease I-Disease 0.9027061462402344
orbital I-Disease I-Disease 0.9904186129570007
toxicity I-Disease I-Disease 0.99951171875
after O O 0.999897837638855
intracarotid O O 0.9835953712463379
injection O O 0.9988763928413391
of O O 0.9989467263221741
carboplatin B-Chemical B-Chemical 0.9998003840446472
for O O 0.9999603033065796
recurrent O O 0.9836799502372742
glioblastomas B-Disease B-Disease 0.9767817854881287
. O O 0.9999580383300781

We O O 0.9995942711830139
suggest O O 0.9999991655349731
that O O 0.9999967813491821
repeated O O 0.9994322657585144
endothelial B-Disease B-Disease 0.6216398477554321
injury I-Disease I-Disease 0.9938676953315735
, O O 0.9984013438224792
including O O 0.9999905824661255
immunologic B-Disease B-Disease 0.6251691579818726
injury I-Disease I-Disease 0.9995825886726379
, O O 0.9985656142234802
may O O 0.999987006187439
be O O 0.9999988079071045
the O O 0.9999842643737793
cause O O 0.999954342842102
of O O 0.9999819993972778
this O O 0.9980237483978271
lesion O O 0.950615406036377
both O O 0.9999842643737793
in O O 0.9997661709785461
allografts O O 0.7876353859901428
and O O 0.9996808767318726
native O O 0.9983708262443542
kidneys O O 0.9632150530815125
. O O 0.9999997615814209

Flestolol B-Chemical O 0.8232657313346863
blood O O 0.8113188743591309
concentrations O O 0.9782544374465942
increased O O 0.9998579025268555
linearly O O 0.999408483505249
with O O 0.9999769926071167
increasing O O 0.9941171407699585
dose O O 0.9938498139381409
and O O 0.9997326731681824
good O O 0.999761164188385
correlation O O 0.9948613047599792
exists O O 0.9999498128890991
between O O 0.9999643564224243
blood O O 0.9555045962333679
concentrations O O 0.9969183206558228
of O O 0.9991509914398193
flestolol B-Chemical B-Chemical 0.9913689494132996
and O O 0.9966277480125427
beta O O 0.7573620676994324
- O O 0.8688843250274658
adrenergic O O 0.6192224025726318
blockade O O 0.9586780071258545
. O O 0.9999996423721313

We O O 0.9998171925544739
examined O O 0.99998939037323
this O O 0.9997425675392151
theory O O 0.999906063079834
using O O 0.9999977350234985
the O O 0.9996881484985352
exo O O 0.8232329487800598
utero O O 0.7921676635742188
development O O 0.9996284246444702
system O O 0.9997941851615906
that O O 0.9999905824661255
allows O O 0.9999014139175415
direct O O 0.9986928105354309
and O O 0.9997386336326599
sequential O O 0.9997624754905701
observations O O 0.9977395534515381
of O O 0.9999618530273438
mid O O 0.9987794756889343
- O O 0.9998779296875
to O O 0.9999948740005493
late O O 0.9999485015869141
- O O 0.9998915195465088
gestation O O 0.993716299533844
mouse O O 0.9971801042556763
embryos O O 0.9962210655212402
. O O 0.9999998807907104

We O O 0.9997175335884094
investigate O O 0.9999895095825195
whether O O 0.9999707937240601
abnormalities O O 0.7884860634803772
in O O 0.9991416931152344
L B-Chemical B-Chemical 0.8696745038032532
- I-Chemical I-Chemical 0.9972860813140869
arginine I-Chemical I-Chemical 0.9994702935218811
uptake O O 0.9910174608230591
contribute O O 0.9999982118606567
to O O 0.9999966621398926
this O O 0.998339056968689
deficiency O O 0.7529813051223755
. O O 0.9999983310699463

In O O 0.9999850988388062
addition O O 0.9999642372131348
, O O 0.9999897480010986
glomerular O O 0.9671251773834229
size O O 0.9931582808494568
was O O 0.9999871253967285
higher O O 0.9996557235717773
in O O 0.9999743700027466
the O O 0.9989774227142334
nitrendipine B-Chemical B-Chemical 0.9997712969779968
- O O 0.9981560111045837
treated O O 0.9994663596153259
group O O 0.9972272515296936
( O O 0.999980092048645
14 O O 0.999470055103302
. O O 0.9999949932098389
9 O O 0.9999407529830933
+ O O 0.9999940395355225
/ O O 0.9999970197677612
- O O 0.9999412298202515
0 O O 0.9997047781944275
. O O 0.9999830722808838
17 O O 0.9994674324989319
10 O O 0.9989990592002869
( O O 0.9999793767929077
- O O 0.9996022582054138
3 O O 0.9991933703422546
) O O 0.9995928406715393
mm2 O O 0.9990276098251343
) O O 0.9998834133148193
but O O 0.9999954700469971
lower O O 0.9991457462310791
in O O 0.999946117401123
the O O 0.9989343285560608
enalapril B-Chemical B-Chemical 0.9992963075637817
- O O 0.9970878958702087
treated O O 0.999298095703125
group O O 0.9980459213256836
( O O 0.9999850988388062
11 O O 0.9996180534362793
. O O 0.9999958276748657
5 O O 0.9999655485153198
+ O O 0.9999945163726807
/ O O 0.999997615814209
- O O 0.9999551773071289
0 O O 0.9997579455375671
. O O 0.9999854564666748
15 O O 0.9994506239891052
10 O O 0.9992446899414062
( O O 0.9999707937240601
- O O 0.9996838569641113
3 O O 0.9994175434112549
) O O 0.9997560381889343
mm2 O O 0.9991534948348999
) O O 0.9998652935028076
compared O O 0.9999899864196777
with O O 0.9999712705612183
the O O 0.9994747042655945
hypertensive B-Disease B-Disease 0.9971556663513184
controls O O 0.6999043226242065
( O O 0.9999657869338989
12 O O 0.9998348951339722
. O O 0.9999972581863403
1 O O 0.9999717473983765
+ O O 0.9999958276748657
/ O O 0.9999984502792358
- O O 0.9999451637268066
0 O O 0.9997969269752502
. O O 0.9999901056289673
17 O O 0.9994692206382751
10 O O 0.9994056224822998
( O O 0.9999666213989258
- O O 0.9997647404670715
3 O O 0.9994649291038513
) O O 0.999822199344635
mm2 O O 0.9985014200210571
) O O 0.9998891353607178
. O O 0.9999955892562866
( O O 0.9999245405197144
ABSTRACT O O 0.9665578603744507
TRUNCATED O O 0.9969369173049927
AT O O 0.9999629259109497
250 O O 0.9994385838508606
WORDS O O 0.9998511075973511
) O O 0.9999504089355469

The O O 0.9999539852142334
incidence O O 0.9986262321472168
of O O 0.9998964071273804
venous O B-Disease 0.850084662437439
discomfort O I-Disease 0.9997311234474182
was O O 0.9993046522140503
lower O O 0.998302698135376
in O O 0.9999194145202637
Group O O 0.956138551235199
L O O 0.8802232146263123
( O O 0.9996966123580933
76 O O 0.9992228746414185
. O O 0.9999942779541016
6 O O 0.999916672706604
% O O 0.9999810457229614
; O O 0.999984622001648
P O O 0.9981822967529297
< O O 0.9999808073043823
0 O O 0.9997326731681824
. O O 0.9999910593032837
05 O O 0.9988858103752136
) O O 0.9998935461044312
than O O 0.9999828338623047
in O O 0.9999643564224243
Group O O 0.9858075380325317
C O O 0.9641335606575012
( O O 0.9999938011169434
100 O O 0.9998835325241089
% O O 0.9999880790710449
) O O 0.9998830556869507
but O O 0.9999935626983643
not O O 0.9999880790710449
different O O 0.9999617338180542
from O O 0.9999680519104004
Group O O 0.9792237281799316
T O O 0.9557426571846008
( O O 0.999997615814209
90 O O 0.9999008178710938
% O O 0.9999842643737793
) O O 0.9996147155761719
. O O 0.999998927116394

We O O 0.9996585845947266
investigated O O 0.9999926090240479
the O O 0.9997952580451965
diagnostic O O 0.9734436869621277
value O O 0.9992795586585999
of O O 0.9998168349266052
cTnI O O 0.9053994417190552
and O O 0.9980704188346863
cTnT O O 0.6387299299240112
for O O 0.9999531507492065
the O O 0.9999064207077026
diagnosis O O 0.9974195957183838
of O O 0.9999796152114868
myocardial B-Disease B-Disease 0.8165261149406433
damage I-Disease I-Disease 0.9999688863754272
in O O 0.9994457364082336
a O O 0.9988892674446106
rat O O 0.9932931661605835
model O O 0.9998396635055542
of O O 0.9996351003646851
doxorubicin B-Chemical B-Chemical 0.9995161294937134
( O O 0.9929187893867493
DOX B-Chemical B-Chemical 0.9999536275863647
) O O 0.9688692092895508
- O O 0.9997983574867249
induced O O 0.9997003078460693
cardiomyopathy B-Disease B-Disease 0.9991875290870667
, O O 0.9999700784683228
and O O 0.9999836683273315
we O O 0.9999196529388428
examined O O 0.999997615814209
the O O 0.9999384880065918
relationship O O 0.9998656511306763
between O O 0.9999922513961792
serial O O 0.9876634478569031
cTnI O O 0.3949013650417328
and O O 0.9986294507980347
cTnT O O 0.5209767818450928
with O O 0.9999040365219116
the O O 0.999940037727356
development O O 0.9993962049484253
of O O 0.9999850988388062
cardiac B-Disease B-Disease 0.9285345077514648
disorders I-Disease I-Disease 0.9999972581863403
monitored O O 0.9893656969070435
by O O 0.9999728202819824
echocardiography O O 0.985968828201294
and O O 0.9999836683273315
histological O O 0.9991064667701721
examinations O O 0.9990453124046326
in O O 0.999998927116394
this O O 0.9989798665046692
model O O 0.999931812286377
. O O 0.9999994039535522

While O O 0.999896764755249
the O O 0.9999265670776367
involvement O O 0.9998928308486938
of O O 0.99972003698349
metronidazole B-Chemical B-Chemical 0.9985600113868713
in O O 0.999822199344635
the O O 0.9997147917747498
aetiology O O 0.9979959726333618
of O O 0.9999741315841675
the O O 0.9996416568756104
haemolytic B-Disease B-Disease 0.7809492945671082
- I-Disease I-Disease 0.6886258125305176
uraemic I-Disease I-Disease 0.9857118725776672
syndrome I-Disease I-Disease 0.9994975328445435
is O O 0.9996576309204102
not O O 0.9999898672103882
established O O 0.9999467134475708
firmly O O 0.99985671043396
, O O 0.9999994039535522
the O O 0.9999743700027466
action O O 0.999728262424469
of O O 0.9999723434448242
this O O 0.9994144439697266
drug O O 0.9994877576828003
in O O 0.999920129776001
sensitizing O O 0.9946873188018799
tissues O O 0.7470144033432007
to O O 0.9996212720870972
oxidation O B-Disease 0.9668115377426147
injury O O 0.8496567010879517
and O O 0.9980282187461853
the O O 0.9999620914459229
reported O O 0.9999889135360718
evidence O O 0.9999871253967285
of O O 0.9999560117721558
oxidation O O 0.698307454586029
changes O O 0.9975067973136902
in O O 0.9999674558639526
the O O 0.9997014403343201
haemolytic B-Disease B-Disease 0.7078818678855896
- I-Disease I-Disease 0.8265079855918884
uraemic I-Disease I-Disease 0.8683080673217773
syndrome I-Disease I-Disease 0.9987493753433228
suggest O O 0.9999755620956421
a O O 0.9999891519546509
possible O O 0.999980092048645
link O O 0.9998931884765625
between O O 0.9999321699142456
metronidazole B-Chemical B-Chemical 0.9997658133506775
treatment O O 0.999315619468689
and O O 0.9999959468841553
some O O 0.9999700784683228
cases O O 0.9995731711387634
of O O 0.9999853372573853
the O O 0.9992839694023132
haemolytic B-Disease B-Disease 0.7564364075660706
- I-Disease I-Disease 0.8868293762207031
uraemic I-Disease I-Disease 0.9978983402252197
syndrome I-Disease I-Disease 0.9998674392700195
. O O 0.9999629259109497

We O O 0.9998701810836792
report O O 0.9999996423721313
an O O 0.999996542930603
interesting O O 0.9987975358963013
case O O 0.9999897480010986
investigating O O 0.9999964237213135
a O O 0.9976881742477417
( O O 0.9997418522834778
near O O 0.9931315779685974
) O O 0.9999053478240967
fatal O O 0.9832758903503418
poisoning B-Disease B-Disease 0.9623836278915405
. O O 0.9998996257781982

METHODS O O 0.9803740978240967
: O O 0.9999587535858154
Cholinergic O O 0.5316985249519348
convulsant O O 0.8108295202255249
sensitivity O O 0.9316502809524536
was O O 0.9999934434890747
examined O O 0.9999397993087769
in O O 0.9999483823776245
alcohol B-Chemical B-Chemical 0.9845591187477112
- O O 0.6370439529418945
na O B-Chemical 0.9898860454559326
ve O O 0.9774317741394043
Withdrawal O O 0.9576483368873596
Seizure B-Disease O 0.5552222728729248
- O O 0.9589325785636902
Prone O O 0.8702946305274963
( O O 0.9999251365661621
WSP O O 0.6834018230438232
) O O 0.999652624130249
and O O 0.9998841285705566
- O O 0.9979329109191895
Resistant O O 0.9900369644165039
( O O 0.999968409538269
WSR O O 0.6351794004440308
) O O 0.9991937279701233
mice O O 0.9994007349014282
. O O 0.9999997615814209

Renal B-Disease B-Disease 0.9403288960456848
papillary I-Disease I-Disease 0.6312590837478638
necrosis I-Disease I-Disease 0.9867782592773438
( O O 0.9988895058631897
RPN B-Disease O 0.39946362376213074
) O O 0.9994163513183594
and O O 0.9999762773513794
a O O 0.9994900226593018
decreased O O 0.9944781064987183
urinary O O 0.9894410371780396
concentrating O O 0.990270733833313
ability O O 0.966486394405365
developed O O 0.9999966621398926
during O O 0.9999922513961792
continuous O O 0.9988951086997986
long O O 0.9987866282463074
- O O 0.9993008375167847
term O O 0.9997146725654602
treatment O O 0.9999651908874512
with O O 0.9999699592590332
aspirin B-Chemical B-Chemical 0.9999552965164185
and O O 0.9966597557067871
paracetamol B-Chemical B-Chemical 0.9999626874923706
in O O 0.9999709129333496
female O O 0.9995995163917542
Fischer O O 0.9957398176193237
344 O O 0.9909765124320984
rats O O 0.9998838901519775
. O O 0.9999998807907104

One O O 0.9999256134033203
week O O 0.9999958276748657
later O O 0.9999992847442627
, O O 0.9999932050704956
by O O 0.9999885559082031
mistake O O 0.9901279807090759
, O O 0.9999880790710449
losartan B-Chemical B-Chemical 0.9998466968536377
was O O 0.9994902610778809
prescribed O O 0.9999661445617676
again O O 0.9999891519546509
and O O 0.9999948740005493
after O O 0.9999973773956299
the O O 0.999975323677063
second O O 0.9999648332595825
dose O O 0.9999815225601196
of O O 0.9999668598175049
50 O O 0.9972541928291321
mg O O 0.9894954562187195
, O O 0.9999819993972778
the O O 0.9999642372131348
patient O O 0.9999843835830688
developed O O 0.9999936819076538
a O O 0.9991366267204285
second O O 0.9996808767318726
episode O O 0.9011659026145935
of O O 0.9996553659439087
transient O O 0.8788169026374817
anuria B-Disease B-Disease 0.7039711475372314
lasting O O 0.9992995262145996
10 O O 0.9997019171714783
hours O O 0.9999411106109619
. O O 0.9999996423721313

Combination O O 0.9851034283638
chemotherapy O O 0.9838125705718994
with O O 0.9998737573623657
mitoxantrone B-Chemical B-Chemical 0.9999504089355469
, O O 0.9998564720153809
high O O 0.9996199607849121
- O O 0.9989803433418274
dose O O 0.9982359409332275
5 B-Chemical B-Chemical 0.9653622508049011
- I-Chemical I-Chemical 0.9984392523765564
fluorouracil I-Chemical I-Chemical 0.9993095397949219
( O O 0.9861502051353455
5 B-Chemical B-Chemical 0.9833057522773743
- I-Chemical I-Chemical 0.9986182451248169
FU I-Chemical I-Chemical 0.9999539852142334
) O O 0.8647388219833374
and O O 0.998507559299469
leucovorin B-Chemical B-Chemical 0.9985795021057129
( O O 0.9984044432640076
MFL B-Chemical B-Chemical 0.9987117052078247
regimen I-Chemical O 0.5273911952972412
) O O 0.9995369911193848
had O O 0.9999995231628418
been O O 0.9999611377716064
reported O O 0.9999964237213135
as O O 0.9999960660934448
an O O 0.9999586343765259
effective O O 0.999327540397644
and O O 0.9999486207962036
well O O 0.998578667640686
tolerated O O 0.9915152788162231
regimen O O 0.9977413415908813
. O O 0.9999998807907104

A O O 0.994285523891449
61 O O 0.9989987015724182
- O O 0.9999805688858032
year O O 0.9999947547912598
- O O 0.9999841451644897
old O O 0.9999392032623291
man O O 0.999157190322876
was O O 0.9999790191650391
treated O O 0.9999934434890747
with O O 0.99998939037323
combination O O 0.9949166774749756
chemotherapy O O 0.9427858591079712
incorporating O O 0.999765932559967
cisplatinum B-Chemical B-Chemical 0.9979881048202515
, O O 0.983151912689209
etoposide B-Chemical B-Chemical 0.992107093334198
, O O 0.9997748732566833
high O O 0.9992730021476746
- O O 0.9986479878425598
dose O O 0.998664379119873
5 B-Chemical B-Chemical 0.939291775226593
- I-Chemical I-Chemical 0.9984728693962097
fluorouracil I-Chemical I-Chemical 0.9976703524589539
( O O 0.9950962662696838
2 O O 0.8701511025428772
, O O 0.9958118200302124
250 O O 0.9993095397949219
mg O O 0.9998993873596191
/ O O 0.999990701675415
m2 O O 0.9999681711196899
/ O O 0.999995231628418
24 O O 0.9999346733093262
hours O O 0.999447762966156
) O O 0.9998645782470703
and O O 0.9999775886535645
folinic B-Chemical B-Chemical 0.5125330090522766
acid I-Chemical I-Chemical 0.9999359846115112
for O O 0.9999871253967285
an O O 0.9999431371688843
inoperable O O 0.9775559306144714
gastric B-Disease B-Disease 0.7926408648490906
adenocarcinoma I-Disease I-Disease 0.9972072243690491
. O O 0.9995778203010559

The O O 0.9999544620513916
other O O 0.9998743534088135
rats O O 0.9997349381446838
showed O O 0.9999988079071045
a O O 0.9997515082359314
strong O O 0.9993535876274109
decrease O O 0.991212785243988
in O O 0.9987756609916687
the O O 0.9938039779663086
rigidity B-Disease B-Disease 0.9896339178085327
and O O 0.9989938139915466
the O O 0.999716579914093
occurrence O O 0.9987433552742004
of O O 0.9999191761016846
stereotyped O O 0.9111878871917725
( O O 0.9901931881904602
S O O 0.8797571659088135
) O O 0.948103666305542
licking O O 0.39969390630722046
and O O 0.9968162178993225
/ O O 0.9955410361289978
or O O 0.9998200535774231
gnawing O O 0.9733823537826538
in O O 0.9997918009757996
presence O O 0.999735414981842
of O O 0.9997367262840271
akinetic B-Disease O 0.5035948157310486
or O O 0.9856578707695007
hyperkinetic B-Disease O 0.698573648929596
( O O 0.9736297726631165
K O O 0.8643786311149597
) O O 0.9151912331581116
behaviour O O 0.9236821532249451
( O O 0.9999672174453735
AS O O 0.9465931057929993
/ O O 0.9999351501464844
KS O O 0.9684785604476929
group O O 0.9996141195297241
) O O 0.9999744892120361
, O O 0.9999994039535522
suggesting O O 0.9999983310699463
signs O O 0.9999736547470093
of O O 0.9998903274536133
dopaminergic O O 0.8534625172615051
activation O O 0.927951991558075
. O O 0.9999996423721313

There O O 0.9999531507492065
is O O 0.9999997615814209
a O O 0.9999923706054688
need O O 0.9999970197677612
for O O 0.9999971389770508
a O O 0.9998090863227844
well O O 0.9949896931648254
- O O 0.9996292591094971
defined O O 0.9993674159049988
animal O O 0.9692633748054504
model O O 0.9979031085968018
in O O 0.9999963045120239
which O O 0.9999970197677612
these O O 0.9999502897262573
blood B-Disease O 0.9254133105278015
dyscrasias I-Disease O 0.9240115284919739
can O O 0.9995635151863098
be O O 0.9999878406524658
studied O O 0.9998437166213989
. O O 0.9999997615814209

Acute O O 0.8042951822280884
confusion B-Disease B-Disease 0.691990077495575
induced O O 0.9994775652885437
by O O 0.9999946355819702
a O O 0.9997268319129944
high O O 0.9994955062866211
- O O 0.9994356036186218
dose O O 0.9983048439025879
infusion O O 0.992156982421875
of O O 0.9994493126869202
5 B-Chemical B-Chemical 0.8695217967033386
- I-Chemical I-Chemical 0.9960823655128479
fluorouracil I-Chemical I-Chemical 0.99981290102005
and O O 0.9920620918273926
folinic B-Chemical B-Chemical 0.9298930764198303
acid I-Chemical I-Chemical 0.9999717473983765
. O O 0.9999657869338989

We O O 0.9997851252555847
report O O 0.9999978542327881
twin O O 0.966052770614624
neonates O O 0.8280385732650757
who O O 0.9999817609786987
were O O 0.9999737739562988
born O O 0.999794065952301
prematurely O O 0.9998645782470703
at O O 0.9999997615814209
32 O O 0.9998090863227844
weeks O O 0.9999923706054688
of O O 0.9999854564666748
gestation O O 0.9988332390785217
to O O 0.9999961853027344
a O O 0.9996527433395386
mother O O 0.9963933825492859
with O O 0.9999978542327881
human B-Disease B-Disease 0.7961999177932739
immunodeficiency I-Disease I-Disease 0.9995977282524109
virus I-Disease I-Disease 0.9998200535774231
infection I-Disease I-Disease 0.9999610185623169
. O O 0.999972939491272

We O O 0.9997288584709167
postulate O O 0.9998989105224609
that O O 0.9999852180480957
the O O 0.9996700286865234
mechanism O O 0.9999339580535889
of O O 0.9999736547470093
the O O 0.9977250695228577
simvastatinezetimibe B-Chemical B-Chemical 0.9998565912246704
- O O 0.9971476197242737
induced O O 0.9998410940170288
hepatotoxicity B-Disease B-Disease 0.9998880624771118
is O O 0.9999951124191284
the O O 0.9999814033508301
increased O O 0.9984556436538696
simvastatin B-Chemical B-Chemical 0.9876531362533569
exposure O O 0.9934391379356384
by O O 0.9999579191207886
ezetimibe B-Chemical B-Chemical 0.9973800778388977
inhibition O O 0.9954831600189209
of O O 0.9999220371246338
UGT O O 0.558908224105835
enzymes O O 0.9937059283256531
. O O 0.9999996423721313

Patients O O 0.9998340606689453
who O O 0.9999973773956299
present O O 0.9999970197677612
with O O 0.9999942779541016
stress B-Disease B-Disease 0.8669723868370056
incontinence I-Disease I-Disease 0.9983365535736084
while O O 0.9996789693832397
taking O O 0.9998272061347961
prazosin B-Chemical B-Chemical 0.9999200105667114
should O O 0.9999501705169678
change O O 0.9999655485153198
their O O 0.9997689127922058
antihypertensive O O 0.8464142084121704
medication O O 0.9946876764297485
before O O 0.9999992847442627
considering O O 0.999984860420227
surgery O O 0.999850869178772
, O O 0.9999982118606567
because O O 0.9999978542327881
their O O 0.9999009370803833
incontinence B-Disease B-Disease 0.9794484972953796
may O O 0.9998204112052917
resolve O O 0.9999790191650391
spontaneously O O 0.9891891479492188
with O O 0.9999949932098389
a O O 0.9993720650672913
change O O 0.999298095703125
in O O 0.9997474551200867
drug O O 0.9852721691131592
therapy O O 0.9973000884056091
. O O 0.9999998807907104

Reduction O O 0.9892233610153198
in O O 0.9962109327316284
caffeine B-Chemical B-Chemical 0.9990680813789368
toxicity B-Disease B-Disease 0.9985849857330322
by O O 0.9999152421951294
acetaminophen B-Chemical B-Chemical 0.9999721050262451
. O O 0.9999769926071167

Hepatitis B-Disease B-Disease 0.9970839619636536
was O O 0.9979897737503052
usually O O 0.9999685287475586
reversible O O 0.9999099969863892
when O O 0.999954104423523
treatment O O 0.9999227523803711
was O O 0.9999837875366211
stopped O O 0.9997583031654358
, O O 0.999998927116394
with O O 0.9999964237213135
the O O 0.9999711513519287
results O O 0.9999828338623047
of O O 0.9999866485595703
liver O O 0.9826580882072449
function O O 0.7959182858467102
tests O O 0.9770352840423584
returning O O 0.9997428059577942
to O O 0.9999940395355225
normal O O 0.9994434714317322
after O O 0.9999992847442627
an O O 0.9999861717224121
average O O 0.9999086856842041
of O O 0.9999817609786987
3 O O 0.99943608045578
. O O 0.9999921321868896
1 O O 0.9998574256896973
months O O 0.99988853931427
. O O 0.9999997615814209

This O O 0.9997989535331726
case O O 0.9998900890350342
emphasizes O O 0.999980092048645
the O O 0.9999443292617798
possibility O O 0.9999984502792358
that O O 0.9999815225601196
HUS B-Disease B-Disease 0.9791617393493652
in O O 0.9991254210472107
adults O O 0.9985746145248413
is O O 0.9999926090240479
not O O 0.9999865293502808
invariably O O 0.9999566078186035
irreversible O O 0.9981790781021118
and O O 0.9999978542327881
that O O 0.9999949932098389
, O O 0.999991774559021
despite O O 0.9999978542327881
prolonged O O 0.9982750415802002
oliguria B-Disease B-Disease 0.9944894313812256
, O O 0.9999707937240601
recovery O O 0.988602340221405
of O O 0.9989294409751892
renal O O 0.9947799444198608
function O O 0.9073355793952942
can O O 0.9999949932098389
be O O 0.9999970197677612
obtained O O 0.999976396560669
. O O 0.9999996423721313

Introduction O O 0.9985253214836121
of O O 0.99825519323349
tacrolimus B-Chemical B-Chemical 0.9999097585678101
as O O 0.999645471572876
an O O 0.9998551607131958
alternative O O 0.9735532402992249
immunosuppressive O O 0.9431539177894592
agent O O 0.9714112281799316
resulted O O 0.9999899864196777
in O O 0.9999852180480957
the O O 0.9998164772987366
recurrence O O 0.9950971007347107
of O O 0.9999206066131592
TMA B-Disease B-Disease 0.960461437702179
and O O 0.9998329877853394
the O O 0.9999691247940063
subsequent O O 0.9998762607574463
loss O O 0.7821792960166931
of O O 0.9806493520736694
the O O 0.9898108243942261
renal O O 0.982900083065033
allograft O O 0.6820522546768188
. O O 0.9999994039535522

This O O 0.9998956918716431
case O O 0.9999731779098511
illustrates O O 0.9999876022338867
that O O 0.9999617338180542
patients O O 0.9998780488967896
receiving O O 0.9999786615371704
ritodrine B-Chemical B-Chemical 0.9999943971633911
for O O 0.999962568283081
preterm B-Disease B-Disease 0.5332379937171936
labor I-Disease I-Disease 0.9981879591941833
may O O 0.9985539317131042
risk O O 0.999985933303833
interactions O O 0.9991776347160339
between O O 0.9999923706054688
the O O 0.9998278617858887
residual O O 0.9929574728012085
betamimetic O O 0.927937924861908
effects O O 0.9999176263809204
of O O 0.9997487664222717
ritodrine B-Chemical B-Chemical 0.9999967813491821
and O O 0.9998037219047546
the O O 0.999866247177124
effects O O 0.9999527931213379
of O O 0.9999098777770996
anesthetics O O 0.9225384593009949
during O O 0.9999945163726807
cesarean O O 0.7526825666427612
section O O 0.9989056587219238
. O O 0.9999990463256836

This O O 0.9999412298202515
report O O 0.9999874830245972
demonstrates O O 0.9999921321868896
that O O 0.9999475479125977
not O O 0.9998959302902222
only O O 0.9999659061431885
intravenous O O 0.6808252930641174
, O O 0.9986054301261902
but O O 0.9999358654022217
also O O 0.9999697208404541
oral O O 0.975174069404602
bisphosphonates B-Chemical B-Chemical 0.9524750709533691
can O O 0.9997978806495667
aggravate O O 0.9882028698921204
proteinuria B-Disease B-Disease 0.9992358684539795
and O O 0.9997890591621399
acute B-Disease B-Disease 0.6607710719108582
renal I-Disease I-Disease 0.9399992823600769
failure I-Disease I-Disease 0.9999994039535522
. O O 0.9999085664749146

Dexamethasone O B-Chemical 0.9938855767250061
is O O 0.9998136162757874
frequently O O 0.9998890161514282
administered O O 0.9998908042907715
to O O 0.9999914169311523
the O O 0.9998492002487183
developing O O 0.9969431757926941
fetus O O 0.9938977360725403
to O O 0.9999982118606567
accelerate O O 0.9957832098007202
pulmonary O O 0.9225060939788818
development O O 0.5006260871887207
. O O 0.9999897480010986

This O O 0.9992007613182068
non O O 0.9880721569061279
- O O 0.9913171529769897
receptor O O 0.9625663757324219
mediated O O 0.999848484992981
inhibition O O 0.8634829521179199
requires O O 0.9999885559082031
de O O 0.9976346492767334
novo O O 0.9909392595291138
synthesis O O 0.9012969732284546
for O O 0.9999984502792358
restoration O O 0.9873129725456238
of O O 0.9991753697395325
functional O O 0.9945291876792908
GABA B-Chemical B-Chemical 0.9805042743682861
catabolism O O 0.595573365688324
. O O 0.999996542930603

DISCUSSION O O 0.9996305704116821
: O O 0.9999974966049194
To O O 0.9999963045120239
our O O 0.9999423027038574
knowledge O O 0.9999772310256958
, O O 0.9999997615814209
this O O 0.9999940395355225
is O O 0.9999991655349731
the O O 0.9999938011169434
first O O 0.9999961853027344
reported O O 0.999988317489624
case O O 0.9999730587005615
of O O 0.9999759197235107
venlafaxine B-Chemical B-Chemical 0.9954434633255005
overdose B-Disease B-Disease 0.9963789582252502
that O O 0.9997981190681458
resulted O O 0.999963641166687
in O O 0.9999940395355225
a O O 0.9994385838508606
generalized O O 0.9790799021720886
seizure B-Disease B-Disease 0.9716203808784485
. O O 0.9999688863754272

Highest O O 0.9948392510414124
stage O O 0.9655106067657471
reached O O 0.9996204376220703
and O O 0.9997254014015198
latency O O 0.9671890735626221
to O O 0.9996957778930664
each O O 0.9998301267623901
stage O O 0.9997773766517639
were O O 0.9999970197677612
recorded O O 0.9999607801437378
for O O 0.9999922513961792
all O O 0.9994780421257019
mice O O 0.9989684820175171
. O O 0.9999996423721313

On O O 0.9997751116752625
two O O 0.9999117851257324
paradoxical O O 0.9875358939170837
side O O 0.9994650483131409
- O O 0.9999401569366455
effects O O 0.9999645948410034
of O O 0.9994957447052002
prednisolone B-Chemical B-Chemical 0.9988491535186768
in O O 0.999340832233429
rats O O 0.9994198083877563
, O O 0.9999953508377075
ribosomal O O 0.8210673928260803
RNA O O 0.5461087226867676
biosyntheses O O 0.9850671291351318
, O O 0.9999985694885254
and O O 0.9999845027923584
a O O 0.9997259974479675
mechanism O O 0.9996719360351562
of O O 0.9999651908874512
action O O 0.9960149526596069
. O O 0.9999996423721313

PURPOSE O O 0.9992061257362366
: O O 0.9999955892562866
To O O 0.9999740123748779
evaluate O O 0.9999511241912842
the O O 0.998943030834198
response O O 0.9988254904747009
rate O O 0.999980092048645
and O O 0.9999552965164185
toxic O O 0.5550996661186218
effects O O 0.9871740341186523
of O O 0.9993141889572144
vinorelbine B-Chemical B-Chemical 0.9998520612716675
( O O 0.9941592216491699
VNB B-Chemical B-Chemical 0.9992590546607971
) O O 0.9861288070678711
administered O O 0.999948263168335
as O O 0.9999938011169434
a O O 0.9998610019683838
single O O 0.9986814856529236
agent O O 0.9953709244728088
in O O 0.9999914169311523
metastatic O O 0.9322919249534607
squamous B-Disease B-Disease 0.7070879936218262
cell I-Disease I-Disease 0.5251374840736389
esophageal I-Disease I-Disease 0.9424382448196411
carcinoma I-Disease I-Disease 0.9999916553497314
. O O 0.9999579191207886

A O O 0.9997673630714417
high O O 0.9996410608291626
percentage O O 0.9999759197235107
of O O 0.9994876384735107
kanamycin B-Chemical B-Chemical 0.9999834299087524
- O I-Chemical 0.578041672706604
colistin B-Chemical I-Chemical 0.5137552618980408
and O O 0.9772561192512512
povidone B-Chemical B-Chemical 0.9990966320037842
- I-Chemical O 0.9615349769592285
iodine I-Chemical O 0.8033493757247925
irrigations O O 0.9556308388710022
were O O 0.9999936819076538
associated O O 0.9999984502792358
with O O 0.999990701675415
erosive O O 0.6658480167388916
cystitis B-Disease B-Disease 0.8625644445419312
and O O 0.9998003840446472
suggested O O 0.9999949932098389
a O O 0.9999803304672241
possible O O 0.9999700784683228
complication O O 0.9990803003311157
with O O 0.9999971389770508
human O O 0.9789865612983704
usage O O 0.9904283285140991
. O O 0.9999992847442627

Potential O O 0.9999455213546753
mechanisms O O 0.9998496770858765
of O O 0.9999761581420898
the O O 0.9991669654846191
pathophysiology O O 0.8412178158760071
are O O 0.9999980926513672
briefly O O 0.9998397827148438
discussed O O 0.9999921321868896
. O O 0.9999997615814209

The O O 0.9996880292892456
3 O O 0.994606077671051
- O O 0.9995318651199341
week O O 0.9993273019790649
sulphasalazine B-Chemical B-Chemical 0.9987291693687439
syndrome O O 0.5674988031387329
strikes O O 0.9889801740646362
again O O 0.9998550415039062
. O O 0.9999994039535522

Carbamazepine B-Chemical B-Chemical 0.9992133378982544
was O O 0.9994645714759827
switched O O 0.9998934268951416
to O O 0.9999728202819824
its O O 0.999725878238678
10 O O 0.9367763996124268
- O O 0.9059765338897705
keto O O 0.5968092679977417
analogue O O 0.894492506980896
oxcarbazepine B-Chemical B-Chemical 0.9978713989257812
among O O 0.9987366795539856
six O O 0.9971544742584229
difficult O O 0.9998608827590942
- O O 0.99974125623703
to O O 0.999915361404419
- O O 0.9995425939559937
treat O O 0.9982166886329651
schizophrenic B-Disease B-Disease 0.9904616475105286
or O O 0.9777730107307434
organic B-Disease O 0.8302793502807617
psychotic I-Disease B-Disease 0.9596918821334839
patients O O 0.9902695417404175
using O O 0.9999865293502808
concomitantly O O 0.9950425624847412
haloperidol B-Chemical B-Chemical 0.9986011385917664
, O O 0.979520857334137
chlorpromazine B-Chemical B-Chemical 0.9995623230934143
or O O 0.99517822265625
clozapine B-Chemical B-Chemical 0.9999957084655762
. O O 0.9999942779541016

In O O 0.9999792575836182
addition O O 0.9999661445617676
, O O 0.999998927116394
the O O 0.9999434947967529
role O O 0.999832034111023
of O O 0.9997397065162659
dopamine B-Chemical B-Chemical 0.9999730587005615
receptors O O 0.9980481863021851
in O O 0.9999700784683228
mediating O O 0.9976872205734253
nicotine B-Chemical B-Chemical 0.9999779462814331
- O O 0.9991288781166077
induced O O 0.9999157190322876
locomotor O O 0.9492278099060059
stimulation O O 0.5053726434707642
was O O 0.9999897480010986
investigated O O 0.9999867677688599
by O O 0.9999916553497314
examining O O 0.9999536275863647
the O O 0.999822199344635
effects O O 0.9999858140945435
of O O 0.9999574422836304
selective O O 0.9867172241210938
D1 O O 0.9293729662895203
and O O 0.9999024868011475
D2 O O 0.9820815920829773
dopamine B-Chemical B-Chemical 0.9992582201957703
receptor O O 0.9959057569503784
antagonists O O 0.9932458996772766
on O O 0.9999507665634155
activity O O 0.9899111390113831
induced O O 0.9999451637268066
by O O 0.9996786117553711
nicotine B-Chemical B-Chemical 0.9999959468841553
. O O 0.9999951124191284

To O O 0.9999866485595703
the O O 0.9999921321868896
best O O 0.9999724626541138
of O O 0.9999897480010986
our O O 0.9999523162841797
knowledge O O 0.9998418092727661
, O O 0.9999994039535522
this O O 0.9999635219573975
constitutes O O 0.9999995231628418
the O O 0.9999915361404419
first O O 0.9999842643737793
report O O 0.9999228715896606
of O O 0.9997286200523376
HBV O O 0.5786777138710022
lamivudine B-Chemical B-Chemical 0.9699353575706482
- O O 0.9983213543891907
resistant O O 0.9998354911804199
strains O O 0.9864895343780518
in O O 0.9998841285705566
therapy O O 0.9996868371963501
- O O 0.9993194341659546
na B-Chemical B-Chemical 0.9960407018661499
ve O O 0.9808269739151001
HBV B-Disease B-Disease 0.8662644624710083
- I-Disease I-Disease 0.8645046949386597
HIV I-Disease I-Disease 0.6060842871665955
co I-Disease I-Disease 0.9943769574165344
- I-Disease I-Disease 0.9946395754814148
infected I-Disease I-Disease 0.9999681711196899
patients O O 0.9908151626586914
. O O 0.9999997615814209

Neuroactive O O 0.9902509450912476
steroids B-Chemical B-Chemical 0.9996914863586426
demonstrate O O 0.9999606609344482
pharmacological O O 0.9886034727096558
actions O O 0.834255039691925
that O O 0.9999665021896362
have O O 0.999984860420227
relevance O O 0.9984059929847717
for O O 0.9999997615814209
a O O 0.9999371767044067
host O O 0.9999086856842041
of O O 0.9999865293502808
neurological B-Disease B-Disease 0.888060986995697
and I-Disease I-Disease 0.9197858572006226
psychiatric I-Disease I-Disease 0.9827332496643066
disorders I-Disease I-Disease 0.9999812841415405
. O O 0.9999678134918213

The O O 0.9999200105667114
emergency O O 0.9868865609169006
nurse O O 0.9973330497741699
ought O O 0.9999995231628418
to O O 0.9999985694885254
be O O 0.9999507665634155
familiar O O 0.9999945163726807
with O O 0.9999938011169434
some O O 0.9999053478240967
of O O 0.9999891519546509
the O O 0.999976634979248
cardiovascular O O 0.7792809009552002
consequences O O 0.9869112968444824
of O O 0.9999301433563232
cocaine B-Chemical B-Chemical 0.9999047517776489
use O O 0.9886491298675537
. O O 0.9999996423721313

RESULTS O O 0.9975772500038147
: O O 0.9999880790710449
Head O O 0.9983331561088562
- O O 0.9990084767341614
up O O 0.9986365437507629
tilt O O 0.997825562953949
caused O O 0.9999974966049194
systolic B-Disease O 0.8618796467781067
orthostatic I-Disease B-Disease 0.3681808114051819
hypotension I-Disease I-Disease 0.797161877155304
which O O 0.999648928642273
was O O 0.9999802112579346
marked O O 0.9998032450675964
in O O 0.9999988079071045
six O O 0.9998729228973389
of O O 0.9999874830245972
20 O O 0.9997614026069641
PD B-Disease B-Disease 0.9775152802467346
patients O O 0.9986656904220581
on O O 0.9997894167900085
selegiline B-Chemical B-Chemical 0.9999101161956787
, O O 0.9999393224716187
one O O 0.9999957084655762
of O O 0.9999985694885254
whom O O 0.9999967813491821
lost O O 0.9950994849205017
consciousness O O 0.8052749037742615
with O O 0.9999957084655762
unrecordable O O 0.9970297813415527
blood O O 0.9292284250259399
pressures O O 0.7953407168388367
. O O 0.9999592304229736

These O O 0.9999003410339355
13 O O 0.9988522529602051
included O O 0.9999920129776001
cases O O 0.9999233484268188
of O O 0.9999872446060181
malignant B-Disease B-Disease 0.7810742855072021
hypertension I-Disease I-Disease 0.8467389345169067
, O O 0.9995667338371277
thrombotic B-Disease B-Disease 0.9959908127784729
microangiopathy I-Disease I-Disease 0.9987325072288513
, O O 0.9993999004364014
lupus B-Disease B-Disease 0.9572335481643677
nephritis I-Disease I-Disease 0.9688951373100281
, O O 0.9995540976524353
Henoch B-Disease B-Disease 0.49776691198349
- I-Disease I-Disease 0.6650605201721191
Schonlein I-Disease I-Disease 0.681755006313324
nephritis I-Disease I-Disease 0.9725730419158936
, O O 0.9989967942237854
crescentic O B-Disease 0.9421971440315247
glomerulonephritis B-Disease I-Disease 0.95932936668396
, O O 0.9923616647720337
and O O 0.9971804618835449
cocaine B-Chemical B-Chemical 0.9998502731323242
- O O 0.9989814162254333
related O O 0.9997971653938293
acute B-Disease B-Disease 0.7621516585350037
renal I-Disease I-Disease 0.9255403280258179
failure I-Disease I-Disease 0.9999997615814209
. O O 0.9999288320541382

The O O 0.9997724890708923
patient O O 0.9999589920043945
required O O 0.9999986886978149
massive O O 0.9924692511558533
transfusion O O 0.7021001577377319
support O O 0.9889698028564453
( O O 0.9999992847442627
55 O O 0.9998551607131958
units O O 0.9999337196350098
of O O 0.9998713731765747
red O O 0.9795829057693481
blood O O 0.9974408149719238
cells O O 0.9998364448547363
, O O 0.9999983310699463
42 O O 0.9999246597290039
units O O 0.9999021291732788
of O O 0.9998143315315247
fresh O O 0.9875968098640442
- O O 0.9982782602310181
frozen O O 0.9851436018943787
plasma O O 0.9922608733177185
, O O 0.9999778270721436
40 O O 0.9997250437736511
units O O 0.9998055100440979
of O O 0.999600350856781
cryoprecipitate O B-Chemical 0.9951452612876892
, O O 0.9959514141082764
40 O O 0.9990450739860535
units O O 0.9997764229774475
of O O 0.9997581839561462
platelets O O 0.7508681416511536
, O O 0.9992007613182068
and O O 0.9999345541000366
three O O 0.9992493987083435
doses O O 0.9998829364776611
of O O 0.9999185800552368
recombinant O O 0.9659394025802612
Factor O O 0.9968135952949524
VIIa O O 0.5458164811134338
) O O 0.999963641166687
for O O 0.9999991655349731
severe O O 0.9955589771270752
intraoperative B-Disease O 0.9000817537307739
and I-Disease O 0.770268440246582
postoperative I-Disease B-Disease 0.5943602919578552
bleeding I-Disease I-Disease 0.998359739780426
. O O 0.999868631362915

In O O 0.9999284744262695
the O O 0.9995670914649963
liver O O 0.9795840382575989
both O O 0.9997838139533997
the O O 0.9996999502182007
content O O 0.9999295473098755
of O O 0.9998107552528381
RNA O O 0.7818036079406738
and O O 0.9999269247055054
the O O 0.9996256828308105
biosynthesis O O 0.9852675199508667
of O O 0.9997705817222595
ribosomal O O 0.7106949090957642
RNA O O 0.46772152185440063
increased O O 0.9998732805252075
while O O 0.9999955892562866
both O O 0.999954342842102
the O O 0.9994377493858337
RNA O O 0.8775964379310608
content O O 0.9996919631958008
and O O 0.9999591112136841
ribosomal O O 0.7421042323112488
RNA O O 0.6525152921676636
biosynthesis O O 0.9871891140937805
were O O 0.9999840259552002
reduced O O 0.9994358420372009
in O O 0.9999148845672607
the O O 0.9993749260902405
gastrocnemius O O 0.6463993787765503
muscle O O 0.7613139748573303
. O O 0.9999849796295166

Epidemiological O O 0.9985523819923401
evidence O O 0.9999092817306519
indicates O O 0.9999997615814209
that O O 0.999991774559021
prenatal O O 0.9911389946937561
nutritional O B-Disease 0.7912347912788391
deprivation O I-Disease 0.9984704852104187
may O O 0.9999363422393799
increase O O 0.9999665021896362
the O O 0.9999123811721802
risk O O 0.9999780654907227
of O O 0.9999704360961914
schizophrenia B-Disease B-Disease 0.9998759031295776
. O O 0.999931812286377

We O O 0.9995942711830139
observed O O 0.9999380111694336
the O O 0.999186098575592
exencephaly B-Disease B-Disease 0.99882572889328
induced O O 0.6641969084739685
by O O 0.9984489679336548
5 B-Chemical B-Chemical 0.9159522652626038
- I-Chemical I-Chemical 0.997748076915741
azacytidine I-Chemical I-Chemical 0.9985009431838989
at O O 0.9999203681945801
embryonic O O 0.6391083002090454
day O O 0.860122799873352
13 O O 0.9898026585578918
. O O 0.9999735355377197
5 O O 0.9959713816642761
( O O 0.9999964237213135
E13 O O 0.9946473240852356
. O O 0.9999884366989136
5 O O 0.9955203533172607
) O O 0.9994292855262756
, O O 0.999997615814209
let O O 0.9993343949317932
the O O 0.9997854828834534
embryos O O 0.9922379851341248
develop O O 0.9999680519104004
exo O O 0.8190912008285522
utero O O 0.8854497075080872
until O O 0.9999977350234985
E18 O O 0.9576489925384521
. O O 0.9999700784683228
5 O O 0.9934251308441162
, O O 0.9996861219406128
and O O 0.9999428987503052
re O O 0.8769054412841797
- O O 0.9998832941055298
observed O O 0.9999678134918213
the O O 0.9999077320098877
same O O 0.9873160123825073
embryos O O 0.9328222870826721
at O O 0.9999966621398926
E18 O O 0.9876486659049988
. O O 0.9999994039535522
5 O O 0.9967407584190369
. O O 0.9999970197677612

BACKGROUND O O 0.9875491857528687
: O O 0.9999722242355347
Lithium B-Chemical B-Chemical 0.9999608993530273
remains O O 0.9999805688858032
a O O 0.999945878982544
first O O 0.9995681643486023
- O O 0.9994687438011169
line O O 0.9998024106025696
treatment O O 0.9999939203262329
for O O 0.9999990463256836
the O O 0.9995830655097961
acute O O 0.9299446940422058
and O O 0.9774066209793091
maintenance O O 0.9875935912132263
treatment O O 0.9999858140945435
of O O 0.999997615814209
bipolar B-Disease B-Disease 0.9953197836875916
disorder I-Disease I-Disease 0.9999988079071045
. O O 0.9999842643737793

The O O 0.9999369382858276
optimal O O 0.9991406202316284
time O O 0.9999706745147705
for O O 0.9999958276748657
the O O 0.999976396560669
initial O O 0.9996551275253296
dose O O 0.9999446868896484
of O O 0.9996739625930786
carbon B-Chemical B-Chemical 0.9792681932449341
tetrachloride I-Chemical I-Chemical 0.9793666005134583
was O O 0.9999510049819946
after O O 0.9999933242797852
14 O O 0.9997668862342834
days O O 0.9999754428863525
on O O 0.9999504089355469
phenobarbitone B-Chemical B-Chemical 0.9993000030517578
. O O 0.999982476234436

However O O 0.9999322891235352
, O O 0.9999973773956299
marked O O 0.9982104301452637
tachycardia B-Disease B-Disease 0.9919593930244446
associated O O 0.9978844523429871
with O O 0.9999860525131226
the O O 0.9996351003646851
use O O 0.9998750686645508
of O O 0.9995538592338562
ephedrine B-Chemical B-Chemical 0.9999650716781616
in O O 0.9999386072158813
combination O O 0.9996531009674072
with O O 0.9999791383743286
propofol B-Chemical B-Chemical 0.9958750605583191
occurred O O 0.9999340772628784
in O O 0.9999985694885254
the O O 0.9999630451202393
majority O O 0.9999223947525024
of O O 0.9999821186065674
patients O O 0.9999955892562866
, O O 0.9999973773956299
occasionally O O 0.9974313378334045
reaching O O 0.9998664855957031
high O O 0.9971747398376465
levels O O 0.999631404876709
in O O 0.9999957084655762
individual O O 0.9921912550926208
patients O O 0.9999738931655884
. O O 0.9999998807907104

Previous O O 0.9999827146530151
clinical O O 0.9999822378158569
studies O O 0.9999756813049316
have O O 0.9999958276748657
proposed O O 0.9999979734420776
that O O 0.9997813105583191
risperidone B-Chemical B-Chemical 0.9997608065605164
' O O 0.9984357953071594
s O O 0.9611507058143616
pharmacologic O O 0.9739174246788025
profile O O 0.9985415935516357
may O O 0.9999994039535522
produce O O 0.9999942779541016
improved O O 0.9990066885948181
efficacy O O 0.9599011540412903
for O O 0.999995231628418
negative O O 0.9564884305000305
psychotic B-Disease O 0.8358685374259949
symptoms I-Disease O 0.9184163212776184
and O O 0.9994943141937256
decreased O O 0.9933798313140869
propensity O O 0.9080873131752014
for O O 0.9999773502349854
extrapyramidal O O 0.8630300164222717
side O O 0.6024340987205505
effects O O 0.9050588011741638
; O O 0.9999586343765259
features O O 0.9992050528526306
shared O O 0.9999822378158569
by O O 0.9999856948852539
so O O 0.9984265565872192
- O O 0.9998799562454224
called O O 0.9999892711639404
' O O 0.9985260963439941
atypical O O 0.8548384308815002
' O O 0.9530945420265198
neuroleptics O O 0.5566981434822083
. O O 0.9999819993972778

These O O 0.9999415874481201
findings O O 0.9999685287475586
suggest O O 0.9999992847442627
that O O 0.9999651908874512
lowered O O 0.9939219951629639
serum O O 0.9987527132034302
prolactin O O 0.9034817218780518
levels O O 0.9977250695228577
in O O 0.9999850988388062
the O O 0.9998582601547241
early O O 0.9994662404060364
phase O O 0.9998904466629028
of O O 0.999479353427887
bromocriptine B-Chemical B-Chemical 0.9999226331710815
treatment O O 0.9994626641273499
may O O 0.9999995231628418
result O O 0.9999874830245972
from O O 0.999991774559021
an O O 0.9999107122421265
impaired O O 0.9423094987869263
secretion O O 0.601854145526886
of O O 0.9585190415382385
prolactin O O 0.606182873249054
due O O 0.9995912909507751
to O O 0.9999899864196777
decreasing O O 0.9930838346481323
numbers O O 0.9946513772010803
of O O 0.9998655319213867
cytoplasmic O O 0.7561261057853699
microtubules O O 0.5365692377090454
. O O 0.9999970197677612

Studies O O 0.9995902180671692
in O O 0.999976634979248
DBA O O 0.5518338084220886
/ O O 0.99988853931427
2J O O 0.9984145164489746
mice O O 0.999461829662323
showed O O 0.9999984502792358
that O O 0.9999258518218994
: O O 0.9997128844261169
1 O O 0.9951706528663635
) O O 0.9971978664398193
pretreatment O O 0.997481644153595
with O O 0.9996883869171143
acetaminophen B-Chemical B-Chemical 0.9999986886978149
( O O 0.9993995428085327
100 O O 0.9993707537651062
mg O O 0.9998387098312378
/ O O 0.9999493360519409
kg O O 0.9996342658996582
) O O 0.999890923500061
increased O O 0.9999438524246216
the O O 0.999433696269989
interval O O 0.9989317059516907
between O O 0.9999932050704956
the O O 0.9992591738700867
administration O O 0.9975065588951111
of O O 0.999599039554596
caffeine B-Chemical B-Chemical 0.9999902248382568
( O O 0.9997383952140808
300 O O 0.9986465573310852
to O O 0.9999865293502808
450 O O 0.9996267557144165
mg O O 0.9998459815979004
/ O O 0.9999500513076782
kg O O 0.9997521042823792
IP O O 0.8763288259506226
) O O 0.9997723698616028
and O O 0.9999886751174927
the O O 0.999943733215332
onset O O 0.9997392296791077
of O O 0.9999896287918091
fatal O O 0.9532657265663147
convulsions B-Disease B-Disease 0.8330081105232239
by O O 0.9998250603675842
a O O 0.9999399185180664
factor O O 0.99996018409729
of O O 0.9999874830245972
about O O 0.9999407529830933
two O O 0.9990487694740295
; O O 0.9999730587005615
and O O 0.9998999834060669
2 O O 0.9951276779174805
) O O 0.9905411601066589
pretreatment O O 0.9975510239601135
with O O 0.9998016953468323
acetaminophen B-Chemical B-Chemical 0.999998927116394
( O O 0.9992635846138
75 O O 0.9993020296096802
mg O O 0.9998950958251953
/ O O 0.9999598264694214
kg O O 0.9997218251228333
) O O 0.9998732805252075
reduced O O 0.9999706745147705
the O O 0.9998855590820312
incidence O O 0.9963207244873047
of O O 0.9998233914375305
audiogenic O B-Disease 0.9199801683425903
seizures B-Disease I-Disease 0.9182158708572388
produced O O 0.997799813747406
in O O 0.9999891519546509
the O O 0.9998774528503418
presence O O 0.999398946762085
of O O 0.9993738532066345
caffeine B-Chemical B-Chemical 0.9999723434448242
( O O 0.9992479681968689
12 O O 0.9972600936889648
. O O 0.9999836683273315
5 O O 0.9997406601905823
to O O 0.9999920129776001
75 O O 0.9998881816864014
mg O O 0.9999539852142334
/ O O 0.9999865293502808
kg O O 0.9999340772628784
IP O O 0.9765053987503052
) O O 0.9997778534889221
. O O 0.9999992847442627

RESULTS O O 0.998941957950592
: O O 0.9999972581863403
The O O 0.9999805688858032
mean O O 0.9999343156814575
+ O O 0.9999926090240479
/ O O 0.9999783039093018
- O O 0.9994207620620728
SD O O 0.8845590949058533
duration O O 0.9996237754821777
of O O 0.9997636675834656
BZD O B-Chemical 0.9925285577774048
/ O O 0.9518430233001709
RD O B-Chemical 0.9242525100708008
use O O 0.9948434829711914
was O O 0.9999991655349731
7 O O 0.9999246597290039
+ O O 0.9999977350234985
/ O O 0.9999988079071045
- O O 0.9999815225601196
7 O O 0.9997708201408386
years O O 0.9999954700469971
( O O 0.9999939203262329
range O O 0.9999532699584961
1 O O 0.999864935874939
- O O 0.999471127986908
31 O O 0.9961180686950684
) O O 0.9997830986976624
. O O 0.9999994039535522

Depression B-Disease B-Disease 0.9966281056404114
and O O 0.9969695210456848
sexual B-Disease B-Disease 0.564299464225769
dysfunction I-Disease I-Disease 0.9999144077301025
have O O 0.9998470544815063
been O O 0.9999897480010986
related O O 0.9999876022338867
to O O 0.9999969005584717
side O O 0.9991683959960938
effects O O 0.999884843826294
of O O 0.9999245405197144
topical O O 0.9864946603775024
beta O O 0.9240217804908752
- O O 0.9232127070426941
blockers O O 0.7804118394851685
. O O 0.9999960660934448

The O O 0.999421238899231
patient O O 0.9996795654296875
was O O 0.9999920129776001
asymptomatic O O 0.5630621910095215
and O O 0.9989836812019348
the O O 0.9998843669891357
aneurysm B-Disease B-Disease 0.998422384262085
was O O 0.9949289560317993
detected O O 0.9992042183876038
in O O 0.9999948740005493
a O O 0.9999446868896484
routine O O 0.9390659928321838
control O O 0.9938949942588806
. O O 0.9999996423721313

Gastric O O 0.9387770891189575
acid O O 0.6105968356132507
back O O 0.9993683695793152
- O O 0.9993739724159241
diffusion O O 0.9633136987686157
, O O 0.9999921321868896
mucosal O O 0.9113776683807373
LPO O O 0.6068373918533325
generation O O 0.9991253018379211
, O O 0.9999605417251587
histamine B-Chemical B-Chemical 0.9995759129524231
concentration O O 0.9966989159584045
, O O 0.9999939203262329
microvascular O O 0.7273862361907959
permeability O O 0.8665328621864319
, O O 0.9999219179153442
luminal B-Chemical O 0.974321722984314
hemoglobin O O 0.6609957218170166
content O O 0.9971831440925598
and O O 0.9999707937240601
ulcer B-Disease O 0.8728511333465576
areas O O 0.9980206489562988
were O O 0.9999980926513672
determined O O 0.9999964237213135
. O O 0.9999995231628418

CONCLUSIONS O O 0.9995984435081482
: O O 0.9999994039535522
Long O O 0.999843955039978
- O O 0.9992330074310303
term O O 0.9996254444122314
use O O 0.9991480112075806
and O O 0.9999775886535645
concomitant O O 0.7542260885238647
use O O 0.9979138970375061
of O O 0.9999574422836304
more O O 0.9997360110282898
than O O 0.9997319579124451
one O O 0.9991927742958069
BZD O O 0.944374144077301
/ O O 0.9903395771980286
RD O O 0.6385307908058167
were O O 0.9999127388000488
common O O 0.9994868040084839
in O O 0.9999923706054688
elderly O O 0.9991897940635681
patients O O 0.9999792575836182
hospitalised O O 0.99831223487854
because O O 0.9999997615814209
of O O 0.999995231628418
acute O B-Disease 0.6163836717605591
illnesses O I-Disease 0.9909607768058777
. O O 0.9996851682662964

99mTc B-Chemical B-Chemical 0.9224529266357422
- I-Chemical I-Chemical 0.9866209030151367
glucarate I-Chemical I-Chemical 0.9993839263916016
for O O 0.9998563528060913
detection O O 0.9972842931747437
of O O 0.9979325532913208
isoproterenol B-Chemical B-Chemical 0.99997878074646
- O O 0.9991675615310669
induced O O 0.9999550580978394
myocardial B-Disease B-Disease 0.9138977527618408
infarction I-Disease I-Disease 0.9999822378158569
in O O 0.9990418553352356
rats O O 0.9997819066047668
. O O 0.9999998807907104

Lone O O 0.9894558787345886
atrial B-Disease B-Disease 0.8905336856842041
fibrillation I-Disease I-Disease 0.9997542500495911
associated O O 0.9996634721755981
with O O 0.9999366998672485
creatine B-Chemical B-Chemical 0.9975455403327942
monohydrate O I-Chemical 0.5978824496269226
supplementation O O 0.6934791803359985
. O O 0.9999991655349731

There O O 0.9999747276306152
was O O 0.9999998807907104
a O O 0.9999926090240479
remarkable O O 0.9998393058776855
reduction O O 0.9801439642906189
in O O 0.9920719265937805
total O O 0.9888368844985962
cholesterol B-Chemical B-Chemical 0.9999924898147583
level O O 0.9999091625213623
as O O 0.9999967813491821
well O O 0.9999459981918335
, O O 0.9999964237213135
to O O 0.9999942779541016
the O O 0.9999586343765259
extent O O 0.9999607801437378
of O O 0.9999792575836182
23 O O 0.9998486042022705
% O O 0.9999620914459229
in O O 0.9999915361404419
young O O 0.9995636343955994
and O O 0.9999606609344482
21 O O 0.999915361404419
% O O 0.9999314546585083
in O O 0.9999611377716064
aged O O 0.9994463324546814
animals O O 0.9983637928962708
with O O 0.9999985694885254
this O O 0.9984976053237915
dose O O 0.9998606443405151
of O O 0.9995502829551697
DCE B-Chemical B-Chemical 0.5861431956291199
. O O 0.9998886585235596

Previous O O 0.9999762773513794
studies O O 0.999983549118042
have O O 0.9999971389770508
suggested O O 0.9999971389770508
that O O 0.9999586343765259
repeated O O 0.9990123510360718
exposure O O 0.9963396787643433
of O O 0.9994698166847229
rats O O 0.9872123599052429
to O O 0.9999797344207764
the O O 0.998789370059967
drug O O 0.99835205078125
or O O 0.999895453453064
to O O 0.9999454021453857
the O O 0.9998482465744019
experimental O O 0.9982835054397583
environment O O 0.9988910555839539
is O O 0.9999992847442627
necessary O O 0.9999983310699463
to O O 0.9999971389770508
observe O O 0.999215841293335
nicotine B-Chemical B-Chemical 0.9999895095825195
- O O 0.999406099319458
induced O O 0.999815046787262
locomotor O O 0.914840817451477
stimulation O O 0.8098465800285339
. O O 0.9999946355819702

A O O 0.9993333220481873
literature O O 0.9995429515838623
review O O 0.9999381303787231
revealed O O 0.9999998807907104
no O O 0.9999876022338867
prior O O 0.9999898672103882
reports O O 0.9999619722366333
of O O 0.9999728202819824
pericarditis B-Disease B-Disease 0.989188015460968
in O O 0.9980985522270203
anti O O 0.9990862607955933
- O O 0.9920448064804077
MPO O O 0.5071589946746826
pANCA O O 0.6751840114593506
- O O 0.9981168508529663
positive O O 0.9364001750946045
vasculitis B-Disease B-Disease 0.9333134293556213
associated O O 0.999758780002594
with O O 0.9997401833534241
propylthio B-Chemical B-Chemical 0.999567449092865
- I-Chemical I-Chemical 0.7648057341575623
uracil I-Chemical I-Chemical 0.9578366875648499
therapy O O 0.9993329644203186
. O O 0.9999997615814209

The O O 0.9998905658721924
acute O O 0.883825421333313
toxicity B-Disease B-Disease 0.9348073601722717
of O O 0.9452611804008484
OPs B-Chemical B-Chemical 0.7959102988243103
is O O 0.9996281862258911
the O O 0.9999963045120239
result O O 0.9999959468841553
of O O 0.9999967813491821
their O O 0.9999806880950928
irreversible O O 0.9954274892807007
binding O O 0.9947133660316467
with O O 0.9999152421951294
AChEs O O 0.6492531299591064
in O O 0.9997748732566833
the O O 0.999126136302948
central O O 0.9932844638824463
nervous O O 0.936552107334137
system O O 0.701267421245575
( O O 0.9979469180107117
CNS O O 0.930635929107666
) O O 0.9994768500328064
, O O 0.999943733215332
which O O 0.9991315007209778
elevates O O 0.9896358847618103
acetylcholine B-Chemical B-Chemical 0.9996211528778076
( O O 0.9984360337257385
ACh B-Chemical B-Chemical 0.9991596937179565
) O O 0.9720088243484497
levels O O 0.9999014139175415
. O O 0.9999997615814209

The O O 0.9999252557754517
main O O 0.9998239874839783
outcome O O 0.9999330043792725
was O O 0.9999997615814209
the O O 0.9999603033065796
number O O 0.9997798800468445
of O O 0.9999743700027466
study O O 0.9994785189628601
participants O O 0.9999220371246338
experiencing O O 0.9999390840530396
akathisia B-Disease B-Disease 0.9991039633750916
within O O 0.999617338180542
60 O O 0.9999008178710938
minutes O O 0.9999732971191406
of O O 0.9999816417694092
administration O O 0.9997636675834656
. O O 0.9999994039535522

In O O 0.9999748468399048
vivo O O 0.996016800403595
microdialysis O O 0.9369004964828491
demonstrated O O 0.9999949932098389
that O O 0.9999748468399048
an O O 0.9997366070747375
intraperitoneal O O 0.897424578666687
administration O O 0.9845709204673767
of O O 0.9985454082489014
pilocarpine B-Chemical B-Chemical 0.9999537467956543
induced O O 0.9999122619628906
a O O 0.9991527795791626
pronounced O O 0.9984788298606873
increment O O 0.897199809551239
of O O 0.9927577972412109
hippocampal O O 0.8695462346076965
glutamate B-Chemical B-Chemical 0.9814280271530151
and O O 0.9979020357131958
aspartate B-Chemical B-Chemical 0.9987163543701172
whereas O O 0.9999891519546509
no O O 0.9999921321868896
significant O O 0.9999823570251465
change O O 0.9994410872459412
was O O 0.9999878406524658
observed O O 0.9997522234916687
on O O 0.9999369382858276
the O O 0.9998090863227844
level O O 0.9998173117637634
of O O 0.9991468191146851
glycine B-Chemical B-Chemical 0.9999284744262695
and O O 0.9985421895980835
GABA B-Chemical B-Chemical 0.9992127418518066
. O O 0.999991774559021

However O O 0.9998570680618286
, O O 0.9999794960021973
cost O O 0.9936549663543701
- O O 0.9984844326972961
effective O O 0.9992600083351135
screening O O 0.9910093545913696
strategies O O 0.9998354911804199
recommended O O 0.9999983310699463
so O O 0.9999873638153076
far O O 0.9998735189437866
missed O O 0.9999983310699463
40 O O 0.999968409538269
to O O 0.9999915361404419
50 O O 0.9999722242355347
% O O 0.9999932050704956
of O O 0.9999783039093018
cases O O 0.9997074007987976
improved O O 0.9999189376831055
with O O 0.9999698400497437
endocrine O B-Chemical 0.9828102588653564
therapy O O 0.9992133378982544
and O O 0.9999951124191284
the O O 0.9999198913574219
pituitary B-Disease B-Disease 0.5702873468399048
tumors I-Disease I-Disease 0.728853166103363
. O O 0.9999825954437256

Angiosarcoma B-Disease B-Disease 0.9239110350608826
was O O 0.9924696087837219
also O O 0.9993064403533936
present O O 0.9999880790710449
within O O 0.9999586343765259
pulmonary O O 0.9898372292518616
and O O 0.9966961145401001
renal O O 0.9889089465141296
arteries O O 0.9637452363967896
. O O 0.9999992847442627

In O O 0.9999914169311523
addition O O 0.9999922513961792
, O O 0.9999983310699463
we O O 0.9999147653579712
analyzed O O 0.9999830722808838
the O O 0.9998832941055298
expression O O 0.9988135099411011
of O O 0.9998441934585571
autophagy O O 0.5291173458099365
associated O O 0.9984415173530579
gene O O 0.8698193430900574
, O O 0.9996955394744873
beclin O O 0.9721915125846863
1 O O 0.9503557682037354
using O O 0.9996895790100098
RT O O 0.7292221188545227
- O O 0.9969340562820435
PCR O O 0.7991037964820862
and O O 0.9999246597290039
Western O O 0.9834175705909729
blotting O O 0.9598575830459595
in O O 0.9999830722808838
an O O 0.9998145699501038
animal O O 0.9627408981323242
model O O 0.9991010427474976
. O O 0.9999997615814209

We O O 0.9999364614486694
report O O 0.9999997615814209
a O O 0.9999901056289673
case O O 0.9999880790710449
of O O 0.9999967813491821
severe O O 0.9946373105049133
hypertension B-Disease B-Disease 0.9994564652442932
with O O 0.9998886585235596
an O O 0.9995542168617249
occluded O O 0.9981018900871277
renal O O 0.988236129283905
artery O O 0.5259133577346802
to O O 0.999971866607666
a O O 0.9993376135826111
solitary O O 0.9532134532928467
kidney O O 0.798637866973877
, O O 0.9999792575836182
who O O 0.9999938011169434
developed O O 0.9999943971633911
sudden B-Disease O 0.9758018851280212
deterioration I-Disease B-Disease 0.9495872259140015
of I-Disease I-Disease 0.9829186201095581
renal I-Disease I-Disease 0.8082481622695923
function I-Disease I-Disease 0.9885880947113037
following O O 0.9993983507156372
treatment O O 0.9999901056289673
with O O 0.9999719858169556
captopril B-Chemical B-Chemical 0.9998496770858765
. O O 0.9999740123748779

Angioedema B-Disease B-Disease 0.9965115189552307
following O O 0.9999431371688843
the O O 0.9999352693557739
intravenous O O 0.9952067732810974
administration O O 0.9979668259620667
of O O 0.9974888563156128
metoprolol B-Chemical B-Chemical 0.9999973773956299
. O O 0.9998897314071655

Although O O 0.9999619722366333
the O O 0.9999738931655884
explanation O O 0.9999499320983887
for O O 0.999998927116394
the O O 0.9999665021896362
association O O 0.998863697052002
between O O 0.9999580383300781
artery B-Disease B-Disease 0.9423108696937561
calcification I-Disease I-Disease 0.9994055032730103
and O O 0.9923730492591858
growth O O 0.5799998044967651
status O O 0.6178969740867615
cannot O O 0.9999275207519531
be O O 0.9999980926513672
determined O O 0.999998927116394
from O O 0.9999953508377075
the O O 0.9999659061431885
present O O 0.9999806880950928
study O O 0.9999909400939941
, O O 0.9999997615814209
there O O 0.9999992847442627
was O O 0.9999997615814209
a O O 0.9999678134918213
relationship O O 0.9997634291648865
between O O 0.9999868869781494
higher O O 0.9918111562728882
serum O O 0.9808121919631958
phosphate B-Chemical B-Chemical 0.980141282081604
and O O 0.9997161030769348
susceptibility O O 0.974159836769104
to O O 0.9999053478240967
artery B-Disease B-Disease 0.7892748713493347
calcification I-Disease I-Disease 0.9992702603340149
, O O 0.999800980091095
with O O 0.9999979734420776
30 O O 0.9998934268951416
% O O 0.9999672174453735
higher O O 0.999339759349823
levels O O 0.9994431138038635
of O O 0.9997366070747375
serum O O 0.9678714871406555
phosphate B-Chemical B-Chemical 0.9590156674385071
in O O 0.9999386072158813
young O O 0.9994295239448547
, O O 0.9996178150177002
ad O O 0.997685432434082
libitum O O 0.912583589553833
- O O 0.9994027614593506
fed O O 0.9984660148620605
rats O O 0.9996167421340942
compared O O 0.9999921321868896
with O O 0.9999488592147827
either O O 0.9999337196350098
of O O 0.9999719858169556
the O O 0.9997538924217224
groups O O 0.9995622038841248
that O O 0.9999821186065674
was O O 0.9996528625488281
resistant O O 0.9994091987609863
to O O 0.9995344877243042
Warfarin B-Chemical B-Chemical 0.999984860420227
- O O 0.998228132724762
induced O O 0.9998505115509033
artery B-Disease B-Disease 0.9557051062583923
calcification I-Disease I-Disease 0.9985711574554443
, O O 0.9985066056251526
ie O O 0.9932836294174194
, O O 0.9999668598175049
the O O 0.9999620914459229
10 O O 0.9985149502754211
- O O 0.9998570680618286
month O O 0.9998506307601929
- O O 0.9999605417251587
old O O 0.9977304339408875
rats O O 0.9997332692146301
and O O 0.99997878074646
the O O 0.9999262094497681
restricted O O 0.9981550574302673
- O O 0.9983356595039368
diet O O 0.9635001420974731
, O O 0.9999291896820068
growth O O 0.958580493927002
- O O 0.9885411262512207
inhibited O O 0.9952207207679749
young O O 0.9977614879608154
rats O O 0.9988055229187012
. O O 0.9999998807907104

Despite O O 0.9998173117637634
inducing O O 0.9999139308929443
extensive O O 0.9980781078338623
erythrocyte O O 0.7471123933792114
lysis O O 0.47485455870628357
, O O 0.999985933303833
TAM B-Chemical B-Chemical 0.9954307079315186
does O O 0.999921441078186
not O O 0.9999865293502808
shift O O 0.9999110698699951
the O O 0.9996834993362427
osmotic O O 0.8864346742630005
fragility O O 0.6613444089889526
curves O O 0.9572700262069702
of O O 0.9993857145309448
erythrocytes O O 0.7531751394271851
. O O 0.9999984502792358

The O O 0.9998517036437988
physician O O 0.999758780002594
should O O 0.9999974966049194
also O O 0.9999971389770508
determine O O 0.9999988079071045
the O O 0.9999878406524658
proper O O 0.9997727274894714
use O O 0.9999483823776245
of O O 0.9999945163726807
any O O 0.9999531507492065
adjunctive O O 0.9620950818061829
medications O O 0.9967367053031921
; O O 0.9999997615814209
such O O 0.9999929666519165
combined O O 0.9993274211883545
therapy O O 0.9994376301765442
has O O 0.9999984502792358
become O O 0.9999868869781494
the O O 0.9999531507492065
standard O O 0.9996101260185242
approach O O 0.9996211528778076
to O O 0.9999840259552002
treatment O O 0.9999606609344482
. O O 0.9999998807907104

The O O 0.999935507774353
results O O 0.9999196529388428
of O O 0.9999948740005493
our O O 0.9999737739562988
study O O 0.9999891519546509
suggest O O 0.9999988079071045
that O O 0.9999377727508545
salvianolic B-Chemical B-Chemical 0.9281500577926636
acid I-Chemical I-Chemical 0.9992733597755432
A I-Chemical I-Chemical 0.9970213770866394
possessing O O 0.9978596568107605
antioxidant O O 0.9126107692718506
activity O O 0.9895830154418945
has O O 0.9999980926513672
a O O 0.9999853372573853
significant O O 0.999882698059082
protective O O 0.9929178357124329
effect O O 0.9983391761779785
against O O 0.9999151229858398
isoproterenol B-Chemical B-Chemical 0.9999896287918091
- O O 0.9992103576660156
induced O O 0.9999419450759888
myocardial B-Disease B-Disease 0.9083724617958069
infarction I-Disease I-Disease 0.9999903440475464
. O O 0.9998985528945923

The O O 0.9995785355567932
potential O O 0.9999905824661255
of O O 0.9998010993003845
compounds O O 0.9726736545562744
to O O 0.9999798536300659
cause O O 0.9999605417251587
TDP B-Disease B-Disease 0.970352828502655
was O O 0.9989653825759888
evaluated O O 0.9999692440032959
by O O 0.9999959468841553
monitoring O O 0.9999140501022339
their O O 0.99989914894104
effects O O 0.999924898147583
on O O 0.9999229907989502
MAPD O B-Chemical 0.8908548355102539
in O O 0.9997046589851379
dog O O 0.941502571105957
. O O 0.9999982118606567

The O O 0.999957799911499
following O O 0.9999978542327881
case O O 0.9999881982803345
is O O 0.9999997615814209
a O O 0.9999788999557495
report O O 0.9999840259552002
of O O 0.9999394416809082
cauda B-Disease B-Disease 0.44840776920318604
equina I-Disease I-Disease 0.9619510173797607
syndrome I-Disease I-Disease 0.9998542070388794
possibly O O 0.9984315037727356
caused O O 0.9999216794967651
by O O 0.9999697208404541
epidural O O 0.9717288613319397
injection O O 0.9919601082801819
of O O 0.9971195459365845
triamcinolone B-Chemical B-Chemical 0.9999216794967651
and O O 0.9947109222412109
bupivacaine B-Chemical B-Chemical 0.9998905658721924
. O O 0.9999923706054688

In O O 0.9999557733535767
conclusion O O 0.9997265934944153
mitochondrial B-Disease B-Disease 0.6850098967552185
toxicity I-Disease I-Disease 0.8659839630126953
is O O 0.9999244213104248
an O O 0.9999973773956299
early O O 0.999862551689148
common O O 0.999840497970581
event O O 0.999398946762085
both O O 0.9999948740005493
in O O 0.9995610117912292
paclitaxel B-Chemical B-Chemical 0.9992387294769287
and O O 0.9974787831306458
cisplatin B-Chemical B-Chemical 0.999976634979248
induced O O 0.9980517625808716
neurotoxicity B-Disease B-Disease 0.9998800754547119
. O O 0.9999775886535645

Patients O O 0.9981070756912231
likely O O 0.9999986886978149
to O O 0.9999979734420776
have O O 0.9999858140945435
both O O 0.9990794658660889
raised O O 0.983640730381012
trough O O 0.9669385552406311
- O O 0.9948137998580933
concentrations O O 0.9383386969566345
and O O 0.9999526739120483
mental O O 0.9980579018592834
confusion B-Disease B-Disease 0.8412224650382996
are O O 0.9999653100967407
those O O 0.9999980926513672
with O O 0.9999990463256836
both O O 0.9993103742599487
severe O O 0.9966327548027039
renal B-Disease B-Disease 0.8079541921615601
and I-Disease I-Disease 0.7618189454078674
hepatic I-Disease I-Disease 0.9374043941497803
dysfunction I-Disease I-Disease 0.9999804496765137
. O O 0.9999258518218994

The O O 0.9991042017936707
combination O O 0.9766775369644165
inhibited O O 0.986672043800354
intestinal O O 0.9614783525466919
transit O O 0.5002413988113403
similar O O 0.9857812523841858
to O O 0.9980981945991516
that O O 0.9974385499954224
produced O O 0.9999366998672485
by O O 0.9999305009841919
morphine B-Chemical B-Chemical 0.9999556541442871
regardless O O 0.9999792575836182
of O O 0.9999699592590332
the O O 0.9999778270721436
time O O 0.9999955892562866
of O O 0.9999774694442749
treatment O O 0.999932050704956
, O O 0.9999990463256836
suggesting O O 0.9999945163726807
that O O 0.9996205568313599
metamizol B-Chemical B-Chemical 0.9999411106109619
did O O 0.9999607801437378
not O O 0.9998120665550232
potentiate O O 0.9999243021011353
morphine B-Chemical B-Chemical 0.9999691247940063
- O O 0.9988046884536743
induced O O 0.9998621940612793
constipation B-Disease B-Disease 0.9971135854721069
. O O 0.9998797178268433

Behavioral O O 0.9745118618011475
effects O O 0.9973415732383728
of O O 0.9994602799415588
diazepam B-Chemical B-Chemical 0.9998939037322998
and O O 0.9978074431419373
propranolol B-Chemical B-Chemical 0.9999797344207764
in O O 0.9999814033508301
patients O O 0.999998927116394
with O O 0.9999959468841553
panic B-Disease B-Disease 0.9893350005149841
disorder I-Disease I-Disease 0.9999995231628418
and O O 0.9979526996612549
agoraphobia B-Disease B-Disease 0.9997478127479553
. O O 0.9999368190765381

Unusual O O 0.9967696666717529
features O O 0.997654139995575
of O O 0.9999740123748779
the O O 0.9983968138694763
arrhythmia B-Disease B-Disease 0.9989826083183289
are O O 0.9999746084213257
repetitive O O 0.7843817472457886
group O O 0.9788113236427307
beating O O 0.962909996509552
, O O 0.9999816417694092
progressive O O 0.9897423982620239
shortening O O 0.9737181067466736
of O O 0.9986867308616638
the O O 0.9981569647789001
R O O 0.9472283720970154
- O O 0.9907224178314209
R O O 0.9639886617660522
interval O O 0.9935711622238159
, O O 0.9999792575836182
progressive O O 0.9963498115539551
widening O O 0.978996753692627
of O O 0.9922248125076294
the O O 0.9791185259819031
QRS O O 0.663699746131897
complex O O 0.9985907673835754
with O O 0.9999983310699463
eventual O O 0.9989099502563477
failure O O 0.8482729196548462
of O O 0.9917399883270264
intraventricular O O 0.9556940197944641
conduction O O 0.5412663221359253
, O O 0.9999563694000244
and O O 0.9999738931655884
changes O O 0.9965535402297974
in O O 0.997747004032135
direction O O 0.9953805208206177
of O O 0.9997860789299011
the O O 0.9989588260650635
QRS O O 0.9354321956634521
axis O O 0.9879999756813049
. O O 0.9999997615814209

Captopril B-Chemical B-Chemical 0.9977453351020813
may O O 0.9999161958694458
, O O 0.9999927282333374
by O O 0.9999979734420776
the O O 0.9999617338180542
same O O 0.9997239708900452
mechanism O O 0.999677300453186
, O O 0.9999996423721313
reduce O O 0.9991636276245117
the O O 0.9981904625892639
increase O O 0.8870524764060974
in O O 0.9511895179748535
glomerular O O 0.711870014667511
filtration O O 0.9584692120552063
that O O 0.9964098334312439
is O O 0.9999037981033325
known O O 0.9999945163726807
to O O 0.9999850988388062
occur O O 0.9999371767044067
after O O 0.9999994039535522
an O O 0.9999592304229736
injection O O 0.997245192527771
of O O 0.9993520379066467
thrombin O O 0.7455341219902039
, O O 0.999902606010437
thereby O O 0.9999957084655762
diminishing O O 0.9998053908348083
the O O 0.9992389678955078
aggregation O O 0.9609278440475464
of O O 0.9983747005462646
fibrin O O 0.8805528879165649
monomers O O 0.7667160630226135
in O O 0.9999374151229858
the O O 0.999569833278656
glomeruli O O 0.8101698756217957
, O O 0.9999805688858032
with O O 0.9999938011169434
the O O 0.9999890327453613
result O O 0.9999871253967285
that O O 0.9999964237213135
less O O 0.9996578693389893
fibrin O B-Chemical 0.9733803272247314
will O O 0.9998229146003723
be O O 0.999174177646637
deposited O O 0.9991843104362488
and O O 0.9999772310256958
thus O O 0.9999983310699463
less O O 0.9999784231185913
kidney B-Disease O 0.9575563073158264
damage I-Disease O 0.9179698824882507
will O O 0.9981572031974792
be O O 0.9998996257781982
produced O O 0.9999332427978516
. O O 0.9999995231628418

Chloroacetaldehyde B-Chemical B-Chemical 0.9963366985321045
and O O 0.9998077750205994
its O O 0.9998227953910828
contribution O O 0.9998414516448975
to O O 0.9999778270721436
urotoxicity O B-Disease 0.9997289776802063
during O O 0.9998601675033569
treatment O O 0.9999768733978271
with O O 0.9999319314956665
cyclophosphamide B-Chemical B-Chemical 0.9999126195907593
or O O 0.9939292669296265
ifosfamide B-Chemical B-Chemical 0.9999057054519653
. O O 0.9999692440032959

MEASUREMENTS O O 0.9980727434158325
AND O O 0.9999849796295166
MAIN O O 0.9999312162399292
RESULTS O O 0.9999097585678101
: O O 0.9999990463256836
None O O 0.9999929666519165
of O O 0.9999942779541016
23 O O 0.9999382495880127
patients O O 0.9999891519546509
who O O 0.9999977350234985
received O O 0.9999533891677856
docetaxel B-Chemical B-Chemical 0.9998192191123962
alone O O 0.9957619309425354
developed O O 0.9999470710754395
VTE B-Disease B-Disease 0.9275833368301392
, O O 0.9991737008094788
whereas O O 0.9999855756759644
9 O O 0.9991125464439392
of O O 0.9999871253967285
47 O O 0.9997232556343079
patients O O 0.9999806880950928
( O O 0.9999991655349731
19 O O 0.9999821186065674
% O O 0.9999969005584717
) O O 0.9999507665634155
who O O 0.9999873638153076
received O O 0.9999058246612549
docetaxel B-Chemical B-Chemical 0.9999285936355591
plus O O 0.9954249262809753
thalidomide B-Chemical B-Chemical 0.9999650716781616
developed O O 0.9998278617858887
VTE B-Disease B-Chemical 0.6966504454612732
( O O 0.9993906021118164
p O O 0.9971911311149597
= O O 0.9999736547470093
0 O O 0.9993999004364014
. O O 0.9999775886535645
025 O O 0.9915737509727478
) O O 0.9998483657836914
. O O 0.9999991655349731

In O O 0.9999951124191284
the O O 0.9999915361404419
current O O 0.9999692440032959
study O O 0.9999911785125732
, O O 0.9999997615814209
the O O 0.9999542236328125
frequency O O 0.9997460246086121
of O O 0.9999361038208008
thrombotic B-Disease B-Disease 0.987571120262146
microangiopathy I-Disease I-Disease 0.9955364465713501
was O O 0.999822199344635
similar O O 0.999991774559021
to O O 0.9999926090240479
the O O 0.9999624490737915
percentage O O 0.9999849796295166
reported O O 0.9999985694885254
in O O 0.9999963045120239
the O O 0.9997814297676086
literature O O 0.9935099482536316
( O O 0.9999994039535522
20 O O 0.9999771118164062
% O O 0.9999942779541016
) O O 0.9998195767402649
. O O 0.9999992847442627

6 O O 0.7849534749984741
. O O 0.9999698400497437

BACKGROUND O O 0.9954068660736084
: O O 0.9999958276748657
Direct O O 0.9990835189819336
thrombin O O 0.9894415140151978
inhibitors O O 0.9981972575187683
( O O 0.9999769926071167
DTIs O O 0.5475838780403137
) O O 0.9990166425704956
provide O O 0.999997615814209
an O O 0.999966025352478
alternative O O 0.9944175481796265
method O O 0.9999301433563232
of O O 0.9999483823776245
anticoagulation O O 0.7047983407974243
for O O 0.9999728202819824
patients O O 0.999997615814209
with O O 0.9999978542327881
a O O 0.9983682036399841
history O O 0.9999574422836304
of O O 0.9998570680618286
heparin B-Chemical B-Chemical 0.9997543692588806
- O O 0.9935780763626099
induced O O 0.9997296929359436
thrombocytopenia B-Disease B-Disease 0.9964086413383484
( O O 0.9906717538833618
HIT B-Disease B-Disease 0.9998248219490051
) O O 0.9519968628883362
or O O 0.9996639490127563
HIT B-Disease B-Disease 0.9976646900177002
with O O 0.9951533079147339
thrombosis B-Disease B-Disease 0.9983154535293579
( O O 0.9982219338417053
HITT B-Disease B-Disease 0.9998223185539246
) O O 0.9945816397666931
undergoing O O 0.999778687953949
cardiopulmonary O O 0.9408839344978333
bypass O O 0.9423146843910217
( O O 0.9333497881889343
CPB O O 0.663119375705719
) O O 0.998475968837738
. O O 0.999998927116394

Together O O 0.9998611211776733
, O O 0.9999986886978149
these O O 0.9999716281890869
results O O 0.9999614953994751
suggest O O 0.9999992847442627
that O O 0.9999672174453735
the O O 0.9990035891532898
beta4 O O 0.9106320142745972
and O O 0.9999186992645264
the O O 0.9996278285980225
alpha3 O O 0.9195697903633118
subunits O O 0.996461808681488
are O O 0.9999971389770508
mediators O O 0.9998641014099121
of O O 0.9993664622306824
nicotine B-Chemical B-Chemical 0.9999951124191284
- O O 0.9995474219322205
induced O O 0.9997033476829529
seizures B-Disease B-Disease 0.999954104423523
and O O 0.9980937838554382
hypolocomotion B-Disease B-Disease 0.9986283779144287
. O O 0.9999752044677734

These O O 0.9999147653579712
data O O 0.9998841285705566
indicate O O 0.9999997615814209
that O O 0.9999808073043823
a O O 0.999900221824646
critical O O 0.999704897403717
percentage O O 0.9999887943267822
of O O 0.9998718500137329
NTE O O 0.7883598804473877
inhibition O O 0.6342160105705261
in O O 0.9946637153625488
brain O O 0.9849483370780945
and O O 0.9985792636871338
spinal O O 0.997731626033783
cord O O 0.9606335163116455
sampled O O 0.9999469518661499
shortly O O 0.9999669790267944
after O O 0.9999641180038452
Mipafox B-Chemical B-Chemical 0.9995792508125305
exposure O O 0.9834780097007751
can O O 0.9999774694442749
predict O O 0.999969482421875
neuropathic B-Disease B-Disease 0.9094868302345276
damage I-Disease I-Disease 0.9999077320098877
in O O 0.9992228746414185
rats O O 0.9997963309288025
several O O 0.9999974966049194
weeks O O 0.9999936819076538
later O O 0.9999988079071045
. O O 0.9999997615814209

The O O 0.9999223947525024
similarities O O 0.9996933937072754
between O O 0.9999911785125732
the O O 0.9999356269836426
effects O O 0.9999912977218628
of O O 0.9999583959579468
structural O O 0.9960029721260071
lesions O O 0.499533087015152
and O O 0.998917818069458
pharmacological O O 0.9154316186904907
depression B-Disease B-Disease 0.5528814196586609
of O O 0.8727800250053406
the O O 0.9463531970977783
brain O O 0.7993753552436829
stem O O 0.9764649271965027
reticular O O 0.8996317386627197
formation O O 0.9341157674789429
are O O 0.9999982118606567
discussed O O 0.9999953508377075
. O O 0.9999998807907104

Levodopa B-Chemical B-Chemical 0.9976084232330322
is O O 0.9999793767929077
the O O 0.9999783039093018
most O O 0.9998502731323242
effective O O 0.9988903403282166
drug O O 0.9992844462394714
for O O 0.9999784231185913
the O O 0.9992209672927856
treatment O O 0.9999598264694214
of O O 0.9999874830245972
Parkinson B-Disease B-Disease 0.9917397499084473
' I-Disease I-Disease 0.9999933242797852
s I-Disease I-Disease 0.9999939203262329
disease I-Disease I-Disease 0.9999908208847046
. O O 0.999936580657959

A O O 0.9948920011520386
63 O O 0.9992944002151489
- O O 0.9999825954437256
year O O 0.9999934434890747
- O O 0.9999817609786987
old O O 0.999958872795105
male O O 0.9985076785087585
experienced O O 0.999991774559021
sudden O O 0.7341203093528748
diplopia B-Disease B-Disease 0.6126256585121155
after O O 0.9999880790710449
9 O O 0.999943733215332
weeks O O 0.9999963045120239
of O O 0.9999830722808838
administration O O 0.9988208413124084
of O O 0.9999164342880249
pegylated B-Chemical B-Chemical 0.748966634273529
interferon I-Chemical I-Chemical 0.998446524143219
( I-Chemical O 0.9890644550323486
IFN I-Chemical B-Chemical 0.9716672301292419
) I-Chemical O 0.9868032336235046
alpha I-Chemical B-Chemical 0.5938525199890137
- I-Chemical I-Chemical 0.7923367619514465
2b I-Chemical I-Chemical 0.9992477893829346
and O O 0.9725687503814697
ribavirin B-Chemical B-Chemical 0.997309684753418
for O O 0.9999943971633911
chronic B-Disease B-Disease 0.5713045597076416
hepatitis I-Disease I-Disease 0.9686686992645264
C I-Disease I-Disease 0.9995087385177612
( O O 0.9965691566467285
CHC B-Disease B-Disease 0.9993939399719238
) O O 0.9962562322616577
. O O 0.9999992847442627

Information O O 0.9996342658996582
regarding O O 0.9998739957809448
midazolam B-Chemical B-Chemical 0.9991129040718079
use O O 0.9896883964538574
is O O 0.9999990463256836
reviewed O O 0.9999988079071045
to O O 0.9999995231628418
provide O O 0.9999988079071045
recommendation O O 0.9999947547912598
for O O 0.9999936819076538
safe O O 0.9941943287849426
administration O O 0.9998052716255188
. O O 0.9999996423721313

Histology O O 0.478870153427124
was O O 0.9998451471328735
performed O O 0.9999946355819702
in O O 0.9999642372131348
DOX B-Chemical B-Chemical 0.9982712268829346
- O O 0.991370439529419
rats O O 0.9990717172622681
at O O 0.9999977350234985
6 O O 0.9996065497398376
and O O 0.9999948740005493
9 O O 0.9998655319213867
weeks O O 0.999984622001648
after O O 0.9999996423721313
the O O 0.9999624490737915
last O O 0.9998363256454468
DOX B-Chemical B-Chemical 0.9997742772102356
dose O O 0.9995318651199341
and O O 0.9999927282333374
in O O 0.9999685287475586
all O O 0.9946080446243286
controls O O 0.998496413230896
. O O 0.9999997615814209

Exposure O O 0.9747690558433533
to O O 0.9995719790458679
tobacco O O 0.8075683116912842
was O O 0.9993711113929749
characterized O O 0.9999874830245972
as O O 0.9999823570251465
low O O 0.9949434399604797
( O O 0.9999713897705078
< O O 0.9999569654464722
5 O O 0.9993321299552917
cigarettes O O 0.9821913838386536
per O O 0.9999755620956421
day O O 0.999872088432312
, O O 0.9999935626983643
n O O 0.9998394250869751
= O O 0.9999877214431763
88 O O 0.9997072815895081
ears O O 0.9974157810211182
) O O 0.9999686479568481
, O O 0.9999973773956299
moderate O O 0.9945201277732849
( O O 0.9998664855957031
5 O O 0.9991403818130493
< O O 0.9999780654907227
or O O 0.9999359846115112
= O O 0.9998644590377808
cigarettes O O 0.7979470491409302
per O O 0.9991945624351501
day O O 0.9998188614845276
< O O 0.9999816417694092
10 O O 0.9997069239616394
, O O 0.9999747276306152
n O O 0.9998134970664978
= O O 0.9999827146530151
76 O O 0.9991747736930847
) O O 0.9997190833091736
or O O 0.9999911785125732
high O O 0.9968795776367188
( O O 0.9997794032096863
> O O 0.9999533891677856
or O O 0.9999791383743286
= O O 0.9999887943267822
10 O O 0.9997689127922058
cigarettes O O 0.9382776021957397
per O O 0.9999022483825684
day O O 0.9999477863311768
, O O 0.9999967813491821
n O O 0.9999431371688843
= O O 0.9999896287918091
36 O O 0.9991995692253113
) O O 0.9997852444648743
. O O 0.9999995231628418

Molecularly O O 0.9943352341651917
, O O 0.9999549388885498
ANF O O 0.7020789980888367
mRNA O O 0.8633479475975037
increased O O 0.9995891451835632
250 O O 0.9996201992034912
% O O 0.9997811913490295
and O O 0.9995229244232178
SERCA2 O O 0.6211683750152588
mRNA O O 0.9613327383995056
decreased O O 0.999882698059082
57 O O 0.9998953342437744
% O O 0.9999651908874512
. O O 0.999997615814209

RESULTS O O 0.9968875050544739
: O O 0.9999707937240601
Immunofluorescence O O 0.6433408856391907
staining O O 0.9939914345741272
with O O 0.9999852180480957
the O O 0.9990572333335876
MRP2 O O 0.7583464980125427
antibody O O 0.9949507713317871
was O O 0.999972939491272
found O O 0.9999955892562866
to O O 0.9999916553497314
label O O 0.9999746084213257
a O O 0.9996201992034912
high O O 0.9988328814506531
number O O 0.9996260404586792
of O O 0.9996639490127563
microvessels O O 0.8322142362594604
throughout O O 0.9998900890350342
the O O 0.9971714615821838
brain O O 0.9690598845481873
in O O 0.9999997615814209
normal O O 0.9998643398284912
Wistar O O 0.9704171419143677
rats O O 0.9993782043457031
, O O 0.9999983310699463
whereas O O 0.9999938011169434
such O O 0.9999251365661621
labeling O O 0.9828222393989563
was O O 0.9999958276748657
absent O O 0.9996607303619385
in O O 0.9999836683273315
TR O O 0.9293602108955383
( O O 0.9998579025268555
- O O 0.9987785220146179
) O O 0.9990719556808472
rats O O 0.9995667338371277
. O O 0.9999997615814209

Severe O O 0.9982768297195435
and O O 0.9997566342353821
clinically O O 0.9999097585678101
evident O O 0.9998268485069275
anemia B-Disease B-Disease 0.9983371496200562
of O O 0.8952933549880981
Hb O O 0.8142831325531006
< O O 0.9996850490570068
11 O O 0.9990382194519043
g O O 0.9993775486946106
/ O O 0.9999730587005615
dl O O 0.999420166015625
with O O 0.9999974966049194
clinical O O 0.9632062911987305
symptoms O O 0.4785304367542267
was O O 0.999962329864502
detected O O 0.9992450475692749
in O O 0.9999936819076538
6 O O 0.9986212253570557
patients O O 0.9999849796295166
( O O 0.9999972581863403
14 O O 0.9999326467514038
. O O 0.9999961853027344
3 O O 0.9999760389328003
% O O 0.9999860525131226
) O O 0.9995249509811401
. O O 0.9999990463256836

Hepatitis B-Disease B-Disease 0.9477617740631104
B I-Disease I-Disease 0.997492790222168
virus O O 0.9333545565605164
( O O 0.904809832572937
HBV O O 0.4498080611228943
) O O 0.907467246055603
is O O 0.9998157620429993
one O O 0.9999867677688599
of O O 0.9999985694885254
the O O 0.9999914169311523
major O O 0.9998986721038818
causes O O 0.9998506307601929
of O O 0.9999953508377075
chronic O B-Disease 0.8585464954376221
liver B-Disease I-Disease 0.5743003487586975
disease I-Disease I-Disease 0.9999923706054688
worldwide O O 0.954939603805542
. O O 0.9999972581863403

Jaundice B-Disease B-Disease 0.9937223792076111
occurred O O 0.9995957016944885
after O O 0.9999979734420776
administration O O 0.9996618032455444
of O O 0.9986332058906555
troleandomycin B-Chemical B-Chemical 0.9999674558639526
for O O 0.9997279047966003
7 O O 0.997379720211029
days O O 0.9998900890350342
and O O 0.9999905824661255
was O O 0.9998912811279297
associated O O 0.9999949932098389
with O O 0.999871015548706
hypereosinophilia B-Disease B-Disease 0.999519944190979
. O O 0.9999269247055054

The O O 0.9999226331710815
high O O 0.9979735016822815
image O O 0.9945493340492249
quality O O 0.9998465776443481
suggests O O 0.9999995231628418
that O O 0.99997878074646
high O O 0.9954173564910889
contrast O O 0.9810429811477661
images O O 0.9813806414604187
can O O 0.9999934434890747
be O O 0.9999912977218628
obtained O O 0.9999582767486572
in O O 0.9999867677688599
humans O O 0.993423581123352
and O O 0.9999910593032837
the O O 0.9998539686203003
96 O O 0.9942189455032349
h O O 0.9801456332206726
stability O O 0.7932377457618713
makes O O 0.9999516010284424
it O O 0.9999542236328125
an O O 0.9999896287918091
ideal O O 0.9988058805465698
agent O O 0.9980539083480835
to O O 0.9999912977218628
detect O O 0.9977229237556458
, O O 0.9996833801269531
in O O 0.9999818801879883
patients O O 0.9999940395355225
, O O 0.9999979734420776
early O O 0.9959360361099243
cardiac B-Disease B-Disease 0.6326569318771362
infarction I-Disease I-Disease 0.9995691180229187
. O O 0.9999105930328369

High O O 0.9931650757789612
- O O 0.9986470341682434
dose O O 0.9974174499511719
5 B-Chemical B-Chemical 0.9789268374443054
- I-Chemical I-Chemical 0.9986677169799805
fluorouracil I-Chemical I-Chemical 0.9991152882575989
/ O I-Chemical 0.5955866575241089
folinic B-Chemical I-Chemical 0.5886362195014954
acid I-Chemical I-Chemical 0.9999854564666748
infusion O O 0.7821831703186035
therapy O O 0.9998635053634644
has O O 0.999997615814209
recently O O 0.9999831914901733
become O O 0.9999873638153076
a O O 0.9999703168869019
popular O O 0.9994887113571167
regimen O O 0.9922211766242981
for O O 0.9999992847442627
various O O 0.9917029738426208
cancers B-Disease B-Disease 0.9168663024902344
. O O 0.9999825954437256

Effect O O 0.9994801878929138
of O O 0.9993957281112671
fucoidan B-Chemical B-Chemical 0.9998663663864136
treatment O O 0.9975761771202087
on O O 0.9995445609092712
collagenase O B-Chemical 0.9964626431465149
- O O 0.997871994972229
induced O O 0.999976396560669
intracerebral B-Disease B-Disease 0.9355838894844055
hemorrhage I-Disease I-Disease 0.9999231100082397
in O O 0.9992552399635315
rats O O 0.999049961566925
. O O 0.9999998807907104

The O O 0.9998412132263184
possibility O O 0.9999994039535522
that O O 0.9999983310699463
habitual O O 0.9923685193061829
use O O 0.9991340041160583
of O O 0.999383807182312
acetaminophen B-Chemical B-Chemical 0.999997615814209
alone O O 0.972175657749176
increases O O 0.9998061060905457
the O O 0.9996300935745239
risk O O 0.9997887015342712
of O O 0.9998776912689209
ESRD B-Disease B-Disease 0.99919193983078
has O O 0.9997221827507019
not O O 0.9999953508377075
been O O 0.9999954700469971
clearly O O 0.9999412298202515
demonstrated O O 0.9999186992645264
, O O 0.9999955892562866
but O O 0.9999934434890747
cannot O O 0.999984622001648
be O O 0.9999955892562866
dismissed O O 0.9999887943267822
. O O 0.9999997615814209

After O O 0.9997727274894714
recovery O O 0.9999281167984009
from O O 0.9999812841415405
hypertension B-Disease B-Disease 0.9996930360794067
, O O 0.9999505281448364
the O O 0.9998217225074768
activity O O 0.9994599223136902
of O O 0.9995546936988831
( O O 0.8395676612854004
Na B-Chemical B-Chemical 0.9999896287918091
, O O 0.9348750710487366
K B-Chemical B-Chemical 0.9999397993087769
) O O 0.9330742359161377
- O O 0.9957455992698669
ATPase O O 0.728236198425293
increased O O 0.9998642206192017
, O O 0.9999810457229614
due O O 0.9999998807907104
to O O 0.9999967813491821
higher O O 0.9995670914649963
affinity O O 0.9990593791007996
of O O 0.999849796295166
the O O 0.9978074431419373
ATP B-Chemical B-Chemical 0.9864489436149597
- O O 0.9990861415863037
binding O O 0.9982166886329651
site O O 0.999567449092865
, O O 0.9999927282333374
as O O 0.9999884366989136
revealed O O 0.999994158744812
from O O 0.9999938011169434
the O O 0.9999140501022339
lowered O O 0.9986357092857361
Km O O 0.853833794593811
value O O 0.9909079074859619
for O O 0.9999959468841553
ATP B-Chemical B-Chemical 0.858572244644165
. O O 0.9999843835830688

We O O 0.9999074935913086
report O O 0.9999996423721313
the O O 0.9999971389770508
first O O 0.999984622001648
case O O 0.9999929666519165
of O O 0.9999936819076538
a O O 0.9997599720954895
serious O O 0.9993589520454407
short O O 0.9925214648246765
- O O 0.9960727691650391
term O O 0.9999445676803589
adverse O O 0.9850103259086609
reaction O O 0.5583966374397278
with O O 0.9999377727508545
the O O 0.9997376799583435
use O O 0.9997575879096985
of O O 0.9994487166404724
omeprazole B-Chemical B-Chemical 0.999847412109375
: O O 0.999309778213501
hemolytic B-Disease B-Disease 0.6310505270957947
anemia I-Disease I-Disease 0.9979471564292908
. O O 0.9999494552612305

Steady O O 0.9945501685142517
state O O 0.9989297986030579
arterial O O 0.9960376024246216
plasma O O 0.9928376078605652
concentrations O O 0.9991922974586487
of O O 0.9998371601104736
atrial O O 0.9899712800979614
natriuretic O O 0.9657097458839417
factor O O 0.9990794658660889
were O O 0.9999990463256836
39 O O 0.9999222755432129
+ O O 0.9999856948852539
/ O O 0.9999973773956299
- O O 0.9999667406082153
10 O O 0.9998972415924072
pg O O 0.999797523021698
/ O O 0.9999926090240479
ml O O 0.9994015693664551
( O O 0.999995231628418
n O O 0.9998494386672974
= O O 0.9999847412109375
6 O O 0.9993263483047485
) O O 0.999854326248169
during O O 0.999987006187439
infusions O O 0.954572319984436
of O O 0.9989087581634521
saline O O 0.9296815991401672
and O O 0.9980894923210144
284 O O 0.9994151592254639
+ O O 0.99997878074646
/ O O 0.9999948740005493
- O O 0.9999395608901978
24 O O 0.9998576641082764
pg O O 0.9994459748268127
/ O O 0.9999833106994629
ml O O 0.9979934692382812
( O O 0.9999828338623047
n O O 0.9996141195297241
= O O 0.9999710321426392
6 O O 0.9993129968643188
) O O 0.9998160004615784
and O O 0.999955415725708
1520 O O 0.999687671661377
+ O O 0.9999895095825195
/ O O 0.9999966621398926
- O O 0.9999403953552246
300 O O 0.9998562335968018
pg O O 0.9997237324714661
/ O O 0.9999895095825195
ml O O 0.9988964796066284
( O O 0.9999890327453613
n O O 0.9997538924217224
= O O 0.9999759197235107
9 O O 0.9990942478179932
) O O 0.9996626377105713
during O O 0.999987006187439
0 O O 0.9981536269187927
. O O 0.9999642372131348
03 O O 0.9973053932189941
and O O 0.9999357461929321
0 O O 0.9990746974945068
. O O 0.9999985694885254
1 O O 0.999873161315918
microgram O O 0.9983626008033752
/ O O 0.9999433755874634
kg O O 0.9993529915809631
/ O O 0.999990701675415
min O O 0.9992745518684387
infusions O O 0.9783689975738525
of O O 0.9999219179153442
the O O 0.9996116757392883
factor O O 0.9995718598365784
. O O 0.9999995231628418
( O O 0.9999408721923828
ABSTRACT O O 0.9614273905754089
TRUNCATED O O 0.9957059025764465
AT O O 0.9999591112136841
250 O O 0.9992632269859314
WORDS O O 0.9998263716697693
) O O 0.9999483823776245

In O O 0.9998793601989746
the O O 0.9984787106513977
forestomach O O 0.5099583268165588
, O O 0.9999346733093262
and O O 0.9998432397842407
also O O 0.999451220035553
in O O 0.9998471736907959
the O O 0.9964812994003296
liver O O 0.8707978129386902
, O O 0.9999861717224121
aspirin B-Chemical B-Chemical 0.9764178395271301
did O O 0.9999815225601196
not O O 0.999988317489624
affect O O 0.9999746084213257
the O O 0.9924834370613098
FANFT B-Chemical B-Chemical 0.9982866644859314
- O O 0.9975031018257141
induced O O 0.9996126294136047
increase O B-Disease 0.9079477190971375
in O I-Disease 0.7933587431907654
labeling O I-Disease 0.9818360805511475
index O I-Disease 0.991401731967926
. O O 0.9990453124046326

The O O 0.9998399019241333
onset O O 0.9997805953025818
of O O 0.9999912977218628
all O O 0.9995265007019043
manifestations O O 0.9602304697036743
( O O 0.9999842643737793
except O O 0.9999469518661499
toxic O B-Disease 0.8739922046661377
encephalopathy B-Disease I-Disease 0.9171838164329529
) O O 0.9825213551521301
was O O 0.9999840259552002
usually O O 0.9999663829803467
subacute O O 0.9084137678146362
, O O 0.9999067783355713
with O O 0.999997615814209
subsequent O O 0.9999902248382568
partial O O 0.9991437196731567
recovery O O 0.99965500831604
. O O 0.9999998807907104

In O O 0.999992847442627
the O O 0.9999622106552124
two O O 0.9998201727867126
patients O O 0.999902606010437
, O O 0.999994158744812
skin O O 0.7060643434524536
and O O 0.9941909909248352
ELISA O O 0.7689734101295471
tests O O 0.9999403953552246
with O O 0.9999698400497437
paramethasone B-Chemical B-Chemical 0.9999346733093262
were O O 0.9999397993087769
negative O O 0.9997977614402771
, O O 0.9999978542327881
as O O 0.9999958276748657
was O O 0.9999911785125732
the O O 0.9999297857284546
prick O O 0.9598234295845032
test O O 0.9999401569366455
with O O 0.9999972581863403
each O O 0.9997952580451965
of O O 0.9999778270721436
its O O 0.9998704195022583
excipients O O 0.9947426319122314
. O O 0.9999998807907104

Assay O O 0.8685343861579895
for O O 0.9999204874038696
mitochondrial O O 0.9735104441642761
respiratory O O 0.9312857985496521
function O O 0.5834748148918152
and O O 0.9999498128890991
histopathological O O 0.9955480098724365
examination O O 0.9978544116020203
of O O 0.9999532699584961
heart O O 0.9074313044548035
tissues O O 0.8006410002708435
were O O 0.9998360872268677
performed O O 0.9999938011169434
. O O 0.9999996423721313

Assessment O O 0.9997939467430115
of O O 0.999968409538269
a O O 0.9997047781944275
new O O 0.9996911287307739
non O O 0.9905753135681152
- O O 0.9991260170936584
invasive O O 0.9966704249382019
index O O 0.9977587461471558
of O O 0.9988387227058411
cardiac O O 0.9799465537071228
performance O O 0.993303120136261
for O O 0.9999955892562866
detection O O 0.9840282797813416
of O O 0.9992769360542297
dobutamine B-Chemical B-Chemical 0.9999672174453735
- O O 0.9996858835220337
induced O O 0.999944806098938
myocardial B-Disease B-Disease 0.9612034559249878
ischemia I-Disease I-Disease 0.999876856803894
. O O 0.9998620748519897

